bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Familienanamnese is an umlsterm, Erytheme is an umlsterm, therapieresistenten is an umlsterm, Erythrodermien is an umlsterm, Blut is an umlsterm, Leukozytose is an umlsterm, Blutlymphozyten is an umlsterm, Durchflusszytometrie is an umlsterm, Histologie is an umlsterm, Diagnose is an umlsterm, Blut is an umlsterm, Lymphomzellen is an umlsterm	DerHautarzt.90500743.ger.abstr_task0	Sentence: Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden .	[ "Wir", "berichten", "ueber", "eine", "47jaehrige", "Patientin", "mit", "atopischer", "Eigen-", "und", "Familienanamnese", ",", "die", "im", "Verlauf", "von", "3", "Jahren", "lokalisierte", "juckende", "Erytheme", ",", "entwickelte", ",", "welche", "innerhalb", "von", "nur", "drei", "Monaten", "generalisierten", ".", "Es", "kam", "zu", "rezidivierenden", "und", "schliesslich", "therapieresistenten", "Erythrodermien", ".", "Neben", "zahlreichen", "Typ", "-", "I", "-", "Sensibilisierungen", "wurden", "einige", "Typ", "-", "IV", "-", "Sensibilisierungen", "nachgewiesen", ".", "Im", "peripheren", "Blut", "kam", "es", "zur", "Leukozytose", "und", "Hypereosinophilie", ".", "Ein", "deutlich", "erhoehter", "IgE", "-", "Spiegel", "war", "im", "Serum", "nachweisbar", ".", "Die", "Immunphaenotypisierung", "der", "peripheren", "Blutlymphozyten", "mittels", "Durchflusszytometrie", "ergab", "erste", "Hinweise", "fuer", "eine", "klonale", "Expansion", "von", "stark", "aktivierten", "CD4", "+", "-T", "-", "Zellen", ",", "die", "eine", "verminderte", "Expression", "von", "CD2", "und", "CD5", "aufwiesen", ".", "Mittels", "Histologie", "und", "einer", "Polymerasekettenreaktionstechnik", "zur", "Untersuchung", "der", "Rearrangierung", "der", "-Kette", "des", "T", "-", "Zellrezeptors", "konnte", "dann", "nach", "3jaehrigem", "Krankheitsverlauf", "die", "Diagnose", "eines", "pleomorphen", "kleinzelligen", "kutanen", "T", "-", "Zell", "-", "Lymphoms", "gestellt", "werden", ".", "Weitere", "Untersuchungen", "zur", "Zytokinexpression", "liessen", "vermuten", ",", "dass", "die", "hohen", "IgE", "-", "Konzentrationen", "im", "Blut", "und", "die", "Hypereosinophilie", "durch", "eine", "starke", "Produktion", "und", "Sezernierung", "von", "IL-5", "und", "IL-13", "in", "den", "Lymphomzellen", "verursacht", "wurden", "." ]	[ "umlsterm" ]
Familienanamnese is an umlsterm, Erytheme is an umlsterm, therapieresistenten is an umlsterm, Erythrodermien is an umlsterm, Blut is an umlsterm, Leukozytose is an umlsterm, Blutlymphozyten is an umlsterm, Durchflusszytometrie is an umlsterm, Histologie is an umlsterm, Diagnose is an umlsterm, Blut is an umlsterm, Lymphomzellen is an umlsterm	DerHautarzt.90500743.ger.abstr_task1	Sentence: Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden . Instructions: please typing these entity words according to sentence: Familienanamnese, Erytheme, therapieresistenten, Erythrodermien, Blut, Leukozytose, Blutlymphozyten, Durchflusszytometrie, Histologie, Diagnose, Blut, Lymphomzellen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden .	[ "Wir", "berichten", "ueber", "eine", "47jaehrige", "Patientin", "mit", "atopischer", "Eigen-", "und", "Familienanamnese", ",", "die", "im", "Verlauf", "von", "3", "Jahren", "lokalisierte", "juckende", "Erytheme", ",", "entwickelte", ",", "welche", "innerhalb", "von", "nur", "drei", "Monaten", "generalisierten", ".", "Es", "kam", "zu", "rezidivierenden", "und", "schliesslich", "therapieresistenten", "Erythrodermien", ".", "Neben", "zahlreichen", "Typ", "-", "I", "-", "Sensibilisierungen", "wurden", "einige", "Typ", "-", "IV", "-", "Sensibilisierungen", "nachgewiesen", ".", "Im", "peripheren", "Blut", "kam", "es", "zur", "Leukozytose", "und", "Hypereosinophilie", ".", "Ein", "deutlich", "erhoehter", "IgE", "-", "Spiegel", "war", "im", "Serum", "nachweisbar", ".", "Die", "Immunphaenotypisierung", "der", "peripheren", "Blutlymphozyten", "mittels", "Durchflusszytometrie", "ergab", "erste", "Hinweise", "fuer", "eine", "klonale", "Expansion", "von", "stark", "aktivierten", "CD4", "+", "-T", "-", "Zellen", ",", "die", "eine", "verminderte", "Expression", "von", "CD2", "und", "CD5", "aufwiesen", ".", "Mittels", "Histologie", "und", "einer", "Polymerasekettenreaktionstechnik", "zur", "Untersuchung", "der", "Rearrangierung", "der", "-Kette", "des", "T", "-", "Zellrezeptors", "konnte", "dann", "nach", "3jaehrigem", "Krankheitsverlauf", "die", "Diagnose", "eines", "pleomorphen", "kleinzelligen", "kutanen", "T", "-", "Zell", "-", "Lymphoms", "gestellt", "werden", ".", "Weitere", "Untersuchungen", "zur", "Zytokinexpression", "liessen", "vermuten", ",", "dass", "die", "hohen", "IgE", "-", "Konzentrationen", "im", "Blut", "und", "die", "Hypereosinophilie", "durch", "eine", "starke", "Produktion", "und", "Sezernierung", "von", "IL-5", "und", "IL-13", "in", "den", "Lymphomzellen", "verursacht", "wurden", "." ]	[ "umlsterm" ]
Familienanamnese, Erytheme, therapieresistenten, Erythrodermien, Blut, Leukozytose, Blutlymphozyten, Durchflusszytometrie, Histologie, Diagnose, Blut, Lymphomzellen	DerHautarzt.90500743.ger.abstr_task2	Sentence: Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden .	[ "Wir", "berichten", "ueber", "eine", "47jaehrige", "Patientin", "mit", "atopischer", "Eigen-", "und", "Familienanamnese", ",", "die", "im", "Verlauf", "von", "3", "Jahren", "lokalisierte", "juckende", "Erytheme", ",", "entwickelte", ",", "welche", "innerhalb", "von", "nur", "drei", "Monaten", "generalisierten", ".", "Es", "kam", "zu", "rezidivierenden", "und", "schliesslich", "therapieresistenten", "Erythrodermien", ".", "Neben", "zahlreichen", "Typ", "-", "I", "-", "Sensibilisierungen", "wurden", "einige", "Typ", "-", "IV", "-", "Sensibilisierungen", "nachgewiesen", ".", "Im", "peripheren", "Blut", "kam", "es", "zur", "Leukozytose", "und", "Hypereosinophilie", ".", "Ein", "deutlich", "erhoehter", "IgE", "-", "Spiegel", "war", "im", "Serum", "nachweisbar", ".", "Die", "Immunphaenotypisierung", "der", "peripheren", "Blutlymphozyten", "mittels", "Durchflusszytometrie", "ergab", "erste", "Hinweise", "fuer", "eine", "klonale", "Expansion", "von", "stark", "aktivierten", "CD4", "+", "-T", "-", "Zellen", ",", "die", "eine", "verminderte", "Expression", "von", "CD2", "und", "CD5", "aufwiesen", ".", "Mittels", "Histologie", "und", "einer", "Polymerasekettenreaktionstechnik", "zur", "Untersuchung", "der", "Rearrangierung", "der", "-Kette", "des", "T", "-", "Zellrezeptors", "konnte", "dann", "nach", "3jaehrigem", "Krankheitsverlauf", "die", "Diagnose", "eines", "pleomorphen", "kleinzelligen", "kutanen", "T", "-", "Zell", "-", "Lymphoms", "gestellt", "werden", ".", "Weitere", "Untersuchungen", "zur", "Zytokinexpression", "liessen", "vermuten", ",", "dass", "die", "hohen", "IgE", "-", "Konzentrationen", "im", "Blut", "und", "die", "Hypereosinophilie", "durch", "eine", "starke", "Produktion", "und", "Sezernierung", "von", "IL-5", "und", "IL-13", "in", "den", "Lymphomzellen", "verursacht", "wurden", "." ]	[ "umlsterm" ]
Analyse is an umlsterm, Praevalenz is an umlsterm, schlafbezogenen is an umlsterm, Atmungsstoerungen is an umlsterm, Patienten is an umlsterm, Arrhythmierezidiven is an umlsterm, Mortalitaet is an umlsterm, Langzeitverlauf is an umlsterm, Grundkrankheit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Cheyne - Stokes - Atmung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Arrhythmierezidive is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Arrhythmien is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Praevalenz is an umlsterm, Patienten is an umlsterm, Mortalitaet is an umlsterm, Arrhythmierezidiven is an umlsterm, Langzeitverlauf is an umlsterm	ZfuerKardiologie.80870826.ger.abstr_task0	Sentence: Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar .	[ "Ziele", "der", "Studie", "waren", "einerseits", "eine", "Analyse", "der", "Praevalenz", "von", "schlafbezogenen", "Atmungsstoerungen", "(", "SBAS", ")", "bei", "Patienten", "mit", "implantierbarem", "Kardioverter", "-", "Defibrillator", "(", "ICD", ")", "und", "andererseits", "die", "prospektive", "Untersuchung", "des", "moeglichen", "Einflusses", "von", "SBAS", "auf", "die", "Haeufigkeit", "und", "zirkadiane", "Verteilung", "von", "Arrhythmierezidiven", "sowie", "auf", "die", "kardiale", "Mortalitaet", "im", "Langzeitverlauf", ".", "Vierzig", "konsekutive", "ICD", "-", "Patienten", "mit", "kardialer", "Grundkrankheit", "und", "dokumentierten", "malignen", "ventrikulaeren", "Tachyarrhythmien", "wurden", "polysomnographisch", "untersucht", "und", "anschliessend", "2", "Jahre", "nachbeobachtet", ".", "Bei", "16", "von", "40", "Patienten", "(", "40", "%", ")", "wurden", "SBAS", "diagnostiziert", "(", "Apnoe", "-", "Hypopnoe", "-", "Index", ">", "10", ")", ":", "bei", "9", "dieser", "16", "Patienten", "(", "56", "%", ")", "traten", "zentrale", "Schlafapnoen", "(", "ZSA", ")", "auf", "(", "bei", "8", "dieser", "9", "Patienten", "Cheyne", "-", "Stokes", "-", "Atmung", ")", "und", "bei", "7", "der", "16", "Patienten", "mit", "SBAS", "(", "44", "%", "obstruktive", "Schlafapnoen", "(", ")", "OSA", ")", ".", "Der", "AHI", "betrug", "32", "+", "/-", "15", "(", "12", "-", "60", ")", "bei", "Patienten", "mit", "ZSA", "und", "32", "+", "/-", "27", "(", "11", "-", "86", ")", "bei", "Patienten", "mit", "OSA", ".", "Patienten", "mit", "und", "ohne", "SBAS", "waren", "vergleichbar", "bezueglich", "des", "Ausmasses", "der", "linksventrikulaeren", "Funktionseinschraenkung", ",", "NYHA", "-", "Klassifikation", ",", "kardialer", "Grunderkrankung", ",", "ICD", "-", "Indikation", "und", "begleitender", "Medikation", ".", "Defibrillatorregistrierte", "Arrhythmierezidive", "traten", "bei", "10", "von", "24", "Patienten", "(", "42", "%", ")", "ohne", "SBAS", ",", "bei", "4", "von", "9", "Patienten", "(", "44", "%", ")", "mit", "ZSA", "und", "bei", "3", "von", "7", "Patienten", "(", "44", "%", ")", "mit", "OSA", "auf", ".", "Anzahl", "und", "tageszeitliche", "Verteilung", "der", "registrierten", "Arrhythmien", "bei", "Patienten", "ohne", "SBAS", ",", "mit", "OSA", "und", "ZSA", "waren", "vergleichbar", "(", "14", "+", "/-", "25", ",", "Median", "4", "vs", ".", "15", "+", "/-", "15", ",", "Median", "7", "vs", ".", "4", "+", "/-", "5", ",", "Median", "2,5", ")", ".", "Die", "kardiale", "2-Jahres", "-", "Mortalitaet", "war", "am", "hoechsten", "bei", "Patienten", "mit", "ZSA", "(", "4/9", "(", "44", "%", ")", "vs", ".", "0/7", "Patienten", "(", "0", "%", ")", "mit", "OSA", "vs", ".", "3/24", "Patienten", "(", "12,5", "%", ")", "ohne", "SBAS", ".", "Die", "Praevalenz", "von", "SBAS", "bei", "Patienten", "mit", "ICD", "ist", "also", "hoch", ",", "wobei", "das", "Auftreten", "von", "ZSA", "mit", "einer", "hohen", "kardialen", "Mortalitaet", "assoziiert", "ist", ".", "Ein", "Einfluss", "von", "maessiggradigen", "SBAS", "auf", "die", "Haeufigkeit", "und", "tageszeitliche", "Verteilung", "von", "Arrhythmierezidiven", "im", "Langzeitverlauf", "ist", "nicht", "nachweisbar", "." ]	[ "umlsterm" ]
Analyse is an umlsterm, Praevalenz is an umlsterm, schlafbezogenen is an umlsterm, Atmungsstoerungen is an umlsterm, Patienten is an umlsterm, Arrhythmierezidiven is an umlsterm, Mortalitaet is an umlsterm, Langzeitverlauf is an umlsterm, Grundkrankheit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Cheyne - Stokes - Atmung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Arrhythmierezidive is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Arrhythmien is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Praevalenz is an umlsterm, Patienten is an umlsterm, Mortalitaet is an umlsterm, Arrhythmierezidiven is an umlsterm, Langzeitverlauf is an umlsterm	ZfuerKardiologie.80870826.ger.abstr_task1	Sentence: Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar . Instructions: please typing these entity words according to sentence: Analyse, Praevalenz, schlafbezogenen, Atmungsstoerungen, Patienten, Arrhythmierezidiven, Mortalitaet, Langzeitverlauf, Grundkrankheit, Patienten, Patienten, Patienten, Cheyne - Stokes - Atmung, Patienten, Patienten, Patienten, Patienten, Arrhythmierezidive, Patienten, Patienten, Patienten, Arrhythmien, Patienten, Patienten, Patienten, Patienten, Praevalenz, Patienten, Mortalitaet, Arrhythmierezidiven, Langzeitverlauf Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar .	[ "Ziele", "der", "Studie", "waren", "einerseits", "eine", "Analyse", "der", "Praevalenz", "von", "schlafbezogenen", "Atmungsstoerungen", "(", "SBAS", ")", "bei", "Patienten", "mit", "implantierbarem", "Kardioverter", "-", "Defibrillator", "(", "ICD", ")", "und", "andererseits", "die", "prospektive", "Untersuchung", "des", "moeglichen", "Einflusses", "von", "SBAS", "auf", "die", "Haeufigkeit", "und", "zirkadiane", "Verteilung", "von", "Arrhythmierezidiven", "sowie", "auf", "die", "kardiale", "Mortalitaet", "im", "Langzeitverlauf", ".", "Vierzig", "konsekutive", "ICD", "-", "Patienten", "mit", "kardialer", "Grundkrankheit", "und", "dokumentierten", "malignen", "ventrikulaeren", "Tachyarrhythmien", "wurden", "polysomnographisch", "untersucht", "und", "anschliessend", "2", "Jahre", "nachbeobachtet", ".", "Bei", "16", "von", "40", "Patienten", "(", "40", "%", ")", "wurden", "SBAS", "diagnostiziert", "(", "Apnoe", "-", "Hypopnoe", "-", "Index", ">", "10", ")", ":", "bei", "9", "dieser", "16", "Patienten", "(", "56", "%", ")", "traten", "zentrale", "Schlafapnoen", "(", "ZSA", ")", "auf", "(", "bei", "8", "dieser", "9", "Patienten", "Cheyne", "-", "Stokes", "-", "Atmung", ")", "und", "bei", "7", "der", "16", "Patienten", "mit", "SBAS", "(", "44", "%", "obstruktive", "Schlafapnoen", "(", ")", "OSA", ")", ".", "Der", "AHI", "betrug", "32", "+", "/-", "15", "(", "12", "-", "60", ")", "bei", "Patienten", "mit", "ZSA", "und", "32", "+", "/-", "27", "(", "11", "-", "86", ")", "bei", "Patienten", "mit", "OSA", ".", "Patienten", "mit", "und", "ohne", "SBAS", "waren", "vergleichbar", "bezueglich", "des", "Ausmasses", "der", "linksventrikulaeren", "Funktionseinschraenkung", ",", "NYHA", "-", "Klassifikation", ",", "kardialer", "Grunderkrankung", ",", "ICD", "-", "Indikation", "und", "begleitender", "Medikation", ".", "Defibrillatorregistrierte", "Arrhythmierezidive", "traten", "bei", "10", "von", "24", "Patienten", "(", "42", "%", ")", "ohne", "SBAS", ",", "bei", "4", "von", "9", "Patienten", "(", "44", "%", ")", "mit", "ZSA", "und", "bei", "3", "von", "7", "Patienten", "(", "44", "%", ")", "mit", "OSA", "auf", ".", "Anzahl", "und", "tageszeitliche", "Verteilung", "der", "registrierten", "Arrhythmien", "bei", "Patienten", "ohne", "SBAS", ",", "mit", "OSA", "und", "ZSA", "waren", "vergleichbar", "(", "14", "+", "/-", "25", ",", "Median", "4", "vs", ".", "15", "+", "/-", "15", ",", "Median", "7", "vs", ".", "4", "+", "/-", "5", ",", "Median", "2,5", ")", ".", "Die", "kardiale", "2-Jahres", "-", "Mortalitaet", "war", "am", "hoechsten", "bei", "Patienten", "mit", "ZSA", "(", "4/9", "(", "44", "%", ")", "vs", ".", "0/7", "Patienten", "(", "0", "%", ")", "mit", "OSA", "vs", ".", "3/24", "Patienten", "(", "12,5", "%", ")", "ohne", "SBAS", ".", "Die", "Praevalenz", "von", "SBAS", "bei", "Patienten", "mit", "ICD", "ist", "also", "hoch", ",", "wobei", "das", "Auftreten", "von", "ZSA", "mit", "einer", "hohen", "kardialen", "Mortalitaet", "assoziiert", "ist", ".", "Ein", "Einfluss", "von", "maessiggradigen", "SBAS", "auf", "die", "Haeufigkeit", "und", "tageszeitliche", "Verteilung", "von", "Arrhythmierezidiven", "im", "Langzeitverlauf", "ist", "nicht", "nachweisbar", "." ]	[ "umlsterm" ]
Analyse, Praevalenz, schlafbezogenen, Atmungsstoerungen, Patienten, Arrhythmierezidiven, Mortalitaet, Langzeitverlauf, Grundkrankheit, Patienten, Patienten, Patienten, Cheyne - Stokes - Atmung, Patienten, Patienten, Patienten, Patienten, Arrhythmierezidive, Patienten, Patienten, Patienten, Arrhythmien, Patienten, Patienten, Patienten, Patienten, Praevalenz, Patienten, Mortalitaet, Arrhythmierezidiven, Langzeitverlauf	ZfuerKardiologie.80870826.ger.abstr_task2	Sentence: Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar .	[ "Ziele", "der", "Studie", "waren", "einerseits", "eine", "Analyse", "der", "Praevalenz", "von", "schlafbezogenen", "Atmungsstoerungen", "(", "SBAS", ")", "bei", "Patienten", "mit", "implantierbarem", "Kardioverter", "-", "Defibrillator", "(", "ICD", ")", "und", "andererseits", "die", "prospektive", "Untersuchung", "des", "moeglichen", "Einflusses", "von", "SBAS", "auf", "die", "Haeufigkeit", "und", "zirkadiane", "Verteilung", "von", "Arrhythmierezidiven", "sowie", "auf", "die", "kardiale", "Mortalitaet", "im", "Langzeitverlauf", ".", "Vierzig", "konsekutive", "ICD", "-", "Patienten", "mit", "kardialer", "Grundkrankheit", "und", "dokumentierten", "malignen", "ventrikulaeren", "Tachyarrhythmien", "wurden", "polysomnographisch", "untersucht", "und", "anschliessend", "2", "Jahre", "nachbeobachtet", ".", "Bei", "16", "von", "40", "Patienten", "(", "40", "%", ")", "wurden", "SBAS", "diagnostiziert", "(", "Apnoe", "-", "Hypopnoe", "-", "Index", ">", "10", ")", ":", "bei", "9", "dieser", "16", "Patienten", "(", "56", "%", ")", "traten", "zentrale", "Schlafapnoen", "(", "ZSA", ")", "auf", "(", "bei", "8", "dieser", "9", "Patienten", "Cheyne", "-", "Stokes", "-", "Atmung", ")", "und", "bei", "7", "der", "16", "Patienten", "mit", "SBAS", "(", "44", "%", "obstruktive", "Schlafapnoen", "(", ")", "OSA", ")", ".", "Der", "AHI", "betrug", "32", "+", "/-", "15", "(", "12", "-", "60", ")", "bei", "Patienten", "mit", "ZSA", "und", "32", "+", "/-", "27", "(", "11", "-", "86", ")", "bei", "Patienten", "mit", "OSA", ".", "Patienten", "mit", "und", "ohne", "SBAS", "waren", "vergleichbar", "bezueglich", "des", "Ausmasses", "der", "linksventrikulaeren", "Funktionseinschraenkung", ",", "NYHA", "-", "Klassifikation", ",", "kardialer", "Grunderkrankung", ",", "ICD", "-", "Indikation", "und", "begleitender", "Medikation", ".", "Defibrillatorregistrierte", "Arrhythmierezidive", "traten", "bei", "10", "von", "24", "Patienten", "(", "42", "%", ")", "ohne", "SBAS", ",", "bei", "4", "von", "9", "Patienten", "(", "44", "%", ")", "mit", "ZSA", "und", "bei", "3", "von", "7", "Patienten", "(", "44", "%", ")", "mit", "OSA", "auf", ".", "Anzahl", "und", "tageszeitliche", "Verteilung", "der", "registrierten", "Arrhythmien", "bei", "Patienten", "ohne", "SBAS", ",", "mit", "OSA", "und", "ZSA", "waren", "vergleichbar", "(", "14", "+", "/-", "25", ",", "Median", "4", "vs", ".", "15", "+", "/-", "15", ",", "Median", "7", "vs", ".", "4", "+", "/-", "5", ",", "Median", "2,5", ")", ".", "Die", "kardiale", "2-Jahres", "-", "Mortalitaet", "war", "am", "hoechsten", "bei", "Patienten", "mit", "ZSA", "(", "4/9", "(", "44", "%", ")", "vs", ".", "0/7", "Patienten", "(", "0", "%", ")", "mit", "OSA", "vs", ".", "3/24", "Patienten", "(", "12,5", "%", ")", "ohne", "SBAS", ".", "Die", "Praevalenz", "von", "SBAS", "bei", "Patienten", "mit", "ICD", "ist", "also", "hoch", ",", "wobei", "das", "Auftreten", "von", "ZSA", "mit", "einer", "hohen", "kardialen", "Mortalitaet", "assoziiert", "ist", ".", "Ein", "Einfluss", "von", "maessiggradigen", "SBAS", "auf", "die", "Haeufigkeit", "und", "tageszeitliche", "Verteilung", "von", "Arrhythmierezidiven", "im", "Langzeitverlauf", "ist", "nicht", "nachweisbar", "." ]	[ "umlsterm" ]
purified chick embryo cell culture rabies vaccine is a Intervention_Pharmacological, human diploid cell vaccine is a Intervention_Pharmacological, purified chick embryo cell culture rabies vaccine ( PCECV ) is a Intervention_Pharmacological, human diploid cell strain rabies vaccine ( HDCSV ) is a Intervention_Pharmacological, 177 is a Participant_Sample-size, persistence of antibody over two years is a Outcome_Other, titres 21 days after the final injection is a Outcome_Other, Neutralizing is a Outcome_Other, antibody titres is a Outcome_Physical, urticarial lesions is a Outcome_Physical	76559_task0	Sentence: Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated .	[ "Pre", "-", "exposure", "studies", "with", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "and", "human", "diploid", "cell", "vaccine", ":", "serological", "and", "clinical", "responses", "in", "man", ".", "Clinical", "reactions", "and", "neutralizing", "antibody", "responses", "to", "six", "pre", "-", "exposure", "regimens", "of", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "(", "PCECV", ")", "and", "human", "diploid", "cell", "strain", "rabies", "vaccine", "(", "HDCSV", ")", "were", "studied", "in", "177", "volunteers", ".", "Antibody", "kinetics", ",", "height", "of", "the", "response", "and", "persistence", "of", "antibody", "over", "two", "years", "were", "virtually", "identical", "after", "PCECV", "and", "HDCSV", ".", "An", "antibody", "response", "was", "detected", "in", "all", "subjects", "on", "day", "14", "when", "the", "highest", "titres", "were", "found", "after", "two", "intramuscular", "(", "i.m", ".", ")", "1.0", "ml", "doses", "of", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "7", "and", "21", ".", "In", "comparison", ",", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "28", "and", "56", "ultimately", "evoked", "the", "highest", "titres", "21", "days", "after", "the", "final", "injection", ",", "but", "antibody", "persisted", "equally", "well", "over", "two", "years", "with", "either", "schedule", ".", "Neutralizing", "antibody", "titres", "were", "lower", "after", "intradermal", "(", "i.d", ".", ")", "vaccination", "with", "0.1", "ml", "compared", "to", "1.0", "ml", "i.m", ".", "on", "days", "0", ",", "7", "and", "21", ",", "but", "when", "given", "on", "days", "0", ",", "28", "and", "56", "the", "responses", "were", "comparable", ".", "Three", "subjects", "with", "a", "personal", "or", "family", "history", "of", "atopy", "developed", "urticarial", "lesions", "after", "PCECV", ".", "Both", "vaccines", "were", "otherwise", "well", "tolerated", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Outcome_Mental", "Participant_Sex", "Participant_Sample-size" ]
purified chick embryo cell culture rabies vaccine is a Intervention_Pharmacological, human diploid cell vaccine is a Intervention_Pharmacological, purified chick embryo cell culture rabies vaccine ( PCECV ) is a Intervention_Pharmacological, human diploid cell strain rabies vaccine ( HDCSV ) is a Intervention_Pharmacological, 177 is a Participant_Sample-size, persistence of antibody over two years is a Outcome_Other, titres 21 days after the final injection is a Outcome_Other, Neutralizing is a Outcome_Other, antibody titres is a Outcome_Physical, urticarial lesions is a Outcome_Physical	76559_task1	Sentence: Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated . Instructions: please typing these entity words according to sentence: purified chick embryo cell culture rabies vaccine, human diploid cell vaccine, purified chick embryo cell culture rabies vaccine ( PCECV ), human diploid cell strain rabies vaccine ( HDCSV ), 177, persistence of antibody over two years, titres 21 days after the final injection, Neutralizing, antibody titres, urticarial lesions Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated .	[ "Pre", "-", "exposure", "studies", "with", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "and", "human", "diploid", "cell", "vaccine", ":", "serological", "and", "clinical", "responses", "in", "man", ".", "Clinical", "reactions", "and", "neutralizing", "antibody", "responses", "to", "six", "pre", "-", "exposure", "regimens", "of", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "(", "PCECV", ")", "and", "human", "diploid", "cell", "strain", "rabies", "vaccine", "(", "HDCSV", ")", "were", "studied", "in", "177", "volunteers", ".", "Antibody", "kinetics", ",", "height", "of", "the", "response", "and", "persistence", "of", "antibody", "over", "two", "years", "were", "virtually", "identical", "after", "PCECV", "and", "HDCSV", ".", "An", "antibody", "response", "was", "detected", "in", "all", "subjects", "on", "day", "14", "when", "the", "highest", "titres", "were", "found", "after", "two", "intramuscular", "(", "i.m", ".", ")", "1.0", "ml", "doses", "of", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "7", "and", "21", ".", "In", "comparison", ",", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "28", "and", "56", "ultimately", "evoked", "the", "highest", "titres", "21", "days", "after", "the", "final", "injection", ",", "but", "antibody", "persisted", "equally", "well", "over", "two", "years", "with", "either", "schedule", ".", "Neutralizing", "antibody", "titres", "were", "lower", "after", "intradermal", "(", "i.d", ".", ")", "vaccination", "with", "0.1", "ml", "compared", "to", "1.0", "ml", "i.m", ".", "on", "days", "0", ",", "7", "and", "21", ",", "but", "when", "given", "on", "days", "0", ",", "28", "and", "56", "the", "responses", "were", "comparable", ".", "Three", "subjects", "with", "a", "personal", "or", "family", "history", "of", "atopy", "developed", "urticarial", "lesions", "after", "PCECV", ".", "Both", "vaccines", "were", "otherwise", "well", "tolerated", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Outcome_Mental", "Participant_Sex", "Participant_Sample-size" ]
purified chick embryo cell culture rabies vaccine, human diploid cell vaccine, purified chick embryo cell culture rabies vaccine ( PCECV ), human diploid cell strain rabies vaccine ( HDCSV ), 177, persistence of antibody over two years, titres 21 days after the final injection, Neutralizing, antibody titres, urticarial lesions	76559_task2	Sentence: Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated .	[ "Pre", "-", "exposure", "studies", "with", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "and", "human", "diploid", "cell", "vaccine", ":", "serological", "and", "clinical", "responses", "in", "man", ".", "Clinical", "reactions", "and", "neutralizing", "antibody", "responses", "to", "six", "pre", "-", "exposure", "regimens", "of", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "(", "PCECV", ")", "and", "human", "diploid", "cell", "strain", "rabies", "vaccine", "(", "HDCSV", ")", "were", "studied", "in", "177", "volunteers", ".", "Antibody", "kinetics", ",", "height", "of", "the", "response", "and", "persistence", "of", "antibody", "over", "two", "years", "were", "virtually", "identical", "after", "PCECV", "and", "HDCSV", ".", "An", "antibody", "response", "was", "detected", "in", "all", "subjects", "on", "day", "14", "when", "the", "highest", "titres", "were", "found", "after", "two", "intramuscular", "(", "i.m", ".", ")", "1.0", "ml", "doses", "of", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "7", "and", "21", ".", "In", "comparison", ",", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "28", "and", "56", "ultimately", "evoked", "the", "highest", "titres", "21", "days", "after", "the", "final", "injection", ",", "but", "antibody", "persisted", "equally", "well", "over", "two", "years", "with", "either", "schedule", ".", "Neutralizing", "antibody", "titres", "were", "lower", "after", "intradermal", "(", "i.d", ".", ")", "vaccination", "with", "0.1", "ml", "compared", "to", "1.0", "ml", "i.m", ".", "on", "days", "0", ",", "7", "and", "21", ",", "but", "when", "given", "on", "days", "0", ",", "28", "and", "56", "the", "responses", "were", "comparable", ".", "Three", "subjects", "with", "a", "personal", "or", "family", "history", "of", "atopy", "developed", "urticarial", "lesions", "after", "PCECV", ".", "Both", "vaccines", "were", "otherwise", "well", "tolerated", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Outcome_Mental", "Participant_Sex", "Participant_Sample-size" ]
XIST is a Protein, locus is a Entity, XIST is a Protein, XIST is a Protein, histone H4 is a Protein, chromatin domains is a Entity, genes is a Entity, ZXDA is a Protein, ZXDB is a Protein, loci is a Entity, PHKA1 is a Protein, loci is a Entity, XIST is a Protein, XIST is a Protein, its AR allele is a Entity, the one on the normal X allele is a Entity	94_task0	Sentence: The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS)	[ "The", "severe", "phenotype", "of", "females", "with", "tiny", "ring", "X", "chromosomes", "is", "associated", "with", "inability", "of", "these", "chromosomes", "to", "undergo", "X", "inactivation", ".", "\n", "Mental", "retardation", "and", "a", "constellation", "of", "congenital", "malformations", "not", "usually", "associated", "with", "Turner", "syndrome", "are", "seen", "in", "some", "females", "with", "a", "mosaic", "45,X/46,X", ",", "r(X", ")", "karyotype", ".", "Studies", "of", "these", "females", "show", "that", "the", "XIST", "locus", "on", "their", "tiny", "ring", "X", "chromosomes", "is", "either", "not", "present", "or", "not", "expressed", ".", "As", "XIST", "transcription", "is", "well", "correlated", "with", "inactivation", "of", "the", "X", "chromosome", "in", "female", "somatic", "cells", "and", "spermatogonia", ",", "nonexpression", "of", "the", "locus", "even", "when", "it", "is", "present", "suggests", "that", "these", "chromosomes", "are", "transcriptionally", "active", ".", "We", "examined", "the", "transcriptional", "activity", "of", "ring", "X", "chromosomes", "lacking", "XIST", "expression", "(", "XISTE-", ")", ",", "from", "three", "females", "with", "severe", "phenotypes", ".", "The", "two", "tiny", "ring", "X", "chromosomes", "studied", "with", "an", "antibody", "specific", "for", "the", "acetylated", "isoforms", "of", "histone", "H4", "marking", "transcribed", "chromatin", "domains", "were", "labeled", "at", "a", "level", "consistent", "with", "their", "being", "active", ".", "We", "also", "examined", "tow", "of", "the", "XISTE-", "ring", "chromosomes", "to", "determine", "whether", "genes", "that", "are", "normally", "silent", "on", "an", "inactive", "X", "are", "expressed", "from", "these", "chromosomes", ".", "Analyses", "of", "hybrid", "cells", "show", "that", "TIMP", ",", "ZXDA", ",", "and", "ZXDB", "loci", "on", "the", "proximal", "short", "arm", ",", "and", "AR", "and", "PHKA1", "loci", "on", "the", "long", "arm", ",", "are", "well", "expressed", "from", "the", "tiny", "ring", "X", "chromosome", "lacking", "XIST", "DNA", ".", "Studies", "of", "the", "ring", "chromosome", "that", "has", "XIST", "DNA", "but", "does", "not", "transcribe", "it", "show", "that", "its", "AR", "allele", "is", "transcribed", "along", "with", "the", "one", "on", "the", "normal", "X", "allele", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]	[ "Entity", "Protein" ]
XIST is a Protein, locus is a Entity, XIST is a Protein, XIST is a Protein, histone H4 is a Protein, chromatin domains is a Entity, genes is a Entity, ZXDA is a Protein, ZXDB is a Protein, loci is a Entity, PHKA1 is a Protein, loci is a Entity, XIST is a Protein, XIST is a Protein, its AR allele is a Entity, the one on the normal X allele is a Entity	94_task1	Sentence: The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please typing these entity words according to sentence: XIST, locus, XIST, XIST, histone H4, chromatin domains, genes, ZXDA, ZXDB, loci, PHKA1, loci, XIST, XIST, its AR allele, the one on the normal X allele Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS)	[ "The", "severe", "phenotype", "of", "females", "with", "tiny", "ring", "X", "chromosomes", "is", "associated", "with", "inability", "of", "these", "chromosomes", "to", "undergo", "X", "inactivation", ".", "\n", "Mental", "retardation", "and", "a", "constellation", "of", "congenital", "malformations", "not", "usually", "associated", "with", "Turner", "syndrome", "are", "seen", "in", "some", "females", "with", "a", "mosaic", "45,X/46,X", ",", "r(X", ")", "karyotype", ".", "Studies", "of", "these", "females", "show", "that", "the", "XIST", "locus", "on", "their", "tiny", "ring", "X", "chromosomes", "is", "either", "not", "present", "or", "not", "expressed", ".", "As", "XIST", "transcription", "is", "well", "correlated", "with", "inactivation", "of", "the", "X", "chromosome", "in", "female", "somatic", "cells", "and", "spermatogonia", ",", "nonexpression", "of", "the", "locus", "even", "when", "it", "is", "present", "suggests", "that", "these", "chromosomes", "are", "transcriptionally", "active", ".", "We", "examined", "the", "transcriptional", "activity", "of", "ring", "X", "chromosomes", "lacking", "XIST", "expression", "(", "XISTE-", ")", ",", "from", "three", "females", "with", "severe", "phenotypes", ".", "The", "two", "tiny", "ring", "X", "chromosomes", "studied", "with", "an", "antibody", "specific", "for", "the", "acetylated", "isoforms", "of", "histone", "H4", "marking", "transcribed", "chromatin", "domains", "were", "labeled", "at", "a", "level", "consistent", "with", "their", "being", "active", ".", "We", "also", "examined", "tow", "of", "the", "XISTE-", "ring", "chromosomes", "to", "determine", "whether", "genes", "that", "are", "normally", "silent", "on", "an", "inactive", "X", "are", "expressed", "from", "these", "chromosomes", ".", "Analyses", "of", "hybrid", "cells", "show", "that", "TIMP", ",", "ZXDA", ",", "and", "ZXDB", "loci", "on", "the", "proximal", "short", "arm", ",", "and", "AR", "and", "PHKA1", "loci", "on", "the", "long", "arm", ",", "are", "well", "expressed", "from", "the", "tiny", "ring", "X", "chromosome", "lacking", "XIST", "DNA", ".", "Studies", "of", "the", "ring", "chromosome", "that", "has", "XIST", "DNA", "but", "does", "not", "transcribe", "it", "show", "that", "its", "AR", "allele", "is", "transcribed", "along", "with", "the", "one", "on", "the", "normal", "X", "allele", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]	[ "Entity", "Protein" ]
XIST, locus, XIST, XIST, histone H4, chromatin domains, genes, ZXDA, ZXDB, loci, PHKA1, loci, XIST, XIST, its AR allele, the one on the normal X allele	94_task2	Sentence: The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS)	[ "The", "severe", "phenotype", "of", "females", "with", "tiny", "ring", "X", "chromosomes", "is", "associated", "with", "inability", "of", "these", "chromosomes", "to", "undergo", "X", "inactivation", ".", "\n", "Mental", "retardation", "and", "a", "constellation", "of", "congenital", "malformations", "not", "usually", "associated", "with", "Turner", "syndrome", "are", "seen", "in", "some", "females", "with", "a", "mosaic", "45,X/46,X", ",", "r(X", ")", "karyotype", ".", "Studies", "of", "these", "females", "show", "that", "the", "XIST", "locus", "on", "their", "tiny", "ring", "X", "chromosomes", "is", "either", "not", "present", "or", "not", "expressed", ".", "As", "XIST", "transcription", "is", "well", "correlated", "with", "inactivation", "of", "the", "X", "chromosome", "in", "female", "somatic", "cells", "and", "spermatogonia", ",", "nonexpression", "of", "the", "locus", "even", "when", "it", "is", "present", "suggests", "that", "these", "chromosomes", "are", "transcriptionally", "active", ".", "We", "examined", "the", "transcriptional", "activity", "of", "ring", "X", "chromosomes", "lacking", "XIST", "expression", "(", "XISTE-", ")", ",", "from", "three", "females", "with", "severe", "phenotypes", ".", "The", "two", "tiny", "ring", "X", "chromosomes", "studied", "with", "an", "antibody", "specific", "for", "the", "acetylated", "isoforms", "of", "histone", "H4", "marking", "transcribed", "chromatin", "domains", "were", "labeled", "at", "a", "level", "consistent", "with", "their", "being", "active", ".", "We", "also", "examined", "tow", "of", "the", "XISTE-", "ring", "chromosomes", "to", "determine", "whether", "genes", "that", "are", "normally", "silent", "on", "an", "inactive", "X", "are", "expressed", "from", "these", "chromosomes", ".", "Analyses", "of", "hybrid", "cells", "show", "that", "TIMP", ",", "ZXDA", ",", "and", "ZXDB", "loci", "on", "the", "proximal", "short", "arm", ",", "and", "AR", "and", "PHKA1", "loci", "on", "the", "long", "arm", ",", "are", "well", "expressed", "from", "the", "tiny", "ring", "X", "chromosome", "lacking", "XIST", "DNA", ".", "Studies", "of", "the", "ring", "chromosome", "that", "has", "XIST", "DNA", "but", "does", "not", "transcribe", "it", "show", "that", "its", "AR", "allele", "is", "transcribed", "along", "with", "the", "one", "on", "the", "normal", "X", "allele", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]	[ "Entity", "Protein" ]
Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non - specific analytical methods is a Participant_Condition	77994_task0	Sentence: Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition	[ "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]	Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods .	[ "Comparison", "of", "some", "pharmacokinetic", "parameters", "of", "(", "+", ")", "-cyanidanol-3", "obtained", "with", "specific", "and", "non", "-", "specific", "analytical", "methods", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]
Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non - specific analytical methods is a Participant_Condition	77994_task1	Sentence: Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods . Instructions: please typing these entity words according to sentence: Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non - specific analytical methods Options: Participant_Condition	[ "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]	Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods .	[ "Comparison", "of", "some", "pharmacokinetic", "parameters", "of", "(", "+", ")", "-cyanidanol-3", "obtained", "with", "specific", "and", "non", "-", "specific", "analytical", "methods", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]
Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non - specific analytical methods	77994_task2	Sentence: Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods . Instructions: please extract entity words from the input sentence	[ "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]	Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods .	[ "Comparison", "of", "some", "pharmacokinetic", "parameters", "of", "(", "+", ")", "-cyanidanol-3", "obtained", "with", "specific", "and", "non", "-", "specific", "analytical", "methods", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]
v - abl is a Protein, v - abl is a Protein, v - abl is a Protein, v - abl is a Protein	7945272_task0	Sentence: Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway.	[ "Arrested", "development", ":", "understanding", "v", "-", "abl", ".", "\n", "The", "protein", "tyrosine", "kinase", "activity", "of", "the", "v", "-", "abl", "oncogene", "has", "been", "demonstrated", "to", "subvert", "the", "normal", "second", "messenger", "systems", "used", "by", "lymphoid", "cells", "for", "growth", "and", "differentiation", ".", "Transformation", "of", "bone", "marrow", "with", "the", "Abelson", "murine", "leukemia", "virus", "results", "in", "the", "appearance", "of", "B", "cell", "lineage", "cells", "arrested", "at", "the", "pre", "-", "B", "cell", "stage", ".", "Recent", "reports", "have", "characterized", "these", "cells", "expressing", "high", "v", "-", "abl", "kinase", "activity", "as", "deficient", "in", "detectable", "NF", "-", "kappaB", "DNA", "binding", "activity", "and", "low", "level", "RAG", "gene", "expression", ".", "These", "observations", "suggest", "that", "v", "-", "abl", "may", "be", "inhibiting", "the", "differentiation", "of", "B", "cells", "by", "blocking", "these", "two", "crucial", "elements", "in", "the", "maturation", "pathway", "." ]	[ "Protein" ]
v - abl is a Protein, v - abl is a Protein, v - abl is a Protein, v - abl is a Protein	7945272_task1	Sentence: Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway. Instructions: please typing these entity words according to sentence: v - abl, v - abl, v - abl, v - abl Options: Protein	[ "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway.	[ "Arrested", "development", ":", "understanding", "v", "-", "abl", ".", "\n", "The", "protein", "tyrosine", "kinase", "activity", "of", "the", "v", "-", "abl", "oncogene", "has", "been", "demonstrated", "to", "subvert", "the", "normal", "second", "messenger", "systems", "used", "by", "lymphoid", "cells", "for", "growth", "and", "differentiation", ".", "Transformation", "of", "bone", "marrow", "with", "the", "Abelson", "murine", "leukemia", "virus", "results", "in", "the", "appearance", "of", "B", "cell", "lineage", "cells", "arrested", "at", "the", "pre", "-", "B", "cell", "stage", ".", "Recent", "reports", "have", "characterized", "these", "cells", "expressing", "high", "v", "-", "abl", "kinase", "activity", "as", "deficient", "in", "detectable", "NF", "-", "kappaB", "DNA", "binding", "activity", "and", "low", "level", "RAG", "gene", "expression", ".", "These", "observations", "suggest", "that", "v", "-", "abl", "may", "be", "inhibiting", "the", "differentiation", "of", "B", "cells", "by", "blocking", "these", "two", "crucial", "elements", "in", "the", "maturation", "pathway", "." ]	[ "Protein" ]
v - abl, v - abl, v - abl, v - abl	7945272_task2	Sentence: Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway.	[ "Arrested", "development", ":", "understanding", "v", "-", "abl", ".", "\n", "The", "protein", "tyrosine", "kinase", "activity", "of", "the", "v", "-", "abl", "oncogene", "has", "been", "demonstrated", "to", "subvert", "the", "normal", "second", "messenger", "systems", "used", "by", "lymphoid", "cells", "for", "growth", "and", "differentiation", ".", "Transformation", "of", "bone", "marrow", "with", "the", "Abelson", "murine", "leukemia", "virus", "results", "in", "the", "appearance", "of", "B", "cell", "lineage", "cells", "arrested", "at", "the", "pre", "-", "B", "cell", "stage", ".", "Recent", "reports", "have", "characterized", "these", "cells", "expressing", "high", "v", "-", "abl", "kinase", "activity", "as", "deficient", "in", "detectable", "NF", "-", "kappaB", "DNA", "binding", "activity", "and", "low", "level", "RAG", "gene", "expression", ".", "These", "observations", "suggest", "that", "v", "-", "abl", "may", "be", "inhibiting", "the", "differentiation", "of", "B", "cells", "by", "blocking", "these", "two", "crucial", "elements", "in", "the", "maturation", "pathway", "." ]	[ "Protein" ]
increasing incidence is an umlsterm, toxic is an umlsterm, shock - like is an umlsterm, syndrome is an umlsterm, adults is an umlsterm, fever is an umlsterm, rash is an umlsterm, hypotension is an umlsterm, shock is an umlsterm, mortality rate is an umlsterm, paper is an umlsterm, history is an umlsterm, patients is an umlsterm, pathophysiology is an umlsterm, diagnosis is an umlsterm, therapy is an umlsterm, surgical is an umlsterm, debridement is an umlsterm, bacterial is an umlsterm, exotoxins is an umlsterm, antibiotic is an umlsterm, therapy is an umlsterm, mortality is an umlsterm	DerChirurg.70680040.eng.abstr_task0	Sentence: In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity .	[ "In", "recent", "years", "there", "has", "been", "an", "increasing", "incidence", "of", "streptococcal", "toxic", "shock", "-", "like", "syndrome", "(", "TSLS", ")", "in", "otherwise", "healthy", "adults", ".", "It", "is", "characterized", "by", "fever", ",", "rash", ",", "hypotension", "and", "early", "shock", "with", "consecutive", "organ", "failure", "and", "a", "mortality", "rate", "of", "about", "30", "%", ".", "This", "paper", "describes", "the", "history", "of", "two", "patients", "with", "severe", "streptococcal", "TSLS", ".", "Various", "aspects", "of", "the", "pathophysiology", ",", "diagnosis", "and", "therapy", "are", "discussed", ".", "Only", "early", ",", "aggressive", "and", "repeated", "surgical", "debridement", "can", "reduce", "the", "bacterial", "load", "and", "decrease", "circulating", "exotoxins", "and", "thereby", ",", "in", "combination", "with", "antibiotic", "therapy", ",", "decrease", "the", "high", "mortality", "of", "this", "entity", "." ]	[ "umlsterm" ]
increasing incidence is an umlsterm, toxic is an umlsterm, shock - like is an umlsterm, syndrome is an umlsterm, adults is an umlsterm, fever is an umlsterm, rash is an umlsterm, hypotension is an umlsterm, shock is an umlsterm, mortality rate is an umlsterm, paper is an umlsterm, history is an umlsterm, patients is an umlsterm, pathophysiology is an umlsterm, diagnosis is an umlsterm, therapy is an umlsterm, surgical is an umlsterm, debridement is an umlsterm, bacterial is an umlsterm, exotoxins is an umlsterm, antibiotic is an umlsterm, therapy is an umlsterm, mortality is an umlsterm	DerChirurg.70680040.eng.abstr_task1	Sentence: In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity . Instructions: please typing these entity words according to sentence: increasing incidence, toxic, shock - like, syndrome, adults, fever, rash, hypotension, shock, mortality rate, paper, history, patients, pathophysiology, diagnosis, therapy, surgical, debridement, bacterial, exotoxins, antibiotic, therapy, mortality Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity .	[ "In", "recent", "years", "there", "has", "been", "an", "increasing", "incidence", "of", "streptococcal", "toxic", "shock", "-", "like", "syndrome", "(", "TSLS", ")", "in", "otherwise", "healthy", "adults", ".", "It", "is", "characterized", "by", "fever", ",", "rash", ",", "hypotension", "and", "early", "shock", "with", "consecutive", "organ", "failure", "and", "a", "mortality", "rate", "of", "about", "30", "%", ".", "This", "paper", "describes", "the", "history", "of", "two", "patients", "with", "severe", "streptococcal", "TSLS", ".", "Various", "aspects", "of", "the", "pathophysiology", ",", "diagnosis", "and", "therapy", "are", "discussed", ".", "Only", "early", ",", "aggressive", "and", "repeated", "surgical", "debridement", "can", "reduce", "the", "bacterial", "load", "and", "decrease", "circulating", "exotoxins", "and", "thereby", ",", "in", "combination", "with", "antibiotic", "therapy", ",", "decrease", "the", "high", "mortality", "of", "this", "entity", "." ]	[ "umlsterm" ]
increasing incidence, toxic, shock - like, syndrome, adults, fever, rash, hypotension, shock, mortality rate, paper, history, patients, pathophysiology, diagnosis, therapy, surgical, debridement, bacterial, exotoxins, antibiotic, therapy, mortality	DerChirurg.70680040.eng.abstr_task2	Sentence: In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity .	[ "In", "recent", "years", "there", "has", "been", "an", "increasing", "incidence", "of", "streptococcal", "toxic", "shock", "-", "like", "syndrome", "(", "TSLS", ")", "in", "otherwise", "healthy", "adults", ".", "It", "is", "characterized", "by", "fever", ",", "rash", ",", "hypotension", "and", "early", "shock", "with", "consecutive", "organ", "failure", "and", "a", "mortality", "rate", "of", "about", "30", "%", ".", "This", "paper", "describes", "the", "history", "of", "two", "patients", "with", "severe", "streptococcal", "TSLS", ".", "Various", "aspects", "of", "the", "pathophysiology", ",", "diagnosis", "and", "therapy", "are", "discussed", ".", "Only", "early", ",", "aggressive", "and", "repeated", "surgical", "debridement", "can", "reduce", "the", "bacterial", "load", "and", "decrease", "circulating", "exotoxins", "and", "thereby", ",", "in", "combination", "with", "antibiotic", "therapy", ",", "decrease", "the", "high", "mortality", "of", "this", "entity", "." ]	[ "umlsterm" ]
promoter is a Entity, CD19 is a Protein, BSAP is a Protein, CD19 is a Protein, CD19 is a Protein, BSAP is a Protein, CD19 is a Protein, BSAP is a Protein, BSAP is a Protein, BSAP is a Protein, CD19 is a Protein, beta - globin reporter is a Protein, BSAP is a Protein, CD19 is a Protein, promoter is a Entity, BSAP is a Protein, CD19 is a Protein	1375324_task0	Sentence: The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene.	[ "The", "promoter", "of", "the", "CD19", "gene", "is", "a", "target", "for", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", ".", "\n", "The", "CD19", "protein", "is", "expressed", "on", "the", "surface", "of", "all", "B", "-", "lymphoid", "cells", "with", "the", "exception", "of", "terminally", "differentiated", "plasma", "cells", "and", "has", "been", "implicated", "as", "a", "signal", "-", "transducing", "receptor", "in", "the", "control", "of", "proliferation", "and", "differentiation", ".", "Here", "we", "demonstrate", "complete", "correlation", "between", "the", "expression", "pattern", "of", "the", "CD19", "gene", "and", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", "in", "a", "large", "panel", "of", "B", "-", "lymphoid", "cell", "lines", ".", "The", "human", "CD19", "gene", "has", "been", "cloned", ",", "and", "several", "BSAP", "-", "binding", "sites", "have", "been", "mapped", "by", "in", "vitro", "protein", "-", "DNA", "binding", "studies", ".", "In", "particular", ",", "a", "high", "-", "affinity", "BSAP", "-", "binding", "site", "instead", "of", "a", "TATA", "sequence", "is", "located", "in", "the", "-30", "promoter", "region", "upstream", "of", "a", "cluster", "of", "heterogeneous", "transcription", "start", "sites", ".", "Moreover", ",", "this", "site", "is", "occupied", "by", "BSAP", "in", "vivo", "in", "a", "CD19-expressing", "B", "-", "cell", "line", "but", "not", "in", "plasma", "or", "HeLa", "cells", ".", "This", "high", "-", "affinity", "site", "has", "been", "conserved", "in", "the", "promoters", "of", "both", "human", "and", "mouse", "CD19", "genes", "and", "was", "furthermore", "shown", "to", "confer", "B", "-", "cell", "specificity", "to", "a", "beta", "-", "globin", "reporter", "gene", "in", "transient", "transfection", "experiments", ".", "In", "addition", ",", "BSAP", "was", "found", "to", "be", "the", "only", "abundant", "DNA", "-", "binding", "activity", "of", "B", "-", "cell", "nuclear", "extracts", "that", "interacts", "with", "the", "CD19", "promoter", ".", "Together", ",", "this", "evidence", "strongly", "implicates", "BSAP", "in", "the", "regulation", "of", "the", "CD19", "gene", "." ]	[ "Protein", "Entity" ]
promoter is a Entity, CD19 is a Protein, BSAP is a Protein, CD19 is a Protein, CD19 is a Protein, BSAP is a Protein, CD19 is a Protein, BSAP is a Protein, BSAP is a Protein, BSAP is a Protein, CD19 is a Protein, beta - globin reporter is a Protein, BSAP is a Protein, CD19 is a Protein, promoter is a Entity, BSAP is a Protein, CD19 is a Protein	1375324_task1	Sentence: The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene. Instructions: please typing these entity words according to sentence: promoter, CD19, BSAP, CD19, CD19, BSAP, CD19, BSAP, BSAP, BSAP, CD19, beta - globin reporter, BSAP, CD19, promoter, BSAP, CD19 Options: Entity, Protein	[ "O", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene.	[ "The", "promoter", "of", "the", "CD19", "gene", "is", "a", "target", "for", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", ".", "\n", "The", "CD19", "protein", "is", "expressed", "on", "the", "surface", "of", "all", "B", "-", "lymphoid", "cells", "with", "the", "exception", "of", "terminally", "differentiated", "plasma", "cells", "and", "has", "been", "implicated", "as", "a", "signal", "-", "transducing", "receptor", "in", "the", "control", "of", "proliferation", "and", "differentiation", ".", "Here", "we", "demonstrate", "complete", "correlation", "between", "the", "expression", "pattern", "of", "the", "CD19", "gene", "and", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", "in", "a", "large", "panel", "of", "B", "-", "lymphoid", "cell", "lines", ".", "The", "human", "CD19", "gene", "has", "been", "cloned", ",", "and", "several", "BSAP", "-", "binding", "sites", "have", "been", "mapped", "by", "in", "vitro", "protein", "-", "DNA", "binding", "studies", ".", "In", "particular", ",", "a", "high", "-", "affinity", "BSAP", "-", "binding", "site", "instead", "of", "a", "TATA", "sequence", "is", "located", "in", "the", "-30", "promoter", "region", "upstream", "of", "a", "cluster", "of", "heterogeneous", "transcription", "start", "sites", ".", "Moreover", ",", "this", "site", "is", "occupied", "by", "BSAP", "in", "vivo", "in", "a", "CD19-expressing", "B", "-", "cell", "line", "but", "not", "in", "plasma", "or", "HeLa", "cells", ".", "This", "high", "-", "affinity", "site", "has", "been", "conserved", "in", "the", "promoters", "of", "both", "human", "and", "mouse", "CD19", "genes", "and", "was", "furthermore", "shown", "to", "confer", "B", "-", "cell", "specificity", "to", "a", "beta", "-", "globin", "reporter", "gene", "in", "transient", "transfection", "experiments", ".", "In", "addition", ",", "BSAP", "was", "found", "to", "be", "the", "only", "abundant", "DNA", "-", "binding", "activity", "of", "B", "-", "cell", "nuclear", "extracts", "that", "interacts", "with", "the", "CD19", "promoter", ".", "Together", ",", "this", "evidence", "strongly", "implicates", "BSAP", "in", "the", "regulation", "of", "the", "CD19", "gene", "." ]	[ "Protein", "Entity" ]
promoter, CD19, BSAP, CD19, CD19, BSAP, CD19, BSAP, BSAP, BSAP, CD19, beta - globin reporter, BSAP, CD19, promoter, BSAP, CD19	1375324_task2	Sentence: The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene. Instructions: please extract entity words from the input sentence	[ "O", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene.	[ "The", "promoter", "of", "the", "CD19", "gene", "is", "a", "target", "for", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", ".", "\n", "The", "CD19", "protein", "is", "expressed", "on", "the", "surface", "of", "all", "B", "-", "lymphoid", "cells", "with", "the", "exception", "of", "terminally", "differentiated", "plasma", "cells", "and", "has", "been", "implicated", "as", "a", "signal", "-", "transducing", "receptor", "in", "the", "control", "of", "proliferation", "and", "differentiation", ".", "Here", "we", "demonstrate", "complete", "correlation", "between", "the", "expression", "pattern", "of", "the", "CD19", "gene", "and", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", "in", "a", "large", "panel", "of", "B", "-", "lymphoid", "cell", "lines", ".", "The", "human", "CD19", "gene", "has", "been", "cloned", ",", "and", "several", "BSAP", "-", "binding", "sites", "have", "been", "mapped", "by", "in", "vitro", "protein", "-", "DNA", "binding", "studies", ".", "In", "particular", ",", "a", "high", "-", "affinity", "BSAP", "-", "binding", "site", "instead", "of", "a", "TATA", "sequence", "is", "located", "in", "the", "-30", "promoter", "region", "upstream", "of", "a", "cluster", "of", "heterogeneous", "transcription", "start", "sites", ".", "Moreover", ",", "this", "site", "is", "occupied", "by", "BSAP", "in", "vivo", "in", "a", "CD19-expressing", "B", "-", "cell", "line", "but", "not", "in", "plasma", "or", "HeLa", "cells", ".", "This", "high", "-", "affinity", "site", "has", "been", "conserved", "in", "the", "promoters", "of", "both", "human", "and", "mouse", "CD19", "genes", "and", "was", "furthermore", "shown", "to", "confer", "B", "-", "cell", "specificity", "to", "a", "beta", "-", "globin", "reporter", "gene", "in", "transient", "transfection", "experiments", ".", "In", "addition", ",", "BSAP", "was", "found", "to", "be", "the", "only", "abundant", "DNA", "-", "binding", "activity", "of", "B", "-", "cell", "nuclear", "extracts", "that", "interacts", "with", "the", "CD19", "promoter", ".", "Together", ",", "this", "evidence", "strongly", "implicates", "BSAP", "in", "the", "regulation", "of", "the", "CD19", "gene", "." ]	[ "Protein", "Entity" ]
neoplasia is a MORFOLOGIA_NEOPLASIA, leucemia is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma ( ADK ) metastásico is a MORFOLOGIA_NEOPLASIA, ADK is a MORFOLOGIA_NEOPLASIA, ADK is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de origen desconocido con metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, afectación ósea is a MORFOLOGIA_NEOPLASIA, infiltración tumoral de medula ósea is a MORFOLOGIA_NEOPLASIA	601_task0	Sentence: Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017.	[ "Anamnesis", "\n", "Presentamos", "un", "varón", "de", "37", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", "y", "fumador", "ocasional", "desde", "la", "adolescencia", ".", "Padre", "de", "dos", "hijos", "de", "3", "y", "7", "años", ".", "\n", "Como", "antecedentes", "patológicos", "únicamente", "presenta", "asma", "alérgica", "y", ",", "como", "antecedentes", "familiares", ",", "se", "ha", "registrado", "abuelo", "paterno", "con", "diagnóstico", "de", "neoplasia", "de", "colon", "y", "abuela", "paterna", "con", "leucemia", ".", "\n", "Sin", "tratamiento", "habitual", ".", "\n\n", "Historia", "oncológica", "\n", "En", "junio", "de", "2017", "ingresa", "en", "el", "hospital", "por", "dolor", "lumbar", "e", "inguinal", "bilateral", "de", "2", "-", "3", "meses", "de", "evolución", ",", "acompañado", "de", "tumoración", "en", "antebrazo", "derecho", ".", "Se", "trata", "de", "un", "dolor", "continuo", ",", "que", "mejora", "con", "el", "reposo", ",", "aumentando", "con", "la", "sedestación", "y", "los", "cambios", "posturales", ",", "provocándole", "parestesias", "en", "ambas", "extremidades", "inferiores", ".", "\n", "Asimismo", ",", "presenta", "pérdida", "de", "aproximadamente", "5", "kg", "de", "peso", "en", "los", "últimos", "3", "meses", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "moderados", "esfuerzos", ".", "Sin", "dolor", "torácico", ",", "tos", ",", "expectoración", ",", "fiebre", "ni", "otra", "clínica", "acompañante", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", "destaca", "una", "hipofonesis", "en", "hemitórax", "inferior", "derecho", "con", "murmullo", "vesicular", "conservado", "en", "pulmón", "izquierdo", ".", "Exploración", "neurológica", "sin", "alteraciones", ".", "A", "nivel", "locomotor", ",", "se", "apreciaba", "una", "tumoración", "de", "consistencia", "dura", "y", "adherida", "a", "planos", "profundos", ",", "no", "dolorosa", "durante", "la", "palpación", "en", "antebrazo", "derecho", "y", "muslo", "izquierdo", ".", "\n\n", "Pruebas", "complementarias", "\n", "Durante", "el", "ingreso", "se", "realizan", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Radiografía", "de", "tórax", ":", "derrame", "pleural", "masivo", "derecho", "sin", "desplazamiento", "mediastínico", ".", "\n", "»", "Marcadores", "tumorales", "CEA", "34,6", ",", "Ca", "19,9", ">", "700", ",", "Ca", "12,5", "260,1", ".", "\n", "»", "TC", "de", "cuello", "-", "tórax", "-", "abdomen", ":", "metástasis", "pleurales", ",", "óseas", ",", "musculares", "múltiples", ",", "cerebrales", "y", "posibles", "pulmonares", "con", "sospecha", "de", "neoplasia", "primario", "pulmonar", ".", "\n", "Por", "presencia", "de", "derrame", "pleural", "derecho", ",", "se", "solicita", "pleurodesis", "guiada", "por", "videotoracoscopia", "con", "solicitud", "de", "biopsia", "pleural", ".", "\n", "Ante", "la", "marcada", "sospecha", "de", "primario", "de", "origen", "pulmonar", ",", "se", "solicita", "el", "perfil", "mutacional", "correspondiente", "(", "KRAS", ",", "EGFR", ",", "ALK", "):", "\n", "»", "Citología", "liquido", "pleural", ":", "compatible", "con", "infiltración", "por", "adenocarcinoma", ".", "TTF-1", "positivo", ",", "lo", "cual", "favorece", "un", "origen", "pulmonar", ".", "\n", "»", "Biopsia", "muscular", ":", "adenocarcinoma", "(", "ADK", ")", "metastásico", ".", "KRAS", "mutado", ".", "EGFR", "wild", "type", ".", "ALK", "no", "traslocado", ".", "\n", "»", "Biopsia", "pleural", ":", "ADK", "con", "fenotipo", "de", "origen", "gastrointestinal", "(", "estómago", ",", "pancreático", "y", "biliar", ")", ".", "\n", "Positividad", "para", "CK7", ",", "CK20", ",", "y", "CDX-2", "(", "aisladas", "células", "TTF-1", ")", ".", "Negativas", "para", "napsina", ",", "PAX", "8", "y", "PSA", ".", "HER-2", "negativo", ".", "\n", "Por", "discordancia", "entre", "una", "primera", "sospecha", "de", "primario", "pulmonar", "y", "el", "resultado", "posterior", "de", "biopsia", "pleural", "compatible", "con", "ADK", "de", "origen", "gastrointestinal", ",", "se", "amplía", "el", "estudio", "con", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Gastroscopia", ":", "examen", "endoscópico", "normal", ".", "\n", "»", "Citología", "orina", ":", "negativo", "para", "malignidad", ".", "Celularidad", "urotelial", "con", "cambios", "reactivos", ".", "\n", "»", "Ecografía", "renal", ":", "ambos", "riñones", ",", "vejiga", "y", "próstata", "sin", "alteraciones", "ecográficamente", "valorables", ".", "\n\n", "Diagnóstico", "\n", "Ante", "el", "diagnóstico", "de", "adenocarcinoma", "de", "origen", "desconocido", "con", "metástasis", "múltiples", ":", "pleurales", ",", "óseas", ",", "musculares", ",", "cerebrales", "y", "posible", "pulmonares", ",", "se", "solicita", "un", "estudio", "de", "secuenciación", "genética", "masiva", ".", "\n\n", "Tratamiento", "\n", "A", "la", "espera", "de", "dichos", "resultados", ",", "se", "realiza", "en", "julio", "de", "2017", "RT", "holocraneal", "(", "entre", "el", "26/6/2017", "y", "el", "10/7/2017", "se", "administraron", "30Gy", "a", "fraccionamiento", "de", "3Gy", "/", "fracción", ")", "y", "se", "inicia", "quimioterapia", "de", "primera", "línea", "esquema", "carboplatino", "AUC", "6", "/", "paclitaxel", "175", "mg", "/", "m2", "cada", "21", "días", "durante", "2", "ciclos", ",", "presentando", "mala", "tolerancia", "con", "náuseas", ",", "vómitos", "grado", "2", "y", "diarrea", "grado", "2", ".", "\n\n", "Evolución", "\n", "Ingreso", "hospitalario", "en", "agosto", "2017", "por", "anemia", "grado", "4", "y", "mal", "control", "del", "dolor", ".", "Se", "realiza", "TC", "toracoabdominopélvica", "que", "evidencia", "progresión", "de", "la", "enfermedad", ".", "Para", "el", "control", "del", "dolor", "se", "inicia", "morfina", "sulfato", "retard", "(", "MST", ")", "60", "mg", "cada", "12", "horas", "y", "rescates", "de", "fentanilo", "sublingual", "200", "mcg", ".", "\n", "Ingresa", "nuevamente", "en", "septiembre", "2017", "por", "síndrome", "febril", "sin", "semiología", "infecciosa", "y", "cultivos", "negativos", ";", "por", "lo", "que", "se", "cataloga", "de", "origen", "tumoral", ",", "y", "se", "inicia", "indometacina", "con", "resolución", "del", "cuadro", ".", "\n", "Asimismo", ",", "presenta", "dolor", "y", "aumento", "del", "perímetro", "de", "la", "extremidad", "inferior", "izquierda", "(", "en", "TC", "se", "observaba", "afectación", "ósea", "en", "cadera", "izquierda", "y", "muscular", "en", "ambos", "miembros", "inferiores", "como", "probable", "causa", ")", ";", "se", "realiza", "Eco", "-", "Doppler", "que", "determina", "trombosis", "venosa", "profunda", "en", "vena", "femoral", "izquierda", ",", "iniciándose", "tinzaparina", "12.000", "UI", "cada", "24", "horas", ".", "Por", "dolor", "mal", "controlado", ",", "precisa", "perfusión", "de", "morfina", "iv", "y", "posterior", "rotación", "de", "opioides", "progresiva", "a", "metadona", ",", "con", "mejor", "control", ",", "pero", "necesitando", "rescates", "de", "morfina", "subcutánea", ".", "\n", "También", "presenta", "astenia", "marcada", "y", "anemia", "grado", "3", "post", "-", "QT", "(", "hemoglobina", "6,9", "g", "/", "dl", ")", "que", "obligan", "a", "transfusión", "de", "concentrados", "de", "hematíes", "en", "varias", "ocasiones", "(", "sospecha", "de", "infiltración", "tumoral", "de", "medula", "ósea", ")", ".", "\n", "Ante", "la", "falta", "de", "respuesta", "clínica", "y", "radiológica", "a", "la", "quimioterapia", "tras", "la", "administración", "de", "2", "ciclos", "de", "tratamiento", ",", "se", "decide", "iniciar", ",", "en", "octubre", "de", "2017", ",", "QT", "paliativa", "con", "irinotecan", "180", "mg", "/", "m2", "cada", "2", "semanas", "según", "resultado", "de", "test", "de", "secuenciación", "genética", ".", "\n", "Se", "da", "de", "alta", "hospitalaria", "y", "acude", "a", "consulta", "para", "administrar", "2º", "ciclo", "de", "irinotecan", "quincenal", ".", "A", "pesar", "de", "presentar", "mejoría", "clínica", "con", "buen", "control", "del", "dolor", ",", "el", "paciente", "fallece", "en", "noviembre", "de", "2017", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
neoplasia is a MORFOLOGIA_NEOPLASIA, leucemia is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma ( ADK ) metastásico is a MORFOLOGIA_NEOPLASIA, ADK is a MORFOLOGIA_NEOPLASIA, ADK is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de origen desconocido con metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, afectación ósea is a MORFOLOGIA_NEOPLASIA, infiltración tumoral de medula ósea is a MORFOLOGIA_NEOPLASIA	601_task1	Sentence: Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017. Instructions: please typing these entity words according to sentence: neoplasia, leucemia, tumoración, tumoración, metástasis, neoplasia, adenocarcinoma, adenocarcinoma ( ADK ) metastásico, ADK, ADK, malignidad, adenocarcinoma de origen desconocido con metástasis, tumoral, afectación ósea, infiltración tumoral de medula ósea Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017.	[ "Anamnesis", "\n", "Presentamos", "un", "varón", "de", "37", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", "y", "fumador", "ocasional", "desde", "la", "adolescencia", ".", "Padre", "de", "dos", "hijos", "de", "3", "y", "7", "años", ".", "\n", "Como", "antecedentes", "patológicos", "únicamente", "presenta", "asma", "alérgica", "y", ",", "como", "antecedentes", "familiares", ",", "se", "ha", "registrado", "abuelo", "paterno", "con", "diagnóstico", "de", "neoplasia", "de", "colon", "y", "abuela", "paterna", "con", "leucemia", ".", "\n", "Sin", "tratamiento", "habitual", ".", "\n\n", "Historia", "oncológica", "\n", "En", "junio", "de", "2017", "ingresa", "en", "el", "hospital", "por", "dolor", "lumbar", "e", "inguinal", "bilateral", "de", "2", "-", "3", "meses", "de", "evolución", ",", "acompañado", "de", "tumoración", "en", "antebrazo", "derecho", ".", "Se", "trata", "de", "un", "dolor", "continuo", ",", "que", "mejora", "con", "el", "reposo", ",", "aumentando", "con", "la", "sedestación", "y", "los", "cambios", "posturales", ",", "provocándole", "parestesias", "en", "ambas", "extremidades", "inferiores", ".", "\n", "Asimismo", ",", "presenta", "pérdida", "de", "aproximadamente", "5", "kg", "de", "peso", "en", "los", "últimos", "3", "meses", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "moderados", "esfuerzos", ".", "Sin", "dolor", "torácico", ",", "tos", ",", "expectoración", ",", "fiebre", "ni", "otra", "clínica", "acompañante", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", "destaca", "una", "hipofonesis", "en", "hemitórax", "inferior", "derecho", "con", "murmullo", "vesicular", "conservado", "en", "pulmón", "izquierdo", ".", "Exploración", "neurológica", "sin", "alteraciones", ".", "A", "nivel", "locomotor", ",", "se", "apreciaba", "una", "tumoración", "de", "consistencia", "dura", "y", "adherida", "a", "planos", "profundos", ",", "no", "dolorosa", "durante", "la", "palpación", "en", "antebrazo", "derecho", "y", "muslo", "izquierdo", ".", "\n\n", "Pruebas", "complementarias", "\n", "Durante", "el", "ingreso", "se", "realizan", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Radiografía", "de", "tórax", ":", "derrame", "pleural", "masivo", "derecho", "sin", "desplazamiento", "mediastínico", ".", "\n", "»", "Marcadores", "tumorales", "CEA", "34,6", ",", "Ca", "19,9", ">", "700", ",", "Ca", "12,5", "260,1", ".", "\n", "»", "TC", "de", "cuello", "-", "tórax", "-", "abdomen", ":", "metástasis", "pleurales", ",", "óseas", ",", "musculares", "múltiples", ",", "cerebrales", "y", "posibles", "pulmonares", "con", "sospecha", "de", "neoplasia", "primario", "pulmonar", ".", "\n", "Por", "presencia", "de", "derrame", "pleural", "derecho", ",", "se", "solicita", "pleurodesis", "guiada", "por", "videotoracoscopia", "con", "solicitud", "de", "biopsia", "pleural", ".", "\n", "Ante", "la", "marcada", "sospecha", "de", "primario", "de", "origen", "pulmonar", ",", "se", "solicita", "el", "perfil", "mutacional", "correspondiente", "(", "KRAS", ",", "EGFR", ",", "ALK", "):", "\n", "»", "Citología", "liquido", "pleural", ":", "compatible", "con", "infiltración", "por", "adenocarcinoma", ".", "TTF-1", "positivo", ",", "lo", "cual", "favorece", "un", "origen", "pulmonar", ".", "\n", "»", "Biopsia", "muscular", ":", "adenocarcinoma", "(", "ADK", ")", "metastásico", ".", "KRAS", "mutado", ".", "EGFR", "wild", "type", ".", "ALK", "no", "traslocado", ".", "\n", "»", "Biopsia", "pleural", ":", "ADK", "con", "fenotipo", "de", "origen", "gastrointestinal", "(", "estómago", ",", "pancreático", "y", "biliar", ")", ".", "\n", "Positividad", "para", "CK7", ",", "CK20", ",", "y", "CDX-2", "(", "aisladas", "células", "TTF-1", ")", ".", "Negativas", "para", "napsina", ",", "PAX", "8", "y", "PSA", ".", "HER-2", "negativo", ".", "\n", "Por", "discordancia", "entre", "una", "primera", "sospecha", "de", "primario", "pulmonar", "y", "el", "resultado", "posterior", "de", "biopsia", "pleural", "compatible", "con", "ADK", "de", "origen", "gastrointestinal", ",", "se", "amplía", "el", "estudio", "con", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Gastroscopia", ":", "examen", "endoscópico", "normal", ".", "\n", "»", "Citología", "orina", ":", "negativo", "para", "malignidad", ".", "Celularidad", "urotelial", "con", "cambios", "reactivos", ".", "\n", "»", "Ecografía", "renal", ":", "ambos", "riñones", ",", "vejiga", "y", "próstata", "sin", "alteraciones", "ecográficamente", "valorables", ".", "\n\n", "Diagnóstico", "\n", "Ante", "el", "diagnóstico", "de", "adenocarcinoma", "de", "origen", "desconocido", "con", "metástasis", "múltiples", ":", "pleurales", ",", "óseas", ",", "musculares", ",", "cerebrales", "y", "posible", "pulmonares", ",", "se", "solicita", "un", "estudio", "de", "secuenciación", "genética", "masiva", ".", "\n\n", "Tratamiento", "\n", "A", "la", "espera", "de", "dichos", "resultados", ",", "se", "realiza", "en", "julio", "de", "2017", "RT", "holocraneal", "(", "entre", "el", "26/6/2017", "y", "el", "10/7/2017", "se", "administraron", "30Gy", "a", "fraccionamiento", "de", "3Gy", "/", "fracción", ")", "y", "se", "inicia", "quimioterapia", "de", "primera", "línea", "esquema", "carboplatino", "AUC", "6", "/", "paclitaxel", "175", "mg", "/", "m2", "cada", "21", "días", "durante", "2", "ciclos", ",", "presentando", "mala", "tolerancia", "con", "náuseas", ",", "vómitos", "grado", "2", "y", "diarrea", "grado", "2", ".", "\n\n", "Evolución", "\n", "Ingreso", "hospitalario", "en", "agosto", "2017", "por", "anemia", "grado", "4", "y", "mal", "control", "del", "dolor", ".", "Se", "realiza", "TC", "toracoabdominopélvica", "que", "evidencia", "progresión", "de", "la", "enfermedad", ".", "Para", "el", "control", "del", "dolor", "se", "inicia", "morfina", "sulfato", "retard", "(", "MST", ")", "60", "mg", "cada", "12", "horas", "y", "rescates", "de", "fentanilo", "sublingual", "200", "mcg", ".", "\n", "Ingresa", "nuevamente", "en", "septiembre", "2017", "por", "síndrome", "febril", "sin", "semiología", "infecciosa", "y", "cultivos", "negativos", ";", "por", "lo", "que", "se", "cataloga", "de", "origen", "tumoral", ",", "y", "se", "inicia", "indometacina", "con", "resolución", "del", "cuadro", ".", "\n", "Asimismo", ",", "presenta", "dolor", "y", "aumento", "del", "perímetro", "de", "la", "extremidad", "inferior", "izquierda", "(", "en", "TC", "se", "observaba", "afectación", "ósea", "en", "cadera", "izquierda", "y", "muscular", "en", "ambos", "miembros", "inferiores", "como", "probable", "causa", ")", ";", "se", "realiza", "Eco", "-", "Doppler", "que", "determina", "trombosis", "venosa", "profunda", "en", "vena", "femoral", "izquierda", ",", "iniciándose", "tinzaparina", "12.000", "UI", "cada", "24", "horas", ".", "Por", "dolor", "mal", "controlado", ",", "precisa", "perfusión", "de", "morfina", "iv", "y", "posterior", "rotación", "de", "opioides", "progresiva", "a", "metadona", ",", "con", "mejor", "control", ",", "pero", "necesitando", "rescates", "de", "morfina", "subcutánea", ".", "\n", "También", "presenta", "astenia", "marcada", "y", "anemia", "grado", "3", "post", "-", "QT", "(", "hemoglobina", "6,9", "g", "/", "dl", ")", "que", "obligan", "a", "transfusión", "de", "concentrados", "de", "hematíes", "en", "varias", "ocasiones", "(", "sospecha", "de", "infiltración", "tumoral", "de", "medula", "ósea", ")", ".", "\n", "Ante", "la", "falta", "de", "respuesta", "clínica", "y", "radiológica", "a", "la", "quimioterapia", "tras", "la", "administración", "de", "2", "ciclos", "de", "tratamiento", ",", "se", "decide", "iniciar", ",", "en", "octubre", "de", "2017", ",", "QT", "paliativa", "con", "irinotecan", "180", "mg", "/", "m2", "cada", "2", "semanas", "según", "resultado", "de", "test", "de", "secuenciación", "genética", ".", "\n", "Se", "da", "de", "alta", "hospitalaria", "y", "acude", "a", "consulta", "para", "administrar", "2º", "ciclo", "de", "irinotecan", "quincenal", ".", "A", "pesar", "de", "presentar", "mejoría", "clínica", "con", "buen", "control", "del", "dolor", ",", "el", "paciente", "fallece", "en", "noviembre", "de", "2017", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
neoplasia, leucemia, tumoración, tumoración, metástasis, neoplasia, adenocarcinoma, adenocarcinoma ( ADK ) metastásico, ADK, ADK, malignidad, adenocarcinoma de origen desconocido con metástasis, tumoral, afectación ósea, infiltración tumoral de medula ósea	601_task2	Sentence: Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017.	[ "Anamnesis", "\n", "Presentamos", "un", "varón", "de", "37", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", "y", "fumador", "ocasional", "desde", "la", "adolescencia", ".", "Padre", "de", "dos", "hijos", "de", "3", "y", "7", "años", ".", "\n", "Como", "antecedentes", "patológicos", "únicamente", "presenta", "asma", "alérgica", "y", ",", "como", "antecedentes", "familiares", ",", "se", "ha", "registrado", "abuelo", "paterno", "con", "diagnóstico", "de", "neoplasia", "de", "colon", "y", "abuela", "paterna", "con", "leucemia", ".", "\n", "Sin", "tratamiento", "habitual", ".", "\n\n", "Historia", "oncológica", "\n", "En", "junio", "de", "2017", "ingresa", "en", "el", "hospital", "por", "dolor", "lumbar", "e", "inguinal", "bilateral", "de", "2", "-", "3", "meses", "de", "evolución", ",", "acompañado", "de", "tumoración", "en", "antebrazo", "derecho", ".", "Se", "trata", "de", "un", "dolor", "continuo", ",", "que", "mejora", "con", "el", "reposo", ",", "aumentando", "con", "la", "sedestación", "y", "los", "cambios", "posturales", ",", "provocándole", "parestesias", "en", "ambas", "extremidades", "inferiores", ".", "\n", "Asimismo", ",", "presenta", "pérdida", "de", "aproximadamente", "5", "kg", "de", "peso", "en", "los", "últimos", "3", "meses", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "moderados", "esfuerzos", ".", "Sin", "dolor", "torácico", ",", "tos", ",", "expectoración", ",", "fiebre", "ni", "otra", "clínica", "acompañante", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", "destaca", "una", "hipofonesis", "en", "hemitórax", "inferior", "derecho", "con", "murmullo", "vesicular", "conservado", "en", "pulmón", "izquierdo", ".", "Exploración", "neurológica", "sin", "alteraciones", ".", "A", "nivel", "locomotor", ",", "se", "apreciaba", "una", "tumoración", "de", "consistencia", "dura", "y", "adherida", "a", "planos", "profundos", ",", "no", "dolorosa", "durante", "la", "palpación", "en", "antebrazo", "derecho", "y", "muslo", "izquierdo", ".", "\n\n", "Pruebas", "complementarias", "\n", "Durante", "el", "ingreso", "se", "realizan", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Radiografía", "de", "tórax", ":", "derrame", "pleural", "masivo", "derecho", "sin", "desplazamiento", "mediastínico", ".", "\n", "»", "Marcadores", "tumorales", "CEA", "34,6", ",", "Ca", "19,9", ">", "700", ",", "Ca", "12,5", "260,1", ".", "\n", "»", "TC", "de", "cuello", "-", "tórax", "-", "abdomen", ":", "metástasis", "pleurales", ",", "óseas", ",", "musculares", "múltiples", ",", "cerebrales", "y", "posibles", "pulmonares", "con", "sospecha", "de", "neoplasia", "primario", "pulmonar", ".", "\n", "Por", "presencia", "de", "derrame", "pleural", "derecho", ",", "se", "solicita", "pleurodesis", "guiada", "por", "videotoracoscopia", "con", "solicitud", "de", "biopsia", "pleural", ".", "\n", "Ante", "la", "marcada", "sospecha", "de", "primario", "de", "origen", "pulmonar", ",", "se", "solicita", "el", "perfil", "mutacional", "correspondiente", "(", "KRAS", ",", "EGFR", ",", "ALK", "):", "\n", "»", "Citología", "liquido", "pleural", ":", "compatible", "con", "infiltración", "por", "adenocarcinoma", ".", "TTF-1", "positivo", ",", "lo", "cual", "favorece", "un", "origen", "pulmonar", ".", "\n", "»", "Biopsia", "muscular", ":", "adenocarcinoma", "(", "ADK", ")", "metastásico", ".", "KRAS", "mutado", ".", "EGFR", "wild", "type", ".", "ALK", "no", "traslocado", ".", "\n", "»", "Biopsia", "pleural", ":", "ADK", "con", "fenotipo", "de", "origen", "gastrointestinal", "(", "estómago", ",", "pancreático", "y", "biliar", ")", ".", "\n", "Positividad", "para", "CK7", ",", "CK20", ",", "y", "CDX-2", "(", "aisladas", "células", "TTF-1", ")", ".", "Negativas", "para", "napsina", ",", "PAX", "8", "y", "PSA", ".", "HER-2", "negativo", ".", "\n", "Por", "discordancia", "entre", "una", "primera", "sospecha", "de", "primario", "pulmonar", "y", "el", "resultado", "posterior", "de", "biopsia", "pleural", "compatible", "con", "ADK", "de", "origen", "gastrointestinal", ",", "se", "amplía", "el", "estudio", "con", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Gastroscopia", ":", "examen", "endoscópico", "normal", ".", "\n", "»", "Citología", "orina", ":", "negativo", "para", "malignidad", ".", "Celularidad", "urotelial", "con", "cambios", "reactivos", ".", "\n", "»", "Ecografía", "renal", ":", "ambos", "riñones", ",", "vejiga", "y", "próstata", "sin", "alteraciones", "ecográficamente", "valorables", ".", "\n\n", "Diagnóstico", "\n", "Ante", "el", "diagnóstico", "de", "adenocarcinoma", "de", "origen", "desconocido", "con", "metástasis", "múltiples", ":", "pleurales", ",", "óseas", ",", "musculares", ",", "cerebrales", "y", "posible", "pulmonares", ",", "se", "solicita", "un", "estudio", "de", "secuenciación", "genética", "masiva", ".", "\n\n", "Tratamiento", "\n", "A", "la", "espera", "de", "dichos", "resultados", ",", "se", "realiza", "en", "julio", "de", "2017", "RT", "holocraneal", "(", "entre", "el", "26/6/2017", "y", "el", "10/7/2017", "se", "administraron", "30Gy", "a", "fraccionamiento", "de", "3Gy", "/", "fracción", ")", "y", "se", "inicia", "quimioterapia", "de", "primera", "línea", "esquema", "carboplatino", "AUC", "6", "/", "paclitaxel", "175", "mg", "/", "m2", "cada", "21", "días", "durante", "2", "ciclos", ",", "presentando", "mala", "tolerancia", "con", "náuseas", ",", "vómitos", "grado", "2", "y", "diarrea", "grado", "2", ".", "\n\n", "Evolución", "\n", "Ingreso", "hospitalario", "en", "agosto", "2017", "por", "anemia", "grado", "4", "y", "mal", "control", "del", "dolor", ".", "Se", "realiza", "TC", "toracoabdominopélvica", "que", "evidencia", "progresión", "de", "la", "enfermedad", ".", "Para", "el", "control", "del", "dolor", "se", "inicia", "morfina", "sulfato", "retard", "(", "MST", ")", "60", "mg", "cada", "12", "horas", "y", "rescates", "de", "fentanilo", "sublingual", "200", "mcg", ".", "\n", "Ingresa", "nuevamente", "en", "septiembre", "2017", "por", "síndrome", "febril", "sin", "semiología", "infecciosa", "y", "cultivos", "negativos", ";", "por", "lo", "que", "se", "cataloga", "de", "origen", "tumoral", ",", "y", "se", "inicia", "indometacina", "con", "resolución", "del", "cuadro", ".", "\n", "Asimismo", ",", "presenta", "dolor", "y", "aumento", "del", "perímetro", "de", "la", "extremidad", "inferior", "izquierda", "(", "en", "TC", "se", "observaba", "afectación", "ósea", "en", "cadera", "izquierda", "y", "muscular", "en", "ambos", "miembros", "inferiores", "como", "probable", "causa", ")", ";", "se", "realiza", "Eco", "-", "Doppler", "que", "determina", "trombosis", "venosa", "profunda", "en", "vena", "femoral", "izquierda", ",", "iniciándose", "tinzaparina", "12.000", "UI", "cada", "24", "horas", ".", "Por", "dolor", "mal", "controlado", ",", "precisa", "perfusión", "de", "morfina", "iv", "y", "posterior", "rotación", "de", "opioides", "progresiva", "a", "metadona", ",", "con", "mejor", "control", ",", "pero", "necesitando", "rescates", "de", "morfina", "subcutánea", ".", "\n", "También", "presenta", "astenia", "marcada", "y", "anemia", "grado", "3", "post", "-", "QT", "(", "hemoglobina", "6,9", "g", "/", "dl", ")", "que", "obligan", "a", "transfusión", "de", "concentrados", "de", "hematíes", "en", "varias", "ocasiones", "(", "sospecha", "de", "infiltración", "tumoral", "de", "medula", "ósea", ")", ".", "\n", "Ante", "la", "falta", "de", "respuesta", "clínica", "y", "radiológica", "a", "la", "quimioterapia", "tras", "la", "administración", "de", "2", "ciclos", "de", "tratamiento", ",", "se", "decide", "iniciar", ",", "en", "octubre", "de", "2017", ",", "QT", "paliativa", "con", "irinotecan", "180", "mg", "/", "m2", "cada", "2", "semanas", "según", "resultado", "de", "test", "de", "secuenciación", "genética", ".", "\n", "Se", "da", "de", "alta", "hospitalaria", "y", "acude", "a", "consulta", "para", "administrar", "2º", "ciclo", "de", "irinotecan", "quincenal", ".", "A", "pesar", "de", "presentar", "mejoría", "clínica", "con", "buen", "control", "del", "dolor", ",", "el", "paciente", "fallece", "en", "noviembre", "de", "2017", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Sec5 is a protein, Ral is a protein-family	1.0alpha7.train.1231_task0	Sentence: Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein	[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002).	[ "Furthermore", ",", " ", "Sec5", "binds", "a", " ", "Ral", "protein", ",", "which", "is", "not", "present", "in", " ", "yeast", "(", "Brymora", " ", "et", "al", ".", ",", "2001", ";", " ", "Moskalenko", " ", "et", "al", ".", ",", "2002", ";", " ", "Sugihara", " ", "et", "al", ".", ",", "2002", ")", "." ]	[ "protein", "protein-family" ]
Sec5 is a protein, Ral is a protein-family	1.0alpha7.train.1231_task1	Sentence: Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002). Instructions: please typing these entity words according to sentence: Sec5, Ral Options: protein-family, protein	[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002).	[ "Furthermore", ",", " ", "Sec5", "binds", "a", " ", "Ral", "protein", ",", "which", "is", "not", "present", "in", " ", "yeast", "(", "Brymora", " ", "et", "al", ".", ",", "2001", ";", " ", "Moskalenko", " ", "et", "al", ".", ",", "2002", ";", " ", "Sugihara", " ", "et", "al", ".", ",", "2002", ")", "." ]	[ "protein", "protein-family" ]
Sec5, Ral	1.0alpha7.train.1231_task2	Sentence: Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002).	[ "Furthermore", ",", " ", "Sec5", "binds", "a", " ", "Ral", "protein", ",", "which", "is", "not", "present", "in", " ", "yeast", "(", "Brymora", " ", "et", "al", ".", ",", "2001", ";", " ", "Moskalenko", " ", "et", "al", ".", ",", "2002", ";", " ", "Sugihara", " ", "et", "al", ".", ",", "2002", ")", "." ]	[ "protein", "protein-family" ]
= 18 years is a Person, High risk is a Condition, General Surgery AKI Risk Index is a Measurement, Class III , IV or V is a Value, Major abdominal surgery is a Procedure	NCT02499185_inc_task0	Sentence: = 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Procedure, Measurement	[ "B-Person", "I-Person", "I-Person", "O", "B-Condition", "I-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O" ]	= 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery	[ "=", "18", "years", "\n", "High", "risk", "patients", ":", "General", "Surgery", "AKI", "Risk", "Index", "Class", "III", ",", "IV", "or", "V", "\n", "Major", "abdominal", "surgery", "\n" ]	[ "Measurement", "Procedure", "Value", "Person", "Condition" ]
= 18 years is a Person, High risk is a Condition, General Surgery AKI Risk Index is a Measurement, Class III , IV or V is a Value, Major abdominal surgery is a Procedure	NCT02499185_inc_task1	Sentence: = 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery Instructions: please typing these entity words according to sentence: = 18 years, High risk, General Surgery AKI Risk Index, Class III , IV or V, Major abdominal surgery Options: Condition, Value, Person, Procedure, Measurement	[ "B-Person", "I-Person", "I-Person", "O", "B-Condition", "I-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O" ]	= 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery	[ "=", "18", "years", "\n", "High", "risk", "patients", ":", "General", "Surgery", "AKI", "Risk", "Index", "Class", "III", ",", "IV", "or", "V", "\n", "Major", "abdominal", "surgery", "\n" ]	[ "Measurement", "Procedure", "Value", "Person", "Condition" ]
= 18 years, High risk, General Surgery AKI Risk Index, Class III , IV or V, Major abdominal surgery	NCT02499185_inc_task2	Sentence: = 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery Instructions: please extract entity words from the input sentence	[ "B-Person", "I-Person", "I-Person", "O", "B-Condition", "I-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O" ]	= 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery	[ "=", "18", "years", "\n", "High", "risk", "patients", ":", "General", "Surgery", "AKI", "Risk", "Index", "Class", "III", ",", "IV", "or", "V", "\n", "Major", "abdominal", "surgery", "\n" ]	[ "Measurement", "Procedure", "Value", "Person", "Condition" ]
Patienten is an umlsterm, Veneninsuffizienz is an umlsterm, Syndroms is an umlsterm, Therapieerfolg is an umlsterm, Schmerzen is an umlsterm, Oedemneigung is an umlsterm, Sprunggelenkbeweglichkeit is an umlsterm, Patienten is an umlsterm, Kompressionstherapie is an umlsterm, Gefaesssporttherapie is an umlsterm, Basistherapie is an umlsterm, Behindertensportabkommens is an umlsterm	DerHautarzt.70480384.ger.abstr_task0	Sentence: In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist .	[ "In", "einer", "klinischen", "Untersuchung", "bei", "33", "Patienten", "mit", "chronischer", "Veneninsuffizienz", "aufgrund", "primaerer", "Varikose", "oder", "eines", "postthrombotischen", "Syndroms", "in", "den", "klinischen", "Stadien", "I", "bis", "III", "nach", "Widmer", "konnte", "der", "Therapieerfolg", "eines", "halbjaehrigen", "krankheitsspezifischen", "ambulanten", "Bewegungstrainings", "dokumentiert", "werden", ".", "Waehrend", "des", "Trainings", "kam", "es", "zu", "einer", "deutlichen", "Besserung", "stauungsbedingter", "subjektiver", "Beschwerden", "wie", "Schmerzen", "und", "Oedemneigung", "sowie", "zu", "einer", "Verbesserung", "von", "Sprunggelenkbeweglichkeit", "und", "venoeser", "Abpumpleistung", ".", "Der", "klinische", "Erfolg", "zeigte", "sich", "in", "einer", "kompletten", "Abheilung", "venoeser", "Ulzera", "bei", "7", "von", "10", "Patienten", ".", "In", "Verbindung", "mit", "einer", "optimierten", "Kompressionstherapie", "stellt", "die", "Gefaesssporttherapie", "eine", "effiziente", "und", "kostenguenstige", "Basistherapie", "bei", "der", "CVI", "dar", ".", "Auf", "der", "Grundlage", "des", "novellierten", "Deutschen", "Behindertensportabkommens", "aus", "dem", "Jahre", "1994", "werden", "die", "Kosten", "von", "den", "gesetzlichen", "Krankenkassen", "getragen", ",", "solange", "das", "Training", "unter", "qualifizierter", "Anleitung", "indiziert", "ist", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Veneninsuffizienz is an umlsterm, Syndroms is an umlsterm, Therapieerfolg is an umlsterm, Schmerzen is an umlsterm, Oedemneigung is an umlsterm, Sprunggelenkbeweglichkeit is an umlsterm, Patienten is an umlsterm, Kompressionstherapie is an umlsterm, Gefaesssporttherapie is an umlsterm, Basistherapie is an umlsterm, Behindertensportabkommens is an umlsterm	DerHautarzt.70480384.ger.abstr_task1	Sentence: In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist . Instructions: please typing these entity words according to sentence: Patienten, Veneninsuffizienz, Syndroms, Therapieerfolg, Schmerzen, Oedemneigung, Sprunggelenkbeweglichkeit, Patienten, Kompressionstherapie, Gefaesssporttherapie, Basistherapie, Behindertensportabkommens Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist .	[ "In", "einer", "klinischen", "Untersuchung", "bei", "33", "Patienten", "mit", "chronischer", "Veneninsuffizienz", "aufgrund", "primaerer", "Varikose", "oder", "eines", "postthrombotischen", "Syndroms", "in", "den", "klinischen", "Stadien", "I", "bis", "III", "nach", "Widmer", "konnte", "der", "Therapieerfolg", "eines", "halbjaehrigen", "krankheitsspezifischen", "ambulanten", "Bewegungstrainings", "dokumentiert", "werden", ".", "Waehrend", "des", "Trainings", "kam", "es", "zu", "einer", "deutlichen", "Besserung", "stauungsbedingter", "subjektiver", "Beschwerden", "wie", "Schmerzen", "und", "Oedemneigung", "sowie", "zu", "einer", "Verbesserung", "von", "Sprunggelenkbeweglichkeit", "und", "venoeser", "Abpumpleistung", ".", "Der", "klinische", "Erfolg", "zeigte", "sich", "in", "einer", "kompletten", "Abheilung", "venoeser", "Ulzera", "bei", "7", "von", "10", "Patienten", ".", "In", "Verbindung", "mit", "einer", "optimierten", "Kompressionstherapie", "stellt", "die", "Gefaesssporttherapie", "eine", "effiziente", "und", "kostenguenstige", "Basistherapie", "bei", "der", "CVI", "dar", ".", "Auf", "der", "Grundlage", "des", "novellierten", "Deutschen", "Behindertensportabkommens", "aus", "dem", "Jahre", "1994", "werden", "die", "Kosten", "von", "den", "gesetzlichen", "Krankenkassen", "getragen", ",", "solange", "das", "Training", "unter", "qualifizierter", "Anleitung", "indiziert", "ist", "." ]	[ "umlsterm" ]
Patienten, Veneninsuffizienz, Syndroms, Therapieerfolg, Schmerzen, Oedemneigung, Sprunggelenkbeweglichkeit, Patienten, Kompressionstherapie, Gefaesssporttherapie, Basistherapie, Behindertensportabkommens	DerHautarzt.70480384.ger.abstr_task2	Sentence: In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist .	[ "In", "einer", "klinischen", "Untersuchung", "bei", "33", "Patienten", "mit", "chronischer", "Veneninsuffizienz", "aufgrund", "primaerer", "Varikose", "oder", "eines", "postthrombotischen", "Syndroms", "in", "den", "klinischen", "Stadien", "I", "bis", "III", "nach", "Widmer", "konnte", "der", "Therapieerfolg", "eines", "halbjaehrigen", "krankheitsspezifischen", "ambulanten", "Bewegungstrainings", "dokumentiert", "werden", ".", "Waehrend", "des", "Trainings", "kam", "es", "zu", "einer", "deutlichen", "Besserung", "stauungsbedingter", "subjektiver", "Beschwerden", "wie", "Schmerzen", "und", "Oedemneigung", "sowie", "zu", "einer", "Verbesserung", "von", "Sprunggelenkbeweglichkeit", "und", "venoeser", "Abpumpleistung", ".", "Der", "klinische", "Erfolg", "zeigte", "sich", "in", "einer", "kompletten", "Abheilung", "venoeser", "Ulzera", "bei", "7", "von", "10", "Patienten", ".", "In", "Verbindung", "mit", "einer", "optimierten", "Kompressionstherapie", "stellt", "die", "Gefaesssporttherapie", "eine", "effiziente", "und", "kostenguenstige", "Basistherapie", "bei", "der", "CVI", "dar", ".", "Auf", "der", "Grundlage", "des", "novellierten", "Deutschen", "Behindertensportabkommens", "aus", "dem", "Jahre", "1994", "werden", "die", "Kosten", "von", "den", "gesetzlichen", "Krankenkassen", "getragen", ",", "solange", "das", "Training", "unter", "qualifizierter", "Anleitung", "indiziert", "ist", "." ]	[ "umlsterm" ]
ligament is an umlsterm, syndrome is an umlsterm, celiac artery is an umlsterm, ligament is an umlsterm, superior mesenteric arteries is an umlsterm, operation is an umlsterm, treatment is an umlsterm, symptoms is an umlsterm, ligament is an umlsterm, syndrome is an umlsterm, two - vessel is an umlsterm, surgical treatment is an umlsterm, ligament is an umlsterm, procedures is an umlsterm, blood is an umlsterm	Gefaesschirurgie.00050049.eng.abstr_task0	Sentence: In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow .	[ "In", "median", "avcuate", "ligament", "syndrome", ",", "compression", "of", "the", "celiac", "artery", "is", "caused", "by", "an", "abnormally", "low", "insertion", "of", "the", "median", "arcuate", "ligament", "in", "the", "presence", "of", "normally", "located", "celiac", "and", "superior", "mesenteric", "arteries", ".", "A", "lot", "of", "controversy", "exists", "concerning", "the", "indication", "for", "operation", "and", "the", "best", "mode", "of", "treatment", ".", "Depending", "on", "the", "presence", "and", "quality", "of", "collateral", "pathways", ",", "the", "symptoms", "vary", "considerably", ".", "We", "report", "a", "rare", "case", "of", "arcuate", "ligament", "syndrome", "with", "two", "-", "vessel", "involvement", ".", "In", "such", "cases", "surgical", "treatment", "seems", "to", "offer", "substantial", "benefit", ".", "Usually", "transsection", "of", "the", "compressing", "arcuate", "ligament", "is", "sufficient", ".", "Bypass", "procedures", "should", "remain", "limited", "to", "cases", "in", "which", "transsection", "does", "not", "enable", "a", "significant", "increase", "in", "splanchnic", "blood", "flow", "." ]	[ "umlsterm" ]
ligament is an umlsterm, syndrome is an umlsterm, celiac artery is an umlsterm, ligament is an umlsterm, superior mesenteric arteries is an umlsterm, operation is an umlsterm, treatment is an umlsterm, symptoms is an umlsterm, ligament is an umlsterm, syndrome is an umlsterm, two - vessel is an umlsterm, surgical treatment is an umlsterm, ligament is an umlsterm, procedures is an umlsterm, blood is an umlsterm	Gefaesschirurgie.00050049.eng.abstr_task1	Sentence: In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow . Instructions: please typing these entity words according to sentence: ligament, syndrome, celiac artery, ligament, superior mesenteric arteries, operation, treatment, symptoms, ligament, syndrome, two - vessel, surgical treatment, ligament, procedures, blood Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow .	[ "In", "median", "avcuate", "ligament", "syndrome", ",", "compression", "of", "the", "celiac", "artery", "is", "caused", "by", "an", "abnormally", "low", "insertion", "of", "the", "median", "arcuate", "ligament", "in", "the", "presence", "of", "normally", "located", "celiac", "and", "superior", "mesenteric", "arteries", ".", "A", "lot", "of", "controversy", "exists", "concerning", "the", "indication", "for", "operation", "and", "the", "best", "mode", "of", "treatment", ".", "Depending", "on", "the", "presence", "and", "quality", "of", "collateral", "pathways", ",", "the", "symptoms", "vary", "considerably", ".", "We", "report", "a", "rare", "case", "of", "arcuate", "ligament", "syndrome", "with", "two", "-", "vessel", "involvement", ".", "In", "such", "cases", "surgical", "treatment", "seems", "to", "offer", "substantial", "benefit", ".", "Usually", "transsection", "of", "the", "compressing", "arcuate", "ligament", "is", "sufficient", ".", "Bypass", "procedures", "should", "remain", "limited", "to", "cases", "in", "which", "transsection", "does", "not", "enable", "a", "significant", "increase", "in", "splanchnic", "blood", "flow", "." ]	[ "umlsterm" ]
ligament, syndrome, celiac artery, ligament, superior mesenteric arteries, operation, treatment, symptoms, ligament, syndrome, two - vessel, surgical treatment, ligament, procedures, blood	Gefaesschirurgie.00050049.eng.abstr_task2	Sentence: In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow .	[ "In", "median", "avcuate", "ligament", "syndrome", ",", "compression", "of", "the", "celiac", "artery", "is", "caused", "by", "an", "abnormally", "low", "insertion", "of", "the", "median", "arcuate", "ligament", "in", "the", "presence", "of", "normally", "located", "celiac", "and", "superior", "mesenteric", "arteries", ".", "A", "lot", "of", "controversy", "exists", "concerning", "the", "indication", "for", "operation", "and", "the", "best", "mode", "of", "treatment", ".", "Depending", "on", "the", "presence", "and", "quality", "of", "collateral", "pathways", ",", "the", "symptoms", "vary", "considerably", ".", "We", "report", "a", "rare", "case", "of", "arcuate", "ligament", "syndrome", "with", "two", "-", "vessel", "involvement", ".", "In", "such", "cases", "surgical", "treatment", "seems", "to", "offer", "substantial", "benefit", ".", "Usually", "transsection", "of", "the", "compressing", "arcuate", "ligament", "is", "sufficient", ".", "Bypass", "procedures", "should", "remain", "limited", "to", "cases", "in", "which", "transsection", "does", "not", "enable", "a", "significant", "increase", "in", "splanchnic", "blood", "flow", "." ]	[ "umlsterm" ]
Circadian rhythm is an other_name, glucocorticoid receptors is a protein_family_or_group, human peripheral leukocytes is a cell_type, glucocorticoids is a lipid	99546_task0	Sentence: Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_family_or_group, lipid, other_name	[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "B-lipid", "O" ]	Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids.	[ "Circadian", "rhythm", "of", "glucocorticoid", "receptors", "in", "human", "peripheral", "leukocytes", "and", "their", "reactivity", "to", "glucocorticoids", "." ]	[ "cell_type", "other_name", "protein_family_or_group", "body_part", "lipid", "multi_cell" ]
Circadian rhythm is an other_name, glucocorticoid receptors is a protein_family_or_group, human peripheral leukocytes is a cell_type, glucocorticoids is a lipid	99546_task1	Sentence: Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids. Instructions: please typing these entity words according to sentence: Circadian rhythm, glucocorticoid receptors, human peripheral leukocytes, glucocorticoids Options: cell_type, protein_family_or_group, lipid, other_name	[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "B-lipid", "O" ]	Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids.	[ "Circadian", "rhythm", "of", "glucocorticoid", "receptors", "in", "human", "peripheral", "leukocytes", "and", "their", "reactivity", "to", "glucocorticoids", "." ]	[ "cell_type", "other_name", "protein_family_or_group", "body_part", "lipid", "multi_cell" ]
Circadian rhythm, glucocorticoid receptors, human peripheral leukocytes, glucocorticoids	99546_task2	Sentence: Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "B-lipid", "O" ]	Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids.	[ "Circadian", "rhythm", "of", "glucocorticoid", "receptors", "in", "human", "peripheral", "leukocytes", "and", "their", "reactivity", "to", "glucocorticoids", "." ]	[ "cell_type", "other_name", "protein_family_or_group", "body_part", "lipid", "multi_cell" ]
Markraums is an umlsterm, Markrauminfektionen is an umlsterm, unteren Extremitaeten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Infektion is an umlsterm, Marknagel is an umlsterm, Patienten is an umlsterm, Nagelimplantation is an umlsterm, Patienten is an umlsterm, Nagels is an umlsterm, Markraumbohrung is an umlsterm, Rezidivfreiheit is an umlsterm, Extremitaet is an umlsterm, Patienten is an umlsterm, Nagel is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Rezidivfreiheit is an umlsterm, Patienten is an umlsterm, Nagel is an umlsterm, Patienten is an umlsterm, offene Fraktur is an umlsterm, Patienten is an umlsterm, Beruf is an umlsterm	DerUnfallchirurg.81010628.ger.abstr_task0	Sentence: Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen .	[ "Untersucht", "wurden", "die", "Ergebnisse", "der", "Aufbohrung", "des", "Markraums", "bei", "Markrauminfektionen", "der", "unteren", "Extremitaeten", "nach", "intramedullaerer", "Stabilisierung", "bei", "55", "Patienten", "aus", "den", "Jahren", "1980", "-", "1991", ".", "Der", "durchschnittliche", "Nachuntersuchungszeitraum", "betrug", "10,1", "+", "/-", "4,9", "Jahre", ";", "34", "Patienten", "erlitten", "die", "Infektion", "unter", "dem", "Marknagel", ",", "21", "Patienten", "hatten", "multiple", "Voreingriffe", "mit", "Infektzeichen", "schon", "vor", "der", "Nagelimplantation", ".", "Bei", "allen", "Patienten", "wurde", "nach", "Entfernung", "des", "Nagels", "eine", "Markraumbohrung", "durchgefuehrt", ".", "In", "38", "Faellen", "bestand", "eine", "Infektpseudarthrose", ",", "so", "dass", "gleichzeitig", "eine", "erneute", "stabilisierende", "Operation", "und", "Spongiosaplastik", "durchgefuehrt", "wurde", ".", "Zum", "Nachuntersuchungszeitpunkt", "wurde", "der", "Erfolg", "des", "Eingriffs", "hinsichtlich", "Rezidivfreiheit", ",", "Funktion", "der", "Extremitaet", "und", "subjektiver", "Zufriedenheit", "ueberprueft", ".", "Anhand", "dieser", "Kriterien", "fanden", "wir", "sehr", "gute", "Ergebnisse", "bei", "78", "%", "der", "Patienten", ".", "Bei", "Infekten", "nach", "primaerem", "Nagel", "war", "die", "Behandlung", "mit", "84", "%", "sehr", "guten", "Ergebnissen", "signifikant", "erfolgreicher", "als", "bei", "den", "Patienten", "mit", "multiplen", "Voreingriffen", ".", "Rezidivfreiheit", "liess", "sich", "in", "der", "Gruppe", "der", "primaeren", "Infekte", "bei", "allen", "Patienten", "erreichen", ",", "bei", "den", "sekundaer", "mit", "Nagel", "versorgen", "Patienten", "in", "62", "%", ".", "Eine", "primaer", "offene", "Fraktur", "verschlechterte", "die", "Erfolgsaussichten", "des", "Eingriffs", "nicht", ";", "82", "%", "der", "Patienten", "konnten", "ihren", "vorherigen", "Beruf", "wieder", "aufnehmen", "." ]	[ "umlsterm" ]
Markraums is an umlsterm, Markrauminfektionen is an umlsterm, unteren Extremitaeten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Infektion is an umlsterm, Marknagel is an umlsterm, Patienten is an umlsterm, Nagelimplantation is an umlsterm, Patienten is an umlsterm, Nagels is an umlsterm, Markraumbohrung is an umlsterm, Rezidivfreiheit is an umlsterm, Extremitaet is an umlsterm, Patienten is an umlsterm, Nagel is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Rezidivfreiheit is an umlsterm, Patienten is an umlsterm, Nagel is an umlsterm, Patienten is an umlsterm, offene Fraktur is an umlsterm, Patienten is an umlsterm, Beruf is an umlsterm	DerUnfallchirurg.81010628.ger.abstr_task1	Sentence: Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen . Instructions: please typing these entity words according to sentence: Markraums, Markrauminfektionen, unteren Extremitaeten, Patienten, Patienten, Infektion, Marknagel, Patienten, Nagelimplantation, Patienten, Nagels, Markraumbohrung, Rezidivfreiheit, Extremitaet, Patienten, Nagel, Behandlung, Patienten, Rezidivfreiheit, Patienten, Nagel, Patienten, offene Fraktur, Patienten, Beruf Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen .	[ "Untersucht", "wurden", "die", "Ergebnisse", "der", "Aufbohrung", "des", "Markraums", "bei", "Markrauminfektionen", "der", "unteren", "Extremitaeten", "nach", "intramedullaerer", "Stabilisierung", "bei", "55", "Patienten", "aus", "den", "Jahren", "1980", "-", "1991", ".", "Der", "durchschnittliche", "Nachuntersuchungszeitraum", "betrug", "10,1", "+", "/-", "4,9", "Jahre", ";", "34", "Patienten", "erlitten", "die", "Infektion", "unter", "dem", "Marknagel", ",", "21", "Patienten", "hatten", "multiple", "Voreingriffe", "mit", "Infektzeichen", "schon", "vor", "der", "Nagelimplantation", ".", "Bei", "allen", "Patienten", "wurde", "nach", "Entfernung", "des", "Nagels", "eine", "Markraumbohrung", "durchgefuehrt", ".", "In", "38", "Faellen", "bestand", "eine", "Infektpseudarthrose", ",", "so", "dass", "gleichzeitig", "eine", "erneute", "stabilisierende", "Operation", "und", "Spongiosaplastik", "durchgefuehrt", "wurde", ".", "Zum", "Nachuntersuchungszeitpunkt", "wurde", "der", "Erfolg", "des", "Eingriffs", "hinsichtlich", "Rezidivfreiheit", ",", "Funktion", "der", "Extremitaet", "und", "subjektiver", "Zufriedenheit", "ueberprueft", ".", "Anhand", "dieser", "Kriterien", "fanden", "wir", "sehr", "gute", "Ergebnisse", "bei", "78", "%", "der", "Patienten", ".", "Bei", "Infekten", "nach", "primaerem", "Nagel", "war", "die", "Behandlung", "mit", "84", "%", "sehr", "guten", "Ergebnissen", "signifikant", "erfolgreicher", "als", "bei", "den", "Patienten", "mit", "multiplen", "Voreingriffen", ".", "Rezidivfreiheit", "liess", "sich", "in", "der", "Gruppe", "der", "primaeren", "Infekte", "bei", "allen", "Patienten", "erreichen", ",", "bei", "den", "sekundaer", "mit", "Nagel", "versorgen", "Patienten", "in", "62", "%", ".", "Eine", "primaer", "offene", "Fraktur", "verschlechterte", "die", "Erfolgsaussichten", "des", "Eingriffs", "nicht", ";", "82", "%", "der", "Patienten", "konnten", "ihren", "vorherigen", "Beruf", "wieder", "aufnehmen", "." ]	[ "umlsterm" ]
Markraums, Markrauminfektionen, unteren Extremitaeten, Patienten, Patienten, Infektion, Marknagel, Patienten, Nagelimplantation, Patienten, Nagels, Markraumbohrung, Rezidivfreiheit, Extremitaet, Patienten, Nagel, Behandlung, Patienten, Rezidivfreiheit, Patienten, Nagel, Patienten, offene Fraktur, Patienten, Beruf	DerUnfallchirurg.81010628.ger.abstr_task2	Sentence: Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen .	[ "Untersucht", "wurden", "die", "Ergebnisse", "der", "Aufbohrung", "des", "Markraums", "bei", "Markrauminfektionen", "der", "unteren", "Extremitaeten", "nach", "intramedullaerer", "Stabilisierung", "bei", "55", "Patienten", "aus", "den", "Jahren", "1980", "-", "1991", ".", "Der", "durchschnittliche", "Nachuntersuchungszeitraum", "betrug", "10,1", "+", "/-", "4,9", "Jahre", ";", "34", "Patienten", "erlitten", "die", "Infektion", "unter", "dem", "Marknagel", ",", "21", "Patienten", "hatten", "multiple", "Voreingriffe", "mit", "Infektzeichen", "schon", "vor", "der", "Nagelimplantation", ".", "Bei", "allen", "Patienten", "wurde", "nach", "Entfernung", "des", "Nagels", "eine", "Markraumbohrung", "durchgefuehrt", ".", "In", "38", "Faellen", "bestand", "eine", "Infektpseudarthrose", ",", "so", "dass", "gleichzeitig", "eine", "erneute", "stabilisierende", "Operation", "und", "Spongiosaplastik", "durchgefuehrt", "wurde", ".", "Zum", "Nachuntersuchungszeitpunkt", "wurde", "der", "Erfolg", "des", "Eingriffs", "hinsichtlich", "Rezidivfreiheit", ",", "Funktion", "der", "Extremitaet", "und", "subjektiver", "Zufriedenheit", "ueberprueft", ".", "Anhand", "dieser", "Kriterien", "fanden", "wir", "sehr", "gute", "Ergebnisse", "bei", "78", "%", "der", "Patienten", ".", "Bei", "Infekten", "nach", "primaerem", "Nagel", "war", "die", "Behandlung", "mit", "84", "%", "sehr", "guten", "Ergebnissen", "signifikant", "erfolgreicher", "als", "bei", "den", "Patienten", "mit", "multiplen", "Voreingriffen", ".", "Rezidivfreiheit", "liess", "sich", "in", "der", "Gruppe", "der", "primaeren", "Infekte", "bei", "allen", "Patienten", "erreichen", ",", "bei", "den", "sekundaer", "mit", "Nagel", "versorgen", "Patienten", "in", "62", "%", ".", "Eine", "primaer", "offene", "Fraktur", "verschlechterte", "die", "Erfolgsaussichten", "des", "Eingriffs", "nicht", ";", "82", "%", "der", "Patienten", "konnten", "ihren", "vorherigen", "Beruf", "wieder", "aufnehmen", "." ]	[ "umlsterm" ]
Pankreatitis is an umlsterm, Patienten is an umlsterm, Pankreatitis is an umlsterm, Therapieergebnisse is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Pankreasnekrosen is an umlsterm, Sonographie is an umlsterm, Computertomographie is an umlsterm, Patienten is an umlsterm, Infektion is an umlsterm, Pankreasnekrosen is an umlsterm, Komplikationen is an umlsterm, Pankreatitis is an umlsterm, Cholezystektomie is an umlsterm, Rezidivprophylaxe is an umlsterm	DerAnaesthesist.80470765.ger.abstr_task0	Sentence: Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden .	[ "Die", "akute", "Pankreatitis", "ist", "eine", "multietiologische", "Erkrankung", "mit", "klinisch", "ausgesprochen", "unterschiedlichen", "Verlaeufen", ".", "Waehrend", "die", "oedematoese", "Verlaufsform", "heute", "eine", "Letalitaet", "von", "weniger", "als", "1", "%", "aufweist", ",", "erliegen", "immer", "noch", "rund", "20", "%", "der", "Patienten", "mit", "einer", "nekrotisierenden", "Pankreatitis", "ihrer", "Erkrankung", ".", "Um", "die", "Therapieergebnisse", "weiter", "zu", "verbessern", ",", "sollte", "die", "Behandlung", "nach", "einem", "standardisierten", "Schema", "vorgenommen", "werden", ".", "Entscheidend", "ist", "hierbei", "die", "Unterscheidung", "zwischen", "oedematoeser", "und", "nekrotisierender", "Verlaufsform", ".", "Alle", "Patienten", "mit", "Zeichen", "fuer", "Pankreasnekrosen", "in", "der", "Sonographie", "und", "jene", "mit", "Organinsuffizienzen", "sollten", "eine", "abdominelle", "Computertomographie", "erhalten", ".", "Primaer", "werden", "alle", "Patienten", "konservativ", "behandelt", ".", "Hauptindikationen", "fuer", "die", "operative", "Intervention", "sind", "Zeichen", "fuer", "eine", "Infektion", "der", "Pankreasnekrosen", "und", "ein", "akutes", "Abomen", "aufgrund", "lokaler", "Komplikationen", "der", "akuten", "Pankreatitis", ".", "In", "Faellen", "biliaerer", "Genese", "sollte", "im", "freien", "Intervall", "eine", "elektive", "Cholezystektomie", "zur", "Rezidivprophylaxe", "vorgenommen", "werden", "." ]	[ "umlsterm" ]
Pankreatitis is an umlsterm, Patienten is an umlsterm, Pankreatitis is an umlsterm, Therapieergebnisse is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Pankreasnekrosen is an umlsterm, Sonographie is an umlsterm, Computertomographie is an umlsterm, Patienten is an umlsterm, Infektion is an umlsterm, Pankreasnekrosen is an umlsterm, Komplikationen is an umlsterm, Pankreatitis is an umlsterm, Cholezystektomie is an umlsterm, Rezidivprophylaxe is an umlsterm	DerAnaesthesist.80470765.ger.abstr_task1	Sentence: Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden . Instructions: please typing these entity words according to sentence: Pankreatitis, Patienten, Pankreatitis, Therapieergebnisse, Behandlung, Patienten, Pankreasnekrosen, Sonographie, Computertomographie, Patienten, Infektion, Pankreasnekrosen, Komplikationen, Pankreatitis, Cholezystektomie, Rezidivprophylaxe Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden .	[ "Die", "akute", "Pankreatitis", "ist", "eine", "multietiologische", "Erkrankung", "mit", "klinisch", "ausgesprochen", "unterschiedlichen", "Verlaeufen", ".", "Waehrend", "die", "oedematoese", "Verlaufsform", "heute", "eine", "Letalitaet", "von", "weniger", "als", "1", "%", "aufweist", ",", "erliegen", "immer", "noch", "rund", "20", "%", "der", "Patienten", "mit", "einer", "nekrotisierenden", "Pankreatitis", "ihrer", "Erkrankung", ".", "Um", "die", "Therapieergebnisse", "weiter", "zu", "verbessern", ",", "sollte", "die", "Behandlung", "nach", "einem", "standardisierten", "Schema", "vorgenommen", "werden", ".", "Entscheidend", "ist", "hierbei", "die", "Unterscheidung", "zwischen", "oedematoeser", "und", "nekrotisierender", "Verlaufsform", ".", "Alle", "Patienten", "mit", "Zeichen", "fuer", "Pankreasnekrosen", "in", "der", "Sonographie", "und", "jene", "mit", "Organinsuffizienzen", "sollten", "eine", "abdominelle", "Computertomographie", "erhalten", ".", "Primaer", "werden", "alle", "Patienten", "konservativ", "behandelt", ".", "Hauptindikationen", "fuer", "die", "operative", "Intervention", "sind", "Zeichen", "fuer", "eine", "Infektion", "der", "Pankreasnekrosen", "und", "ein", "akutes", "Abomen", "aufgrund", "lokaler", "Komplikationen", "der", "akuten", "Pankreatitis", ".", "In", "Faellen", "biliaerer", "Genese", "sollte", "im", "freien", "Intervall", "eine", "elektive", "Cholezystektomie", "zur", "Rezidivprophylaxe", "vorgenommen", "werden", "." ]	[ "umlsterm" ]
Pankreatitis, Patienten, Pankreatitis, Therapieergebnisse, Behandlung, Patienten, Pankreasnekrosen, Sonographie, Computertomographie, Patienten, Infektion, Pankreasnekrosen, Komplikationen, Pankreatitis, Cholezystektomie, Rezidivprophylaxe	DerAnaesthesist.80470765.ger.abstr_task2	Sentence: Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden .	[ "Die", "akute", "Pankreatitis", "ist", "eine", "multietiologische", "Erkrankung", "mit", "klinisch", "ausgesprochen", "unterschiedlichen", "Verlaeufen", ".", "Waehrend", "die", "oedematoese", "Verlaufsform", "heute", "eine", "Letalitaet", "von", "weniger", "als", "1", "%", "aufweist", ",", "erliegen", "immer", "noch", "rund", "20", "%", "der", "Patienten", "mit", "einer", "nekrotisierenden", "Pankreatitis", "ihrer", "Erkrankung", ".", "Um", "die", "Therapieergebnisse", "weiter", "zu", "verbessern", ",", "sollte", "die", "Behandlung", "nach", "einem", "standardisierten", "Schema", "vorgenommen", "werden", ".", "Entscheidend", "ist", "hierbei", "die", "Unterscheidung", "zwischen", "oedematoeser", "und", "nekrotisierender", "Verlaufsform", ".", "Alle", "Patienten", "mit", "Zeichen", "fuer", "Pankreasnekrosen", "in", "der", "Sonographie", "und", "jene", "mit", "Organinsuffizienzen", "sollten", "eine", "abdominelle", "Computertomographie", "erhalten", ".", "Primaer", "werden", "alle", "Patienten", "konservativ", "behandelt", ".", "Hauptindikationen", "fuer", "die", "operative", "Intervention", "sind", "Zeichen", "fuer", "eine", "Infektion", "der", "Pankreasnekrosen", "und", "ein", "akutes", "Abomen", "aufgrund", "lokaler", "Komplikationen", "der", "akuten", "Pankreatitis", ".", "In", "Faellen", "biliaerer", "Genese", "sollte", "im", "freien", "Intervall", "eine", "elektive", "Cholezystektomie", "zur", "Rezidivprophylaxe", "vorgenommen", "werden", "." ]	[ "umlsterm" ]
Retrospective is an umlsterm, evaluation is an umlsterm, treatment is an umlsterm, carcinoma is an umlsterm	DerRadiologe.90390795.eng.abstr_task0	Sentence: Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma .	[ "Purpose", ":", "Retrospective", "evaluation", "of", "percutaneous", "interventional", "treatment", "of", "locally", "advanced", "cervical", "carcinoma", "." ]	[ "umlsterm" ]
Retrospective is an umlsterm, evaluation is an umlsterm, treatment is an umlsterm, carcinoma is an umlsterm	DerRadiologe.90390795.eng.abstr_task1	Sentence: Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma . Instructions: please typing these entity words according to sentence: Retrospective, evaluation, treatment, carcinoma Options: umlsterm	[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma .	[ "Purpose", ":", "Retrospective", "evaluation", "of", "percutaneous", "interventional", "treatment", "of", "locally", "advanced", "cervical", "carcinoma", "." ]	[ "umlsterm" ]
Retrospective, evaluation, treatment, carcinoma	DerRadiologe.90390795.eng.abstr_task2	Sentence: Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma .	[ "Purpose", ":", "Retrospective", "evaluation", "of", "percutaneous", "interventional", "treatment", "of", "locally", "advanced", "cervical", "carcinoma", "." ]	[ "umlsterm" ]
2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose is a CHEMICAL, TNF - α is a GENE-Y, glucose is a CHEMICAL, 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose is a CHEMICAL, Glucose is a CHEMICAL, glucose is a CHEMICAL, insulin is a GENE-N, TNF - α is a GENE-Y, Vescalagin is a CHEMICAL, glucose is a CHEMICAL, insulin is a GENE-N, vescalagin is a CHEMICAL, insulin is a GENE-N	10578_task0	Sentence: Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]	Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes.	[ "Effect", "of", "water", "extracts", "from", "edible", "myrtaceae", "plants", "on", "uptake", "of", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "in", "TNF", "-", "α", "-", "treated", "FL83B", "mouse", "hepatocytes", ".", "\n", "This", "study", "investigated", "the", "glucose", "uptake", "activity", "of", "the", "water", "extracts", "from", "the", "leaves", "and", "fruit", "of", "edible", "Myrtaceae", "plants", ",", "including", "guava", "(", "Psidium", "guajava", "Linn", ".", ")", ",", "wax", "apples", "[", "Syzygium", "samarangense", "(", "Blume", ")", "Merr", ".", "and", "L.M.", "Perry", "]", ",", "Pu", "-", "Tau", "[", "Syzygium", "jambo", "(", "L.", ")", "Alston", "]", ",", "and", "Kan", "-", "Shi", "Pu", "-", "Tau", "(", "Syzygium", "cumini", "Linn", ".", ")", "in", "FL83B", "mouse", "hepatocytes", ".", "The", "fluorescent", "dye", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "was", "used", "to", "estimate", "the", "uptake", "ability", "of", "the", "cells", ".", "Glucose", "uptake", "test", "showed", "that", "pink", "wax", "apple", "fruit", "extract", "(", "PWFE", ")", "exhibits", "the", "highest", "glucose", "uptake", "activity", ",", "at", "an", "increment", "of", "21", "%", "in", "the", "insulin", "-", "resistant", "FL83B", "mouse", "hepatocytes", "as", "compared", "with", "the", "TNF", "-", "α", "-", "treated", "control", "group", ".", "Vescalagin", "was", "isolated", "using", "column", "chromatography", "of", "PWFE", ".", "This", "compound", ",", "at", "the", "concentration", "of", "6.25", " ", "µg", "/", "mL", ",", "exhibits", "the", "same", "glucose", "uptake", "improvement", "in", "insulin", "-", "resistant", "cells", "as", "PWFE", "at", "a", "100-µg", "/", "mL", "dose", ".", "We", "postulate", "that", "vescalagin", "is", "an", "active", "component", "in", "PWFE", "that", "may", "alleviate", "the", "insulin", "resistance", "in", "mouse", "hepatocytes", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose is a CHEMICAL, TNF - α is a GENE-Y, glucose is a CHEMICAL, 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose is a CHEMICAL, Glucose is a CHEMICAL, glucose is a CHEMICAL, insulin is a GENE-N, TNF - α is a GENE-Y, Vescalagin is a CHEMICAL, glucose is a CHEMICAL, insulin is a GENE-N, vescalagin is a CHEMICAL, insulin is a GENE-N	10578_task1	Sentence: Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes. Instructions: please typing these entity words according to sentence: 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, TNF - α, glucose, 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, Glucose, glucose, insulin, TNF - α, Vescalagin, glucose, insulin, vescalagin, insulin Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]	Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes.	[ "Effect", "of", "water", "extracts", "from", "edible", "myrtaceae", "plants", "on", "uptake", "of", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "in", "TNF", "-", "α", "-", "treated", "FL83B", "mouse", "hepatocytes", ".", "\n", "This", "study", "investigated", "the", "glucose", "uptake", "activity", "of", "the", "water", "extracts", "from", "the", "leaves", "and", "fruit", "of", "edible", "Myrtaceae", "plants", ",", "including", "guava", "(", "Psidium", "guajava", "Linn", ".", ")", ",", "wax", "apples", "[", "Syzygium", "samarangense", "(", "Blume", ")", "Merr", ".", "and", "L.M.", "Perry", "]", ",", "Pu", "-", "Tau", "[", "Syzygium", "jambo", "(", "L.", ")", "Alston", "]", ",", "and", "Kan", "-", "Shi", "Pu", "-", "Tau", "(", "Syzygium", "cumini", "Linn", ".", ")", "in", "FL83B", "mouse", "hepatocytes", ".", "The", "fluorescent", "dye", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "was", "used", "to", "estimate", "the", "uptake", "ability", "of", "the", "cells", ".", "Glucose", "uptake", "test", "showed", "that", "pink", "wax", "apple", "fruit", "extract", "(", "PWFE", ")", "exhibits", "the", "highest", "glucose", "uptake", "activity", ",", "at", "an", "increment", "of", "21", "%", "in", "the", "insulin", "-", "resistant", "FL83B", "mouse", "hepatocytes", "as", "compared", "with", "the", "TNF", "-", "α", "-", "treated", "control", "group", ".", "Vescalagin", "was", "isolated", "using", "column", "chromatography", "of", "PWFE", ".", "This", "compound", ",", "at", "the", "concentration", "of", "6.25", " ", "µg", "/", "mL", ",", "exhibits", "the", "same", "glucose", "uptake", "improvement", "in", "insulin", "-", "resistant", "cells", "as", "PWFE", "at", "a", "100-µg", "/", "mL", "dose", ".", "We", "postulate", "that", "vescalagin", "is", "an", "active", "component", "in", "PWFE", "that", "may", "alleviate", "the", "insulin", "resistance", "in", "mouse", "hepatocytes", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, TNF - α, glucose, 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, Glucose, glucose, insulin, TNF - α, Vescalagin, glucose, insulin, vescalagin, insulin	10578_task2	Sentence: Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]	Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes.	[ "Effect", "of", "water", "extracts", "from", "edible", "myrtaceae", "plants", "on", "uptake", "of", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "in", "TNF", "-", "α", "-", "treated", "FL83B", "mouse", "hepatocytes", ".", "\n", "This", "study", "investigated", "the", "glucose", "uptake", "activity", "of", "the", "water", "extracts", "from", "the", "leaves", "and", "fruit", "of", "edible", "Myrtaceae", "plants", ",", "including", "guava", "(", "Psidium", "guajava", "Linn", ".", ")", ",", "wax", "apples", "[", "Syzygium", "samarangense", "(", "Blume", ")", "Merr", ".", "and", "L.M.", "Perry", "]", ",", "Pu", "-", "Tau", "[", "Syzygium", "jambo", "(", "L.", ")", "Alston", "]", ",", "and", "Kan", "-", "Shi", "Pu", "-", "Tau", "(", "Syzygium", "cumini", "Linn", ".", ")", "in", "FL83B", "mouse", "hepatocytes", ".", "The", "fluorescent", "dye", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "was", "used", "to", "estimate", "the", "uptake", "ability", "of", "the", "cells", ".", "Glucose", "uptake", "test", "showed", "that", "pink", "wax", "apple", "fruit", "extract", "(", "PWFE", ")", "exhibits", "the", "highest", "glucose", "uptake", "activity", ",", "at", "an", "increment", "of", "21", "%", "in", "the", "insulin", "-", "resistant", "FL83B", "mouse", "hepatocytes", "as", "compared", "with", "the", "TNF", "-", "α", "-", "treated", "control", "group", ".", "Vescalagin", "was", "isolated", "using", "column", "chromatography", "of", "PWFE", ".", "This", "compound", ",", "at", "the", "concentration", "of", "6.25", " ", "µg", "/", "mL", ",", "exhibits", "the", "same", "glucose", "uptake", "improvement", "in", "insulin", "-", "resistant", "cells", "as", "PWFE", "at", "a", "100-µg", "/", "mL", "dose", ".", "We", "postulate", "that", "vescalagin", "is", "an", "active", "component", "in", "PWFE", "that", "may", "alleviate", "the", "insulin", "resistance", "in", "mouse", "hepatocytes", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Cell specific expression is an other_name, human Bruton 's agammaglobulinemia tyrosine kinase gene is a DNA_domain_or_region, Btk is a protein_molecule, Sp1- is a protein_family_or_group, Spi-1 / PU.1-family members is a protein_family_or_group	18949_task0	Sentence: Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, protein_family_or_group, protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-protein_molecule", "O", "O", "O", "O", "B-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]	Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members.	[ "Cell", "specific", "expression", "of", "human", "Bruton", "'s", "agammaglobulinemia", "tyrosine", "kinase", "gene", "(", "Btk", ")", "is", "regulated", "by", "Sp1-", "and", "Spi-1", "/", "PU.1-family", "members", "." ]	[ "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "(AND protein_family_or_group protein_family_or_group)", "protein_family_or_group", "(AND cell_type cell_type)", "cell_type", "", "multi_cell", "body_part" ]
Cell specific expression is an other_name, human Bruton 's agammaglobulinemia tyrosine kinase gene is a DNA_domain_or_region, Btk is a protein_molecule, Sp1- is a protein_family_or_group, Spi-1 / PU.1-family members is a protein_family_or_group	18949_task1	Sentence: Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Instructions: please typing these entity words according to sentence: Cell specific expression, human Bruton 's agammaglobulinemia tyrosine kinase gene, Btk, Sp1-, Spi-1 / PU.1-family members Options: DNA_domain_or_region, protein_family_or_group, protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-protein_molecule", "O", "O", "O", "O", "B-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]	Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members.	[ "Cell", "specific", "expression", "of", "human", "Bruton", "'s", "agammaglobulinemia", "tyrosine", "kinase", "gene", "(", "Btk", ")", "is", "regulated", "by", "Sp1-", "and", "Spi-1", "/", "PU.1-family", "members", "." ]	[ "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "(AND protein_family_or_group protein_family_or_group)", "protein_family_or_group", "(AND cell_type cell_type)", "cell_type", "", "multi_cell", "body_part" ]
Cell specific expression, human Bruton 's agammaglobulinemia tyrosine kinase gene, Btk, Sp1-, Spi-1 / PU.1-family members	18949_task2	Sentence: Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "I-other_name", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-protein_molecule", "O", "O", "O", "O", "B-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]	Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members.	[ "Cell", "specific", "expression", "of", "human", "Bruton", "'s", "agammaglobulinemia", "tyrosine", "kinase", "gene", "(", "Btk", ")", "is", "regulated", "by", "Sp1-", "and", "Spi-1", "/", "PU.1-family", "members", "." ]	[ "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "(AND protein_family_or_group protein_family_or_group)", "protein_family_or_group", "(AND cell_type cell_type)", "cell_type", "", "multi_cell", "body_part" ]
histone H4 is a Protein, histone is a Protein, K5 is a Entity, K8 is a Entity, histone H4 is a Protein, histone H4 is a Protein, histone is a Protein	439_task0	Sentence: Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors.	[ "Real", "-", "time", "imaging", "of", "histone", "H4", "hyperacetylation", "in", "living", "cells", ".", "\n", "To", "visualize", "histone", "acetylation", "in", "living", "cells", ",", "we", "developed", "a", "genetically", "encoded", "fluorescent", "resonance", "energy", "transfer", "(", "FRET)-based", "indicator", ".", "Response", "of", "the", "indicator", "reflects", "changes", "in", "the", "acetylation", "state", "of", "both", "K5", "and", "K8", "in", "histone", "H4", ".", "Using", "this", "acetylation", "indicator", ",", "we", "were", "able", "to", "monitor", "the", "dynamic", "fluctuation", "of", "histone", "H4", "acetylation", "levels", "during", "mitosis", ",", "as", "well", "as", "acetylation", "changes", "in", "response", "to", "structurally", "distinct", "histone", "deacetylase", "inhibitors", ".", "\n" ]	[ "Protein", "Entity" ]
histone H4 is a Protein, histone is a Protein, K5 is a Entity, K8 is a Entity, histone H4 is a Protein, histone H4 is a Protein, histone is a Protein	439_task1	Sentence: Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors. Instructions: please typing these entity words according to sentence: histone H4, histone, K5, K8, histone H4, histone H4, histone Options: Entity, Protein	[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors.	[ "Real", "-", "time", "imaging", "of", "histone", "H4", "hyperacetylation", "in", "living", "cells", ".", "\n", "To", "visualize", "histone", "acetylation", "in", "living", "cells", ",", "we", "developed", "a", "genetically", "encoded", "fluorescent", "resonance", "energy", "transfer", "(", "FRET)-based", "indicator", ".", "Response", "of", "the", "indicator", "reflects", "changes", "in", "the", "acetylation", "state", "of", "both", "K5", "and", "K8", "in", "histone", "H4", ".", "Using", "this", "acetylation", "indicator", ",", "we", "were", "able", "to", "monitor", "the", "dynamic", "fluctuation", "of", "histone", "H4", "acetylation", "levels", "during", "mitosis", ",", "as", "well", "as", "acetylation", "changes", "in", "response", "to", "structurally", "distinct", "histone", "deacetylase", "inhibitors", ".", "\n" ]	[ "Protein", "Entity" ]
histone H4, histone, K5, K8, histone H4, histone H4, histone	439_task2	Sentence: Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors.	[ "Real", "-", "time", "imaging", "of", "histone", "H4", "hyperacetylation", "in", "living", "cells", ".", "\n", "To", "visualize", "histone", "acetylation", "in", "living", "cells", ",", "we", "developed", "a", "genetically", "encoded", "fluorescent", "resonance", "energy", "transfer", "(", "FRET)-based", "indicator", ".", "Response", "of", "the", "indicator", "reflects", "changes", "in", "the", "acetylation", "state", "of", "both", "K5", "and", "K8", "in", "histone", "H4", ".", "Using", "this", "acetylation", "indicator", ",", "we", "were", "able", "to", "monitor", "the", "dynamic", "fluctuation", "of", "histone", "H4", "acetylation", "levels", "during", "mitosis", ",", "as", "well", "as", "acetylation", "changes", "in", "response", "to", "structurally", "distinct", "histone", "deacetylase", "inhibitors", ".", "\n" ]	[ "Protein", "Entity" ]
Surgery is an umlsterm, direct is an umlsterm, media is an umlsterm, cause is an umlsterm, Economic is an umlsterm, pressures is an umlsterm, resources is an umlsterm, medicine is an umlsterm, medicine is an umlsterm, patient is an umlsterm, conflict is an umlsterm, power is an umlsterm, media is an umlsterm, public relations is an umlsterm, surgery is an umlsterm, surgical is an umlsterm, competence is an umlsterm, communication is an umlsterm	DerChirurg.80691292.eng.abstr_task0	Sentence: Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication .	[ "Surgery", "and", "surgeons", "have", "a", "direct", "relationship", "to", "publicity", ".", "In", "the", "media", ",", "the", "entertainment", "aspect", "prevails", "over", "information", "(", "infotainment", ")", ",", "and", "scandal", "also", "dominates", "because", "of", "negative", "reports", ".", "The", "cause", "in", "many", "cases", "is", "a", "lack", "of", "information", ",", "which", "is", "always", "a", "problem", "when", "transmitting", "scientific", "information", "to", "the", "public", ".", "Economic", "pressures", "and", "diminished", "resources", "as", "well", "as", "a", "simultaneous", "increase", "in", "the", "demands", "made", "on", "medicine", "make", "it", "mandatory", "that", "surgeons", "communicate", "properly", ".", "They", "are", "being", "degraded", "more", "and", "more", "to", "\"", "delivering", "\"", "medicine", ",", "and", "the", "relationship", "between", "the", "surgeon", "and", "his", "patient", "has", "been", "reduced", "to", "a", "collision", "of", "greediness", "on", "both", "sides", ".", "We", "are", "in", "continuous", "conflict", "with", "the", "power", "of", "the", "media", "and", "are", "being", "challenged", "to", "improve", "our", "public", "relations", ".", "The", "public", "image", "of", "surgery", "today", "is", "determined", "by", "surgical", "performance", "and", "competence", "in", "communication", "." ]	[ "umlsterm" ]
Surgery is an umlsterm, direct is an umlsterm, media is an umlsterm, cause is an umlsterm, Economic is an umlsterm, pressures is an umlsterm, resources is an umlsterm, medicine is an umlsterm, medicine is an umlsterm, patient is an umlsterm, conflict is an umlsterm, power is an umlsterm, media is an umlsterm, public relations is an umlsterm, surgery is an umlsterm, surgical is an umlsterm, competence is an umlsterm, communication is an umlsterm	DerChirurg.80691292.eng.abstr_task1	Sentence: Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication . Instructions: please typing these entity words according to sentence: Surgery, direct, media, cause, Economic, pressures, resources, medicine, medicine, patient, conflict, power, media, public relations, surgery, surgical, competence, communication Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication .	[ "Surgery", "and", "surgeons", "have", "a", "direct", "relationship", "to", "publicity", ".", "In", "the", "media", ",", "the", "entertainment", "aspect", "prevails", "over", "information", "(", "infotainment", ")", ",", "and", "scandal", "also", "dominates", "because", "of", "negative", "reports", ".", "The", "cause", "in", "many", "cases", "is", "a", "lack", "of", "information", ",", "which", "is", "always", "a", "problem", "when", "transmitting", "scientific", "information", "to", "the", "public", ".", "Economic", "pressures", "and", "diminished", "resources", "as", "well", "as", "a", "simultaneous", "increase", "in", "the", "demands", "made", "on", "medicine", "make", "it", "mandatory", "that", "surgeons", "communicate", "properly", ".", "They", "are", "being", "degraded", "more", "and", "more", "to", "\"", "delivering", "\"", "medicine", ",", "and", "the", "relationship", "between", "the", "surgeon", "and", "his", "patient", "has", "been", "reduced", "to", "a", "collision", "of", "greediness", "on", "both", "sides", ".", "We", "are", "in", "continuous", "conflict", "with", "the", "power", "of", "the", "media", "and", "are", "being", "challenged", "to", "improve", "our", "public", "relations", ".", "The", "public", "image", "of", "surgery", "today", "is", "determined", "by", "surgical", "performance", "and", "competence", "in", "communication", "." ]	[ "umlsterm" ]
Surgery, direct, media, cause, Economic, pressures, resources, medicine, medicine, patient, conflict, power, media, public relations, surgery, surgical, competence, communication	DerChirurg.80691292.eng.abstr_task2	Sentence: Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication .	[ "Surgery", "and", "surgeons", "have", "a", "direct", "relationship", "to", "publicity", ".", "In", "the", "media", ",", "the", "entertainment", "aspect", "prevails", "over", "information", "(", "infotainment", ")", ",", "and", "scandal", "also", "dominates", "because", "of", "negative", "reports", ".", "The", "cause", "in", "many", "cases", "is", "a", "lack", "of", "information", ",", "which", "is", "always", "a", "problem", "when", "transmitting", "scientific", "information", "to", "the", "public", ".", "Economic", "pressures", "and", "diminished", "resources", "as", "well", "as", "a", "simultaneous", "increase", "in", "the", "demands", "made", "on", "medicine", "make", "it", "mandatory", "that", "surgeons", "communicate", "properly", ".", "They", "are", "being", "degraded", "more", "and", "more", "to", "\"", "delivering", "\"", "medicine", ",", "and", "the", "relationship", "between", "the", "surgeon", "and", "his", "patient", "has", "been", "reduced", "to", "a", "collision", "of", "greediness", "on", "both", "sides", ".", "We", "are", "in", "continuous", "conflict", "with", "the", "power", "of", "the", "media", "and", "are", "being", "challenged", "to", "improve", "our", "public", "relations", ".", "The", "public", "image", "of", "surgery", "today", "is", "determined", "by", "surgical", "performance", "and", "competence", "in", "communication", "." ]	[ "umlsterm" ]
thermotherapy is an umlsterm, method is an umlsterm, treatment is an umlsterm, liver tumors is an umlsterm, treatment is an umlsterm, use is an umlsterm, development is an umlsterm, test is an umlsterm, tip is an umlsterm, test is an umlsterm, connective - tissue is an umlsterm, organization is an umlsterm, period is an umlsterm, laser is an umlsterm, test is an umlsterm, liver is an umlsterm, perfusion is an umlsterm, animal is an umlsterm, blood is an umlsterm, perfusion is an umlsterm, laser is an umlsterm, thermotherapy is an umlsterm	DerChirurg.80690930.eng.abstr_task0	Sentence: Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled .	[ "Laser", "-", "induced", "thermotherapy", "is", "an", "in", "situ", "ablation", "method", "for", "the", "local", "treatment", "of", "liver", "tumors", ".", "The", "basic", "prerequisite", "for", "induction", "of", "adequate", "treatment", "volumes", "for", "clinical", "use", "was", "the", "development", "of", "a", "thermostable", "application", "system", ".", "In", "an", "ex", "vivo", "test", "series", ",", "the", "specially", "developed", "application", "system", "(", "diffuser", "tip", ")", "with", "5760", "J", "had", "a", "higher", "thermic", "loading", "capacity", "than", "the", "Ringmode", "applicator", "with", "4200", "J", ",", "thus", "enabling", "the", "induction", "of", "significantly", "larger", "lesions", "with", "a", "volume", "of", "7.6", "cm3", ".", "The", "results", "of", "a", "further", "in", "vivo", "test", "series", "demonstrated", "that", "the", "lesions", "were", "subject", "to", "a", "four", "-", "phase", "connective", "-", "tissue", "organization", "within", "a", "6-month", "period", ".", "Furthermore", ",", "the", "same", "laser", "energy", "(", "4200", "J", ")", "was", "associated", "with", "a", "significantly", "lower", "lesion", "volume", "of", "2.5", "cm3", "in", "the", "in", "vivo", "than", "in", "the", "ex", "vivo", "test", "series", ".", "The", "influence", "of", "liver", "perfusion", "on", "the", "inducible", "lesion", "volume", "was", "examined", "in", "a", "further", "animal", "experimental", "study", ".", "By", "temporarily", "interrupting", "hepatic", "blood", "perfusion", "(", "Pringle", "'s", "maneuver", ")", "during", "laser", "application", ",", "the", "effective", "volume", "could", "be", "increased", "to", "50.3", "cm3", "(", "P", "0.01", ")", "using", "an", "optical", "beam", "splitter", ".", "These", "results", "show", "that", "the", "technical", "prerequisites", "for", "reliable", "clinical", "application", "of", "laser", "-", "induced", "thermotherapy", "have", "been", "fulfilled", "." ]	[ "umlsterm" ]
thermotherapy is an umlsterm, method is an umlsterm, treatment is an umlsterm, liver tumors is an umlsterm, treatment is an umlsterm, use is an umlsterm, development is an umlsterm, test is an umlsterm, tip is an umlsterm, test is an umlsterm, connective - tissue is an umlsterm, organization is an umlsterm, period is an umlsterm, laser is an umlsterm, test is an umlsterm, liver is an umlsterm, perfusion is an umlsterm, animal is an umlsterm, blood is an umlsterm, perfusion is an umlsterm, laser is an umlsterm, thermotherapy is an umlsterm	DerChirurg.80690930.eng.abstr_task1	Sentence: Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled . Instructions: please typing these entity words according to sentence: thermotherapy, method, treatment, liver tumors, treatment, use, development, test, tip, test, connective - tissue, organization, period, laser, test, liver, perfusion, animal, blood, perfusion, laser, thermotherapy Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled .	[ "Laser", "-", "induced", "thermotherapy", "is", "an", "in", "situ", "ablation", "method", "for", "the", "local", "treatment", "of", "liver", "tumors", ".", "The", "basic", "prerequisite", "for", "induction", "of", "adequate", "treatment", "volumes", "for", "clinical", "use", "was", "the", "development", "of", "a", "thermostable", "application", "system", ".", "In", "an", "ex", "vivo", "test", "series", ",", "the", "specially", "developed", "application", "system", "(", "diffuser", "tip", ")", "with", "5760", "J", "had", "a", "higher", "thermic", "loading", "capacity", "than", "the", "Ringmode", "applicator", "with", "4200", "J", ",", "thus", "enabling", "the", "induction", "of", "significantly", "larger", "lesions", "with", "a", "volume", "of", "7.6", "cm3", ".", "The", "results", "of", "a", "further", "in", "vivo", "test", "series", "demonstrated", "that", "the", "lesions", "were", "subject", "to", "a", "four", "-", "phase", "connective", "-", "tissue", "organization", "within", "a", "6-month", "period", ".", "Furthermore", ",", "the", "same", "laser", "energy", "(", "4200", "J", ")", "was", "associated", "with", "a", "significantly", "lower", "lesion", "volume", "of", "2.5", "cm3", "in", "the", "in", "vivo", "than", "in", "the", "ex", "vivo", "test", "series", ".", "The", "influence", "of", "liver", "perfusion", "on", "the", "inducible", "lesion", "volume", "was", "examined", "in", "a", "further", "animal", "experimental", "study", ".", "By", "temporarily", "interrupting", "hepatic", "blood", "perfusion", "(", "Pringle", "'s", "maneuver", ")", "during", "laser", "application", ",", "the", "effective", "volume", "could", "be", "increased", "to", "50.3", "cm3", "(", "P", "0.01", ")", "using", "an", "optical", "beam", "splitter", ".", "These", "results", "show", "that", "the", "technical", "prerequisites", "for", "reliable", "clinical", "application", "of", "laser", "-", "induced", "thermotherapy", "have", "been", "fulfilled", "." ]	[ "umlsterm" ]
thermotherapy, method, treatment, liver tumors, treatment, use, development, test, tip, test, connective - tissue, organization, period, laser, test, liver, perfusion, animal, blood, perfusion, laser, thermotherapy	DerChirurg.80690930.eng.abstr_task2	Sentence: Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled .	[ "Laser", "-", "induced", "thermotherapy", "is", "an", "in", "situ", "ablation", "method", "for", "the", "local", "treatment", "of", "liver", "tumors", ".", "The", "basic", "prerequisite", "for", "induction", "of", "adequate", "treatment", "volumes", "for", "clinical", "use", "was", "the", "development", "of", "a", "thermostable", "application", "system", ".", "In", "an", "ex", "vivo", "test", "series", ",", "the", "specially", "developed", "application", "system", "(", "diffuser", "tip", ")", "with", "5760", "J", "had", "a", "higher", "thermic", "loading", "capacity", "than", "the", "Ringmode", "applicator", "with", "4200", "J", ",", "thus", "enabling", "the", "induction", "of", "significantly", "larger", "lesions", "with", "a", "volume", "of", "7.6", "cm3", ".", "The", "results", "of", "a", "further", "in", "vivo", "test", "series", "demonstrated", "that", "the", "lesions", "were", "subject", "to", "a", "four", "-", "phase", "connective", "-", "tissue", "organization", "within", "a", "6-month", "period", ".", "Furthermore", ",", "the", "same", "laser", "energy", "(", "4200", "J", ")", "was", "associated", "with", "a", "significantly", "lower", "lesion", "volume", "of", "2.5", "cm3", "in", "the", "in", "vivo", "than", "in", "the", "ex", "vivo", "test", "series", ".", "The", "influence", "of", "liver", "perfusion", "on", "the", "inducible", "lesion", "volume", "was", "examined", "in", "a", "further", "animal", "experimental", "study", ".", "By", "temporarily", "interrupting", "hepatic", "blood", "perfusion", "(", "Pringle", "'s", "maneuver", ")", "during", "laser", "application", ",", "the", "effective", "volume", "could", "be", "increased", "to", "50.3", "cm3", "(", "P", "0.01", ")", "using", "an", "optical", "beam", "splitter", ".", "These", "results", "show", "that", "the", "technical", "prerequisites", "for", "reliable", "clinical", "application", "of", "laser", "-", "induced", "thermotherapy", "have", "been", "fulfilled", "." ]	[ "umlsterm" ]
Naevus is an umlsterm, Naevus is an umlsterm, Naevus is an umlsterm, Fallberichte is an umlsterm, Japan is an umlsterm, Naevus flammeus is an umlsterm, Ruecken is an umlsterm, Arm is an umlsterm, Naevus is an umlsterm	DerHautarzt.70480653.ger.abstr_task0	Sentence: Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies .	[ "Kombiniert", "auftretende", "Naevi", "flammei", "mit", "dermalen", "melanozytaeren", "Naevi", "wie", "Mongolenfleck", ",", "Naevus", "fuscocoeruleus", ",", "Naevus", "spilus", "und", "fakultativ", "kombiniert", "mit", "Naevus", "anaemicus", "werden", "klinisch", "-", "morphologisch", "nach", "den", "Erstbeschreibern", "Ota", "et", "al", ".", "als", "Phacomatosis", "pigmentovascularis", "bezeichnet", ".", "Zu", "dieser", "Gruppe", "gehoeren", "4", "Typen", ",", "die", "entweder", "ausschliesslich", "als", "kutane", "Naevi", "oder", "gemeinsam", "mit", "extrakutanen", "Organdefekten", ",", "hauptsaechlich", "in", "Form", "des", "Klippel", "-", "Trenaunay-", "und", "des", "Sturge", "-", "Weber", "-", "Krabbe", "-", "Syndroms", ",", "auftreten", "koennen", ".", "Die", "meisten", "Fallberichte", "ueber", "Phacomatosis", "pigmentovascularis", "stammen", "aus", "Japan", ".", "Wir", "berichten", "ueber", "eine", "30", "Jahre", "alte", "Patientin", ",", "die", "neben", "einem", "Naevus", "flammeus", "am", "Ruecken", "und", "rechten", "Arm", "einen", "dorsalen", "Naevus", "fuscocoeruleus", "aufwies", "." ]	[ "umlsterm" ]
Naevus is an umlsterm, Naevus is an umlsterm, Naevus is an umlsterm, Fallberichte is an umlsterm, Japan is an umlsterm, Naevus flammeus is an umlsterm, Ruecken is an umlsterm, Arm is an umlsterm, Naevus is an umlsterm	DerHautarzt.70480653.ger.abstr_task1	Sentence: Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies . Instructions: please typing these entity words according to sentence: Naevus, Naevus, Naevus, Fallberichte, Japan, Naevus flammeus, Ruecken, Arm, Naevus Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies .	[ "Kombiniert", "auftretende", "Naevi", "flammei", "mit", "dermalen", "melanozytaeren", "Naevi", "wie", "Mongolenfleck", ",", "Naevus", "fuscocoeruleus", ",", "Naevus", "spilus", "und", "fakultativ", "kombiniert", "mit", "Naevus", "anaemicus", "werden", "klinisch", "-", "morphologisch", "nach", "den", "Erstbeschreibern", "Ota", "et", "al", ".", "als", "Phacomatosis", "pigmentovascularis", "bezeichnet", ".", "Zu", "dieser", "Gruppe", "gehoeren", "4", "Typen", ",", "die", "entweder", "ausschliesslich", "als", "kutane", "Naevi", "oder", "gemeinsam", "mit", "extrakutanen", "Organdefekten", ",", "hauptsaechlich", "in", "Form", "des", "Klippel", "-", "Trenaunay-", "und", "des", "Sturge", "-", "Weber", "-", "Krabbe", "-", "Syndroms", ",", "auftreten", "koennen", ".", "Die", "meisten", "Fallberichte", "ueber", "Phacomatosis", "pigmentovascularis", "stammen", "aus", "Japan", ".", "Wir", "berichten", "ueber", "eine", "30", "Jahre", "alte", "Patientin", ",", "die", "neben", "einem", "Naevus", "flammeus", "am", "Ruecken", "und", "rechten", "Arm", "einen", "dorsalen", "Naevus", "fuscocoeruleus", "aufwies", "." ]	[ "umlsterm" ]
Naevus, Naevus, Naevus, Fallberichte, Japan, Naevus flammeus, Ruecken, Arm, Naevus	DerHautarzt.70480653.ger.abstr_task2	Sentence: Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies .	[ "Kombiniert", "auftretende", "Naevi", "flammei", "mit", "dermalen", "melanozytaeren", "Naevi", "wie", "Mongolenfleck", ",", "Naevus", "fuscocoeruleus", ",", "Naevus", "spilus", "und", "fakultativ", "kombiniert", "mit", "Naevus", "anaemicus", "werden", "klinisch", "-", "morphologisch", "nach", "den", "Erstbeschreibern", "Ota", "et", "al", ".", "als", "Phacomatosis", "pigmentovascularis", "bezeichnet", ".", "Zu", "dieser", "Gruppe", "gehoeren", "4", "Typen", ",", "die", "entweder", "ausschliesslich", "als", "kutane", "Naevi", "oder", "gemeinsam", "mit", "extrakutanen", "Organdefekten", ",", "hauptsaechlich", "in", "Form", "des", "Klippel", "-", "Trenaunay-", "und", "des", "Sturge", "-", "Weber", "-", "Krabbe", "-", "Syndroms", ",", "auftreten", "koennen", ".", "Die", "meisten", "Fallberichte", "ueber", "Phacomatosis", "pigmentovascularis", "stammen", "aus", "Japan", ".", "Wir", "berichten", "ueber", "eine", "30", "Jahre", "alte", "Patientin", ",", "die", "neben", "einem", "Naevus", "flammeus", "am", "Ruecken", "und", "rechten", "Arm", "einen", "dorsalen", "Naevus", "fuscocoeruleus", "aufwies", "." ]	[ "umlsterm" ]
Healthy is a Condition, women is a Person, ages is a Person, 18 to 39yo is a Value, BMI is a Measurement, < 30 is a Value, Regular menstrual cycles is a Condition, duration is a Measurement, between 24 - 35 days is a Value, progesterone level is a Measurement, 5ng / mL or greater is a Value, non - hormonal form of contraception is a Procedure, sterilization ( tubal ligation , Essure ) , copper IUD ( intrauterine device ) , barrier methods or abstinence is a Scope	NCT03120728_inc_task0	Sentence: Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Procedure, Scope, Measurement	[ "B-Condition", "O", "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O" ]	Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish	[ "Healthy", ",", "women", "ages", "18", "to", "39yo", "with", "BMI", "<", "30", "\n", "Regular", "menstrual", "cycles", "with", "duration", "between", "24", "-", "35", "days", "\n", "Completion", "of", "screening", "visit", "where", "ovulation", "will", "be", "assessed", "with", "blood", "draw", "for", "progesterone", "level", "(", "must", "be", "5ng", "/", "mL", "or", "greater", ")", "\n", "Not", "seeking", "pregnancy", "during", "the", "study", "period", "\n", "Use", "of", "a", "non", "-", "hormonal", "form", "of", "contraception", ",", "such", "as", ":", "sterilization", "(", "tubal", "ligation", ",", "Essure", ")", ",", "copper", "IUD", "(", "intrauterine", "device", ")", ",", "barrier", "methods", "or", "abstinence", "\n", "Must", "speak", "English", "or", "Spanish", "\n" ]	[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Observation", "Person" ]
Healthy is a Condition, women is a Person, ages is a Person, 18 to 39yo is a Value, BMI is a Measurement, < 30 is a Value, Regular menstrual cycles is a Condition, duration is a Measurement, between 24 - 35 days is a Value, progesterone level is a Measurement, 5ng / mL or greater is a Value, non - hormonal form of contraception is a Procedure, sterilization ( tubal ligation , Essure ) , copper IUD ( intrauterine device ) , barrier methods or abstinence is a Scope	NCT03120728_inc_task1	Sentence: Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish Instructions: please typing these entity words according to sentence: Healthy, women, ages, 18 to 39yo, BMI, < 30, Regular menstrual cycles, duration, between 24 - 35 days, progesterone level, 5ng / mL or greater, non - hormonal form of contraception, sterilization ( tubal ligation , Essure ) , copper IUD ( intrauterine device ) , barrier methods or abstinence Options: Condition, Value, Person, Procedure, Scope, Measurement	[ "B-Condition", "O", "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O" ]	Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish	[ "Healthy", ",", "women", "ages", "18", "to", "39yo", "with", "BMI", "<", "30", "\n", "Regular", "menstrual", "cycles", "with", "duration", "between", "24", "-", "35", "days", "\n", "Completion", "of", "screening", "visit", "where", "ovulation", "will", "be", "assessed", "with", "blood", "draw", "for", "progesterone", "level", "(", "must", "be", "5ng", "/", "mL", "or", "greater", ")", "\n", "Not", "seeking", "pregnancy", "during", "the", "study", "period", "\n", "Use", "of", "a", "non", "-", "hormonal", "form", "of", "contraception", ",", "such", "as", ":", "sterilization", "(", "tubal", "ligation", ",", "Essure", ")", ",", "copper", "IUD", "(", "intrauterine", "device", ")", ",", "barrier", "methods", "or", "abstinence", "\n", "Must", "speak", "English", "or", "Spanish", "\n" ]	[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Observation", "Person" ]
Healthy, women, ages, 18 to 39yo, BMI, < 30, Regular menstrual cycles, duration, between 24 - 35 days, progesterone level, 5ng / mL or greater, non - hormonal form of contraception, sterilization ( tubal ligation , Essure ) , copper IUD ( intrauterine device ) , barrier methods or abstinence	NCT03120728_inc_task2	Sentence: Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish Instructions: please extract entity words from the input sentence	[ "B-Condition", "O", "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O" ]	Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish	[ "Healthy", ",", "women", "ages", "18", "to", "39yo", "with", "BMI", "<", "30", "\n", "Regular", "menstrual", "cycles", "with", "duration", "between", "24", "-", "35", "days", "\n", "Completion", "of", "screening", "visit", "where", "ovulation", "will", "be", "assessed", "with", "blood", "draw", "for", "progesterone", "level", "(", "must", "be", "5ng", "/", "mL", "or", "greater", ")", "\n", "Not", "seeking", "pregnancy", "during", "the", "study", "period", "\n", "Use", "of", "a", "non", "-", "hormonal", "form", "of", "contraception", ",", "such", "as", ":", "sterilization", "(", "tubal", "ligation", ",", "Essure", ")", ",", "copper", "IUD", "(", "intrauterine", "device", ")", ",", "barrier", "methods", "or", "abstinence", "\n", "Must", "speak", "English", "or", "Spanish", "\n" ]	[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Observation", "Person" ]
INVIRASE is a BRAND, FORTOVASE is a BRAND, FORTOVASE is a BRAND, INVIRASE is a BRAND, ritonavir is a DRUG, ritonavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, INVIRASE is a BRAND, Ritonavir is a DRUG, Antiarrhythmics is a GROUP, Amiodarone is a DRUG, bepridil is a DRUG, flecainide is a DRUG, propafenone is a DRUG, quinidine is a DRUG, Antihistamines is a DRUG, astemizole is a DRUG, terfenadine is a DRUG, Ergot Derivatives is a GROUP, Dihydroergotamine is a DRUG, ergonovine is a DRUG, ergotamine is a DRUG, methylergonovine is a DRUG, ergot is a GROUP, Antimycobacterial Agents is a GROUP, rifampin is a DRUG, saquinavir is a DRUG, antiretroviral is a GROUP, saquinavir is a DRUG, saquinavir is a DRUG, FORTOVASE is a BRAND, protease inhibitor is a GROUP, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, FORTOVASE is a BRAND, ritonavir is a DRUG, cisapride is a DRUG, INVIRASE is a BRAND, HMG - CoA Reductase Inhibitors is a GROUP, lovastatin is a DRUG, simvastatin is a DRUG, Sedatives is a GROUP, Hypnotics is a GROUP, triazolam is a DRUG, midazolam is a DRUG, calcium channel blockers is a GROUP, dapsone is a DRUG, disopyramide is a DRUG, quinine is a DRUG, amiodarone is a DRUG, quinidine is a DRUG, warfarin is a DRUG, tacrolimus is a DRUG, cyclosporine is a DRUG, ergot derivatives is a GROUP, pimozide is a DRUG, carbamazepine is a DRUG, fentanyl is a DRUG, alfentanyl is a DRUG, alprazolam is a DRUG, triazolam is a DRUG, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, ritonavir is a DRUG, phenobarbital is a DRUG, phenytoin is a DRUG, dexamethasone is a DRUG, carbamazepine is a DRUG, saquinavir is a DRUG	Saquinavir_ddi_task0	Sentence: DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole, terfenadine CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG, BRAND	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]	DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole, terfenadine CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.	[ "DRUG", "INTERACTIONS", "Several", "drug", "interaction", "studies", "have", "been", "completed", "with", "both", "INVIRASE", "and", "FORTOVASE", ".", "Observations", "from", "drug", "interaction", "studies", "with", "FORTOVASE", "may", "not", "be", "predictive", "for", "INVIRASE", ".", "Because", "ritonavir", "is", "coadministered", ",", "prescribers", "should", "also", "refer", "to", "the", "prescribing", "information", "for", "ritonavir", "regarding", "drug", "interactions", "associated", "with", "this", "agent", ".", "The", "metabolism", "of", "saquinavir", "is", "mediated", "by", "cytochrome", "P450", ",", "with", "the", "specific", "isoenzyme", "CYP3A4", "responsible", "for", "90", "%", "of", "the", "hepatic", "metabolism", ".", "Additionally", ",", "saquinavir", "is", "a", "substrate", "for", "P", "-", "Glycoprotein", "(", "Pgp", ")", ".", "Therefore", ",", "drugs", "that", "affect", "CYP3A4", "and", "/", "or", "Pgp", ",", "may", "modify", "the", "pharmacokinetics", "of", "saquinavir", ".", "Similarly", ",", "saquinavir", "might", "also", "modify", "the", "pharmacokinetics", "of", "other", "drugs", "that", "are", "substrates", "for", "CYP3A4", "or", "Pgp", ".", "Drugs", "that", "are", "contraindicated", "specifically", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "adverse", "events", "are", "listed", "CONTRAINDICATIONS", ".", "Additional", "drugs", "that", "are", "not", "recommended", "for", "coadministration", "with", "INVIRASE", "and", "ritonavir", "are", "included", "below", ".", "These", "recommendations", "are", "based", "on", "either", "drug", "interaction", "studies", "or", "predicted", "interactions", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "events", "or", "loss", "of", "efficacy", ".", "With", "some", "agents", ",", "the", "metabolism", "may", "be", "induced", ",", "resulting", "in", "decreased", "concentrations", ".", "Drugs", "That", "Should", "Not", "Be", "Coadministered", "With", "INVIRASE", "/", "Ritonavir", "Drug", "Class", ":", "Drug", "Name", "Clinical", "Comment", "Antiarrhythmics", ":", "Amiodarone", ",", "bepridil", ",", "flecainide", ",", "propafenone", ",", "quinidine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", ".", "Antihistamines", ":", "astemizole", "", ",", "terfenadine", "", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "cardiac", "arrhythmias", ".", "Ergot", "Derivatives", ":", "Dihydroergotamine", ",", "ergonovine", ",", "ergotamine", ",", "methylergonovine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "life", "-", "threatening", "reactions", "such", "as", "acute", "ergot", "toxicity", "characterized", "by", "peripheral", "vasospasm", "and", "ischemia", "of", "the", "extremities", "and", "other", "tissues", ".", "Antimycobacterial", "Agents", ":", "rifampin", "CONTRAINDICATED", "since", "the", "coadministration", "of", "this", "product", "with", "saquinavir", "in", "an", "antiretroviral", "regimen", "reduces", "the", "plasma", "concentrations", "of", "saquinavir", ".", "Garlic", "Capsules", "Garlic", "capsules", "should", "not", "be", "used", "while", "taking", "saquinavir", "(", "FORTOVASE", ")", "as", "the", "sole", "protease", "inhibitor", "due", "to", "the", "risk", "of", "decreased", "saquinavir", "plasma", "concentrations", ".", "No", "data", "are", "available", "for", "the", "coadministration", "of", "INVIRASE", "/", "ritonavir", "or", "FORTOVASE", "/", "ritonavir", "and", "garlic", "capsules", ".", "GI", "Motility", "Agent", ":", "cisapride", "", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "cardiac", "arrhythmias", ".", "Herbal", "Products", ":", "St", ".", "John", "s", "wort", "(", "hypericum", "perforatum", ")", "WARNING", "coadministration", "may", "lead", "to", "loss", "of", "virologic", "response", "and", "possible", "resistance", "to", "INVIRASE", "or", "to", "the", "class", "of", "protease", "inhibitors", ".", "HMG", "-", "CoA", "Reductase", "Inhibitors", ":", "lovastatin", ",", "simvastatin", "WARNING", "potential", "for", "serious", "reactions", "such", "as", "risk", "of", "myopathy", "including", "rhabdomyolysis", ".", "Sedatives", "/", "Hypnotics", ":", "triazolam", ",", "midazolam", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "prolonged", "or", "increased", "sedation", "or", "respiratory", "depression", ".", "", "No", "longer", "marketed", "in", "the", "US", ".", "Drugs", "That", "Are", "Mainly", "Metabolized", "by", "CYP3A4", "Although", "specific", "studies", "have", "not", "been", "performed", ",", "coadministration", "with", "drugs", "that", "are", "mainly", "metabolized", "by", "CYP3A4", "(", "eg", ",", "calcium", "channel", "blockers", ",", "dapsone", ",", "disopyramide", ",", "quinine", ",", "amiodarone", ",", "quinidine", ",", "warfarin", ",", "tacrolimus", ",", "cyclosporine", ",", "ergot", "derivatives", ",", "pimozide", ",", "carbamazepine", ",", "fentanyl", ",", "alfentanyl", ",", "alprazolam", ",", "and", "triazolam", ")", "may", "have", "elevated", "plasma", "concentrations", "when", "coadministered", "with", "saquinavir", ";", "therefore", ",", "these", "combinations", "should", "be", "used", "with", "caution", ".", "Since", "INVIRASE", "is", "coadministered", "with", "ritonavir", ",", "the", "ritonavir", "label", "should", "be", "reviewed", "for", "additional", "drugs", "that", "should", "not", "be", "coadministered", ".", "Inducers", "of", "CYP3A4", "Coadministration", "with", "compounds", "that", "are", "potent", "inducers", "of", "CYP3A4", "(", "eg", ",", "phenobarbital", ",", "phenytoin", ",", "dexamethasone", ",", "carbamazepine", ")", "may", "result", "in", "decreased", "plasma", "levels", "of", "saquinavir", "." ]	[ "GROUP", "DRUG", "BRAND" ]
INVIRASE is a BRAND, FORTOVASE is a BRAND, FORTOVASE is a BRAND, INVIRASE is a BRAND, ritonavir is a DRUG, ritonavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, INVIRASE is a BRAND, Ritonavir is a DRUG, Antiarrhythmics is a GROUP, Amiodarone is a DRUG, bepridil is a DRUG, flecainide is a DRUG, propafenone is a DRUG, quinidine is a DRUG, Antihistamines is a DRUG, astemizole is a DRUG, terfenadine is a DRUG, Ergot Derivatives is a GROUP, Dihydroergotamine is a DRUG, ergonovine is a DRUG, ergotamine is a DRUG, methylergonovine is a DRUG, ergot is a GROUP, Antimycobacterial Agents is a GROUP, rifampin is a DRUG, saquinavir is a DRUG, antiretroviral is a GROUP, saquinavir is a DRUG, saquinavir is a DRUG, FORTOVASE is a BRAND, protease inhibitor is a GROUP, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, FORTOVASE is a BRAND, ritonavir is a DRUG, cisapride is a DRUG, INVIRASE is a BRAND, HMG - CoA Reductase Inhibitors is a GROUP, lovastatin is a DRUG, simvastatin is a DRUG, Sedatives is a GROUP, Hypnotics is a GROUP, triazolam is a DRUG, midazolam is a DRUG, calcium channel blockers is a GROUP, dapsone is a DRUG, disopyramide is a DRUG, quinine is a DRUG, amiodarone is a DRUG, quinidine is a DRUG, warfarin is a DRUG, tacrolimus is a DRUG, cyclosporine is a DRUG, ergot derivatives is a GROUP, pimozide is a DRUG, carbamazepine is a DRUG, fentanyl is a DRUG, alfentanyl is a DRUG, alprazolam is a DRUG, triazolam is a DRUG, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, ritonavir is a DRUG, phenobarbital is a DRUG, phenytoin is a DRUG, dexamethasone is a DRUG, carbamazepine is a DRUG, saquinavir is a DRUG	Saquinavir_ddi_task1	Sentence: DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole, terfenadine CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir. Instructions: please typing these entity words according to sentence: INVIRASE, FORTOVASE, FORTOVASE, INVIRASE, ritonavir, ritonavir, saquinavir, saquinavir, saquinavir, saquinavir, INVIRASE, ritonavir, INVIRASE, Ritonavir, Antiarrhythmics, Amiodarone, bepridil, flecainide, propafenone, quinidine, Antihistamines, astemizole, terfenadine, Ergot Derivatives, Dihydroergotamine, ergonovine, ergotamine, methylergonovine, ergot, Antimycobacterial Agents, rifampin, saquinavir, antiretroviral, saquinavir, saquinavir, FORTOVASE, protease inhibitor, saquinavir, INVIRASE, ritonavir, FORTOVASE, ritonavir, cisapride, INVIRASE, HMG - CoA Reductase Inhibitors, lovastatin, simvastatin, Sedatives, Hypnotics, triazolam, midazolam, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, triazolam, saquinavir, INVIRASE, ritonavir, ritonavir, phenobarbital, phenytoin, dexamethasone, carbamazepine, saquinavir Options: GROUP, DRUG, BRAND	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]	DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole, terfenadine CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.	[ "DRUG", "INTERACTIONS", "Several", "drug", "interaction", "studies", "have", "been", "completed", "with", "both", "INVIRASE", "and", "FORTOVASE", ".", "Observations", "from", "drug", "interaction", "studies", "with", "FORTOVASE", "may", "not", "be", "predictive", "for", "INVIRASE", ".", "Because", "ritonavir", "is", "coadministered", ",", "prescribers", "should", "also", "refer", "to", "the", "prescribing", "information", "for", "ritonavir", "regarding", "drug", "interactions", "associated", "with", "this", "agent", ".", "The", "metabolism", "of", "saquinavir", "is", "mediated", "by", "cytochrome", "P450", ",", "with", "the", "specific", "isoenzyme", "CYP3A4", "responsible", "for", "90", "%", "of", "the", "hepatic", "metabolism", ".", "Additionally", ",", "saquinavir", "is", "a", "substrate", "for", "P", "-", "Glycoprotein", "(", "Pgp", ")", ".", "Therefore", ",", "drugs", "that", "affect", "CYP3A4", "and", "/", "or", "Pgp", ",", "may", "modify", "the", "pharmacokinetics", "of", "saquinavir", ".", "Similarly", ",", "saquinavir", "might", "also", "modify", "the", "pharmacokinetics", "of", "other", "drugs", "that", "are", "substrates", "for", "CYP3A4", "or", "Pgp", ".", "Drugs", "that", "are", "contraindicated", "specifically", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "adverse", "events", "are", "listed", "CONTRAINDICATIONS", ".", "Additional", "drugs", "that", "are", "not", "recommended", "for", "coadministration", "with", "INVIRASE", "and", "ritonavir", "are", "included", "below", ".", "These", "recommendations", "are", "based", "on", "either", "drug", "interaction", "studies", "or", "predicted", "interactions", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "events", "or", "loss", "of", "efficacy", ".", "With", "some", "agents", ",", "the", "metabolism", "may", "be", "induced", ",", "resulting", "in", "decreased", "concentrations", ".", "Drugs", "That", "Should", "Not", "Be", "Coadministered", "With", "INVIRASE", "/", "Ritonavir", "Drug", "Class", ":", "Drug", "Name", "Clinical", "Comment", "Antiarrhythmics", ":", "Amiodarone", ",", "bepridil", ",", "flecainide", ",", "propafenone", ",", "quinidine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", ".", "Antihistamines", ":", "astemizole", "", ",", "terfenadine", "", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "cardiac", "arrhythmias", ".", "Ergot", "Derivatives", ":", "Dihydroergotamine", ",", "ergonovine", ",", "ergotamine", ",", "methylergonovine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "life", "-", "threatening", "reactions", "such", "as", "acute", "ergot", "toxicity", "characterized", "by", "peripheral", "vasospasm", "and", "ischemia", "of", "the", "extremities", "and", "other", "tissues", ".", "Antimycobacterial", "Agents", ":", "rifampin", "CONTRAINDICATED", "since", "the", "coadministration", "of", "this", "product", "with", "saquinavir", "in", "an", "antiretroviral", "regimen", "reduces", "the", "plasma", "concentrations", "of", "saquinavir", ".", "Garlic", "Capsules", "Garlic", "capsules", "should", "not", "be", "used", "while", "taking", "saquinavir", "(", "FORTOVASE", ")", "as", "the", "sole", "protease", "inhibitor", "due", "to", "the", "risk", "of", "decreased", "saquinavir", "plasma", "concentrations", ".", "No", "data", "are", "available", "for", "the", "coadministration", "of", "INVIRASE", "/", "ritonavir", "or", "FORTOVASE", "/", "ritonavir", "and", "garlic", "capsules", ".", "GI", "Motility", "Agent", ":", "cisapride", "", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "cardiac", "arrhythmias", ".", "Herbal", "Products", ":", "St", ".", "John", "s", "wort", "(", "hypericum", "perforatum", ")", "WARNING", "coadministration", "may", "lead", "to", "loss", "of", "virologic", "response", "and", "possible", "resistance", "to", "INVIRASE", "or", "to", "the", "class", "of", "protease", "inhibitors", ".", "HMG", "-", "CoA", "Reductase", "Inhibitors", ":", "lovastatin", ",", "simvastatin", "WARNING", "potential", "for", "serious", "reactions", "such", "as", "risk", "of", "myopathy", "including", "rhabdomyolysis", ".", "Sedatives", "/", "Hypnotics", ":", "triazolam", ",", "midazolam", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "prolonged", "or", "increased", "sedation", "or", "respiratory", "depression", ".", "", "No", "longer", "marketed", "in", "the", "US", ".", "Drugs", "That", "Are", "Mainly", "Metabolized", "by", "CYP3A4", "Although", "specific", "studies", "have", "not", "been", "performed", ",", "coadministration", "with", "drugs", "that", "are", "mainly", "metabolized", "by", "CYP3A4", "(", "eg", ",", "calcium", "channel", "blockers", ",", "dapsone", ",", "disopyramide", ",", "quinine", ",", "amiodarone", ",", "quinidine", ",", "warfarin", ",", "tacrolimus", ",", "cyclosporine", ",", "ergot", "derivatives", ",", "pimozide", ",", "carbamazepine", ",", "fentanyl", ",", "alfentanyl", ",", "alprazolam", ",", "and", "triazolam", ")", "may", "have", "elevated", "plasma", "concentrations", "when", "coadministered", "with", "saquinavir", ";", "therefore", ",", "these", "combinations", "should", "be", "used", "with", "caution", ".", "Since", "INVIRASE", "is", "coadministered", "with", "ritonavir", ",", "the", "ritonavir", "label", "should", "be", "reviewed", "for", "additional", "drugs", "that", "should", "not", "be", "coadministered", ".", "Inducers", "of", "CYP3A4", "Coadministration", "with", "compounds", "that", "are", "potent", "inducers", "of", "CYP3A4", "(", "eg", ",", "phenobarbital", ",", "phenytoin", ",", "dexamethasone", ",", "carbamazepine", ")", "may", "result", "in", "decreased", "plasma", "levels", "of", "saquinavir", "." ]	[ "GROUP", "DRUG", "BRAND" ]
INVIRASE, FORTOVASE, FORTOVASE, INVIRASE, ritonavir, ritonavir, saquinavir, saquinavir, saquinavir, saquinavir, INVIRASE, ritonavir, INVIRASE, Ritonavir, Antiarrhythmics, Amiodarone, bepridil, flecainide, propafenone, quinidine, Antihistamines, astemizole, terfenadine, Ergot Derivatives, Dihydroergotamine, ergonovine, ergotamine, methylergonovine, ergot, Antimycobacterial Agents, rifampin, saquinavir, antiretroviral, saquinavir, saquinavir, FORTOVASE, protease inhibitor, saquinavir, INVIRASE, ritonavir, FORTOVASE, ritonavir, cisapride, INVIRASE, HMG - CoA Reductase Inhibitors, lovastatin, simvastatin, Sedatives, Hypnotics, triazolam, midazolam, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, triazolam, saquinavir, INVIRASE, ritonavir, ritonavir, phenobarbital, phenytoin, dexamethasone, carbamazepine, saquinavir	Saquinavir_ddi_task2	Sentence: DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole, terfenadine CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]	DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole, terfenadine CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.	[ "DRUG", "INTERACTIONS", "Several", "drug", "interaction", "studies", "have", "been", "completed", "with", "both", "INVIRASE", "and", "FORTOVASE", ".", "Observations", "from", "drug", "interaction", "studies", "with", "FORTOVASE", "may", "not", "be", "predictive", "for", "INVIRASE", ".", "Because", "ritonavir", "is", "coadministered", ",", "prescribers", "should", "also", "refer", "to", "the", "prescribing", "information", "for", "ritonavir", "regarding", "drug", "interactions", "associated", "with", "this", "agent", ".", "The", "metabolism", "of", "saquinavir", "is", "mediated", "by", "cytochrome", "P450", ",", "with", "the", "specific", "isoenzyme", "CYP3A4", "responsible", "for", "90", "%", "of", "the", "hepatic", "metabolism", ".", "Additionally", ",", "saquinavir", "is", "a", "substrate", "for", "P", "-", "Glycoprotein", "(", "Pgp", ")", ".", "Therefore", ",", "drugs", "that", "affect", "CYP3A4", "and", "/", "or", "Pgp", ",", "may", "modify", "the", "pharmacokinetics", "of", "saquinavir", ".", "Similarly", ",", "saquinavir", "might", "also", "modify", "the", "pharmacokinetics", "of", "other", "drugs", "that", "are", "substrates", "for", "CYP3A4", "or", "Pgp", ".", "Drugs", "that", "are", "contraindicated", "specifically", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "adverse", "events", "are", "listed", "CONTRAINDICATIONS", ".", "Additional", "drugs", "that", "are", "not", "recommended", "for", "coadministration", "with", "INVIRASE", "and", "ritonavir", "are", "included", "below", ".", "These", "recommendations", "are", "based", "on", "either", "drug", "interaction", "studies", "or", "predicted", "interactions", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "events", "or", "loss", "of", "efficacy", ".", "With", "some", "agents", ",", "the", "metabolism", "may", "be", "induced", ",", "resulting", "in", "decreased", "concentrations", ".", "Drugs", "That", "Should", "Not", "Be", "Coadministered", "With", "INVIRASE", "/", "Ritonavir", "Drug", "Class", ":", "Drug", "Name", "Clinical", "Comment", "Antiarrhythmics", ":", "Amiodarone", ",", "bepridil", ",", "flecainide", ",", "propafenone", ",", "quinidine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", ".", "Antihistamines", ":", "astemizole", "", ",", "terfenadine", "", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "cardiac", "arrhythmias", ".", "Ergot", "Derivatives", ":", "Dihydroergotamine", ",", "ergonovine", ",", "ergotamine", ",", "methylergonovine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "life", "-", "threatening", "reactions", "such", "as", "acute", "ergot", "toxicity", "characterized", "by", "peripheral", "vasospasm", "and", "ischemia", "of", "the", "extremities", "and", "other", "tissues", ".", "Antimycobacterial", "Agents", ":", "rifampin", "CONTRAINDICATED", "since", "the", "coadministration", "of", "this", "product", "with", "saquinavir", "in", "an", "antiretroviral", "regimen", "reduces", "the", "plasma", "concentrations", "of", "saquinavir", ".", "Garlic", "Capsules", "Garlic", "capsules", "should", "not", "be", "used", "while", "taking", "saquinavir", "(", "FORTOVASE", ")", "as", "the", "sole", "protease", "inhibitor", "due", "to", "the", "risk", "of", "decreased", "saquinavir", "plasma", "concentrations", ".", "No", "data", "are", "available", "for", "the", "coadministration", "of", "INVIRASE", "/", "ritonavir", "or", "FORTOVASE", "/", "ritonavir", "and", "garlic", "capsules", ".", "GI", "Motility", "Agent", ":", "cisapride", "", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "cardiac", "arrhythmias", ".", "Herbal", "Products", ":", "St", ".", "John", "s", "wort", "(", "hypericum", "perforatum", ")", "WARNING", "coadministration", "may", "lead", "to", "loss", "of", "virologic", "response", "and", "possible", "resistance", "to", "INVIRASE", "or", "to", "the", "class", "of", "protease", "inhibitors", ".", "HMG", "-", "CoA", "Reductase", "Inhibitors", ":", "lovastatin", ",", "simvastatin", "WARNING", "potential", "for", "serious", "reactions", "such", "as", "risk", "of", "myopathy", "including", "rhabdomyolysis", ".", "Sedatives", "/", "Hypnotics", ":", "triazolam", ",", "midazolam", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "prolonged", "or", "increased", "sedation", "or", "respiratory", "depression", ".", "", "No", "longer", "marketed", "in", "the", "US", ".", "Drugs", "That", "Are", "Mainly", "Metabolized", "by", "CYP3A4", "Although", "specific", "studies", "have", "not", "been", "performed", ",", "coadministration", "with", "drugs", "that", "are", "mainly", "metabolized", "by", "CYP3A4", "(", "eg", ",", "calcium", "channel", "blockers", ",", "dapsone", ",", "disopyramide", ",", "quinine", ",", "amiodarone", ",", "quinidine", ",", "warfarin", ",", "tacrolimus", ",", "cyclosporine", ",", "ergot", "derivatives", ",", "pimozide", ",", "carbamazepine", ",", "fentanyl", ",", "alfentanyl", ",", "alprazolam", ",", "and", "triazolam", ")", "may", "have", "elevated", "plasma", "concentrations", "when", "coadministered", "with", "saquinavir", ";", "therefore", ",", "these", "combinations", "should", "be", "used", "with", "caution", ".", "Since", "INVIRASE", "is", "coadministered", "with", "ritonavir", ",", "the", "ritonavir", "label", "should", "be", "reviewed", "for", "additional", "drugs", "that", "should", "not", "be", "coadministered", ".", "Inducers", "of", "CYP3A4", "Coadministration", "with", "compounds", "that", "are", "potent", "inducers", "of", "CYP3A4", "(", "eg", ",", "phenobarbital", ",", "phenytoin", ",", "dexamethasone", ",", "carbamazepine", ")", "may", "result", "in", "decreased", "plasma", "levels", "of", "saquinavir", "." ]	[ "GROUP", "DRUG", "BRAND" ]
APC is a protein, β - Catenin is a protein-family, β - Catenin is a protein-family, Wingless ( Wnt ) signal transduction pathway is a process	1.0alpha7.train.1303_task0	Sentence: In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: process, protein-family, protein	[ "O", "O", "O", "O", "O", "B-protein", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "B-process", "I-process", "I-process", "I-process", "I-process", "I-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999).	[ "In", "particular", ",", "binding", "of", "APC", "to", "β", "-", "Catenin", "(", "Rubinfeld", "et", "al", ".", "1993", ")", "is", "thought", "to", "regulate", "the", "activity", "of", "β", "-", "Catenin", "in", "the", "evolutionary", "conserved", "Wingless", "(", "Wnt", ")", "signal", "transduction", "pathway", "(", "for", "review", ",", "see", "Polakis", "1997", ";", "Wodarz", "and", "Nusse", "1998", ";", "Peifer", "1999", ")", "." ]	[ "process", "protein-family", "protein" ]
APC is a protein, β - Catenin is a protein-family, β - Catenin is a protein-family, Wingless ( Wnt ) signal transduction pathway is a process	1.0alpha7.train.1303_task1	Sentence: In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999). Instructions: please typing these entity words according to sentence: APC, β - Catenin, β - Catenin, Wingless ( Wnt ) signal transduction pathway Options: process, protein-family, protein	[ "O", "O", "O", "O", "O", "B-protein", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "B-process", "I-process", "I-process", "I-process", "I-process", "I-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999).	[ "In", "particular", ",", "binding", "of", "APC", "to", "β", "-", "Catenin", "(", "Rubinfeld", "et", "al", ".", "1993", ")", "is", "thought", "to", "regulate", "the", "activity", "of", "β", "-", "Catenin", "in", "the", "evolutionary", "conserved", "Wingless", "(", "Wnt", ")", "signal", "transduction", "pathway", "(", "for", "review", ",", "see", "Polakis", "1997", ";", "Wodarz", "and", "Nusse", "1998", ";", "Peifer", "1999", ")", "." ]	[ "process", "protein-family", "protein" ]
APC, β - Catenin, β - Catenin, Wingless ( Wnt ) signal transduction pathway	1.0alpha7.train.1303_task2	Sentence: In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-protein", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "B-process", "I-process", "I-process", "I-process", "I-process", "I-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999).	[ "In", "particular", ",", "binding", "of", "APC", "to", "β", "-", "Catenin", "(", "Rubinfeld", "et", "al", ".", "1993", ")", "is", "thought", "to", "regulate", "the", "activity", "of", "β", "-", "Catenin", "in", "the", "evolutionary", "conserved", "Wingless", "(", "Wnt", ")", "signal", "transduction", "pathway", "(", "for", "review", ",", "see", "Polakis", "1997", ";", "Wodarz", "and", "Nusse", "1998", ";", "Peifer", "1999", ")", "." ]	[ "process", "protein-family", "protein" ]
lorglumide is a CHEMICAL, cholecystokinin is a GENE-Y, 5-(dipentylamino)-5-oxo - pentanoic acid is a CHEMICAL, cholecystokinin is a GENE-Y, CCK is a GENE-Y, D , L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo - pen tanoic acid is a CHEMICAL, lorglumide is a CHEMICAL, CR 1409 is a CHEMICAL, CCK receptors is a GENE-N, CCK is a GENE-Y, CCK is a GENE-Y, amylase is a GENE-N, lorglumide is a CHEMICAL, CCK-8 is a GENE-N, ceruletide is a CHEMICAL, caerulein is a CHEMICAL, CCK-8 is a GENE-Y, Lorglumide is a CHEMICAL, CCK is a GENE-Y, lorglumide is a CHEMICAL, CCK is a GENE-Y	24137_task0	Sentence: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O" ]	Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected.	[ "Pharmacological", "properties", "of", "lorglumide", "as", "a", "member", "of", "a", "new", "class", "of", "cholecystokinin", "antagonists", ".", "\n", "Derivatives", "of", "5-(dipentylamino)-5-oxo", "-", "pentanoic", "acid", "are", "a", "new", "class", "of", "non", "-", "peptide", "cholecystokinin", "(", "CCK", ")", "antagonists", ".", "The", "most", "potent", "compound", ",", "D", ",", "L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo", "-", "pen", "tanoic", "acid", "(", "lorglumide", ",", "CR", "1409", ")", ",", "has", "a", "great", "affinity", "for", "the", "pancreatic", "CCK", "receptors", "and", "is", "a", "competitive", ",", "specific", "and", "potent", "CCK", "antagonist", "on", "the", "smooth", "muscles", "of", "the", "gall", "bladder", "and", "ileum", "of", "the", "guinea", "pig", "and", "on", "the", "CCK", "-", "induced", "amylase", "secretion", "of", "isolated", "pancreatic", "acini", ".", "In", "vivo", "lorglumide", "antagonizes", "the", "contraction", "of", "the", "gall", "bladder", "of", "the", "guinea", "pig", "and", "of", "the", "dog", "provoked", "by", "i.v", ".", "CCK-8", "or", "ceruletide", "(", "caerulein", ")", ".", "It", "antagonizes", "the", "satiety", "effect", "of", "CCK-8", "in", "the", "rat", "and", "is", "protective", "against", "ceruletide-", ",", "taurocholate-", "and", "diet", "-", "induced", "pancreatitis", ".", "Lorglumide", "is", "therefore", "a", "useful", "pharmacological", "tool", "to", "study", "the", "functions", "of", "CCK", ".", "For", "its", "pharmacological", "properties", ",", "its", "relatively", "low", "toxicity", "and", "because", "it", "is", "active", "also", "after", "oral", "administration", ",", "lorglumide", "is", "a", "candidate", "for", "diagnostic", "or", "therapeutic", "use", "in", "man", "when", "an", "involvement", "of", "CCK", "is", "suspected", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
lorglumide is a CHEMICAL, cholecystokinin is a GENE-Y, 5-(dipentylamino)-5-oxo - pentanoic acid is a CHEMICAL, cholecystokinin is a GENE-Y, CCK is a GENE-Y, D , L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo - pen tanoic acid is a CHEMICAL, lorglumide is a CHEMICAL, CR 1409 is a CHEMICAL, CCK receptors is a GENE-N, CCK is a GENE-Y, CCK is a GENE-Y, amylase is a GENE-N, lorglumide is a CHEMICAL, CCK-8 is a GENE-N, ceruletide is a CHEMICAL, caerulein is a CHEMICAL, CCK-8 is a GENE-Y, Lorglumide is a CHEMICAL, CCK is a GENE-Y, lorglumide is a CHEMICAL, CCK is a GENE-Y	24137_task1	Sentence: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected. Instructions: please typing these entity words according to sentence: lorglumide, cholecystokinin, 5-(dipentylamino)-5-oxo - pentanoic acid, cholecystokinin, CCK, D , L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo - pen tanoic acid, lorglumide, CR 1409, CCK receptors, CCK, CCK, amylase, lorglumide, CCK-8, ceruletide, caerulein, CCK-8, Lorglumide, CCK, lorglumide, CCK Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O" ]	Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected.	[ "Pharmacological", "properties", "of", "lorglumide", "as", "a", "member", "of", "a", "new", "class", "of", "cholecystokinin", "antagonists", ".", "\n", "Derivatives", "of", "5-(dipentylamino)-5-oxo", "-", "pentanoic", "acid", "are", "a", "new", "class", "of", "non", "-", "peptide", "cholecystokinin", "(", "CCK", ")", "antagonists", ".", "The", "most", "potent", "compound", ",", "D", ",", "L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo", "-", "pen", "tanoic", "acid", "(", "lorglumide", ",", "CR", "1409", ")", ",", "has", "a", "great", "affinity", "for", "the", "pancreatic", "CCK", "receptors", "and", "is", "a", "competitive", ",", "specific", "and", "potent", "CCK", "antagonist", "on", "the", "smooth", "muscles", "of", "the", "gall", "bladder", "and", "ileum", "of", "the", "guinea", "pig", "and", "on", "the", "CCK", "-", "induced", "amylase", "secretion", "of", "isolated", "pancreatic", "acini", ".", "In", "vivo", "lorglumide", "antagonizes", "the", "contraction", "of", "the", "gall", "bladder", "of", "the", "guinea", "pig", "and", "of", "the", "dog", "provoked", "by", "i.v", ".", "CCK-8", "or", "ceruletide", "(", "caerulein", ")", ".", "It", "antagonizes", "the", "satiety", "effect", "of", "CCK-8", "in", "the", "rat", "and", "is", "protective", "against", "ceruletide-", ",", "taurocholate-", "and", "diet", "-", "induced", "pancreatitis", ".", "Lorglumide", "is", "therefore", "a", "useful", "pharmacological", "tool", "to", "study", "the", "functions", "of", "CCK", ".", "For", "its", "pharmacological", "properties", ",", "its", "relatively", "low", "toxicity", "and", "because", "it", "is", "active", "also", "after", "oral", "administration", ",", "lorglumide", "is", "a", "candidate", "for", "diagnostic", "or", "therapeutic", "use", "in", "man", "when", "an", "involvement", "of", "CCK", "is", "suspected", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
lorglumide, cholecystokinin, 5-(dipentylamino)-5-oxo - pentanoic acid, cholecystokinin, CCK, D , L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo - pen tanoic acid, lorglumide, CR 1409, CCK receptors, CCK, CCK, amylase, lorglumide, CCK-8, ceruletide, caerulein, CCK-8, Lorglumide, CCK, lorglumide, CCK	24137_task2	Sentence: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O" ]	Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected.	[ "Pharmacological", "properties", "of", "lorglumide", "as", "a", "member", "of", "a", "new", "class", "of", "cholecystokinin", "antagonists", ".", "\n", "Derivatives", "of", "5-(dipentylamino)-5-oxo", "-", "pentanoic", "acid", "are", "a", "new", "class", "of", "non", "-", "peptide", "cholecystokinin", "(", "CCK", ")", "antagonists", ".", "The", "most", "potent", "compound", ",", "D", ",", "L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo", "-", "pen", "tanoic", "acid", "(", "lorglumide", ",", "CR", "1409", ")", ",", "has", "a", "great", "affinity", "for", "the", "pancreatic", "CCK", "receptors", "and", "is", "a", "competitive", ",", "specific", "and", "potent", "CCK", "antagonist", "on", "the", "smooth", "muscles", "of", "the", "gall", "bladder", "and", "ileum", "of", "the", "guinea", "pig", "and", "on", "the", "CCK", "-", "induced", "amylase", "secretion", "of", "isolated", "pancreatic", "acini", ".", "In", "vivo", "lorglumide", "antagonizes", "the", "contraction", "of", "the", "gall", "bladder", "of", "the", "guinea", "pig", "and", "of", "the", "dog", "provoked", "by", "i.v", ".", "CCK-8", "or", "ceruletide", "(", "caerulein", ")", ".", "It", "antagonizes", "the", "satiety", "effect", "of", "CCK-8", "in", "the", "rat", "and", "is", "protective", "against", "ceruletide-", ",", "taurocholate-", "and", "diet", "-", "induced", "pancreatitis", ".", "Lorglumide", "is", "therefore", "a", "useful", "pharmacological", "tool", "to", "study", "the", "functions", "of", "CCK", ".", "For", "its", "pharmacological", "properties", ",", "its", "relatively", "low", "toxicity", "and", "because", "it", "is", "active", "also", "after", "oral", "administration", ",", "lorglumide", "is", "a", "candidate", "for", "diagnostic", "or", "therapeutic", "use", "in", "man", "when", "an", "involvement", "of", "CCK", "is", "suspected", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
vascular endothelial growth factor receptors is a Gene_or_gene_product, tumor is a Pathological_formation, Vascular endothelial growth factor is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, neuroblastoma is a Pathological_formation, Tumor biopsy specimens is a Multi-tissue_structure, serum is a Organism_substance, neuroblastoma is a Pathological_formation, patients is a Organism, adrenal biopsy sections is a Multi-tissue_structure, sera is a Organism_substance, children is a Organism, Biopsy specimens is a Multi-tissue_structure, serum is a Organism_substance, VEGF - A(165 ) is a Gene_or_gene_product, B is a Gene_or_gene_product, C is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, neuroblastoma is a Pathological_formation, tissues is a Tissue, VEGF - B is a Gene_or_gene_product, C is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, tissue lysates is a Organism_substance, VEGF - A is a Gene_or_gene_product, Serum is a Organism_substance, VEGF is a Gene_or_gene_product, VEGF - A(165 ) is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, KDR is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, stage III neuroblastoma is a Pathological_formation, VEGF - A(165 ) is a Gene_or_gene_product, serum is a Organism_substance, VEGF is a Gene_or_gene_product	100_task0	Sentence: Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Gene_or_gene_product, Pathological_formation, Organism, Multi-tissue_structure, Organism_substance	[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "O", "B-Pathological_formation", "B-Organism", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma.	[ "Upregulation", "of", "vascular", "endothelial", "growth", "factor", "receptors", "is", "associated", "with", "advanced", "neuroblastoma", ".", "\n\n", "BACKGROUND", ":", "Angiogenesis", "is", "essential", "for", "tumor", "growth", "and", "relies", "on", "the", "production", "of", "angiogenic", "factors", ".", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "is", "a", "major", "regulator", "of", "angiogenesis", "that", "binds", "to", "tyrosine", "kinase", "receptors", "Flt-1", "and", "KDR", ".", "The", "interaction", "of", "VEGF", "and", "its", "receptors", "at", "gene", "and", "protein", "levels", "in", "neuroblastoma", "remains", "widely", "unknown", ".", "METHODS", ":", "Tumor", "biopsy", "specimens", "and", "serum", "were", "obtained", "from", "37", "neuroblastoma", "patients", ";", "adrenal", "biopsy", "sections", "and", "sera", "of", "7", "normal", "children", "served", "as", "controls", ".", "Biopsy", "specimens", "were", "examined", "by", "real", "-", "time", "reverse", "transcription", "polymerase", "chain", "reaction", "(", "RT", "-", "PCR", ")", "and", "Western", "blotting", ";", "serum", "was", "analyzed", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "VEGF", "-", "A(165", ")", ",", "B", ",", "C", ",", "Flt-1", ",", "and", "KDR", "were", "analyzed", ".", "RESULTS", ":", "VEGF", "isoforms", "and", "its", "receptors", "'", "mRNA", "were", "expressed", "in", "neuroblastoma", "and", "control", "tissues", ".", "Whereas", "the", "ligands", "were", "increased", "in", "stages", "III", "and", "IV", ",", "the", "receptors", "were", "upregulated", "in", "stage", "III", "only", ".", "At", "protein", "level", ",", "VEGF", "-", "B", "and", "C", ",", "Flt-1", ",", "and", "KDR", "were", "not", "detectable", "in", "tissue", "lysates", ",", "whereas", "VEGF", "-", "A", "was", "increased", "in", "stages", "III", "and", "IV", ".", "Serum", "VEGF", "protein", "levels", "were", "upregulated", "in", "stage", "III", ".", "CONCLUSIONS", ":", "VEGF", "-", "A(165", ")", "is", "one", "of", "the", "major", "angiogenesis", "regulators", "among", "the", "ligands", "'", "family", "of", "VEGF", ",", "whereas", "its", "receptors", "KDR", ",", "and", "most", "probably", "Flt-1", ",", "may", "contribute", "to", "a", "poor", "prognosis", "(", "angiogenic", ")", "phenotype", ",", "as", "indicated", "by", "their", "upregulated", "MRNA", "levels", "in", "stage", "III", "neuroblastoma", ".", "VEGF", "-", "A(165", ")", "mainly", "contributes", "to", "increased", "serum", "VEGF", "levels", "and", "may", "serve", "as", "a", "diagnostic", "tool", "in", "advanced", "-", "stage", "neuroblastoma", ".", "\n" ]	[ "Gene_or_gene_product", "Multi-tissue_structure", "Pathological_formation", "Organism_substance", "Organism", "Tissue" ]
vascular endothelial growth factor receptors is a Gene_or_gene_product, tumor is a Pathological_formation, Vascular endothelial growth factor is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, neuroblastoma is a Pathological_formation, Tumor biopsy specimens is a Multi-tissue_structure, serum is a Organism_substance, neuroblastoma is a Pathological_formation, patients is a Organism, adrenal biopsy sections is a Multi-tissue_structure, sera is a Organism_substance, children is a Organism, Biopsy specimens is a Multi-tissue_structure, serum is a Organism_substance, VEGF - A(165 ) is a Gene_or_gene_product, B is a Gene_or_gene_product, C is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, neuroblastoma is a Pathological_formation, tissues is a Tissue, VEGF - B is a Gene_or_gene_product, C is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, tissue lysates is a Organism_substance, VEGF - A is a Gene_or_gene_product, Serum is a Organism_substance, VEGF is a Gene_or_gene_product, VEGF - A(165 ) is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, KDR is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, stage III neuroblastoma is a Pathological_formation, VEGF - A(165 ) is a Gene_or_gene_product, serum is a Organism_substance, VEGF is a Gene_or_gene_product	100_task1	Sentence: Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma. Instructions: please typing these entity words according to sentence: vascular endothelial growth factor receptors, tumor, Vascular endothelial growth factor, VEGF, Flt-1, KDR, VEGF, neuroblastoma, Tumor biopsy specimens, serum, neuroblastoma, patients, adrenal biopsy sections, sera, children, Biopsy specimens, serum, VEGF - A(165 ), B, C, Flt-1, KDR, VEGF, neuroblastoma, tissues, VEGF - B, C, Flt-1, KDR, tissue lysates, VEGF - A, Serum, VEGF, VEGF - A(165 ), VEGF, KDR, Flt-1, stage III neuroblastoma, VEGF - A(165 ), serum, VEGF Options: Tissue, Gene_or_gene_product, Pathological_formation, Organism, Multi-tissue_structure, Organism_substance	[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "O", "B-Pathological_formation", "B-Organism", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma.	[ "Upregulation", "of", "vascular", "endothelial", "growth", "factor", "receptors", "is", "associated", "with", "advanced", "neuroblastoma", ".", "\n\n", "BACKGROUND", ":", "Angiogenesis", "is", "essential", "for", "tumor", "growth", "and", "relies", "on", "the", "production", "of", "angiogenic", "factors", ".", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "is", "a", "major", "regulator", "of", "angiogenesis", "that", "binds", "to", "tyrosine", "kinase", "receptors", "Flt-1", "and", "KDR", ".", "The", "interaction", "of", "VEGF", "and", "its", "receptors", "at", "gene", "and", "protein", "levels", "in", "neuroblastoma", "remains", "widely", "unknown", ".", "METHODS", ":", "Tumor", "biopsy", "specimens", "and", "serum", "were", "obtained", "from", "37", "neuroblastoma", "patients", ";", "adrenal", "biopsy", "sections", "and", "sera", "of", "7", "normal", "children", "served", "as", "controls", ".", "Biopsy", "specimens", "were", "examined", "by", "real", "-", "time", "reverse", "transcription", "polymerase", "chain", "reaction", "(", "RT", "-", "PCR", ")", "and", "Western", "blotting", ";", "serum", "was", "analyzed", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "VEGF", "-", "A(165", ")", ",", "B", ",", "C", ",", "Flt-1", ",", "and", "KDR", "were", "analyzed", ".", "RESULTS", ":", "VEGF", "isoforms", "and", "its", "receptors", "'", "mRNA", "were", "expressed", "in", "neuroblastoma", "and", "control", "tissues", ".", "Whereas", "the", "ligands", "were", "increased", "in", "stages", "III", "and", "IV", ",", "the", "receptors", "were", "upregulated", "in", "stage", "III", "only", ".", "At", "protein", "level", ",", "VEGF", "-", "B", "and", "C", ",", "Flt-1", ",", "and", "KDR", "were", "not", "detectable", "in", "tissue", "lysates", ",", "whereas", "VEGF", "-", "A", "was", "increased", "in", "stages", "III", "and", "IV", ".", "Serum", "VEGF", "protein", "levels", "were", "upregulated", "in", "stage", "III", ".", "CONCLUSIONS", ":", "VEGF", "-", "A(165", ")", "is", "one", "of", "the", "major", "angiogenesis", "regulators", "among", "the", "ligands", "'", "family", "of", "VEGF", ",", "whereas", "its", "receptors", "KDR", ",", "and", "most", "probably", "Flt-1", ",", "may", "contribute", "to", "a", "poor", "prognosis", "(", "angiogenic", ")", "phenotype", ",", "as", "indicated", "by", "their", "upregulated", "MRNA", "levels", "in", "stage", "III", "neuroblastoma", ".", "VEGF", "-", "A(165", ")", "mainly", "contributes", "to", "increased", "serum", "VEGF", "levels", "and", "may", "serve", "as", "a", "diagnostic", "tool", "in", "advanced", "-", "stage", "neuroblastoma", ".", "\n" ]	[ "Gene_or_gene_product", "Multi-tissue_structure", "Pathological_formation", "Organism_substance", "Organism", "Tissue" ]
vascular endothelial growth factor receptors, tumor, Vascular endothelial growth factor, VEGF, Flt-1, KDR, VEGF, neuroblastoma, Tumor biopsy specimens, serum, neuroblastoma, patients, adrenal biopsy sections, sera, children, Biopsy specimens, serum, VEGF - A(165 ), B, C, Flt-1, KDR, VEGF, neuroblastoma, tissues, VEGF - B, C, Flt-1, KDR, tissue lysates, VEGF - A, Serum, VEGF, VEGF - A(165 ), VEGF, KDR, Flt-1, stage III neuroblastoma, VEGF - A(165 ), serum, VEGF	100_task2	Sentence: Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "O", "B-Pathological_formation", "B-Organism", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma.	[ "Upregulation", "of", "vascular", "endothelial", "growth", "factor", "receptors", "is", "associated", "with", "advanced", "neuroblastoma", ".", "\n\n", "BACKGROUND", ":", "Angiogenesis", "is", "essential", "for", "tumor", "growth", "and", "relies", "on", "the", "production", "of", "angiogenic", "factors", ".", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "is", "a", "major", "regulator", "of", "angiogenesis", "that", "binds", "to", "tyrosine", "kinase", "receptors", "Flt-1", "and", "KDR", ".", "The", "interaction", "of", "VEGF", "and", "its", "receptors", "at", "gene", "and", "protein", "levels", "in", "neuroblastoma", "remains", "widely", "unknown", ".", "METHODS", ":", "Tumor", "biopsy", "specimens", "and", "serum", "were", "obtained", "from", "37", "neuroblastoma", "patients", ";", "adrenal", "biopsy", "sections", "and", "sera", "of", "7", "normal", "children", "served", "as", "controls", ".", "Biopsy", "specimens", "were", "examined", "by", "real", "-", "time", "reverse", "transcription", "polymerase", "chain", "reaction", "(", "RT", "-", "PCR", ")", "and", "Western", "blotting", ";", "serum", "was", "analyzed", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "VEGF", "-", "A(165", ")", ",", "B", ",", "C", ",", "Flt-1", ",", "and", "KDR", "were", "analyzed", ".", "RESULTS", ":", "VEGF", "isoforms", "and", "its", "receptors", "'", "mRNA", "were", "expressed", "in", "neuroblastoma", "and", "control", "tissues", ".", "Whereas", "the", "ligands", "were", "increased", "in", "stages", "III", "and", "IV", ",", "the", "receptors", "were", "upregulated", "in", "stage", "III", "only", ".", "At", "protein", "level", ",", "VEGF", "-", "B", "and", "C", ",", "Flt-1", ",", "and", "KDR", "were", "not", "detectable", "in", "tissue", "lysates", ",", "whereas", "VEGF", "-", "A", "was", "increased", "in", "stages", "III", "and", "IV", ".", "Serum", "VEGF", "protein", "levels", "were", "upregulated", "in", "stage", "III", ".", "CONCLUSIONS", ":", "VEGF", "-", "A(165", ")", "is", "one", "of", "the", "major", "angiogenesis", "regulators", "among", "the", "ligands", "'", "family", "of", "VEGF", ",", "whereas", "its", "receptors", "KDR", ",", "and", "most", "probably", "Flt-1", ",", "may", "contribute", "to", "a", "poor", "prognosis", "(", "angiogenic", ")", "phenotype", ",", "as", "indicated", "by", "their", "upregulated", "MRNA", "levels", "in", "stage", "III", "neuroblastoma", ".", "VEGF", "-", "A(165", ")", "mainly", "contributes", "to", "increased", "serum", "VEGF", "levels", "and", "may", "serve", "as", "a", "diagnostic", "tool", "in", "advanced", "-", "stage", "neuroblastoma", ".", "\n" ]	[ "Gene_or_gene_product", "Multi-tissue_structure", "Pathological_formation", "Organism_substance", "Organism", "Tissue" ]
apelin is a Protein, APJ is a Protein, Apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin-13 is a Protein, APJ is a Protein, APJ is a Protein, apelin is a Protein, apelin-13 is a Protein, apelin is a Protein, APJ is a Protein	218_task0	Sentence: Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy.	[ "Ischemic", "heart", "failure", "enhances", "endogenous", "myocardial", "apelin", "and", "APJ", "receptor", "expression", ".", "\n", "Apelin", "interacts", "with", "the", "APJ", "receptor", "to", "enhance", "inotropy", ".", "In", "heart", "failure", ",", "apelin", "-", "APJ", "coupling", "may", "provide", "a", "means", "of", "enhancing", "myocardial", "function", ".", "The", "alterations", "in", "apelin", "and", "APJ", "receptor", "concentrations", "with", "ischemic", "cardiomyopathy", "are", "poorly", "understood", ".", "We", "investigated", "the", "compensatory", "changes", "in", "endogenous", "apelin", "and", "APJ", "levels", "in", "the", "setting", "of", "ischemic", "cardiomyopathy", ".", "Male", ",", "Lewis", "rats", "underwent", "LAD", "ligation", "and", "progressed", "into", "heart", "failure", "over", "6", "weeks", ".", "Corresponding", "animals", "underwent", "sham", "thoracotomy", "as", "control", ".", "Six", "weeks", "after", "initial", "surgery", ",", "the", "animals", "underwent", "hemodynamic", "functional", "analysis", "in", "the", "presence", "of", "exogenous", "apelin-13", "infusion", "and", "the", "hearts", "were", "explanted", "for", "western", "blot", "and", "enzyme", "immunoassay", "analysis", ".", "Western", "blot", "analysis", "of", "myocardial", "APJ", "concentration", "demonstrated", "increased", "APJ", "receptor", "protein", "levels", "with", "heart", "failure", "(", "1890750+/-133500", "vs", ".", "901600+/-143120", "intensity", "units", ",", "n=8", ",", "p=0.00001", ")", ".", "Total", "apelin", "protein", "levels", "increased", "with", "ischemic", "heart", "failure", "as", "demonstrated", "by", "enzyme", "immunoassay", "(", "12.0+/-4.6", "vs", ".", "1.0+/-1.2", "ng", "/", "ml", ",", "n=5", ",", "p=0.006", ")", "and", "western", "blot", "(", "1579400+/-477733", "vs", ".", "943000+/-157600", "intensity", "units", ",", "n=10", ",", "p=0.008", ")", ".", "Infusion", "of", "apelin-13", "significantly", "enhanced", "myocardial", "function", "in", "sham", "and", "failing", "hearts", ".", "We", "conclude", "that", "total", "myocardial", "apelin", "and", "APJ", "receptor", "levels", "increase", "in", "compensation", "for", "ischemic", "cardiomyopathy", ".", "\n" ]	[ "Protein" ]
apelin is a Protein, APJ is a Protein, Apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin-13 is a Protein, APJ is a Protein, APJ is a Protein, apelin is a Protein, apelin-13 is a Protein, apelin is a Protein, APJ is a Protein	218_task1	Sentence: Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy. Instructions: please typing these entity words according to sentence: apelin, APJ, Apelin, APJ, apelin, APJ, apelin, APJ, apelin, APJ, apelin-13, APJ, APJ, apelin, apelin-13, apelin, APJ Options: Protein	[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy.	[ "Ischemic", "heart", "failure", "enhances", "endogenous", "myocardial", "apelin", "and", "APJ", "receptor", "expression", ".", "\n", "Apelin", "interacts", "with", "the", "APJ", "receptor", "to", "enhance", "inotropy", ".", "In", "heart", "failure", ",", "apelin", "-", "APJ", "coupling", "may", "provide", "a", "means", "of", "enhancing", "myocardial", "function", ".", "The", "alterations", "in", "apelin", "and", "APJ", "receptor", "concentrations", "with", "ischemic", "cardiomyopathy", "are", "poorly", "understood", ".", "We", "investigated", "the", "compensatory", "changes", "in", "endogenous", "apelin", "and", "APJ", "levels", "in", "the", "setting", "of", "ischemic", "cardiomyopathy", ".", "Male", ",", "Lewis", "rats", "underwent", "LAD", "ligation", "and", "progressed", "into", "heart", "failure", "over", "6", "weeks", ".", "Corresponding", "animals", "underwent", "sham", "thoracotomy", "as", "control", ".", "Six", "weeks", "after", "initial", "surgery", ",", "the", "animals", "underwent", "hemodynamic", "functional", "analysis", "in", "the", "presence", "of", "exogenous", "apelin-13", "infusion", "and", "the", "hearts", "were", "explanted", "for", "western", "blot", "and", "enzyme", "immunoassay", "analysis", ".", "Western", "blot", "analysis", "of", "myocardial", "APJ", "concentration", "demonstrated", "increased", "APJ", "receptor", "protein", "levels", "with", "heart", "failure", "(", "1890750+/-133500", "vs", ".", "901600+/-143120", "intensity", "units", ",", "n=8", ",", "p=0.00001", ")", ".", "Total", "apelin", "protein", "levels", "increased", "with", "ischemic", "heart", "failure", "as", "demonstrated", "by", "enzyme", "immunoassay", "(", "12.0+/-4.6", "vs", ".", "1.0+/-1.2", "ng", "/", "ml", ",", "n=5", ",", "p=0.006", ")", "and", "western", "blot", "(", "1579400+/-477733", "vs", ".", "943000+/-157600", "intensity", "units", ",", "n=10", ",", "p=0.008", ")", ".", "Infusion", "of", "apelin-13", "significantly", "enhanced", "myocardial", "function", "in", "sham", "and", "failing", "hearts", ".", "We", "conclude", "that", "total", "myocardial", "apelin", "and", "APJ", "receptor", "levels", "increase", "in", "compensation", "for", "ischemic", "cardiomyopathy", ".", "\n" ]	[ "Protein" ]
apelin, APJ, Apelin, APJ, apelin, APJ, apelin, APJ, apelin, APJ, apelin-13, APJ, APJ, apelin, apelin-13, apelin, APJ	218_task2	Sentence: Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy.	[ "Ischemic", "heart", "failure", "enhances", "endogenous", "myocardial", "apelin", "and", "APJ", "receptor", "expression", ".", "\n", "Apelin", "interacts", "with", "the", "APJ", "receptor", "to", "enhance", "inotropy", ".", "In", "heart", "failure", ",", "apelin", "-", "APJ", "coupling", "may", "provide", "a", "means", "of", "enhancing", "myocardial", "function", ".", "The", "alterations", "in", "apelin", "and", "APJ", "receptor", "concentrations", "with", "ischemic", "cardiomyopathy", "are", "poorly", "understood", ".", "We", "investigated", "the", "compensatory", "changes", "in", "endogenous", "apelin", "and", "APJ", "levels", "in", "the", "setting", "of", "ischemic", "cardiomyopathy", ".", "Male", ",", "Lewis", "rats", "underwent", "LAD", "ligation", "and", "progressed", "into", "heart", "failure", "over", "6", "weeks", ".", "Corresponding", "animals", "underwent", "sham", "thoracotomy", "as", "control", ".", "Six", "weeks", "after", "initial", "surgery", ",", "the", "animals", "underwent", "hemodynamic", "functional", "analysis", "in", "the", "presence", "of", "exogenous", "apelin-13", "infusion", "and", "the", "hearts", "were", "explanted", "for", "western", "blot", "and", "enzyme", "immunoassay", "analysis", ".", "Western", "blot", "analysis", "of", "myocardial", "APJ", "concentration", "demonstrated", "increased", "APJ", "receptor", "protein", "levels", "with", "heart", "failure", "(", "1890750+/-133500", "vs", ".", "901600+/-143120", "intensity", "units", ",", "n=8", ",", "p=0.00001", ")", ".", "Total", "apelin", "protein", "levels", "increased", "with", "ischemic", "heart", "failure", "as", "demonstrated", "by", "enzyme", "immunoassay", "(", "12.0+/-4.6", "vs", ".", "1.0+/-1.2", "ng", "/", "ml", ",", "n=5", ",", "p=0.006", ")", "and", "western", "blot", "(", "1579400+/-477733", "vs", ".", "943000+/-157600", "intensity", "units", ",", "n=10", ",", "p=0.008", ")", ".", "Infusion", "of", "apelin-13", "significantly", "enhanced", "myocardial", "function", "in", "sham", "and", "failing", "hearts", ".", "We", "conclude", "that", "total", "myocardial", "apelin", "and", "APJ", "receptor", "levels", "increase", "in", "compensation", "for", "ischemic", "cardiomyopathy", ".", "\n" ]	[ "Protein" ]
fractures is an umlsterm, knee is an umlsterm, arthroscopy is an umlsterm, visualization is an umlsterm, joint is an umlsterm, dissection is an umlsterm, irrigation is an umlsterm, paper is an umlsterm, fractures is an umlsterm, knee is an umlsterm, May is an umlsterm, patients is an umlsterm, fractures is an umlsterm, knee is an umlsterm, patients is an umlsterm, fracture is an umlsterm, classification is an umlsterm, patients is an umlsterm, fracture is an umlsterm, anterior cruciate ligament is an umlsterm, classification is an umlsterm, patients is an umlsterm, fractures is an umlsterm, patient is an umlsterm, fracture is an umlsterm, patella is an umlsterm, passive motion is an umlsterm, exercises is an umlsterm, Patients is an umlsterm, fractures is an umlsterm, patient is an umlsterm, fracture is an umlsterm, patella is an umlsterm, weight bearing is an umlsterm, patients is an umlsterm, fractures is an umlsterm, fractures is an umlsterm, weight is an umlsterm, fractures is an umlsterm, dislocation is an umlsterm, dislocation is an umlsterm, All is an umlsterm, patients is an umlsterm, knees is an umlsterm, range of motion is an umlsterm, patients is an umlsterm, fracture is an umlsterm, anterior cruciate ligament is an umlsterm, patient is an umlsterm, fractures is an umlsterm, anatomical is an umlsterm, fractures healed is an umlsterm, patients is an umlsterm, pain is an umlsterm, fracture is an umlsterm, patella is an umlsterm, knee is an umlsterm, synovitis is an umlsterm, complications is an umlsterm, fractures is an umlsterm, knee is an umlsterm, treatment is an umlsterm, surgical treatment is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, hospitalization is an umlsterm, rehabilitation is an umlsterm, times is an umlsterm	Arthroskopie.80110246.eng.abstr_task0	Sentence: Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented .	[ "Certain", "intra", "-", "articular", "fractures", "of", "the", "knee", "can", "be", "managed", "by", "arthroscopically", "assisted", "reduction", "and", "fixation", ".", "The", "known", "benefits", "of", "arthroscopy", "include", "better", "visualization", "of", "the", "entire", "joint", ",", "limited", "dissection", ",", "and", "thorough", "irrigation", ".", "The", "purpose", "of", "this", "paper", "is", "to", "present", "our", "experience", "with", "arthroscopically", "assisted", "reduction", "and", "fixation", "of", "certain", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "From", "May", "1995", "to", "November", "1997", ",", "34", "patients", "with", "intra", "-", "articular", "fractures", "of", "the", "knee", "were", "treated", "by", "arthroscopic", "reduction", "and", "fixation", ".", "We", "treated", "11", "patients", "with", "tibial", "plateau", "fracture", "type", "I", ",", "II", "and", "III", "(", "according", "to", "J.", "Schatzker", "classification", ")", ",", "20", "patients", "with", "avulsion", "fracture", "of", "the", "tibial", "insertion", "of", "the", "anterior", "cruciate", "ligament", "(", "intercondylar", "eminence", ")", "type", "II", ",", "III", "and", "IV", "(", "according", "to", "Meyers", ",", "McKeever", "and", "Zariczny", "classification", ")", ",", "two", "patients", "with", "completely", "dislocated", "osteochondral", "flake", "fractures", "of", "the", "femoral", "condyle", ",", "and", "one", "patient", "with", "a", "minimally", "displaced", "fracture", "of", "the", "patella", ".", "Postoperatively", "they", "were", "all", "allowed", "passive", "motion", "exercises", ".", "Patients", "with", "avulsion", "fractures", "of", "the", "ACL", "and", "the", "patient", "with", "fracture", "of", "the", "patella", "were", "allowed", "immediate", "weight", "bearing", ",", "while", "patients", "with", "tibial", "plateau", "fractures", "and", "osteochondral", "fractures", "were", "allowed", "weight", "bearing", "only", "after", "12", "weeks", ".", "Results", ":", "Of", "the", "11", "tibial", "plateau", "fractures", ",", "8", "were", "anatomically", "reduced", ",", "and", "in", "2", "the", "dislocation", "was", "less", "than", "2", "mm", ".", "No", "further", "dislocation", "of", "the", "fragment", "followed", ".", "All", "patients", "but", "one", "reported", "stable", "knees", "and", "they", "all", "had", "a", "full", "range", "of", "motion", "at", "follow", "-", "up", ".", "Of", "the", "20", "patients", "with", "avulsion", "fracture", "of", "the", "anterior", "cruciate", "ligament", ",", "19", "were", "anatomically", "reduced", ".", "Except", "in", "one", "patient", ",", "functional", "results", "were", "excellent", "(", "KT1000", "was", "1.3", "mm", ",", "average", "loss", "of", "flexion", "was", "2.5", "°", ",", "loss", "of", "extension", "was", "1.3", "°", ")", ".", "In", "two", "cases", "of", "osteochondral", "fractures", "of", "the", "femoral", "condyle", ",", "reduction", "was", "anatomical", ".", "The", "fractures", "healed", ",", "the", "patients", "were", "free", "of", "pain", "and", "had", "full", "ROM", "at", "the", "follow", "-", "up", ".", "The", "fracture", "of", "the", "patella", "healed", "in", "4", "weeks", "with", "full", "ROM", "of", "the", "knee", ".", "There", "was", "one", "case", "of", "aseptic", "synovitis", "and", "no", "other", "major", "complications", ".", "Conclusions", ":", "Arthroscopic", "reduction", "and", "fixation", "are", "technically", "possible", "in", "certain", "types", "of", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "Provided", "indications", "are", "good", ",", "results", "of", "arthroscopic", "treatment", "are", "better", "than", "in", "classical", "surgical", "treatment", "through", "arthrotomy", ".", "There", "is", "less", "postoperative", "morbidity", ",", "and", "hospitalization", "and", "total", "rehabilitation", "times", "are", "shorter", ".", "Some", "technical", "hints", "are", "presented", "." ]	[ "umlsterm" ]
fractures is an umlsterm, knee is an umlsterm, arthroscopy is an umlsterm, visualization is an umlsterm, joint is an umlsterm, dissection is an umlsterm, irrigation is an umlsterm, paper is an umlsterm, fractures is an umlsterm, knee is an umlsterm, May is an umlsterm, patients is an umlsterm, fractures is an umlsterm, knee is an umlsterm, patients is an umlsterm, fracture is an umlsterm, classification is an umlsterm, patients is an umlsterm, fracture is an umlsterm, anterior cruciate ligament is an umlsterm, classification is an umlsterm, patients is an umlsterm, fractures is an umlsterm, patient is an umlsterm, fracture is an umlsterm, patella is an umlsterm, passive motion is an umlsterm, exercises is an umlsterm, Patients is an umlsterm, fractures is an umlsterm, patient is an umlsterm, fracture is an umlsterm, patella is an umlsterm, weight bearing is an umlsterm, patients is an umlsterm, fractures is an umlsterm, fractures is an umlsterm, weight is an umlsterm, fractures is an umlsterm, dislocation is an umlsterm, dislocation is an umlsterm, All is an umlsterm, patients is an umlsterm, knees is an umlsterm, range of motion is an umlsterm, patients is an umlsterm, fracture is an umlsterm, anterior cruciate ligament is an umlsterm, patient is an umlsterm, fractures is an umlsterm, anatomical is an umlsterm, fractures healed is an umlsterm, patients is an umlsterm, pain is an umlsterm, fracture is an umlsterm, patella is an umlsterm, knee is an umlsterm, synovitis is an umlsterm, complications is an umlsterm, fractures is an umlsterm, knee is an umlsterm, treatment is an umlsterm, surgical treatment is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, hospitalization is an umlsterm, rehabilitation is an umlsterm, times is an umlsterm	Arthroskopie.80110246.eng.abstr_task1	Sentence: Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented . Instructions: please typing these entity words according to sentence: fractures, knee, arthroscopy, visualization, joint, dissection, irrigation, paper, fractures, knee, May, patients, fractures, knee, patients, fracture, classification, patients, fracture, anterior cruciate ligament, classification, patients, fractures, patient, fracture, patella, passive motion, exercises, Patients, fractures, patient, fracture, patella, weight bearing, patients, fractures, fractures, weight, fractures, dislocation, dislocation, All, patients, knees, range of motion, patients, fracture, anterior cruciate ligament, patient, fractures, anatomical, fractures healed, patients, pain, fracture, patella, knee, synovitis, complications, fractures, knee, treatment, surgical treatment, postoperative, morbidity, hospitalization, rehabilitation, times Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented .	[ "Certain", "intra", "-", "articular", "fractures", "of", "the", "knee", "can", "be", "managed", "by", "arthroscopically", "assisted", "reduction", "and", "fixation", ".", "The", "known", "benefits", "of", "arthroscopy", "include", "better", "visualization", "of", "the", "entire", "joint", ",", "limited", "dissection", ",", "and", "thorough", "irrigation", ".", "The", "purpose", "of", "this", "paper", "is", "to", "present", "our", "experience", "with", "arthroscopically", "assisted", "reduction", "and", "fixation", "of", "certain", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "From", "May", "1995", "to", "November", "1997", ",", "34", "patients", "with", "intra", "-", "articular", "fractures", "of", "the", "knee", "were", "treated", "by", "arthroscopic", "reduction", "and", "fixation", ".", "We", "treated", "11", "patients", "with", "tibial", "plateau", "fracture", "type", "I", ",", "II", "and", "III", "(", "according", "to", "J.", "Schatzker", "classification", ")", ",", "20", "patients", "with", "avulsion", "fracture", "of", "the", "tibial", "insertion", "of", "the", "anterior", "cruciate", "ligament", "(", "intercondylar", "eminence", ")", "type", "II", ",", "III", "and", "IV", "(", "according", "to", "Meyers", ",", "McKeever", "and", "Zariczny", "classification", ")", ",", "two", "patients", "with", "completely", "dislocated", "osteochondral", "flake", "fractures", "of", "the", "femoral", "condyle", ",", "and", "one", "patient", "with", "a", "minimally", "displaced", "fracture", "of", "the", "patella", ".", "Postoperatively", "they", "were", "all", "allowed", "passive", "motion", "exercises", ".", "Patients", "with", "avulsion", "fractures", "of", "the", "ACL", "and", "the", "patient", "with", "fracture", "of", "the", "patella", "were", "allowed", "immediate", "weight", "bearing", ",", "while", "patients", "with", "tibial", "plateau", "fractures", "and", "osteochondral", "fractures", "were", "allowed", "weight", "bearing", "only", "after", "12", "weeks", ".", "Results", ":", "Of", "the", "11", "tibial", "plateau", "fractures", ",", "8", "were", "anatomically", "reduced", ",", "and", "in", "2", "the", "dislocation", "was", "less", "than", "2", "mm", ".", "No", "further", "dislocation", "of", "the", "fragment", "followed", ".", "All", "patients", "but", "one", "reported", "stable", "knees", "and", "they", "all", "had", "a", "full", "range", "of", "motion", "at", "follow", "-", "up", ".", "Of", "the", "20", "patients", "with", "avulsion", "fracture", "of", "the", "anterior", "cruciate", "ligament", ",", "19", "were", "anatomically", "reduced", ".", "Except", "in", "one", "patient", ",", "functional", "results", "were", "excellent", "(", "KT1000", "was", "1.3", "mm", ",", "average", "loss", "of", "flexion", "was", "2.5", "°", ",", "loss", "of", "extension", "was", "1.3", "°", ")", ".", "In", "two", "cases", "of", "osteochondral", "fractures", "of", "the", "femoral", "condyle", ",", "reduction", "was", "anatomical", ".", "The", "fractures", "healed", ",", "the", "patients", "were", "free", "of", "pain", "and", "had", "full", "ROM", "at", "the", "follow", "-", "up", ".", "The", "fracture", "of", "the", "patella", "healed", "in", "4", "weeks", "with", "full", "ROM", "of", "the", "knee", ".", "There", "was", "one", "case", "of", "aseptic", "synovitis", "and", "no", "other", "major", "complications", ".", "Conclusions", ":", "Arthroscopic", "reduction", "and", "fixation", "are", "technically", "possible", "in", "certain", "types", "of", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "Provided", "indications", "are", "good", ",", "results", "of", "arthroscopic", "treatment", "are", "better", "than", "in", "classical", "surgical", "treatment", "through", "arthrotomy", ".", "There", "is", "less", "postoperative", "morbidity", ",", "and", "hospitalization", "and", "total", "rehabilitation", "times", "are", "shorter", ".", "Some", "technical", "hints", "are", "presented", "." ]	[ "umlsterm" ]
fractures, knee, arthroscopy, visualization, joint, dissection, irrigation, paper, fractures, knee, May, patients, fractures, knee, patients, fracture, classification, patients, fracture, anterior cruciate ligament, classification, patients, fractures, patient, fracture, patella, passive motion, exercises, Patients, fractures, patient, fracture, patella, weight bearing, patients, fractures, fractures, weight, fractures, dislocation, dislocation, All, patients, knees, range of motion, patients, fracture, anterior cruciate ligament, patient, fractures, anatomical, fractures healed, patients, pain, fracture, patella, knee, synovitis, complications, fractures, knee, treatment, surgical treatment, postoperative, morbidity, hospitalization, rehabilitation, times	Arthroskopie.80110246.eng.abstr_task2	Sentence: Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented .	[ "Certain", "intra", "-", "articular", "fractures", "of", "the", "knee", "can", "be", "managed", "by", "arthroscopically", "assisted", "reduction", "and", "fixation", ".", "The", "known", "benefits", "of", "arthroscopy", "include", "better", "visualization", "of", "the", "entire", "joint", ",", "limited", "dissection", ",", "and", "thorough", "irrigation", ".", "The", "purpose", "of", "this", "paper", "is", "to", "present", "our", "experience", "with", "arthroscopically", "assisted", "reduction", "and", "fixation", "of", "certain", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "From", "May", "1995", "to", "November", "1997", ",", "34", "patients", "with", "intra", "-", "articular", "fractures", "of", "the", "knee", "were", "treated", "by", "arthroscopic", "reduction", "and", "fixation", ".", "We", "treated", "11", "patients", "with", "tibial", "plateau", "fracture", "type", "I", ",", "II", "and", "III", "(", "according", "to", "J.", "Schatzker", "classification", ")", ",", "20", "patients", "with", "avulsion", "fracture", "of", "the", "tibial", "insertion", "of", "the", "anterior", "cruciate", "ligament", "(", "intercondylar", "eminence", ")", "type", "II", ",", "III", "and", "IV", "(", "according", "to", "Meyers", ",", "McKeever", "and", "Zariczny", "classification", ")", ",", "two", "patients", "with", "completely", "dislocated", "osteochondral", "flake", "fractures", "of", "the", "femoral", "condyle", ",", "and", "one", "patient", "with", "a", "minimally", "displaced", "fracture", "of", "the", "patella", ".", "Postoperatively", "they", "were", "all", "allowed", "passive", "motion", "exercises", ".", "Patients", "with", "avulsion", "fractures", "of", "the", "ACL", "and", "the", "patient", "with", "fracture", "of", "the", "patella", "were", "allowed", "immediate", "weight", "bearing", ",", "while", "patients", "with", "tibial", "plateau", "fractures", "and", "osteochondral", "fractures", "were", "allowed", "weight", "bearing", "only", "after", "12", "weeks", ".", "Results", ":", "Of", "the", "11", "tibial", "plateau", "fractures", ",", "8", "were", "anatomically", "reduced", ",", "and", "in", "2", "the", "dislocation", "was", "less", "than", "2", "mm", ".", "No", "further", "dislocation", "of", "the", "fragment", "followed", ".", "All", "patients", "but", "one", "reported", "stable", "knees", "and", "they", "all", "had", "a", "full", "range", "of", "motion", "at", "follow", "-", "up", ".", "Of", "the", "20", "patients", "with", "avulsion", "fracture", "of", "the", "anterior", "cruciate", "ligament", ",", "19", "were", "anatomically", "reduced", ".", "Except", "in", "one", "patient", ",", "functional", "results", "were", "excellent", "(", "KT1000", "was", "1.3", "mm", ",", "average", "loss", "of", "flexion", "was", "2.5", "°", ",", "loss", "of", "extension", "was", "1.3", "°", ")", ".", "In", "two", "cases", "of", "osteochondral", "fractures", "of", "the", "femoral", "condyle", ",", "reduction", "was", "anatomical", ".", "The", "fractures", "healed", ",", "the", "patients", "were", "free", "of", "pain", "and", "had", "full", "ROM", "at", "the", "follow", "-", "up", ".", "The", "fracture", "of", "the", "patella", "healed", "in", "4", "weeks", "with", "full", "ROM", "of", "the", "knee", ".", "There", "was", "one", "case", "of", "aseptic", "synovitis", "and", "no", "other", "major", "complications", ".", "Conclusions", ":", "Arthroscopic", "reduction", "and", "fixation", "are", "technically", "possible", "in", "certain", "types", "of", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "Provided", "indications", "are", "good", ",", "results", "of", "arthroscopic", "treatment", "are", "better", "than", "in", "classical", "surgical", "treatment", "through", "arthrotomy", ".", "There", "is", "less", "postoperative", "morbidity", ",", "and", "hospitalization", "and", "total", "rehabilitation", "times", "are", "shorter", ".", "Some", "technical", "hints", "are", "presented", "." ]	[ "umlsterm" ]
Risiko is an umlsterm, tierexperimentell is an umlsterm	DerNervenarzt.90701104.ger.abstr_task0	Sentence: Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge .	[ "Anhand", "einer", "Kasuistik", "weisen", "wir", "auf", "das", "Risiko", "des", "Auftretens", "nonkonvulsiver", "Status", "epileptici", "(", "NCSE", ")", "bei", "der", "Gabe", "des", "Antikonvulsivums", "Tiagabin", "in", "hoeheren", "Dosierungen", "und", "bei", "Dosissteigerungen", "hin", ".", "Das", "mehrmalige", "Auftreten", "von", "NCSE", "kurz", "nach", "der", "Tiagabin", "-", "Einnahme", "bei", "bisher", "unauffaelliger", "Status", "-", "Anamnese", "macht", "einen", "kausale", "Zusammenhang", "in", "diesem", "Fall", "sehr", "wahrscheinlich", ".", "Eine", "solche", "inverse", "Wirkung", "ist", "auch", "tierexperimentell", "gezeigt", "worden", ".", "Ein", "dosisabhaengiges", "Ungleichgewicht", "zwischen", "glialer", "und", "neuronaler", "GABA", "-", "Aufnahme", "hat", "ein", "Versagen", "der", "inhibitorischen", "GABA", "-", "Wirkung", "zur", "Folge", "." ]	[ "umlsterm" ]
Risiko is an umlsterm, tierexperimentell is an umlsterm	DerNervenarzt.90701104.ger.abstr_task1	Sentence: Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge . Instructions: please typing these entity words according to sentence: Risiko, tierexperimentell Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge .	[ "Anhand", "einer", "Kasuistik", "weisen", "wir", "auf", "das", "Risiko", "des", "Auftretens", "nonkonvulsiver", "Status", "epileptici", "(", "NCSE", ")", "bei", "der", "Gabe", "des", "Antikonvulsivums", "Tiagabin", "in", "hoeheren", "Dosierungen", "und", "bei", "Dosissteigerungen", "hin", ".", "Das", "mehrmalige", "Auftreten", "von", "NCSE", "kurz", "nach", "der", "Tiagabin", "-", "Einnahme", "bei", "bisher", "unauffaelliger", "Status", "-", "Anamnese", "macht", "einen", "kausale", "Zusammenhang", "in", "diesem", "Fall", "sehr", "wahrscheinlich", ".", "Eine", "solche", "inverse", "Wirkung", "ist", "auch", "tierexperimentell", "gezeigt", "worden", ".", "Ein", "dosisabhaengiges", "Ungleichgewicht", "zwischen", "glialer", "und", "neuronaler", "GABA", "-", "Aufnahme", "hat", "ein", "Versagen", "der", "inhibitorischen", "GABA", "-", "Wirkung", "zur", "Folge", "." ]	[ "umlsterm" ]
Risiko, tierexperimentell	DerNervenarzt.90701104.ger.abstr_task2	Sentence: Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge .	[ "Anhand", "einer", "Kasuistik", "weisen", "wir", "auf", "das", "Risiko", "des", "Auftretens", "nonkonvulsiver", "Status", "epileptici", "(", "NCSE", ")", "bei", "der", "Gabe", "des", "Antikonvulsivums", "Tiagabin", "in", "hoeheren", "Dosierungen", "und", "bei", "Dosissteigerungen", "hin", ".", "Das", "mehrmalige", "Auftreten", "von", "NCSE", "kurz", "nach", "der", "Tiagabin", "-", "Einnahme", "bei", "bisher", "unauffaelliger", "Status", "-", "Anamnese", "macht", "einen", "kausale", "Zusammenhang", "in", "diesem", "Fall", "sehr", "wahrscheinlich", ".", "Eine", "solche", "inverse", "Wirkung", "ist", "auch", "tierexperimentell", "gezeigt", "worden", ".", "Ein", "dosisabhaengiges", "Ungleichgewicht", "zwischen", "glialer", "und", "neuronaler", "GABA", "-", "Aufnahme", "hat", "ein", "Versagen", "der", "inhibitorischen", "GABA", "-", "Wirkung", "zur", "Folge", "." ]	[ "umlsterm" ]
promoter is a DNA_domain_or_region, enhancer shuffling is an other_name	89925_task0	Sentence: Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling? Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, other_name	[ "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling?	[ "Every", "enhancer", "works", "with", "every", "promoter", "for", "all", "the", "combinations", "tested", ":", "could", "new", "regulatory", "pathways", "evolve", "by", "enhancer", "shuffling", "?" ]	[ "DNA_domain_or_region", "other_name", "protein_subunit", "multi_cell", "cell_line", "DNA_family_or_group" ]
promoter is a DNA_domain_or_region, enhancer shuffling is an other_name	89925_task1	Sentence: Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling? Instructions: please typing these entity words according to sentence: promoter, enhancer shuffling Options: DNA_domain_or_region, other_name	[ "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling?	[ "Every", "enhancer", "works", "with", "every", "promoter", "for", "all", "the", "combinations", "tested", ":", "could", "new", "regulatory", "pathways", "evolve", "by", "enhancer", "shuffling", "?" ]	[ "DNA_domain_or_region", "other_name", "protein_subunit", "multi_cell", "cell_line", "DNA_family_or_group" ]
promoter, enhancer shuffling	89925_task2	Sentence: Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling? Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling?	[ "Every", "enhancer", "works", "with", "every", "promoter", "for", "all", "the", "combinations", "tested", ":", "could", "new", "regulatory", "pathways", "evolve", "by", "enhancer", "shuffling", "?" ]	[ "DNA_domain_or_region", "other_name", "protein_subunit", "multi_cell", "cell_line", "DNA_family_or_group" ]
Hh is a protein, Ptc is a protein-family, Smo is a protein, Ptc is a protein-family	1.0alpha7.train.887_task0	Sentence: Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein	[ "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes.	[ "Binding", "of", " ", "Hh", "to", " ", "Ptc", "frees", " ", "Smo", "from", " ", "Ptc", "repression", ",", "which", "then", "goes", "on", "to", "activate", "downstream", " ", "target", "genes", "." ]	[ "protein", "protein-family" ]
Hh is a protein, Ptc is a protein-family, Smo is a protein, Ptc is a protein-family	1.0alpha7.train.887_task1	Sentence: Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes. Instructions: please typing these entity words according to sentence: Hh, Ptc, Smo, Ptc Options: protein-family, protein	[ "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes.	[ "Binding", "of", " ", "Hh", "to", " ", "Ptc", "frees", " ", "Smo", "from", " ", "Ptc", "repression", ",", "which", "then", "goes", "on", "to", "activate", "downstream", " ", "target", "genes", "." ]	[ "protein", "protein-family" ]
Hh, Ptc, Smo, Ptc	1.0alpha7.train.887_task2	Sentence: Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes.	[ "Binding", "of", " ", "Hh", "to", " ", "Ptc", "frees", " ", "Smo", "from", " ", "Ptc", "repression", ",", "which", "then", "goes", "on", "to", "activate", "downstream", " ", "target", "genes", "." ]	[ "protein", "protein-family" ]
Androgenablation is an umlsterm, therapy is an umlsterm, choice is an umlsterm, treatment is an umlsterm, metastatic is an umlsterm, prostate cancer is an umlsterm, patients is an umlsterm, disease is an umlsterm, androgenablation is an umlsterm, castration is an umlsterm, apoptotic is an umlsterm, treatment is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, toxicity is an umlsterm, treatment costs is an umlsterm, tumor is an umlsterm, survival is an umlsterm, clinical trials is an umlsterm	DerUrologeA.80370153.eng.abstr_task0	Sentence: Androgenablation is the therapy of choice for the treatment of advanced and metastatic prostate cancer . However , in more than half of the patients the disease will ultimately progress within 2 years . Intermittent androgenablation through medical castration maintains the apoptotic potential . By periodically changing phases on and off treatment the quality of life of the patients is improved . Apart from reduced toxicity treatment costs are lowered and tumor progression is possibly delayed . In how far survival is influenced is presently not clear and remains to be evaluated in further clinical trials . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Androgenablation is the therapy of choice for the treatment of advanced and metastatic prostate cancer . However , in more than half of the patients the disease will ultimately progress within 2 years . Intermittent androgenablation through medical castration maintains the apoptotic potential . By periodically changing phases on and off treatment the quality of life of the patients is improved . Apart from reduced toxicity treatment costs are lowered and tumor progression is possibly delayed . In how far survival is influenced is presently not clear and remains to be evaluated in further clinical trials .	[ "Androgenablation", "is", "the", "therapy", "of", "choice", "for", "the", "treatment", "of", "advanced", "and", "metastatic", "prostate", "cancer", ".", "However", ",", "in", "more", "than", "half", "of", "the", "patients", "the", "disease", "will", "ultimately", "progress", "within", "2", "years", ".", "Intermittent", "androgenablation", "through", "medical", "castration", "maintains", "the", "apoptotic", "potential", ".", "By", "periodically", "changing", "phases", "on", "and", "off", "treatment", "the", "quality", "of", "life", "of", "the", "patients", "is", "improved", ".", "Apart", "from", "reduced", "toxicity", "treatment", "costs", "are", "lowered", "and", "tumor", "progression", "is", "possibly", "delayed", ".", "In", "how", "far", "survival", "is", "influenced", "is", "presently", "not", "clear", "and", "remains", "to", "be", "evaluated", "in", "further", "clinical", "trials", "." ]	[ "umlsterm" ]

Familienanamnese is an umlsterm, Erytheme is an umlsterm, therapieresistenten is an umlsterm, Erythrodermien is an umlsterm, Blut is an umlsterm, Leukozytose is an umlsterm, Blutlymphozyten is an umlsterm, Durchflusszytometrie is an umlsterm, Histologie is an umlsterm, Diagnose is an umlsterm, Blut is an umlsterm, Lymphomzellen is an umlsterm

DerHautarzt.90500743.ger.abstr_task0

Sentence: Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden .

[ "Wir", "berichten", "ueber", "eine", "47jaehrige", "Patientin", "mit", "atopischer", "Eigen-", "und", "Familienanamnese", ",", "die", "im", "Verlauf", "von", "3", "Jahren", "lokalisierte", "juckende", "Erytheme", ",", "entwickelte", ",", "welche", "innerhalb", "von", "nur", "drei", "Monaten", "generalisierten", ".", "Es", "kam", "zu", "rezidivierenden", "und", "schliesslich", "therapieresistenten", "Erythrodermien", ".", "Neben", "zahlreichen", "Typ", "-", "I", "-", "Sensibilisierungen", "wurden", "einige", "Typ", "-", "IV", "-", "Sensibilisierungen", "nachgewiesen", ".", "Im", "peripheren", "Blut", "kam", "es", "zur", "Leukozytose", "und", "Hypereosinophilie", ".", "Ein", "deutlich", "erhoehter", "IgE", "-", "Spiegel", "war", "im", "Serum", "nachweisbar", ".", "Die", "Immunphaenotypisierung", "der", "peripheren", "Blutlymphozyten", "mittels", "Durchflusszytometrie", "ergab", "erste", "Hinweise", "fuer", "eine", "klonale", "Expansion", "von", "stark", "aktivierten", "CD4", "+", "-T", "-", "Zellen", ",", "die", "eine", "verminderte", "Expression", "von", "CD2", "und", "CD5", "aufwiesen", ".", "Mittels", "Histologie", "und", "einer", "Polymerasekettenreaktionstechnik", "zur", "Untersuchung", "der", "Rearrangierung", "der", "-Kette", "des", "T", "-", "Zellrezeptors", "konnte", "dann", "nach", "3jaehrigem", "Krankheitsverlauf", "die", "Diagnose", "eines", "pleomorphen", "kleinzelligen", "kutanen", "T", "-", "Zell", "-", "Lymphoms", "gestellt", "werden", ".", "Weitere", "Untersuchungen", "zur", "Zytokinexpression", "liessen", "vermuten", ",", "dass", "die", "hohen", "IgE", "-", "Konzentrationen", "im", "Blut", "und", "die", "Hypereosinophilie", "durch", "eine", "starke", "Produktion", "und", "Sezernierung", "von", "IL-5", "und", "IL-13", "in", "den", "Lymphomzellen", "verursacht", "wurden", "." ]

[ "umlsterm" ]

Familienanamnese is an umlsterm, Erytheme is an umlsterm, therapieresistenten is an umlsterm, Erythrodermien is an umlsterm, Blut is an umlsterm, Leukozytose is an umlsterm, Blutlymphozyten is an umlsterm, Durchflusszytometrie is an umlsterm, Histologie is an umlsterm, Diagnose is an umlsterm, Blut is an umlsterm, Lymphomzellen is an umlsterm

DerHautarzt.90500743.ger.abstr_task1

Sentence: Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden . Instructions: please typing these entity words according to sentence: Familienanamnese, Erytheme, therapieresistenten, Erythrodermien, Blut, Leukozytose, Blutlymphozyten, Durchflusszytometrie, Histologie, Diagnose, Blut, Lymphomzellen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden .

[ "Wir", "berichten", "ueber", "eine", "47jaehrige", "Patientin", "mit", "atopischer", "Eigen-", "und", "Familienanamnese", ",", "die", "im", "Verlauf", "von", "3", "Jahren", "lokalisierte", "juckende", "Erytheme", ",", "entwickelte", ",", "welche", "innerhalb", "von", "nur", "drei", "Monaten", "generalisierten", ".", "Es", "kam", "zu", "rezidivierenden", "und", "schliesslich", "therapieresistenten", "Erythrodermien", ".", "Neben", "zahlreichen", "Typ", "-", "I", "-", "Sensibilisierungen", "wurden", "einige", "Typ", "-", "IV", "-", "Sensibilisierungen", "nachgewiesen", ".", "Im", "peripheren", "Blut", "kam", "es", "zur", "Leukozytose", "und", "Hypereosinophilie", ".", "Ein", "deutlich", "erhoehter", "IgE", "-", "Spiegel", "war", "im", "Serum", "nachweisbar", ".", "Die", "Immunphaenotypisierung", "der", "peripheren", "Blutlymphozyten", "mittels", "Durchflusszytometrie", "ergab", "erste", "Hinweise", "fuer", "eine", "klonale", "Expansion", "von", "stark", "aktivierten", "CD4", "+", "-T", "-", "Zellen", ",", "die", "eine", "verminderte", "Expression", "von", "CD2", "und", "CD5", "aufwiesen", ".", "Mittels", "Histologie", "und", "einer", "Polymerasekettenreaktionstechnik", "zur", "Untersuchung", "der", "Rearrangierung", "der", "-Kette", "des", "T", "-", "Zellrezeptors", "konnte", "dann", "nach", "3jaehrigem", "Krankheitsverlauf", "die", "Diagnose", "eines", "pleomorphen", "kleinzelligen", "kutanen", "T", "-", "Zell", "-", "Lymphoms", "gestellt", "werden", ".", "Weitere", "Untersuchungen", "zur", "Zytokinexpression", "liessen", "vermuten", ",", "dass", "die", "hohen", "IgE", "-", "Konzentrationen", "im", "Blut", "und", "die", "Hypereosinophilie", "durch", "eine", "starke", "Produktion", "und", "Sezernierung", "von", "IL-5", "und", "IL-13", "in", "den", "Lymphomzellen", "verursacht", "wurden", "." ]

[ "umlsterm" ]

Familienanamnese, Erytheme, therapieresistenten, Erythrodermien, Blut, Leukozytose, Blutlymphozyten, Durchflusszytometrie, Histologie, Diagnose, Blut, Lymphomzellen

DerHautarzt.90500743.ger.abstr_task2

Sentence: Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Wir berichten ueber eine 47jaehrige Patientin mit atopischer Eigen- und Familienanamnese , die im Verlauf von 3 Jahren lokalisierte juckende Erytheme , entwickelte , welche innerhalb von nur drei Monaten generalisierten . Es kam zu rezidivierenden und schliesslich therapieresistenten Erythrodermien . Neben zahlreichen Typ-I-Sensibilisierungen wurden einige Typ-IV-Sensibilisierungen nachgewiesen . Im peripheren Blut kam es zur Leukozytose und Hypereosinophilie . Ein deutlich erhoehter IgE-Spiegel war im Serum nachweisbar . Die Immunphaenotypisierung der peripheren Blutlymphozyten mittels Durchflusszytometrie ergab erste Hinweise fuer eine klonale Expansion von stark aktivierten CD4+-T-Zellen, die eine verminderte Expression von CD2 und CD5 aufwiesen . Mittels Histologie und einer Polymerasekettenreaktionstechnik zur Untersuchung der Rearrangierung der -Kette des T-Zellrezeptors konnte dann nach 3jaehrigem Krankheitsverlauf die Diagnose eines pleomorphen kleinzelligen kutanen T-Zell-Lymphoms gestellt werden . Weitere Untersuchungen zur Zytokinexpression liessen vermuten , dass die hohen IgE-Konzentrationen im Blut und die Hypereosinophilie durch eine starke Produktion und Sezernierung von IL-5 und IL-13 in den Lymphomzellen verursacht wurden .

[ "Wir", "berichten", "ueber", "eine", "47jaehrige", "Patientin", "mit", "atopischer", "Eigen-", "und", "Familienanamnese", ",", "die", "im", "Verlauf", "von", "3", "Jahren", "lokalisierte", "juckende", "Erytheme", ",", "entwickelte", ",", "welche", "innerhalb", "von", "nur", "drei", "Monaten", "generalisierten", ".", "Es", "kam", "zu", "rezidivierenden", "und", "schliesslich", "therapieresistenten", "Erythrodermien", ".", "Neben", "zahlreichen", "Typ", "-", "I", "-", "Sensibilisierungen", "wurden", "einige", "Typ", "-", "IV", "-", "Sensibilisierungen", "nachgewiesen", ".", "Im", "peripheren", "Blut", "kam", "es", "zur", "Leukozytose", "und", "Hypereosinophilie", ".", "Ein", "deutlich", "erhoehter", "IgE", "-", "Spiegel", "war", "im", "Serum", "nachweisbar", ".", "Die", "Immunphaenotypisierung", "der", "peripheren", "Blutlymphozyten", "mittels", "Durchflusszytometrie", "ergab", "erste", "Hinweise", "fuer", "eine", "klonale", "Expansion", "von", "stark", "aktivierten", "CD4", "+", "-T", "-", "Zellen", ",", "die", "eine", "verminderte", "Expression", "von", "CD2", "und", "CD5", "aufwiesen", ".", "Mittels", "Histologie", "und", "einer", "Polymerasekettenreaktionstechnik", "zur", "Untersuchung", "der", "Rearrangierung", "der", "-Kette", "des", "T", "-", "Zellrezeptors", "konnte", "dann", "nach", "3jaehrigem", "Krankheitsverlauf", "die", "Diagnose", "eines", "pleomorphen", "kleinzelligen", "kutanen", "T", "-", "Zell", "-", "Lymphoms", "gestellt", "werden", ".", "Weitere", "Untersuchungen", "zur", "Zytokinexpression", "liessen", "vermuten", ",", "dass", "die", "hohen", "IgE", "-", "Konzentrationen", "im", "Blut", "und", "die", "Hypereosinophilie", "durch", "eine", "starke", "Produktion", "und", "Sezernierung", "von", "IL-5", "und", "IL-13", "in", "den", "Lymphomzellen", "verursacht", "wurden", "." ]

[ "umlsterm" ]

Analyse is an umlsterm, Praevalenz is an umlsterm, schlafbezogenen is an umlsterm, Atmungsstoerungen is an umlsterm, Patienten is an umlsterm, Arrhythmierezidiven is an umlsterm, Mortalitaet is an umlsterm, Langzeitverlauf is an umlsterm, Grundkrankheit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Cheyne - Stokes - Atmung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Arrhythmierezidive is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Arrhythmien is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Praevalenz is an umlsterm, Patienten is an umlsterm, Mortalitaet is an umlsterm, Arrhythmierezidiven is an umlsterm, Langzeitverlauf is an umlsterm

ZfuerKardiologie.80870826.ger.abstr_task0

Sentence: Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar .

[ "Ziele", "der", "Studie", "waren", "einerseits", "eine", "Analyse", "der", "Praevalenz", "von", "schlafbezogenen", "Atmungsstoerungen", "(", "SBAS", ")", "bei", "Patienten", "mit", "implantierbarem", "Kardioverter", "-", "Defibrillator", "(", "ICD", ")", "und", "andererseits", "die", "prospektive", "Untersuchung", "des", "moeglichen", "Einflusses", "von", "SBAS", "auf", "die", "Haeufigkeit", "und", "zirkadiane", "Verteilung", "von", "Arrhythmierezidiven", "sowie", "auf", "die", "kardiale", "Mortalitaet", "im", "Langzeitverlauf", ".", "Vierzig", "konsekutive", "ICD", "-", "Patienten", "mit", "kardialer", "Grundkrankheit", "und", "dokumentierten", "malignen", "ventrikulaeren", "Tachyarrhythmien", "wurden", "polysomnographisch", "untersucht", "und", "anschliessend", "2", "Jahre", "nachbeobachtet", ".", "Bei", "16", "von", "40", "Patienten", "(", "40", "%", ")", "wurden", "SBAS", "diagnostiziert", "(", "Apnoe", "-", "Hypopnoe", "-", "Index", ">", "10", ")", ":", "bei", "9", "dieser", "16", "Patienten", "(", "56", "%", ")", "traten", "zentrale", "Schlafapnoen", "(", "ZSA", ")", "auf", "(", "bei", "8", "dieser", "9", "Patienten", "Cheyne", "-", "Stokes", "-", "Atmung", ")", "und", "bei", "7", "der", "16", "Patienten", "mit", "SBAS", "(", "44", "%", "obstruktive", "Schlafapnoen", "(", ")", "OSA", ")", ".", "Der", "AHI", "betrug", "32", "+", "/-", "15", "(", "12", "-", "60", ")", "bei", "Patienten", "mit", "ZSA", "und", "32", "+", "/-", "27", "(", "11", "-", "86", ")", "bei", "Patienten", "mit", "OSA", ".", "Patienten", "mit", "und", "ohne", "SBAS", "waren", "vergleichbar", "bezueglich", "des", "Ausmasses", "der", "linksventrikulaeren", "Funktionseinschraenkung", ",", "NYHA", "-", "Klassifikation", ",", "kardialer", "Grunderkrankung", ",", "ICD", "-", "Indikation", "und", "begleitender", "Medikation", ".", "Defibrillatorregistrierte", "Arrhythmierezidive", "traten", "bei", "10", "von", "24", "Patienten", "(", "42", "%", ")", "ohne", "SBAS", ",", "bei", "4", "von", "9", "Patienten", "(", "44", "%", ")", "mit", "ZSA", "und", "bei", "3", "von", "7", "Patienten", "(", "44", "%", ")", "mit", "OSA", "auf", ".", "Anzahl", "und", "tageszeitliche", "Verteilung", "der", "registrierten", "Arrhythmien", "bei", "Patienten", "ohne", "SBAS", ",", "mit", "OSA", "und", "ZSA", "waren", "vergleichbar", "(", "14", "+", "/-", "25", ",", "Median", "4", "vs", ".", "15", "+", "/-", "15", ",", "Median", "7", "vs", ".", "4", "+", "/-", "5", ",", "Median", "2,5", ")", ".", "Die", "kardiale", "2-Jahres", "-", "Mortalitaet", "war", "am", "hoechsten", "bei", "Patienten", "mit", "ZSA", "(", "4/9", "(", "44", "%", ")", "vs", ".", "0/7", "Patienten", "(", "0", "%", ")", "mit", "OSA", "vs", ".", "3/24", "Patienten", "(", "12,5", "%", ")", "ohne", "SBAS", ".", "Die", "Praevalenz", "von", "SBAS", "bei", "Patienten", "mit", "ICD", "ist", "also", "hoch", ",", "wobei", "das", "Auftreten", "von", "ZSA", "mit", "einer", "hohen", "kardialen", "Mortalitaet", "assoziiert", "ist", ".", "Ein", "Einfluss", "von", "maessiggradigen", "SBAS", "auf", "die", "Haeufigkeit", "und", "tageszeitliche", "Verteilung", "von", "Arrhythmierezidiven", "im", "Langzeitverlauf", "ist", "nicht", "nachweisbar", "." ]

[ "umlsterm" ]

Analyse is an umlsterm, Praevalenz is an umlsterm, schlafbezogenen is an umlsterm, Atmungsstoerungen is an umlsterm, Patienten is an umlsterm, Arrhythmierezidiven is an umlsterm, Mortalitaet is an umlsterm, Langzeitverlauf is an umlsterm, Grundkrankheit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Cheyne - Stokes - Atmung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Arrhythmierezidive is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Arrhythmien is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Praevalenz is an umlsterm, Patienten is an umlsterm, Mortalitaet is an umlsterm, Arrhythmierezidiven is an umlsterm, Langzeitverlauf is an umlsterm

ZfuerKardiologie.80870826.ger.abstr_task1

Sentence: Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar . Instructions: please typing these entity words according to sentence: Analyse, Praevalenz, schlafbezogenen, Atmungsstoerungen, Patienten, Arrhythmierezidiven, Mortalitaet, Langzeitverlauf, Grundkrankheit, Patienten, Patienten, Patienten, Cheyne - Stokes - Atmung, Patienten, Patienten, Patienten, Patienten, Arrhythmierezidive, Patienten, Patienten, Patienten, Arrhythmien, Patienten, Patienten, Patienten, Patienten, Praevalenz, Patienten, Mortalitaet, Arrhythmierezidiven, Langzeitverlauf Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar .

[ "Ziele", "der", "Studie", "waren", "einerseits", "eine", "Analyse", "der", "Praevalenz", "von", "schlafbezogenen", "Atmungsstoerungen", "(", "SBAS", ")", "bei", "Patienten", "mit", "implantierbarem", "Kardioverter", "-", "Defibrillator", "(", "ICD", ")", "und", "andererseits", "die", "prospektive", "Untersuchung", "des", "moeglichen", "Einflusses", "von", "SBAS", "auf", "die", "Haeufigkeit", "und", "zirkadiane", "Verteilung", "von", "Arrhythmierezidiven", "sowie", "auf", "die", "kardiale", "Mortalitaet", "im", "Langzeitverlauf", ".", "Vierzig", "konsekutive", "ICD", "-", "Patienten", "mit", "kardialer", "Grundkrankheit", "und", "dokumentierten", "malignen", "ventrikulaeren", "Tachyarrhythmien", "wurden", "polysomnographisch", "untersucht", "und", "anschliessend", "2", "Jahre", "nachbeobachtet", ".", "Bei", "16", "von", "40", "Patienten", "(", "40", "%", ")", "wurden", "SBAS", "diagnostiziert", "(", "Apnoe", "-", "Hypopnoe", "-", "Index", ">", "10", ")", ":", "bei", "9", "dieser", "16", "Patienten", "(", "56", "%", ")", "traten", "zentrale", "Schlafapnoen", "(", "ZSA", ")", "auf", "(", "bei", "8", "dieser", "9", "Patienten", "Cheyne", "-", "Stokes", "-", "Atmung", ")", "und", "bei", "7", "der", "16", "Patienten", "mit", "SBAS", "(", "44", "%", "obstruktive", "Schlafapnoen", "(", ")", "OSA", ")", ".", "Der", "AHI", "betrug", "32", "+", "/-", "15", "(", "12", "-", "60", ")", "bei", "Patienten", "mit", "ZSA", "und", "32", "+", "/-", "27", "(", "11", "-", "86", ")", "bei", "Patienten", "mit", "OSA", ".", "Patienten", "mit", "und", "ohne", "SBAS", "waren", "vergleichbar", "bezueglich", "des", "Ausmasses", "der", "linksventrikulaeren", "Funktionseinschraenkung", ",", "NYHA", "-", "Klassifikation", ",", "kardialer", "Grunderkrankung", ",", "ICD", "-", "Indikation", "und", "begleitender", "Medikation", ".", "Defibrillatorregistrierte", "Arrhythmierezidive", "traten", "bei", "10", "von", "24", "Patienten", "(", "42", "%", ")", "ohne", "SBAS", ",", "bei", "4", "von", "9", "Patienten", "(", "44", "%", ")", "mit", "ZSA", "und", "bei", "3", "von", "7", "Patienten", "(", "44", "%", ")", "mit", "OSA", "auf", ".", "Anzahl", "und", "tageszeitliche", "Verteilung", "der", "registrierten", "Arrhythmien", "bei", "Patienten", "ohne", "SBAS", ",", "mit", "OSA", "und", "ZSA", "waren", "vergleichbar", "(", "14", "+", "/-", "25", ",", "Median", "4", "vs", ".", "15", "+", "/-", "15", ",", "Median", "7", "vs", ".", "4", "+", "/-", "5", ",", "Median", "2,5", ")", ".", "Die", "kardiale", "2-Jahres", "-", "Mortalitaet", "war", "am", "hoechsten", "bei", "Patienten", "mit", "ZSA", "(", "4/9", "(", "44", "%", ")", "vs", ".", "0/7", "Patienten", "(", "0", "%", ")", "mit", "OSA", "vs", ".", "3/24", "Patienten", "(", "12,5", "%", ")", "ohne", "SBAS", ".", "Die", "Praevalenz", "von", "SBAS", "bei", "Patienten", "mit", "ICD", "ist", "also", "hoch", ",", "wobei", "das", "Auftreten", "von", "ZSA", "mit", "einer", "hohen", "kardialen", "Mortalitaet", "assoziiert", "ist", ".", "Ein", "Einfluss", "von", "maessiggradigen", "SBAS", "auf", "die", "Haeufigkeit", "und", "tageszeitliche", "Verteilung", "von", "Arrhythmierezidiven", "im", "Langzeitverlauf", "ist", "nicht", "nachweisbar", "." ]

[ "umlsterm" ]

Analyse, Praevalenz, schlafbezogenen, Atmungsstoerungen, Patienten, Arrhythmierezidiven, Mortalitaet, Langzeitverlauf, Grundkrankheit, Patienten, Patienten, Patienten, Cheyne - Stokes - Atmung, Patienten, Patienten, Patienten, Patienten, Arrhythmierezidive, Patienten, Patienten, Patienten, Arrhythmien, Patienten, Patienten, Patienten, Patienten, Praevalenz, Patienten, Mortalitaet, Arrhythmierezidiven, Langzeitverlauf

ZfuerKardiologie.80870826.ger.abstr_task2

Sentence: Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Ziele der Studie waren einerseits eine Analyse der Praevalenz von schlafbezogenen Atmungsstoerungen ( SBAS ) bei Patienten mit implantierbarem Kardioverter-Defibrillator ( ICD ) und andererseits die prospektive Untersuchung des moeglichen Einflusses von SBAS auf die Haeufigkeit und zirkadiane Verteilung von Arrhythmierezidiven sowie auf die kardiale Mortalitaet im Langzeitverlauf . Vierzig konsekutive ICD-Patienten mit kardialer Grundkrankheit und dokumentierten malignen ventrikulaeren Tachyarrhythmien wurden polysomnographisch untersucht und anschliessend 2 Jahre nachbeobachtet . Bei 16 von 40 Patienten ( 40% ) wurden SBAS diagnostiziert ( Apnoe-Hypopnoe-Index > 10 ) : bei 9 dieser 16 Patienten ( 56% ) traten zentrale Schlafapnoen ( ZSA ) auf ( bei 8 dieser 9 Patienten Cheyne-Stokes-Atmung ) und bei 7 der 16 Patienten mit SBAS ( 44% obstruktive Schlafapnoen ( ) OSA ) . Der AHI betrug 32 +/- 15 ( 12-60 ) bei Patienten mit ZSA und 32 +/- 27 ( 11-86 ) bei Patienten mit OSA . Patienten mit und ohne SBAS waren vergleichbar bezueglich des Ausmasses der linksventrikulaeren Funktionseinschraenkung , NYHA-Klassifikation , kardialer Grunderkrankung , ICD-Indikation und begleitender Medikation . Defibrillatorregistrierte Arrhythmierezidive traten bei 10 von 24 Patienten ( 42% ) ohne SBAS , bei 4 von 9 Patienten ( 44% ) mit ZSA und bei 3 von 7 Patienten ( 44% ) mit OSA auf . Anzahl und tageszeitliche Verteilung der registrierten Arrhythmien bei Patienten ohne SBAS , mit OSA und ZSA waren vergleichbar ( 14 +/- 25 , Median 4 vs. 15 +/- 15 , Median 7 vs. 4 +/- 5 , Median 2,5 ) . Die kardiale 2-Jahres-Mortalitaet war am hoechsten bei Patienten mit ZSA ( 4/9 ( 44% ) vs. 0/7 Patienten ( 0% ) mit OSA vs. 3/24 Patienten ( 12,5% ) ohne SBAS . Die Praevalenz von SBAS bei Patienten mit ICD ist also hoch , wobei das Auftreten von ZSA mit einer hohen kardialen Mortalitaet assoziiert ist . Ein Einfluss von maessiggradigen SBAS auf die Haeufigkeit und tageszeitliche Verteilung von Arrhythmierezidiven im Langzeitverlauf ist nicht nachweisbar .

[ "Ziele", "der", "Studie", "waren", "einerseits", "eine", "Analyse", "der", "Praevalenz", "von", "schlafbezogenen", "Atmungsstoerungen", "(", "SBAS", ")", "bei", "Patienten", "mit", "implantierbarem", "Kardioverter", "-", "Defibrillator", "(", "ICD", ")", "und", "andererseits", "die", "prospektive", "Untersuchung", "des", "moeglichen", "Einflusses", "von", "SBAS", "auf", "die", "Haeufigkeit", "und", "zirkadiane", "Verteilung", "von", "Arrhythmierezidiven", "sowie", "auf", "die", "kardiale", "Mortalitaet", "im", "Langzeitverlauf", ".", "Vierzig", "konsekutive", "ICD", "-", "Patienten", "mit", "kardialer", "Grundkrankheit", "und", "dokumentierten", "malignen", "ventrikulaeren", "Tachyarrhythmien", "wurden", "polysomnographisch", "untersucht", "und", "anschliessend", "2", "Jahre", "nachbeobachtet", ".", "Bei", "16", "von", "40", "Patienten", "(", "40", "%", ")", "wurden", "SBAS", "diagnostiziert", "(", "Apnoe", "-", "Hypopnoe", "-", "Index", ">", "10", ")", ":", "bei", "9", "dieser", "16", "Patienten", "(", "56", "%", ")", "traten", "zentrale", "Schlafapnoen", "(", "ZSA", ")", "auf", "(", "bei", "8", "dieser", "9", "Patienten", "Cheyne", "-", "Stokes", "-", "Atmung", ")", "und", "bei", "7", "der", "16", "Patienten", "mit", "SBAS", "(", "44", "%", "obstruktive", "Schlafapnoen", "(", ")", "OSA", ")", ".", "Der", "AHI", "betrug", "32", "+", "/-", "15", "(", "12", "-", "60", ")", "bei", "Patienten", "mit", "ZSA", "und", "32", "+", "/-", "27", "(", "11", "-", "86", ")", "bei", "Patienten", "mit", "OSA", ".", "Patienten", "mit", "und", "ohne", "SBAS", "waren", "vergleichbar", "bezueglich", "des", "Ausmasses", "der", "linksventrikulaeren", "Funktionseinschraenkung", ",", "NYHA", "-", "Klassifikation", ",", "kardialer", "Grunderkrankung", ",", "ICD", "-", "Indikation", "und", "begleitender", "Medikation", ".", "Defibrillatorregistrierte", "Arrhythmierezidive", "traten", "bei", "10", "von", "24", "Patienten", "(", "42", "%", ")", "ohne", "SBAS", ",", "bei", "4", "von", "9", "Patienten", "(", "44", "%", ")", "mit", "ZSA", "und", "bei", "3", "von", "7", "Patienten", "(", "44", "%", ")", "mit", "OSA", "auf", ".", "Anzahl", "und", "tageszeitliche", "Verteilung", "der", "registrierten", "Arrhythmien", "bei", "Patienten", "ohne", "SBAS", ",", "mit", "OSA", "und", "ZSA", "waren", "vergleichbar", "(", "14", "+", "/-", "25", ",", "Median", "4", "vs", ".", "15", "+", "/-", "15", ",", "Median", "7", "vs", ".", "4", "+", "/-", "5", ",", "Median", "2,5", ")", ".", "Die", "kardiale", "2-Jahres", "-", "Mortalitaet", "war", "am", "hoechsten", "bei", "Patienten", "mit", "ZSA", "(", "4/9", "(", "44", "%", ")", "vs", ".", "0/7", "Patienten", "(", "0", "%", ")", "mit", "OSA", "vs", ".", "3/24", "Patienten", "(", "12,5", "%", ")", "ohne", "SBAS", ".", "Die", "Praevalenz", "von", "SBAS", "bei", "Patienten", "mit", "ICD", "ist", "also", "hoch", ",", "wobei", "das", "Auftreten", "von", "ZSA", "mit", "einer", "hohen", "kardialen", "Mortalitaet", "assoziiert", "ist", ".", "Ein", "Einfluss", "von", "maessiggradigen", "SBAS", "auf", "die", "Haeufigkeit", "und", "tageszeitliche", "Verteilung", "von", "Arrhythmierezidiven", "im", "Langzeitverlauf", "ist", "nicht", "nachweisbar", "." ]

[ "umlsterm" ]

purified chick embryo cell culture rabies vaccine is a Intervention_Pharmacological, human diploid cell vaccine is a Intervention_Pharmacological, purified chick embryo cell culture rabies vaccine ( PCECV ) is a Intervention_Pharmacological, human diploid cell strain rabies vaccine ( HDCSV ) is a Intervention_Pharmacological, 177 is a Participant_Sample-size, persistence of antibody over two years is a Outcome_Other, titres 21 days after the final injection is a Outcome_Other, Neutralizing is a Outcome_Other, antibody titres is a Outcome_Physical, urticarial lesions is a Outcome_Physical

76559_task0

Sentence: Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated .

[ "Pre", "-", "exposure", "studies", "with", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "and", "human", "diploid", "cell", "vaccine", ":", "serological", "and", "clinical", "responses", "in", "man", ".", "Clinical", "reactions", "and", "neutralizing", "antibody", "responses", "to", "six", "pre", "-", "exposure", "regimens", "of", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "(", "PCECV", ")", "and", "human", "diploid", "cell", "strain", "rabies", "vaccine", "(", "HDCSV", ")", "were", "studied", "in", "177", "volunteers", ".", "Antibody", "kinetics", ",", "height", "of", "the", "response", "and", "persistence", "of", "antibody", "over", "two", "years", "were", "virtually", "identical", "after", "PCECV", "and", "HDCSV", ".", "An", "antibody", "response", "was", "detected", "in", "all", "subjects", "on", "day", "14", "when", "the", "highest", "titres", "were", "found", "after", "two", "intramuscular", "(", "i.m", ".", ")", "1.0", "ml", "doses", "of", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "7", "and", "21", ".", "In", "comparison", ",", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "28", "and", "56", "ultimately", "evoked", "the", "highest", "titres", "21", "days", "after", "the", "final", "injection", ",", "but", "antibody", "persisted", "equally", "well", "over", "two", "years", "with", "either", "schedule", ".", "Neutralizing", "antibody", "titres", "were", "lower", "after", "intradermal", "(", "i.d", ".", ")", "vaccination", "with", "0.1", "ml", "compared", "to", "1.0", "ml", "i.m", ".", "on", "days", "0", ",", "7", "and", "21", ",", "but", "when", "given", "on", "days", "0", ",", "28", "and", "56", "the", "responses", "were", "comparable", ".", "Three", "subjects", "with", "a", "personal", "or", "family", "history", "of", "atopy", "developed", "urticarial", "lesions", "after", "PCECV", ".", "Both", "vaccines", "were", "otherwise", "well", "tolerated", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Outcome_Mental", "Participant_Sex", "Participant_Sample-size" ]

purified chick embryo cell culture rabies vaccine is a Intervention_Pharmacological, human diploid cell vaccine is a Intervention_Pharmacological, purified chick embryo cell culture rabies vaccine ( PCECV ) is a Intervention_Pharmacological, human diploid cell strain rabies vaccine ( HDCSV ) is a Intervention_Pharmacological, 177 is a Participant_Sample-size, persistence of antibody over two years is a Outcome_Other, titres 21 days after the final injection is a Outcome_Other, Neutralizing is a Outcome_Other, antibody titres is a Outcome_Physical, urticarial lesions is a Outcome_Physical

76559_task1

Sentence: Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated . Instructions: please typing these entity words according to sentence: purified chick embryo cell culture rabies vaccine, human diploid cell vaccine, purified chick embryo cell culture rabies vaccine ( PCECV ), human diploid cell strain rabies vaccine ( HDCSV ), 177, persistence of antibody over two years, titres 21 days after the final injection, Neutralizing, antibody titres, urticarial lesions Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated .

[ "Pre", "-", "exposure", "studies", "with", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "and", "human", "diploid", "cell", "vaccine", ":", "serological", "and", "clinical", "responses", "in", "man", ".", "Clinical", "reactions", "and", "neutralizing", "antibody", "responses", "to", "six", "pre", "-", "exposure", "regimens", "of", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "(", "PCECV", ")", "and", "human", "diploid", "cell", "strain", "rabies", "vaccine", "(", "HDCSV", ")", "were", "studied", "in", "177", "volunteers", ".", "Antibody", "kinetics", ",", "height", "of", "the", "response", "and", "persistence", "of", "antibody", "over", "two", "years", "were", "virtually", "identical", "after", "PCECV", "and", "HDCSV", ".", "An", "antibody", "response", "was", "detected", "in", "all", "subjects", "on", "day", "14", "when", "the", "highest", "titres", "were", "found", "after", "two", "intramuscular", "(", "i.m", ".", ")", "1.0", "ml", "doses", "of", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "7", "and", "21", ".", "In", "comparison", ",", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "28", "and", "56", "ultimately", "evoked", "the", "highest", "titres", "21", "days", "after", "the", "final", "injection", ",", "but", "antibody", "persisted", "equally", "well", "over", "two", "years", "with", "either", "schedule", ".", "Neutralizing", "antibody", "titres", "were", "lower", "after", "intradermal", "(", "i.d", ".", ")", "vaccination", "with", "0.1", "ml", "compared", "to", "1.0", "ml", "i.m", ".", "on", "days", "0", ",", "7", "and", "21", ",", "but", "when", "given", "on", "days", "0", ",", "28", "and", "56", "the", "responses", "were", "comparable", ".", "Three", "subjects", "with", "a", "personal", "or", "family", "history", "of", "atopy", "developed", "urticarial", "lesions", "after", "PCECV", ".", "Both", "vaccines", "were", "otherwise", "well", "tolerated", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Outcome_Mental", "Participant_Sex", "Participant_Sample-size" ]

purified chick embryo cell culture rabies vaccine, human diploid cell vaccine, purified chick embryo cell culture rabies vaccine ( PCECV ), human diploid cell strain rabies vaccine ( HDCSV ), 177, persistence of antibody over two years, titres 21 days after the final injection, Neutralizing, antibody titres, urticarial lesions

76559_task2

Sentence: Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated .

[ "Pre", "-", "exposure", "studies", "with", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "and", "human", "diploid", "cell", "vaccine", ":", "serological", "and", "clinical", "responses", "in", "man", ".", "Clinical", "reactions", "and", "neutralizing", "antibody", "responses", "to", "six", "pre", "-", "exposure", "regimens", "of", "purified", "chick", "embryo", "cell", "culture", "rabies", "vaccine", "(", "PCECV", ")", "and", "human", "diploid", "cell", "strain", "rabies", "vaccine", "(", "HDCSV", ")", "were", "studied", "in", "177", "volunteers", ".", "Antibody", "kinetics", ",", "height", "of", "the", "response", "and", "persistence", "of", "antibody", "over", "two", "years", "were", "virtually", "identical", "after", "PCECV", "and", "HDCSV", ".", "An", "antibody", "response", "was", "detected", "in", "all", "subjects", "on", "day", "14", "when", "the", "highest", "titres", "were", "found", "after", "two", "intramuscular", "(", "i.m", ".", ")", "1.0", "ml", "doses", "of", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "7", "and", "21", ".", "In", "comparison", ",", "a", "schedule", "of", "immunization", "on", "days", "0", ",", "28", "and", "56", "ultimately", "evoked", "the", "highest", "titres", "21", "days", "after", "the", "final", "injection", ",", "but", "antibody", "persisted", "equally", "well", "over", "two", "years", "with", "either", "schedule", ".", "Neutralizing", "antibody", "titres", "were", "lower", "after", "intradermal", "(", "i.d", ".", ")", "vaccination", "with", "0.1", "ml", "compared", "to", "1.0", "ml", "i.m", ".", "on", "days", "0", ",", "7", "and", "21", ",", "but", "when", "given", "on", "days", "0", ",", "28", "and", "56", "the", "responses", "were", "comparable", ".", "Three", "subjects", "with", "a", "personal", "or", "family", "history", "of", "atopy", "developed", "urticarial", "lesions", "after", "PCECV", ".", "Both", "vaccines", "were", "otherwise", "well", "tolerated", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Outcome_Mental", "Participant_Sex", "Participant_Sample-size" ]

XIST is a Protein, locus is a Entity, XIST is a Protein, XIST is a Protein, histone H4 is a Protein, chromatin domains is a Entity, genes is a Entity, ZXDA is a Protein, ZXDB is a Protein, loci is a Entity, PHKA1 is a Protein, loci is a Entity, XIST is a Protein, XIST is a Protein, its AR allele is a Entity, the one on the normal X allele is a Entity

94_task0

Sentence: The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS)

[ "The", "severe", "phenotype", "of", "females", "with", "tiny", "ring", "X", "chromosomes", "is", "associated", "with", "inability", "of", "these", "chromosomes", "to", "undergo", "X", "inactivation", ".", "\n", "Mental", "retardation", "and", "a", "constellation", "of", "congenital", "malformations", "not", "usually", "associated", "with", "Turner", "syndrome", "are", "seen", "in", "some", "females", "with", "a", "mosaic", "45,X/46,X", ",", "r(X", ")", "karyotype", ".", "Studies", "of", "these", "females", "show", "that", "the", "XIST", "locus", "on", "their", "tiny", "ring", "X", "chromosomes", "is", "either", "not", "present", "or", "not", "expressed", ".", "As", "XIST", "transcription", "is", "well", "correlated", "with", "inactivation", "of", "the", "X", "chromosome", "in", "female", "somatic", "cells", "and", "spermatogonia", ",", "nonexpression", "of", "the", "locus", "even", "when", "it", "is", "present", "suggests", "that", "these", "chromosomes", "are", "transcriptionally", "active", ".", "We", "examined", "the", "transcriptional", "activity", "of", "ring", "X", "chromosomes", "lacking", "XIST", "expression", "(", "XISTE-", ")", ",", "from", "three", "females", "with", "severe", "phenotypes", ".", "The", "two", "tiny", "ring", "X", "chromosomes", "studied", "with", "an", "antibody", "specific", "for", "the", "acetylated", "isoforms", "of", "histone", "H4", "marking", "transcribed", "chromatin", "domains", "were", "labeled", "at", "a", "level", "consistent", "with", "their", "being", "active", ".", "We", "also", "examined", "tow", "of", "the", "XISTE-", "ring", "chromosomes", "to", "determine", "whether", "genes", "that", "are", "normally", "silent", "on", "an", "inactive", "X", "are", "expressed", "from", "these", "chromosomes", ".", "Analyses", "of", "hybrid", "cells", "show", "that", "TIMP", ",", "ZXDA", ",", "and", "ZXDB", "loci", "on", "the", "proximal", "short", "arm", ",", "and", "AR", "and", "PHKA1", "loci", "on", "the", "long", "arm", ",", "are", "well", "expressed", "from", "the", "tiny", "ring", "X", "chromosome", "lacking", "XIST", "DNA", ".", "Studies", "of", "the", "ring", "chromosome", "that", "has", "XIST", "DNA", "but", "does", "not", "transcribe", "it", "show", "that", "its", "AR", "allele", "is", "transcribed", "along", "with", "the", "one", "on", "the", "normal", "X", "allele", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]

[ "Entity", "Protein" ]

XIST is a Protein, locus is a Entity, XIST is a Protein, XIST is a Protein, histone H4 is a Protein, chromatin domains is a Entity, genes is a Entity, ZXDA is a Protein, ZXDB is a Protein, loci is a Entity, PHKA1 is a Protein, loci is a Entity, XIST is a Protein, XIST is a Protein, its AR allele is a Entity, the one on the normal X allele is a Entity

94_task1

Sentence: The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please typing these entity words according to sentence: XIST, locus, XIST, XIST, histone H4, chromatin domains, genes, ZXDA, ZXDB, loci, PHKA1, loci, XIST, XIST, its AR allele, the one on the normal X allele Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS)

[ "The", "severe", "phenotype", "of", "females", "with", "tiny", "ring", "X", "chromosomes", "is", "associated", "with", "inability", "of", "these", "chromosomes", "to", "undergo", "X", "inactivation", ".", "\n", "Mental", "retardation", "and", "a", "constellation", "of", "congenital", "malformations", "not", "usually", "associated", "with", "Turner", "syndrome", "are", "seen", "in", "some", "females", "with", "a", "mosaic", "45,X/46,X", ",", "r(X", ")", "karyotype", ".", "Studies", "of", "these", "females", "show", "that", "the", "XIST", "locus", "on", "their", "tiny", "ring", "X", "chromosomes", "is", "either", "not", "present", "or", "not", "expressed", ".", "As", "XIST", "transcription", "is", "well", "correlated", "with", "inactivation", "of", "the", "X", "chromosome", "in", "female", "somatic", "cells", "and", "spermatogonia", ",", "nonexpression", "of", "the", "locus", "even", "when", "it", "is", "present", "suggests", "that", "these", "chromosomes", "are", "transcriptionally", "active", ".", "We", "examined", "the", "transcriptional", "activity", "of", "ring", "X", "chromosomes", "lacking", "XIST", "expression", "(", "XISTE-", ")", ",", "from", "three", "females", "with", "severe", "phenotypes", ".", "The", "two", "tiny", "ring", "X", "chromosomes", "studied", "with", "an", "antibody", "specific", "for", "the", "acetylated", "isoforms", "of", "histone", "H4", "marking", "transcribed", "chromatin", "domains", "were", "labeled", "at", "a", "level", "consistent", "with", "their", "being", "active", ".", "We", "also", "examined", "tow", "of", "the", "XISTE-", "ring", "chromosomes", "to", "determine", "whether", "genes", "that", "are", "normally", "silent", "on", "an", "inactive", "X", "are", "expressed", "from", "these", "chromosomes", ".", "Analyses", "of", "hybrid", "cells", "show", "that", "TIMP", ",", "ZXDA", ",", "and", "ZXDB", "loci", "on", "the", "proximal", "short", "arm", ",", "and", "AR", "and", "PHKA1", "loci", "on", "the", "long", "arm", ",", "are", "well", "expressed", "from", "the", "tiny", "ring", "X", "chromosome", "lacking", "XIST", "DNA", ".", "Studies", "of", "the", "ring", "chromosome", "that", "has", "XIST", "DNA", "but", "does", "not", "transcribe", "it", "show", "that", "its", "AR", "allele", "is", "transcribed", "along", "with", "the", "one", "on", "the", "normal", "X", "allele", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]

[ "Entity", "Protein" ]

XIST, locus, XIST, XIST, histone H4, chromatin domains, genes, ZXDA, ZXDB, loci, PHKA1, loci, XIST, XIST, its AR allele, the one on the normal X allele

94_task2

Sentence: The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Mental retardation and a constellation of congenital malformations not usually associated with Turner syndrome are seen in some females with a mosaic 45,X/46,X,r(X) karyotype. Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed. As XIST transcription is well correlated with inactivation of the X chromosome in female somatic cells and spermatogonia, nonexpression of the locus even when it is present suggests that these chromosomes are transcriptionally active. We examined the transcriptional activity of ring X chromosomes lacking XIST expression (XISTE-), from three females with severe phenotypes. The two tiny ring X chromosomes studied with an antibody specific for the acetylated isoforms of histone H4 marking transcribed chromatin domains were labeled at a level consistent with their being active. We also examined tow of the XISTE- ring chromosomes to determine whether genes that are normally silent on an inactive X are expressed from these chromosomes. Analyses of hybrid cells show that TIMP, ZXDA, and ZXDB loci on the proximal short arm, and AR and PHKA1 loci on the long arm, are well expressed from the tiny ring X chromosome lacking XIST DNA. Studies of the ring chromosome that has XIST DNA but does not transcribe it show that its AR allele is transcribed along with the one on the normal X allele. (ABSTRACT TRUNCATED AT 250 WORDS)

[ "The", "severe", "phenotype", "of", "females", "with", "tiny", "ring", "X", "chromosomes", "is", "associated", "with", "inability", "of", "these", "chromosomes", "to", "undergo", "X", "inactivation", ".", "\n", "Mental", "retardation", "and", "a", "constellation", "of", "congenital", "malformations", "not", "usually", "associated", "with", "Turner", "syndrome", "are", "seen", "in", "some", "females", "with", "a", "mosaic", "45,X/46,X", ",", "r(X", ")", "karyotype", ".", "Studies", "of", "these", "females", "show", "that", "the", "XIST", "locus", "on", "their", "tiny", "ring", "X", "chromosomes", "is", "either", "not", "present", "or", "not", "expressed", ".", "As", "XIST", "transcription", "is", "well", "correlated", "with", "inactivation", "of", "the", "X", "chromosome", "in", "female", "somatic", "cells", "and", "spermatogonia", ",", "nonexpression", "of", "the", "locus", "even", "when", "it", "is", "present", "suggests", "that", "these", "chromosomes", "are", "transcriptionally", "active", ".", "We", "examined", "the", "transcriptional", "activity", "of", "ring", "X", "chromosomes", "lacking", "XIST", "expression", "(", "XISTE-", ")", ",", "from", "three", "females", "with", "severe", "phenotypes", ".", "The", "two", "tiny", "ring", "X", "chromosomes", "studied", "with", "an", "antibody", "specific", "for", "the", "acetylated", "isoforms", "of", "histone", "H4", "marking", "transcribed", "chromatin", "domains", "were", "labeled", "at", "a", "level", "consistent", "with", "their", "being", "active", ".", "We", "also", "examined", "tow", "of", "the", "XISTE-", "ring", "chromosomes", "to", "determine", "whether", "genes", "that", "are", "normally", "silent", "on", "an", "inactive", "X", "are", "expressed", "from", "these", "chromosomes", ".", "Analyses", "of", "hybrid", "cells", "show", "that", "TIMP", ",", "ZXDA", ",", "and", "ZXDB", "loci", "on", "the", "proximal", "short", "arm", ",", "and", "AR", "and", "PHKA1", "loci", "on", "the", "long", "arm", ",", "are", "well", "expressed", "from", "the", "tiny", "ring", "X", "chromosome", "lacking", "XIST", "DNA", ".", "Studies", "of", "the", "ring", "chromosome", "that", "has", "XIST", "DNA", "but", "does", "not", "transcribe", "it", "show", "that", "its", "AR", "allele", "is", "transcribed", "along", "with", "the", "one", "on", "the", "normal", "X", "allele", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]

[ "Entity", "Protein" ]

Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non - specific analytical methods is a Participant_Condition

77994_task0

Sentence: Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition

[ "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]

Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods .

[ "Comparison", "of", "some", "pharmacokinetic", "parameters", "of", "(", "+", ")", "-cyanidanol-3", "obtained", "with", "specific", "and", "non", "-", "specific", "analytical", "methods", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]

Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non - specific analytical methods is a Participant_Condition

77994_task1

Sentence: Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods . Instructions: please typing these entity words according to sentence: Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non - specific analytical methods Options: Participant_Condition

[ "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]

Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods .

[ "Comparison", "of", "some", "pharmacokinetic", "parameters", "of", "(", "+", ")", "-cyanidanol-3", "obtained", "with", "specific", "and", "non", "-", "specific", "analytical", "methods", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]

Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non - specific analytical methods

77994_task2

Sentence: Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods . Instructions: please extract entity words from the input sentence

[ "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]

Comparison of some pharmacokinetic parameters of ( + ) -cyanidanol-3 obtained with specific and non-specific analytical methods .

[ "Comparison", "of", "some", "pharmacokinetic", "parameters", "of", "(", "+", ")", "-cyanidanol-3", "obtained", "with", "specific", "and", "non", "-", "specific", "analytical", "methods", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological" ]

v - abl is a Protein, v - abl is a Protein, v - abl is a Protein, v - abl is a Protein

7945272_task0

Sentence: Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway.

[ "Arrested", "development", ":", "understanding", "v", "-", "abl", ".", "\n", "The", "protein", "tyrosine", "kinase", "activity", "of", "the", "v", "-", "abl", "oncogene", "has", "been", "demonstrated", "to", "subvert", "the", "normal", "second", "messenger", "systems", "used", "by", "lymphoid", "cells", "for", "growth", "and", "differentiation", ".", "Transformation", "of", "bone", "marrow", "with", "the", "Abelson", "murine", "leukemia", "virus", "results", "in", "the", "appearance", "of", "B", "cell", "lineage", "cells", "arrested", "at", "the", "pre", "-", "B", "cell", "stage", ".", "Recent", "reports", "have", "characterized", "these", "cells", "expressing", "high", "v", "-", "abl", "kinase", "activity", "as", "deficient", "in", "detectable", "NF", "-", "kappaB", "DNA", "binding", "activity", "and", "low", "level", "RAG", "gene", "expression", ".", "These", "observations", "suggest", "that", "v", "-", "abl", "may", "be", "inhibiting", "the", "differentiation", "of", "B", "cells", "by", "blocking", "these", "two", "crucial", "elements", "in", "the", "maturation", "pathway", "." ]

[ "Protein" ]

v - abl is a Protein, v - abl is a Protein, v - abl is a Protein, v - abl is a Protein

7945272_task1

Sentence: Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway. Instructions: please typing these entity words according to sentence: v - abl, v - abl, v - abl, v - abl Options: Protein

[ "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway.

[ "Arrested", "development", ":", "understanding", "v", "-", "abl", ".", "\n", "The", "protein", "tyrosine", "kinase", "activity", "of", "the", "v", "-", "abl", "oncogene", "has", "been", "demonstrated", "to", "subvert", "the", "normal", "second", "messenger", "systems", "used", "by", "lymphoid", "cells", "for", "growth", "and", "differentiation", ".", "Transformation", "of", "bone", "marrow", "with", "the", "Abelson", "murine", "leukemia", "virus", "results", "in", "the", "appearance", "of", "B", "cell", "lineage", "cells", "arrested", "at", "the", "pre", "-", "B", "cell", "stage", ".", "Recent", "reports", "have", "characterized", "these", "cells", "expressing", "high", "v", "-", "abl", "kinase", "activity", "as", "deficient", "in", "detectable", "NF", "-", "kappaB", "DNA", "binding", "activity", "and", "low", "level", "RAG", "gene", "expression", ".", "These", "observations", "suggest", "that", "v", "-", "abl", "may", "be", "inhibiting", "the", "differentiation", "of", "B", "cells", "by", "blocking", "these", "two", "crucial", "elements", "in", "the", "maturation", "pathway", "." ]

[ "Protein" ]

v - abl, v - abl, v - abl, v - abl

7945272_task2

Sentence: Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Arrested development: understanding v-abl. The protein tyrosine kinase activity of the v-abl oncogene has been demonstrated to subvert the normal second messenger systems used by lymphoid cells for growth and differentiation. Transformation of bone marrow with the Abelson murine leukemia virus results in the appearance of B cell lineage cells arrested at the pre-B cell stage. Recent reports have characterized these cells expressing high v-abl kinase activity as deficient in detectable NF-kappaB DNA binding activity and low level RAG gene expression. These observations suggest that v-abl may be inhibiting the differentiation of B cells by blocking these two crucial elements in the maturation pathway.

[ "Arrested", "development", ":", "understanding", "v", "-", "abl", ".", "\n", "The", "protein", "tyrosine", "kinase", "activity", "of", "the", "v", "-", "abl", "oncogene", "has", "been", "demonstrated", "to", "subvert", "the", "normal", "second", "messenger", "systems", "used", "by", "lymphoid", "cells", "for", "growth", "and", "differentiation", ".", "Transformation", "of", "bone", "marrow", "with", "the", "Abelson", "murine", "leukemia", "virus", "results", "in", "the", "appearance", "of", "B", "cell", "lineage", "cells", "arrested", "at", "the", "pre", "-", "B", "cell", "stage", ".", "Recent", "reports", "have", "characterized", "these", "cells", "expressing", "high", "v", "-", "abl", "kinase", "activity", "as", "deficient", "in", "detectable", "NF", "-", "kappaB", "DNA", "binding", "activity", "and", "low", "level", "RAG", "gene", "expression", ".", "These", "observations", "suggest", "that", "v", "-", "abl", "may", "be", "inhibiting", "the", "differentiation", "of", "B", "cells", "by", "blocking", "these", "two", "crucial", "elements", "in", "the", "maturation", "pathway", "." ]

[ "Protein" ]

increasing incidence is an umlsterm, toxic is an umlsterm, shock - like is an umlsterm, syndrome is an umlsterm, adults is an umlsterm, fever is an umlsterm, rash is an umlsterm, hypotension is an umlsterm, shock is an umlsterm, mortality rate is an umlsterm, paper is an umlsterm, history is an umlsterm, patients is an umlsterm, pathophysiology is an umlsterm, diagnosis is an umlsterm, therapy is an umlsterm, surgical is an umlsterm, debridement is an umlsterm, bacterial is an umlsterm, exotoxins is an umlsterm, antibiotic is an umlsterm, therapy is an umlsterm, mortality is an umlsterm

DerChirurg.70680040.eng.abstr_task0

Sentence: In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity .

[ "In", "recent", "years", "there", "has", "been", "an", "increasing", "incidence", "of", "streptococcal", "toxic", "shock", "-", "like", "syndrome", "(", "TSLS", ")", "in", "otherwise", "healthy", "adults", ".", "It", "is", "characterized", "by", "fever", ",", "rash", ",", "hypotension", "and", "early", "shock", "with", "consecutive", "organ", "failure", "and", "a", "mortality", "rate", "of", "about", "30", "%", ".", "This", "paper", "describes", "the", "history", "of", "two", "patients", "with", "severe", "streptococcal", "TSLS", ".", "Various", "aspects", "of", "the", "pathophysiology", ",", "diagnosis", "and", "therapy", "are", "discussed", ".", "Only", "early", ",", "aggressive", "and", "repeated", "surgical", "debridement", "can", "reduce", "the", "bacterial", "load", "and", "decrease", "circulating", "exotoxins", "and", "thereby", ",", "in", "combination", "with", "antibiotic", "therapy", ",", "decrease", "the", "high", "mortality", "of", "this", "entity", "." ]

[ "umlsterm" ]

increasing incidence is an umlsterm, toxic is an umlsterm, shock - like is an umlsterm, syndrome is an umlsterm, adults is an umlsterm, fever is an umlsterm, rash is an umlsterm, hypotension is an umlsterm, shock is an umlsterm, mortality rate is an umlsterm, paper is an umlsterm, history is an umlsterm, patients is an umlsterm, pathophysiology is an umlsterm, diagnosis is an umlsterm, therapy is an umlsterm, surgical is an umlsterm, debridement is an umlsterm, bacterial is an umlsterm, exotoxins is an umlsterm, antibiotic is an umlsterm, therapy is an umlsterm, mortality is an umlsterm

DerChirurg.70680040.eng.abstr_task1

Sentence: In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity . Instructions: please typing these entity words according to sentence: increasing incidence, toxic, shock - like, syndrome, adults, fever, rash, hypotension, shock, mortality rate, paper, history, patients, pathophysiology, diagnosis, therapy, surgical, debridement, bacterial, exotoxins, antibiotic, therapy, mortality Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity .

[ "In", "recent", "years", "there", "has", "been", "an", "increasing", "incidence", "of", "streptococcal", "toxic", "shock", "-", "like", "syndrome", "(", "TSLS", ")", "in", "otherwise", "healthy", "adults", ".", "It", "is", "characterized", "by", "fever", ",", "rash", ",", "hypotension", "and", "early", "shock", "with", "consecutive", "organ", "failure", "and", "a", "mortality", "rate", "of", "about", "30", "%", ".", "This", "paper", "describes", "the", "history", "of", "two", "patients", "with", "severe", "streptococcal", "TSLS", ".", "Various", "aspects", "of", "the", "pathophysiology", ",", "diagnosis", "and", "therapy", "are", "discussed", ".", "Only", "early", ",", "aggressive", "and", "repeated", "surgical", "debridement", "can", "reduce", "the", "bacterial", "load", "and", "decrease", "circulating", "exotoxins", "and", "thereby", ",", "in", "combination", "with", "antibiotic", "therapy", ",", "decrease", "the", "high", "mortality", "of", "this", "entity", "." ]

[ "umlsterm" ]

increasing incidence, toxic, shock - like, syndrome, adults, fever, rash, hypotension, shock, mortality rate, paper, history, patients, pathophysiology, diagnosis, therapy, surgical, debridement, bacterial, exotoxins, antibiotic, therapy, mortality

DerChirurg.70680040.eng.abstr_task2

Sentence: In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

In recent years there has been an increasing incidence of streptococcal toxic shock-like syndrome ( TSLS ) in otherwise healthy adults . It is characterized by fever , rash , hypotension and early shock with consecutive organ failure and a mortality rate of about 30 % . This paper describes the history of two patients with severe streptococcal TSLS . Various aspects of the pathophysiology , diagnosis and therapy are discussed . Only early , aggressive and repeated surgical debridement can reduce the bacterial load and decrease circulating exotoxins and thereby , in combination with antibiotic therapy , decrease the high mortality of this entity .

[ "In", "recent", "years", "there", "has", "been", "an", "increasing", "incidence", "of", "streptococcal", "toxic", "shock", "-", "like", "syndrome", "(", "TSLS", ")", "in", "otherwise", "healthy", "adults", ".", "It", "is", "characterized", "by", "fever", ",", "rash", ",", "hypotension", "and", "early", "shock", "with", "consecutive", "organ", "failure", "and", "a", "mortality", "rate", "of", "about", "30", "%", ".", "This", "paper", "describes", "the", "history", "of", "two", "patients", "with", "severe", "streptococcal", "TSLS", ".", "Various", "aspects", "of", "the", "pathophysiology", ",", "diagnosis", "and", "therapy", "are", "discussed", ".", "Only", "early", ",", "aggressive", "and", "repeated", "surgical", "debridement", "can", "reduce", "the", "bacterial", "load", "and", "decrease", "circulating", "exotoxins", "and", "thereby", ",", "in", "combination", "with", "antibiotic", "therapy", ",", "decrease", "the", "high", "mortality", "of", "this", "entity", "." ]

[ "umlsterm" ]

promoter is a Entity, CD19 is a Protein, BSAP is a Protein, CD19 is a Protein, CD19 is a Protein, BSAP is a Protein, CD19 is a Protein, BSAP is a Protein, BSAP is a Protein, BSAP is a Protein, CD19 is a Protein, beta - globin reporter is a Protein, BSAP is a Protein, CD19 is a Protein, promoter is a Entity, BSAP is a Protein, CD19 is a Protein

1375324_task0

Sentence: The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene.

[ "The", "promoter", "of", "the", "CD19", "gene", "is", "a", "target", "for", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", ".", "\n", "The", "CD19", "protein", "is", "expressed", "on", "the", "surface", "of", "all", "B", "-", "lymphoid", "cells", "with", "the", "exception", "of", "terminally", "differentiated", "plasma", "cells", "and", "has", "been", "implicated", "as", "a", "signal", "-", "transducing", "receptor", "in", "the", "control", "of", "proliferation", "and", "differentiation", ".", "Here", "we", "demonstrate", "complete", "correlation", "between", "the", "expression", "pattern", "of", "the", "CD19", "gene", "and", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", "in", "a", "large", "panel", "of", "B", "-", "lymphoid", "cell", "lines", ".", "The", "human", "CD19", "gene", "has", "been", "cloned", ",", "and", "several", "BSAP", "-", "binding", "sites", "have", "been", "mapped", "by", "in", "vitro", "protein", "-", "DNA", "binding", "studies", ".", "In", "particular", ",", "a", "high", "-", "affinity", "BSAP", "-", "binding", "site", "instead", "of", "a", "TATA", "sequence", "is", "located", "in", "the", "-30", "promoter", "region", "upstream", "of", "a", "cluster", "of", "heterogeneous", "transcription", "start", "sites", ".", "Moreover", ",", "this", "site", "is", "occupied", "by", "BSAP", "in", "vivo", "in", "a", "CD19-expressing", "B", "-", "cell", "line", "but", "not", "in", "plasma", "or", "HeLa", "cells", ".", "This", "high", "-", "affinity", "site", "has", "been", "conserved", "in", "the", "promoters", "of", "both", "human", "and", "mouse", "CD19", "genes", "and", "was", "furthermore", "shown", "to", "confer", "B", "-", "cell", "specificity", "to", "a", "beta", "-", "globin", "reporter", "gene", "in", "transient", "transfection", "experiments", ".", "In", "addition", ",", "BSAP", "was", "found", "to", "be", "the", "only", "abundant", "DNA", "-", "binding", "activity", "of", "B", "-", "cell", "nuclear", "extracts", "that", "interacts", "with", "the", "CD19", "promoter", ".", "Together", ",", "this", "evidence", "strongly", "implicates", "BSAP", "in", "the", "regulation", "of", "the", "CD19", "gene", "." ]

[ "Protein", "Entity" ]

promoter is a Entity, CD19 is a Protein, BSAP is a Protein, CD19 is a Protein, CD19 is a Protein, BSAP is a Protein, CD19 is a Protein, BSAP is a Protein, BSAP is a Protein, BSAP is a Protein, CD19 is a Protein, beta - globin reporter is a Protein, BSAP is a Protein, CD19 is a Protein, promoter is a Entity, BSAP is a Protein, CD19 is a Protein

1375324_task1

Sentence: The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene. Instructions: please typing these entity words according to sentence: promoter, CD19, BSAP, CD19, CD19, BSAP, CD19, BSAP, BSAP, BSAP, CD19, beta - globin reporter, BSAP, CD19, promoter, BSAP, CD19 Options: Entity, Protein

[ "O", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene.

[ "The", "promoter", "of", "the", "CD19", "gene", "is", "a", "target", "for", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", ".", "\n", "The", "CD19", "protein", "is", "expressed", "on", "the", "surface", "of", "all", "B", "-", "lymphoid", "cells", "with", "the", "exception", "of", "terminally", "differentiated", "plasma", "cells", "and", "has", "been", "implicated", "as", "a", "signal", "-", "transducing", "receptor", "in", "the", "control", "of", "proliferation", "and", "differentiation", ".", "Here", "we", "demonstrate", "complete", "correlation", "between", "the", "expression", "pattern", "of", "the", "CD19", "gene", "and", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", "in", "a", "large", "panel", "of", "B", "-", "lymphoid", "cell", "lines", ".", "The", "human", "CD19", "gene", "has", "been", "cloned", ",", "and", "several", "BSAP", "-", "binding", "sites", "have", "been", "mapped", "by", "in", "vitro", "protein", "-", "DNA", "binding", "studies", ".", "In", "particular", ",", "a", "high", "-", "affinity", "BSAP", "-", "binding", "site", "instead", "of", "a", "TATA", "sequence", "is", "located", "in", "the", "-30", "promoter", "region", "upstream", "of", "a", "cluster", "of", "heterogeneous", "transcription", "start", "sites", ".", "Moreover", ",", "this", "site", "is", "occupied", "by", "BSAP", "in", "vivo", "in", "a", "CD19-expressing", "B", "-", "cell", "line", "but", "not", "in", "plasma", "or", "HeLa", "cells", ".", "This", "high", "-", "affinity", "site", "has", "been", "conserved", "in", "the", "promoters", "of", "both", "human", "and", "mouse", "CD19", "genes", "and", "was", "furthermore", "shown", "to", "confer", "B", "-", "cell", "specificity", "to", "a", "beta", "-", "globin", "reporter", "gene", "in", "transient", "transfection", "experiments", ".", "In", "addition", ",", "BSAP", "was", "found", "to", "be", "the", "only", "abundant", "DNA", "-", "binding", "activity", "of", "B", "-", "cell", "nuclear", "extracts", "that", "interacts", "with", "the", "CD19", "promoter", ".", "Together", ",", "this", "evidence", "strongly", "implicates", "BSAP", "in", "the", "regulation", "of", "the", "CD19", "gene", "." ]

[ "Protein", "Entity" ]

promoter, CD19, BSAP, CD19, CD19, BSAP, CD19, BSAP, BSAP, BSAP, CD19, beta - globin reporter, BSAP, CD19, promoter, BSAP, CD19

1375324_task2

Sentence: The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene. Instructions: please extract entity words from the input sentence

[ "O", "B-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. The CD19 protein is expressed on the surface of all B-lymphoid cells with the exception of terminally differentiated plasma cells and has been implicated as a signal-transducing receptor in the control of proliferation and differentiation. Here we demonstrate complete correlation between the expression pattern of the CD19 gene and the B-cell-specific transcription factor BSAP in a large panel of B-lymphoid cell lines. The human CD19 gene has been cloned, and several BSAP-binding sites have been mapped by in vitro protein-DNA binding studies. In particular, a high-affinity BSAP-binding site instead of a TATA sequence is located in the -30 promoter region upstream of a cluster of heterogeneous transcription start sites. Moreover, this site is occupied by BSAP in vivo in a CD19-expressing B-cell line but not in plasma or HeLa cells. This high-affinity site has been conserved in the promoters of both human and mouse CD19 genes and was furthermore shown to confer B-cell specificity to a beta-globin reporter gene in transient transfection experiments. In addition, BSAP was found to be the only abundant DNA-binding activity of B-cell nuclear extracts that interacts with the CD19 promoter. Together, this evidence strongly implicates BSAP in the regulation of the CD19 gene.

[ "The", "promoter", "of", "the", "CD19", "gene", "is", "a", "target", "for", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", ".", "\n", "The", "CD19", "protein", "is", "expressed", "on", "the", "surface", "of", "all", "B", "-", "lymphoid", "cells", "with", "the", "exception", "of", "terminally", "differentiated", "plasma", "cells", "and", "has", "been", "implicated", "as", "a", "signal", "-", "transducing", "receptor", "in", "the", "control", "of", "proliferation", "and", "differentiation", ".", "Here", "we", "demonstrate", "complete", "correlation", "between", "the", "expression", "pattern", "of", "the", "CD19", "gene", "and", "the", "B", "-", "cell", "-", "specific", "transcription", "factor", "BSAP", "in", "a", "large", "panel", "of", "B", "-", "lymphoid", "cell", "lines", ".", "The", "human", "CD19", "gene", "has", "been", "cloned", ",", "and", "several", "BSAP", "-", "binding", "sites", "have", "been", "mapped", "by", "in", "vitro", "protein", "-", "DNA", "binding", "studies", ".", "In", "particular", ",", "a", "high", "-", "affinity", "BSAP", "-", "binding", "site", "instead", "of", "a", "TATA", "sequence", "is", "located", "in", "the", "-30", "promoter", "region", "upstream", "of", "a", "cluster", "of", "heterogeneous", "transcription", "start", "sites", ".", "Moreover", ",", "this", "site", "is", "occupied", "by", "BSAP", "in", "vivo", "in", "a", "CD19-expressing", "B", "-", "cell", "line", "but", "not", "in", "plasma", "or", "HeLa", "cells", ".", "This", "high", "-", "affinity", "site", "has", "been", "conserved", "in", "the", "promoters", "of", "both", "human", "and", "mouse", "CD19", "genes", "and", "was", "furthermore", "shown", "to", "confer", "B", "-", "cell", "specificity", "to", "a", "beta", "-", "globin", "reporter", "gene", "in", "transient", "transfection", "experiments", ".", "In", "addition", ",", "BSAP", "was", "found", "to", "be", "the", "only", "abundant", "DNA", "-", "binding", "activity", "of", "B", "-", "cell", "nuclear", "extracts", "that", "interacts", "with", "the", "CD19", "promoter", ".", "Together", ",", "this", "evidence", "strongly", "implicates", "BSAP", "in", "the", "regulation", "of", "the", "CD19", "gene", "." ]

[ "Protein", "Entity" ]

neoplasia is a MORFOLOGIA_NEOPLASIA, leucemia is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma ( ADK ) metastásico is a MORFOLOGIA_NEOPLASIA, ADK is a MORFOLOGIA_NEOPLASIA, ADK is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de origen desconocido con metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, afectación ósea is a MORFOLOGIA_NEOPLASIA, infiltración tumoral de medula ósea is a MORFOLOGIA_NEOPLASIA

601_task0

Sentence: Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017.

[ "Anamnesis", "\n", "Presentamos", "un", "varón", "de", "37", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", "y", "fumador", "ocasional", "desde", "la", "adolescencia", ".", "Padre", "de", "dos", "hijos", "de", "3", "y", "7", "años", ".", "\n", "Como", "antecedentes", "patológicos", "únicamente", "presenta", "asma", "alérgica", "y", ",", "como", "antecedentes", "familiares", ",", "se", "ha", "registrado", "abuelo", "paterno", "con", "diagnóstico", "de", "neoplasia", "de", "colon", "y", "abuela", "paterna", "con", "leucemia", ".", "\n", "Sin", "tratamiento", "habitual", ".", "\n\n", "Historia", "oncológica", "\n", "En", "junio", "de", "2017", "ingresa", "en", "el", "hospital", "por", "dolor", "lumbar", "e", "inguinal", "bilateral", "de", "2", "-", "3", "meses", "de", "evolución", ",", "acompañado", "de", "tumoración", "en", "antebrazo", "derecho", ".", "Se", "trata", "de", "un", "dolor", "continuo", ",", "que", "mejora", "con", "el", "reposo", ",", "aumentando", "con", "la", "sedestación", "y", "los", "cambios", "posturales", ",", "provocándole", "parestesias", "en", "ambas", "extremidades", "inferiores", ".", "\n", "Asimismo", ",", "presenta", "pérdida", "de", "aproximadamente", "5", "kg", "de", "peso", "en", "los", "últimos", "3", "meses", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "moderados", "esfuerzos", ".", "Sin", "dolor", "torácico", ",", "tos", ",", "expectoración", ",", "fiebre", "ni", "otra", "clínica", "acompañante", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", "destaca", "una", "hipofonesis", "en", "hemitórax", "inferior", "derecho", "con", "murmullo", "vesicular", "conservado", "en", "pulmón", "izquierdo", ".", "Exploración", "neurológica", "sin", "alteraciones", ".", "A", "nivel", "locomotor", ",", "se", "apreciaba", "una", "tumoración", "de", "consistencia", "dura", "y", "adherida", "a", "planos", "profundos", ",", "no", "dolorosa", "durante", "la", "palpación", "en", "antebrazo", "derecho", "y", "muslo", "izquierdo", ".", "\n\n", "Pruebas", "complementarias", "\n", "Durante", "el", "ingreso", "se", "realizan", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Radiografía", "de", "tórax", ":", "derrame", "pleural", "masivo", "derecho", "sin", "desplazamiento", "mediastínico", ".", "\n", "»", "Marcadores", "tumorales", "CEA", "34,6", ",", "Ca", "19,9", ">", "700", ",", "Ca", "12,5", "260,1", ".", "\n", "»", "TC", "de", "cuello", "-", "tórax", "-", "abdomen", ":", "metástasis", "pleurales", ",", "óseas", ",", "musculares", "múltiples", ",", "cerebrales", "y", "posibles", "pulmonares", "con", "sospecha", "de", "neoplasia", "primario", "pulmonar", ".", "\n", "Por", "presencia", "de", "derrame", "pleural", "derecho", ",", "se", "solicita", "pleurodesis", "guiada", "por", "videotoracoscopia", "con", "solicitud", "de", "biopsia", "pleural", ".", "\n", "Ante", "la", "marcada", "sospecha", "de", "primario", "de", "origen", "pulmonar", ",", "se", "solicita", "el", "perfil", "mutacional", "correspondiente", "(", "KRAS", ",", "EGFR", ",", "ALK", "):", "\n", "»", "Citología", "liquido", "pleural", ":", "compatible", "con", "infiltración", "por", "adenocarcinoma", ".", "TTF-1", "positivo", ",", "lo", "cual", "favorece", "un", "origen", "pulmonar", ".", "\n", "»", "Biopsia", "muscular", ":", "adenocarcinoma", "(", "ADK", ")", "metastásico", ".", "KRAS", "mutado", ".", "EGFR", "wild", "type", ".", "ALK", "no", "traslocado", ".", "\n", "»", "Biopsia", "pleural", ":", "ADK", "con", "fenotipo", "de", "origen", "gastrointestinal", "(", "estómago", ",", "pancreático", "y", "biliar", ")", ".", "\n", "Positividad", "para", "CK7", ",", "CK20", ",", "y", "CDX-2", "(", "aisladas", "células", "TTF-1", ")", ".", "Negativas", "para", "napsina", ",", "PAX", "8", "y", "PSA", ".", "HER-2", "negativo", ".", "\n", "Por", "discordancia", "entre", "una", "primera", "sospecha", "de", "primario", "pulmonar", "y", "el", "resultado", "posterior", "de", "biopsia", "pleural", "compatible", "con", "ADK", "de", "origen", "gastrointestinal", ",", "se", "amplía", "el", "estudio", "con", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Gastroscopia", ":", "examen", "endoscópico", "normal", ".", "\n", "»", "Citología", "orina", ":", "negativo", "para", "malignidad", ".", "Celularidad", "urotelial", "con", "cambios", "reactivos", ".", "\n", "»", "Ecografía", "renal", ":", "ambos", "riñones", ",", "vejiga", "y", "próstata", "sin", "alteraciones", "ecográficamente", "valorables", ".", "\n\n", "Diagnóstico", "\n", "Ante", "el", "diagnóstico", "de", "adenocarcinoma", "de", "origen", "desconocido", "con", "metástasis", "múltiples", ":", "pleurales", ",", "óseas", ",", "musculares", ",", "cerebrales", "y", "posible", "pulmonares", ",", "se", "solicita", "un", "estudio", "de", "secuenciación", "genética", "masiva", ".", "\n\n", "Tratamiento", "\n", "A", "la", "espera", "de", "dichos", "resultados", ",", "se", "realiza", "en", "julio", "de", "2017", "RT", "holocraneal", "(", "entre", "el", "26/6/2017", "y", "el", "10/7/2017", "se", "administraron", "30Gy", "a", "fraccionamiento", "de", "3Gy", "/", "fracción", ")", "y", "se", "inicia", "quimioterapia", "de", "primera", "línea", "esquema", "carboplatino", "AUC", "6", "/", "paclitaxel", "175", "mg", "/", "m2", "cada", "21", "días", "durante", "2", "ciclos", ",", "presentando", "mala", "tolerancia", "con", "náuseas", ",", "vómitos", "grado", "2", "y", "diarrea", "grado", "2", ".", "\n\n", "Evolución", "\n", "Ingreso", "hospitalario", "en", "agosto", "2017", "por", "anemia", "grado", "4", "y", "mal", "control", "del", "dolor", ".", "Se", "realiza", "TC", "toracoabdominopélvica", "que", "evidencia", "progresión", "de", "la", "enfermedad", ".", "Para", "el", "control", "del", "dolor", "se", "inicia", "morfina", "sulfato", "retard", "(", "MST", ")", "60", "mg", "cada", "12", "horas", "y", "rescates", "de", "fentanilo", "sublingual", "200", "mcg", ".", "\n", "Ingresa", "nuevamente", "en", "septiembre", "2017", "por", "síndrome", "febril", "sin", "semiología", "infecciosa", "y", "cultivos", "negativos", ";", "por", "lo", "que", "se", "cataloga", "de", "origen", "tumoral", ",", "y", "se", "inicia", "indometacina", "con", "resolución", "del", "cuadro", ".", "\n", "Asimismo", ",", "presenta", "dolor", "y", "aumento", "del", "perímetro", "de", "la", "extremidad", "inferior", "izquierda", "(", "en", "TC", "se", "observaba", "afectación", "ósea", "en", "cadera", "izquierda", "y", "muscular", "en", "ambos", "miembros", "inferiores", "como", "probable", "causa", ")", ";", "se", "realiza", "Eco", "-", "Doppler", "que", "determina", "trombosis", "venosa", "profunda", "en", "vena", "femoral", "izquierda", ",", "iniciándose", "tinzaparina", "12.000", "UI", "cada", "24", "horas", ".", "Por", "dolor", "mal", "controlado", ",", "precisa", "perfusión", "de", "morfina", "iv", "y", "posterior", "rotación", "de", "opioides", "progresiva", "a", "metadona", ",", "con", "mejor", "control", ",", "pero", "necesitando", "rescates", "de", "morfina", "subcutánea", ".", "\n", "También", "presenta", "astenia", "marcada", "y", "anemia", "grado", "3", "post", "-", "QT", "(", "hemoglobina", "6,9", "g", "/", "dl", ")", "que", "obligan", "a", "transfusión", "de", "concentrados", "de", "hematíes", "en", "varias", "ocasiones", "(", "sospecha", "de", "infiltración", "tumoral", "de", "medula", "ósea", ")", ".", "\n", "Ante", "la", "falta", "de", "respuesta", "clínica", "y", "radiológica", "a", "la", "quimioterapia", "tras", "la", "administración", "de", "2", "ciclos", "de", "tratamiento", ",", "se", "decide", "iniciar", ",", "en", "octubre", "de", "2017", ",", "QT", "paliativa", "con", "irinotecan", "180", "mg", "/", "m2", "cada", "2", "semanas", "según", "resultado", "de", "test", "de", "secuenciación", "genética", ".", "\n", "Se", "da", "de", "alta", "hospitalaria", "y", "acude", "a", "consulta", "para", "administrar", "2º", "ciclo", "de", "irinotecan", "quincenal", ".", "A", "pesar", "de", "presentar", "mejoría", "clínica", "con", "buen", "control", "del", "dolor", ",", "el", "paciente", "fallece", "en", "noviembre", "de", "2017", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

neoplasia is a MORFOLOGIA_NEOPLASIA, leucemia is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma ( ADK ) metastásico is a MORFOLOGIA_NEOPLASIA, ADK is a MORFOLOGIA_NEOPLASIA, ADK is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de origen desconocido con metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, afectación ósea is a MORFOLOGIA_NEOPLASIA, infiltración tumoral de medula ósea is a MORFOLOGIA_NEOPLASIA

601_task1

Sentence: Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017. Instructions: please typing these entity words according to sentence: neoplasia, leucemia, tumoración, tumoración, metástasis, neoplasia, adenocarcinoma, adenocarcinoma ( ADK ) metastásico, ADK, ADK, malignidad, adenocarcinoma de origen desconocido con metástasis, tumoral, afectación ósea, infiltración tumoral de medula ósea Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017.

[ "Anamnesis", "\n", "Presentamos", "un", "varón", "de", "37", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", "y", "fumador", "ocasional", "desde", "la", "adolescencia", ".", "Padre", "de", "dos", "hijos", "de", "3", "y", "7", "años", ".", "\n", "Como", "antecedentes", "patológicos", "únicamente", "presenta", "asma", "alérgica", "y", ",", "como", "antecedentes", "familiares", ",", "se", "ha", "registrado", "abuelo", "paterno", "con", "diagnóstico", "de", "neoplasia", "de", "colon", "y", "abuela", "paterna", "con", "leucemia", ".", "\n", "Sin", "tratamiento", "habitual", ".", "\n\n", "Historia", "oncológica", "\n", "En", "junio", "de", "2017", "ingresa", "en", "el", "hospital", "por", "dolor", "lumbar", "e", "inguinal", "bilateral", "de", "2", "-", "3", "meses", "de", "evolución", ",", "acompañado", "de", "tumoración", "en", "antebrazo", "derecho", ".", "Se", "trata", "de", "un", "dolor", "continuo", ",", "que", "mejora", "con", "el", "reposo", ",", "aumentando", "con", "la", "sedestación", "y", "los", "cambios", "posturales", ",", "provocándole", "parestesias", "en", "ambas", "extremidades", "inferiores", ".", "\n", "Asimismo", ",", "presenta", "pérdida", "de", "aproximadamente", "5", "kg", "de", "peso", "en", "los", "últimos", "3", "meses", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "moderados", "esfuerzos", ".", "Sin", "dolor", "torácico", ",", "tos", ",", "expectoración", ",", "fiebre", "ni", "otra", "clínica", "acompañante", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", "destaca", "una", "hipofonesis", "en", "hemitórax", "inferior", "derecho", "con", "murmullo", "vesicular", "conservado", "en", "pulmón", "izquierdo", ".", "Exploración", "neurológica", "sin", "alteraciones", ".", "A", "nivel", "locomotor", ",", "se", "apreciaba", "una", "tumoración", "de", "consistencia", "dura", "y", "adherida", "a", "planos", "profundos", ",", "no", "dolorosa", "durante", "la", "palpación", "en", "antebrazo", "derecho", "y", "muslo", "izquierdo", ".", "\n\n", "Pruebas", "complementarias", "\n", "Durante", "el", "ingreso", "se", "realizan", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Radiografía", "de", "tórax", ":", "derrame", "pleural", "masivo", "derecho", "sin", "desplazamiento", "mediastínico", ".", "\n", "»", "Marcadores", "tumorales", "CEA", "34,6", ",", "Ca", "19,9", ">", "700", ",", "Ca", "12,5", "260,1", ".", "\n", "»", "TC", "de", "cuello", "-", "tórax", "-", "abdomen", ":", "metástasis", "pleurales", ",", "óseas", ",", "musculares", "múltiples", ",", "cerebrales", "y", "posibles", "pulmonares", "con", "sospecha", "de", "neoplasia", "primario", "pulmonar", ".", "\n", "Por", "presencia", "de", "derrame", "pleural", "derecho", ",", "se", "solicita", "pleurodesis", "guiada", "por", "videotoracoscopia", "con", "solicitud", "de", "biopsia", "pleural", ".", "\n", "Ante", "la", "marcada", "sospecha", "de", "primario", "de", "origen", "pulmonar", ",", "se", "solicita", "el", "perfil", "mutacional", "correspondiente", "(", "KRAS", ",", "EGFR", ",", "ALK", "):", "\n", "»", "Citología", "liquido", "pleural", ":", "compatible", "con", "infiltración", "por", "adenocarcinoma", ".", "TTF-1", "positivo", ",", "lo", "cual", "favorece", "un", "origen", "pulmonar", ".", "\n", "»", "Biopsia", "muscular", ":", "adenocarcinoma", "(", "ADK", ")", "metastásico", ".", "KRAS", "mutado", ".", "EGFR", "wild", "type", ".", "ALK", "no", "traslocado", ".", "\n", "»", "Biopsia", "pleural", ":", "ADK", "con", "fenotipo", "de", "origen", "gastrointestinal", "(", "estómago", ",", "pancreático", "y", "biliar", ")", ".", "\n", "Positividad", "para", "CK7", ",", "CK20", ",", "y", "CDX-2", "(", "aisladas", "células", "TTF-1", ")", ".", "Negativas", "para", "napsina", ",", "PAX", "8", "y", "PSA", ".", "HER-2", "negativo", ".", "\n", "Por", "discordancia", "entre", "una", "primera", "sospecha", "de", "primario", "pulmonar", "y", "el", "resultado", "posterior", "de", "biopsia", "pleural", "compatible", "con", "ADK", "de", "origen", "gastrointestinal", ",", "se", "amplía", "el", "estudio", "con", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Gastroscopia", ":", "examen", "endoscópico", "normal", ".", "\n", "»", "Citología", "orina", ":", "negativo", "para", "malignidad", ".", "Celularidad", "urotelial", "con", "cambios", "reactivos", ".", "\n", "»", "Ecografía", "renal", ":", "ambos", "riñones", ",", "vejiga", "y", "próstata", "sin", "alteraciones", "ecográficamente", "valorables", ".", "\n\n", "Diagnóstico", "\n", "Ante", "el", "diagnóstico", "de", "adenocarcinoma", "de", "origen", "desconocido", "con", "metástasis", "múltiples", ":", "pleurales", ",", "óseas", ",", "musculares", ",", "cerebrales", "y", "posible", "pulmonares", ",", "se", "solicita", "un", "estudio", "de", "secuenciación", "genética", "masiva", ".", "\n\n", "Tratamiento", "\n", "A", "la", "espera", "de", "dichos", "resultados", ",", "se", "realiza", "en", "julio", "de", "2017", "RT", "holocraneal", "(", "entre", "el", "26/6/2017", "y", "el", "10/7/2017", "se", "administraron", "30Gy", "a", "fraccionamiento", "de", "3Gy", "/", "fracción", ")", "y", "se", "inicia", "quimioterapia", "de", "primera", "línea", "esquema", "carboplatino", "AUC", "6", "/", "paclitaxel", "175", "mg", "/", "m2", "cada", "21", "días", "durante", "2", "ciclos", ",", "presentando", "mala", "tolerancia", "con", "náuseas", ",", "vómitos", "grado", "2", "y", "diarrea", "grado", "2", ".", "\n\n", "Evolución", "\n", "Ingreso", "hospitalario", "en", "agosto", "2017", "por", "anemia", "grado", "4", "y", "mal", "control", "del", "dolor", ".", "Se", "realiza", "TC", "toracoabdominopélvica", "que", "evidencia", "progresión", "de", "la", "enfermedad", ".", "Para", "el", "control", "del", "dolor", "se", "inicia", "morfina", "sulfato", "retard", "(", "MST", ")", "60", "mg", "cada", "12", "horas", "y", "rescates", "de", "fentanilo", "sublingual", "200", "mcg", ".", "\n", "Ingresa", "nuevamente", "en", "septiembre", "2017", "por", "síndrome", "febril", "sin", "semiología", "infecciosa", "y", "cultivos", "negativos", ";", "por", "lo", "que", "se", "cataloga", "de", "origen", "tumoral", ",", "y", "se", "inicia", "indometacina", "con", "resolución", "del", "cuadro", ".", "\n", "Asimismo", ",", "presenta", "dolor", "y", "aumento", "del", "perímetro", "de", "la", "extremidad", "inferior", "izquierda", "(", "en", "TC", "se", "observaba", "afectación", "ósea", "en", "cadera", "izquierda", "y", "muscular", "en", "ambos", "miembros", "inferiores", "como", "probable", "causa", ")", ";", "se", "realiza", "Eco", "-", "Doppler", "que", "determina", "trombosis", "venosa", "profunda", "en", "vena", "femoral", "izquierda", ",", "iniciándose", "tinzaparina", "12.000", "UI", "cada", "24", "horas", ".", "Por", "dolor", "mal", "controlado", ",", "precisa", "perfusión", "de", "morfina", "iv", "y", "posterior", "rotación", "de", "opioides", "progresiva", "a", "metadona", ",", "con", "mejor", "control", ",", "pero", "necesitando", "rescates", "de", "morfina", "subcutánea", ".", "\n", "También", "presenta", "astenia", "marcada", "y", "anemia", "grado", "3", "post", "-", "QT", "(", "hemoglobina", "6,9", "g", "/", "dl", ")", "que", "obligan", "a", "transfusión", "de", "concentrados", "de", "hematíes", "en", "varias", "ocasiones", "(", "sospecha", "de", "infiltración", "tumoral", "de", "medula", "ósea", ")", ".", "\n", "Ante", "la", "falta", "de", "respuesta", "clínica", "y", "radiológica", "a", "la", "quimioterapia", "tras", "la", "administración", "de", "2", "ciclos", "de", "tratamiento", ",", "se", "decide", "iniciar", ",", "en", "octubre", "de", "2017", ",", "QT", "paliativa", "con", "irinotecan", "180", "mg", "/", "m2", "cada", "2", "semanas", "según", "resultado", "de", "test", "de", "secuenciación", "genética", ".", "\n", "Se", "da", "de", "alta", "hospitalaria", "y", "acude", "a", "consulta", "para", "administrar", "2º", "ciclo", "de", "irinotecan", "quincenal", ".", "A", "pesar", "de", "presentar", "mejoría", "clínica", "con", "buen", "control", "del", "dolor", ",", "el", "paciente", "fallece", "en", "noviembre", "de", "2017", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

neoplasia, leucemia, tumoración, tumoración, metástasis, neoplasia, adenocarcinoma, adenocarcinoma ( ADK ) metastásico, ADK, ADK, malignidad, adenocarcinoma de origen desconocido con metástasis, tumoral, afectación ósea, infiltración tumoral de medula ósea

601_task2

Sentence: Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Presentamos un varón de 37 años, sin alergias medicamentosas conocidas y fumador ocasional desde la adolescencia. Padre de dos hijos de 3 y 7 años. Como antecedentes patológicos únicamente presenta asma alérgica y, como antecedentes familiares, se ha registrado abuelo paterno con diagnóstico de neoplasia de colon y abuela paterna con leucemia. Sin tratamiento habitual. Historia oncológica En junio de 2017 ingresa en el hospital por dolor lumbar e inguinal bilateral de 2-3 meses de evolución, acompañado de tumoración en antebrazo derecho. Se trata de un dolor continuo, que mejora con el reposo, aumentando con la sedestación y los cambios posturales, provocándole parestesias en ambas extremidades inferiores. Asimismo, presenta pérdida de aproximadamente 5 kg de peso en los últimos 3 meses y disnea progresiva hasta hacerse de moderados esfuerzos. Sin dolor torácico, tos, expectoración, fiebre ni otra clínica acompañante. Exploración física Durante la exploración física destaca una hipofonesis en hemitórax inferior derecho con murmullo vesicular conservado en pulmón izquierdo. Exploración neurológica sin alteraciones. A nivel locomotor, se apreciaba una tumoración de consistencia dura y adherida a planos profundos, no dolorosa durante la palpación en antebrazo derecho y muslo izquierdo. Pruebas complementarias Durante el ingreso se realizan las siguientes pruebas complementarias: » Radiografía de tórax: derrame pleural masivo derecho sin desplazamiento mediastínico. » Marcadores tumorales CEA 34,6, Ca 19,9 > 700, Ca 12,5 260,1. » TC de cuello-tórax-abdomen: metástasis pleurales, óseas, musculares múltiples, cerebrales y posibles pulmonares con sospecha de neoplasia primario pulmonar. Por presencia de derrame pleural derecho, se solicita pleurodesis guiada por videotoracoscopia con solicitud de biopsia pleural. Ante la marcada sospecha de primario de origen pulmonar, se solicita el perfil mutacional correspondiente (KRAS, EGFR, ALK): » Citología liquido pleural: compatible con infiltración por adenocarcinoma. TTF-1 positivo, lo cual favorece un origen pulmonar. » Biopsia muscular: adenocarcinoma (ADK) metastásico. KRAS mutado. EGFR wild type. ALK no traslocado. » Biopsia pleural: ADK con fenotipo de origen gastrointestinal (estómago, pancreático y biliar). Positividad para CK7, CK20, y CDX-2 (aisladas células TTF-1). Negativas para napsina, PAX 8 y PSA. HER-2 negativo. Por discordancia entre una primera sospecha de primario pulmonar y el resultado posterior de biopsia pleural compatible con ADK de origen gastrointestinal, se amplía el estudio con las siguientes pruebas complementarias: » Gastroscopia: examen endoscópico normal. » Citología orina: negativo para malignidad. Celularidad urotelial con cambios reactivos. » Ecografía renal: ambos riñones, vejiga y próstata sin alteraciones ecográficamente valorables. Diagnóstico Ante el diagnóstico de adenocarcinoma de origen desconocido con metástasis múltiples: pleurales, óseas, musculares, cerebrales y posible pulmonares, se solicita un estudio de secuenciación genética masiva. Tratamiento A la espera de dichos resultados, se realiza en julio de 2017 RT holocraneal (entre el 26/6/2017 y el 10/7/2017 se administraron 30Gy a fraccionamiento de 3Gy/fracción) y se inicia quimioterapia de primera línea esquema carboplatino AUC 6/paclitaxel 175 mg/m2 cada 21 días durante 2 ciclos, presentando mala tolerancia con náuseas, vómitos grado 2 y diarrea grado 2. Evolución Ingreso hospitalario en agosto 2017 por anemia grado 4 y mal control del dolor. Se realiza TC toracoabdominopélvica que evidencia progresión de la enfermedad. Para el control del dolor se inicia morfina sulfato retard (MST) 60 mg cada 12 horas y rescates de fentanilo sublingual 200 mcg. Ingresa nuevamente en septiembre 2017 por síndrome febril sin semiología infecciosa y cultivos negativos; por lo que se cataloga de origen tumoral, y se inicia indometacina con resolución del cuadro. Asimismo, presenta dolor y aumento del perímetro de la extremidad inferior izquierda (en TC se observaba afectación ósea en cadera izquierda y muscular en ambos miembros inferiores como probable causa); se realiza Eco-Doppler que determina trombosis venosa profunda en vena femoral izquierda, iniciándose tinzaparina 12.000 UI cada 24 horas. Por dolor mal controlado, precisa perfusión de morfina iv y posterior rotación de opioides progresiva a metadona, con mejor control, pero necesitando rescates de morfina subcutánea. También presenta astenia marcada y anemia grado 3 post-QT (hemoglobina 6,9 g/dl) que obligan a transfusión de concentrados de hematíes en varias ocasiones (sospecha de infiltración tumoral de medula ósea). Ante la falta de respuesta clínica y radiológica a la quimioterapia tras la administración de 2 ciclos de tratamiento, se decide iniciar, en octubre de 2017, QT paliativa con irinotecan 180 mg/m2 cada 2 semanas según resultado de test de secuenciación genética. Se da de alta hospitalaria y acude a consulta para administrar 2º ciclo de irinotecan quincenal. A pesar de presentar mejoría clínica con buen control del dolor, el paciente fallece en noviembre de 2017.

[ "Anamnesis", "\n", "Presentamos", "un", "varón", "de", "37", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", "y", "fumador", "ocasional", "desde", "la", "adolescencia", ".", "Padre", "de", "dos", "hijos", "de", "3", "y", "7", "años", ".", "\n", "Como", "antecedentes", "patológicos", "únicamente", "presenta", "asma", "alérgica", "y", ",", "como", "antecedentes", "familiares", ",", "se", "ha", "registrado", "abuelo", "paterno", "con", "diagnóstico", "de", "neoplasia", "de", "colon", "y", "abuela", "paterna", "con", "leucemia", ".", "\n", "Sin", "tratamiento", "habitual", ".", "\n\n", "Historia", "oncológica", "\n", "En", "junio", "de", "2017", "ingresa", "en", "el", "hospital", "por", "dolor", "lumbar", "e", "inguinal", "bilateral", "de", "2", "-", "3", "meses", "de", "evolución", ",", "acompañado", "de", "tumoración", "en", "antebrazo", "derecho", ".", "Se", "trata", "de", "un", "dolor", "continuo", ",", "que", "mejora", "con", "el", "reposo", ",", "aumentando", "con", "la", "sedestación", "y", "los", "cambios", "posturales", ",", "provocándole", "parestesias", "en", "ambas", "extremidades", "inferiores", ".", "\n", "Asimismo", ",", "presenta", "pérdida", "de", "aproximadamente", "5", "kg", "de", "peso", "en", "los", "últimos", "3", "meses", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "moderados", "esfuerzos", ".", "Sin", "dolor", "torácico", ",", "tos", ",", "expectoración", ",", "fiebre", "ni", "otra", "clínica", "acompañante", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", "destaca", "una", "hipofonesis", "en", "hemitórax", "inferior", "derecho", "con", "murmullo", "vesicular", "conservado", "en", "pulmón", "izquierdo", ".", "Exploración", "neurológica", "sin", "alteraciones", ".", "A", "nivel", "locomotor", ",", "se", "apreciaba", "una", "tumoración", "de", "consistencia", "dura", "y", "adherida", "a", "planos", "profundos", ",", "no", "dolorosa", "durante", "la", "palpación", "en", "antebrazo", "derecho", "y", "muslo", "izquierdo", ".", "\n\n", "Pruebas", "complementarias", "\n", "Durante", "el", "ingreso", "se", "realizan", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Radiografía", "de", "tórax", ":", "derrame", "pleural", "masivo", "derecho", "sin", "desplazamiento", "mediastínico", ".", "\n", "»", "Marcadores", "tumorales", "CEA", "34,6", ",", "Ca", "19,9", ">", "700", ",", "Ca", "12,5", "260,1", ".", "\n", "»", "TC", "de", "cuello", "-", "tórax", "-", "abdomen", ":", "metástasis", "pleurales", ",", "óseas", ",", "musculares", "múltiples", ",", "cerebrales", "y", "posibles", "pulmonares", "con", "sospecha", "de", "neoplasia", "primario", "pulmonar", ".", "\n", "Por", "presencia", "de", "derrame", "pleural", "derecho", ",", "se", "solicita", "pleurodesis", "guiada", "por", "videotoracoscopia", "con", "solicitud", "de", "biopsia", "pleural", ".", "\n", "Ante", "la", "marcada", "sospecha", "de", "primario", "de", "origen", "pulmonar", ",", "se", "solicita", "el", "perfil", "mutacional", "correspondiente", "(", "KRAS", ",", "EGFR", ",", "ALK", "):", "\n", "»", "Citología", "liquido", "pleural", ":", "compatible", "con", "infiltración", "por", "adenocarcinoma", ".", "TTF-1", "positivo", ",", "lo", "cual", "favorece", "un", "origen", "pulmonar", ".", "\n", "»", "Biopsia", "muscular", ":", "adenocarcinoma", "(", "ADK", ")", "metastásico", ".", "KRAS", "mutado", ".", "EGFR", "wild", "type", ".", "ALK", "no", "traslocado", ".", "\n", "»", "Biopsia", "pleural", ":", "ADK", "con", "fenotipo", "de", "origen", "gastrointestinal", "(", "estómago", ",", "pancreático", "y", "biliar", ")", ".", "\n", "Positividad", "para", "CK7", ",", "CK20", ",", "y", "CDX-2", "(", "aisladas", "células", "TTF-1", ")", ".", "Negativas", "para", "napsina", ",", "PAX", "8", "y", "PSA", ".", "HER-2", "negativo", ".", "\n", "Por", "discordancia", "entre", "una", "primera", "sospecha", "de", "primario", "pulmonar", "y", "el", "resultado", "posterior", "de", "biopsia", "pleural", "compatible", "con", "ADK", "de", "origen", "gastrointestinal", ",", "se", "amplía", "el", "estudio", "con", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Gastroscopia", ":", "examen", "endoscópico", "normal", ".", "\n", "»", "Citología", "orina", ":", "negativo", "para", "malignidad", ".", "Celularidad", "urotelial", "con", "cambios", "reactivos", ".", "\n", "»", "Ecografía", "renal", ":", "ambos", "riñones", ",", "vejiga", "y", "próstata", "sin", "alteraciones", "ecográficamente", "valorables", ".", "\n\n", "Diagnóstico", "\n", "Ante", "el", "diagnóstico", "de", "adenocarcinoma", "de", "origen", "desconocido", "con", "metástasis", "múltiples", ":", "pleurales", ",", "óseas", ",", "musculares", ",", "cerebrales", "y", "posible", "pulmonares", ",", "se", "solicita", "un", "estudio", "de", "secuenciación", "genética", "masiva", ".", "\n\n", "Tratamiento", "\n", "A", "la", "espera", "de", "dichos", "resultados", ",", "se", "realiza", "en", "julio", "de", "2017", "RT", "holocraneal", "(", "entre", "el", "26/6/2017", "y", "el", "10/7/2017", "se", "administraron", "30Gy", "a", "fraccionamiento", "de", "3Gy", "/", "fracción", ")", "y", "se", "inicia", "quimioterapia", "de", "primera", "línea", "esquema", "carboplatino", "AUC", "6", "/", "paclitaxel", "175", "mg", "/", "m2", "cada", "21", "días", "durante", "2", "ciclos", ",", "presentando", "mala", "tolerancia", "con", "náuseas", ",", "vómitos", "grado", "2", "y", "diarrea", "grado", "2", ".", "\n\n", "Evolución", "\n", "Ingreso", "hospitalario", "en", "agosto", "2017", "por", "anemia", "grado", "4", "y", "mal", "control", "del", "dolor", ".", "Se", "realiza", "TC", "toracoabdominopélvica", "que", "evidencia", "progresión", "de", "la", "enfermedad", ".", "Para", "el", "control", "del", "dolor", "se", "inicia", "morfina", "sulfato", "retard", "(", "MST", ")", "60", "mg", "cada", "12", "horas", "y", "rescates", "de", "fentanilo", "sublingual", "200", "mcg", ".", "\n", "Ingresa", "nuevamente", "en", "septiembre", "2017", "por", "síndrome", "febril", "sin", "semiología", "infecciosa", "y", "cultivos", "negativos", ";", "por", "lo", "que", "se", "cataloga", "de", "origen", "tumoral", ",", "y", "se", "inicia", "indometacina", "con", "resolución", "del", "cuadro", ".", "\n", "Asimismo", ",", "presenta", "dolor", "y", "aumento", "del", "perímetro", "de", "la", "extremidad", "inferior", "izquierda", "(", "en", "TC", "se", "observaba", "afectación", "ósea", "en", "cadera", "izquierda", "y", "muscular", "en", "ambos", "miembros", "inferiores", "como", "probable", "causa", ")", ";", "se", "realiza", "Eco", "-", "Doppler", "que", "determina", "trombosis", "venosa", "profunda", "en", "vena", "femoral", "izquierda", ",", "iniciándose", "tinzaparina", "12.000", "UI", "cada", "24", "horas", ".", "Por", "dolor", "mal", "controlado", ",", "precisa", "perfusión", "de", "morfina", "iv", "y", "posterior", "rotación", "de", "opioides", "progresiva", "a", "metadona", ",", "con", "mejor", "control", ",", "pero", "necesitando", "rescates", "de", "morfina", "subcutánea", ".", "\n", "También", "presenta", "astenia", "marcada", "y", "anemia", "grado", "3", "post", "-", "QT", "(", "hemoglobina", "6,9", "g", "/", "dl", ")", "que", "obligan", "a", "transfusión", "de", "concentrados", "de", "hematíes", "en", "varias", "ocasiones", "(", "sospecha", "de", "infiltración", "tumoral", "de", "medula", "ósea", ")", ".", "\n", "Ante", "la", "falta", "de", "respuesta", "clínica", "y", "radiológica", "a", "la", "quimioterapia", "tras", "la", "administración", "de", "2", "ciclos", "de", "tratamiento", ",", "se", "decide", "iniciar", ",", "en", "octubre", "de", "2017", ",", "QT", "paliativa", "con", "irinotecan", "180", "mg", "/", "m2", "cada", "2", "semanas", "según", "resultado", "de", "test", "de", "secuenciación", "genética", ".", "\n", "Se", "da", "de", "alta", "hospitalaria", "y", "acude", "a", "consulta", "para", "administrar", "2º", "ciclo", "de", "irinotecan", "quincenal", ".", "A", "pesar", "de", "presentar", "mejoría", "clínica", "con", "buen", "control", "del", "dolor", ",", "el", "paciente", "fallece", "en", "noviembre", "de", "2017", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Sec5 is a protein, Ral is a protein-family

1.0alpha7.train.1231_task0

Sentence: Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein

[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002).

[ "Furthermore", ",", " ", "Sec5", "binds", "a", " ", "Ral", "protein", ",", "which", "is", "not", "present", "in", " ", "yeast", "(", "Brymora", " ", "et", "al", ".", ",", "2001", ";", " ", "Moskalenko", " ", "et", "al", ".", ",", "2002", ";", " ", "Sugihara", " ", "et", "al", ".", ",", "2002", ")", "." ]

[ "protein", "protein-family" ]

Sec5 is a protein, Ral is a protein-family

1.0alpha7.train.1231_task1

Sentence: Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002). Instructions: please typing these entity words according to sentence: Sec5, Ral Options: protein-family, protein

[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002).

[ "Furthermore", ",", " ", "Sec5", "binds", "a", " ", "Ral", "protein", ",", "which", "is", "not", "present", "in", " ", "yeast", "(", "Brymora", " ", "et", "al", ".", ",", "2001", ";", " ", "Moskalenko", " ", "et", "al", ".", ",", "2002", ";", " ", "Sugihara", " ", "et", "al", ".", ",", "2002", ")", "." ]

[ "protein", "protein-family" ]

Sec5, Ral

1.0alpha7.train.1231_task2

Sentence: Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Furthermore, Sec5 binds a Ral protein, which is not present in yeast ( Brymora et al., 2001; Moskalenko et al., 2002; Sugihara et al., 2002).

[ "Furthermore", ",", " ", "Sec5", "binds", "a", " ", "Ral", "protein", ",", "which", "is", "not", "present", "in", " ", "yeast", "(", "Brymora", " ", "et", "al", ".", ",", "2001", ";", " ", "Moskalenko", " ", "et", "al", ".", ",", "2002", ";", " ", "Sugihara", " ", "et", "al", ".", ",", "2002", ")", "." ]

[ "protein", "protein-family" ]

= 18 years is a Person, High risk is a Condition, General Surgery AKI Risk Index is a Measurement, Class III , IV or V is a Value, Major abdominal surgery is a Procedure

NCT02499185_inc_task0

Sentence: = 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Procedure, Measurement

[ "B-Person", "I-Person", "I-Person", "O", "B-Condition", "I-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O" ]

= 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery

[ "=", "18", "years", "\n", "High", "risk", "patients", ":", "General", "Surgery", "AKI", "Risk", "Index", "Class", "III", ",", "IV", "or", "V", "\n", "Major", "abdominal", "surgery", "\n" ]

[ "Measurement", "Procedure", "Value", "Person", "Condition" ]

= 18 years is a Person, High risk is a Condition, General Surgery AKI Risk Index is a Measurement, Class III , IV or V is a Value, Major abdominal surgery is a Procedure

NCT02499185_inc_task1

Sentence: = 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery Instructions: please typing these entity words according to sentence: = 18 years, High risk, General Surgery AKI Risk Index, Class III , IV or V, Major abdominal surgery Options: Condition, Value, Person, Procedure, Measurement

[ "B-Person", "I-Person", "I-Person", "O", "B-Condition", "I-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O" ]

= 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery

[ "=", "18", "years", "\n", "High", "risk", "patients", ":", "General", "Surgery", "AKI", "Risk", "Index", "Class", "III", ",", "IV", "or", "V", "\n", "Major", "abdominal", "surgery", "\n" ]

[ "Measurement", "Procedure", "Value", "Person", "Condition" ]

= 18 years, High risk, General Surgery AKI Risk Index, Class III , IV or V, Major abdominal surgery

NCT02499185_inc_task2

Sentence: = 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery Instructions: please extract entity words from the input sentence

[ "B-Person", "I-Person", "I-Person", "O", "B-Condition", "I-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O" ]

= 18 years High risk patients: General Surgery AKI Risk Index Class III, IV or V Major abdominal surgery

[ "=", "18", "years", "\n", "High", "risk", "patients", ":", "General", "Surgery", "AKI", "Risk", "Index", "Class", "III", ",", "IV", "or", "V", "\n", "Major", "abdominal", "surgery", "\n" ]

[ "Measurement", "Procedure", "Value", "Person", "Condition" ]

Patienten is an umlsterm, Veneninsuffizienz is an umlsterm, Syndroms is an umlsterm, Therapieerfolg is an umlsterm, Schmerzen is an umlsterm, Oedemneigung is an umlsterm, Sprunggelenkbeweglichkeit is an umlsterm, Patienten is an umlsterm, Kompressionstherapie is an umlsterm, Gefaesssporttherapie is an umlsterm, Basistherapie is an umlsterm, Behindertensportabkommens is an umlsterm

DerHautarzt.70480384.ger.abstr_task0

Sentence: In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist .

[ "In", "einer", "klinischen", "Untersuchung", "bei", "33", "Patienten", "mit", "chronischer", "Veneninsuffizienz", "aufgrund", "primaerer", "Varikose", "oder", "eines", "postthrombotischen", "Syndroms", "in", "den", "klinischen", "Stadien", "I", "bis", "III", "nach", "Widmer", "konnte", "der", "Therapieerfolg", "eines", "halbjaehrigen", "krankheitsspezifischen", "ambulanten", "Bewegungstrainings", "dokumentiert", "werden", ".", "Waehrend", "des", "Trainings", "kam", "es", "zu", "einer", "deutlichen", "Besserung", "stauungsbedingter", "subjektiver", "Beschwerden", "wie", "Schmerzen", "und", "Oedemneigung", "sowie", "zu", "einer", "Verbesserung", "von", "Sprunggelenkbeweglichkeit", "und", "venoeser", "Abpumpleistung", ".", "Der", "klinische", "Erfolg", "zeigte", "sich", "in", "einer", "kompletten", "Abheilung", "venoeser", "Ulzera", "bei", "7", "von", "10", "Patienten", ".", "In", "Verbindung", "mit", "einer", "optimierten", "Kompressionstherapie", "stellt", "die", "Gefaesssporttherapie", "eine", "effiziente", "und", "kostenguenstige", "Basistherapie", "bei", "der", "CVI", "dar", ".", "Auf", "der", "Grundlage", "des", "novellierten", "Deutschen", "Behindertensportabkommens", "aus", "dem", "Jahre", "1994", "werden", "die", "Kosten", "von", "den", "gesetzlichen", "Krankenkassen", "getragen", ",", "solange", "das", "Training", "unter", "qualifizierter", "Anleitung", "indiziert", "ist", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Veneninsuffizienz is an umlsterm, Syndroms is an umlsterm, Therapieerfolg is an umlsterm, Schmerzen is an umlsterm, Oedemneigung is an umlsterm, Sprunggelenkbeweglichkeit is an umlsterm, Patienten is an umlsterm, Kompressionstherapie is an umlsterm, Gefaesssporttherapie is an umlsterm, Basistherapie is an umlsterm, Behindertensportabkommens is an umlsterm

DerHautarzt.70480384.ger.abstr_task1

Sentence: In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist . Instructions: please typing these entity words according to sentence: Patienten, Veneninsuffizienz, Syndroms, Therapieerfolg, Schmerzen, Oedemneigung, Sprunggelenkbeweglichkeit, Patienten, Kompressionstherapie, Gefaesssporttherapie, Basistherapie, Behindertensportabkommens Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist .

[ "In", "einer", "klinischen", "Untersuchung", "bei", "33", "Patienten", "mit", "chronischer", "Veneninsuffizienz", "aufgrund", "primaerer", "Varikose", "oder", "eines", "postthrombotischen", "Syndroms", "in", "den", "klinischen", "Stadien", "I", "bis", "III", "nach", "Widmer", "konnte", "der", "Therapieerfolg", "eines", "halbjaehrigen", "krankheitsspezifischen", "ambulanten", "Bewegungstrainings", "dokumentiert", "werden", ".", "Waehrend", "des", "Trainings", "kam", "es", "zu", "einer", "deutlichen", "Besserung", "stauungsbedingter", "subjektiver", "Beschwerden", "wie", "Schmerzen", "und", "Oedemneigung", "sowie", "zu", "einer", "Verbesserung", "von", "Sprunggelenkbeweglichkeit", "und", "venoeser", "Abpumpleistung", ".", "Der", "klinische", "Erfolg", "zeigte", "sich", "in", "einer", "kompletten", "Abheilung", "venoeser", "Ulzera", "bei", "7", "von", "10", "Patienten", ".", "In", "Verbindung", "mit", "einer", "optimierten", "Kompressionstherapie", "stellt", "die", "Gefaesssporttherapie", "eine", "effiziente", "und", "kostenguenstige", "Basistherapie", "bei", "der", "CVI", "dar", ".", "Auf", "der", "Grundlage", "des", "novellierten", "Deutschen", "Behindertensportabkommens", "aus", "dem", "Jahre", "1994", "werden", "die", "Kosten", "von", "den", "gesetzlichen", "Krankenkassen", "getragen", ",", "solange", "das", "Training", "unter", "qualifizierter", "Anleitung", "indiziert", "ist", "." ]

[ "umlsterm" ]

Patienten, Veneninsuffizienz, Syndroms, Therapieerfolg, Schmerzen, Oedemneigung, Sprunggelenkbeweglichkeit, Patienten, Kompressionstherapie, Gefaesssporttherapie, Basistherapie, Behindertensportabkommens

DerHautarzt.70480384.ger.abstr_task2

Sentence: In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In einer klinischen Untersuchung bei 33 Patienten mit chronischer Veneninsuffizienz aufgrund primaerer Varikose oder eines postthrombotischen Syndroms in den klinischen Stadien I bis III nach Widmer konnte der Therapieerfolg eines halbjaehrigen krankheitsspezifischen ambulanten Bewegungstrainings dokumentiert werden . Waehrend des Trainings kam es zu einer deutlichen Besserung stauungsbedingter subjektiver Beschwerden wie Schmerzen und Oedemneigung sowie zu einer Verbesserung von Sprunggelenkbeweglichkeit und venoeser Abpumpleistung . Der klinische Erfolg zeigte sich in einer kompletten Abheilung venoeser Ulzera bei 7 von 10 Patienten . In Verbindung mit einer optimierten Kompressionstherapie stellt die Gefaesssporttherapie eine effiziente und kostenguenstige Basistherapie bei der CVI dar . Auf der Grundlage des novellierten Deutschen Behindertensportabkommens aus dem Jahre 1994 werden die Kosten von den gesetzlichen Krankenkassen getragen , solange das Training unter qualifizierter Anleitung indiziert ist .

[ "In", "einer", "klinischen", "Untersuchung", "bei", "33", "Patienten", "mit", "chronischer", "Veneninsuffizienz", "aufgrund", "primaerer", "Varikose", "oder", "eines", "postthrombotischen", "Syndroms", "in", "den", "klinischen", "Stadien", "I", "bis", "III", "nach", "Widmer", "konnte", "der", "Therapieerfolg", "eines", "halbjaehrigen", "krankheitsspezifischen", "ambulanten", "Bewegungstrainings", "dokumentiert", "werden", ".", "Waehrend", "des", "Trainings", "kam", "es", "zu", "einer", "deutlichen", "Besserung", "stauungsbedingter", "subjektiver", "Beschwerden", "wie", "Schmerzen", "und", "Oedemneigung", "sowie", "zu", "einer", "Verbesserung", "von", "Sprunggelenkbeweglichkeit", "und", "venoeser", "Abpumpleistung", ".", "Der", "klinische", "Erfolg", "zeigte", "sich", "in", "einer", "kompletten", "Abheilung", "venoeser", "Ulzera", "bei", "7", "von", "10", "Patienten", ".", "In", "Verbindung", "mit", "einer", "optimierten", "Kompressionstherapie", "stellt", "die", "Gefaesssporttherapie", "eine", "effiziente", "und", "kostenguenstige", "Basistherapie", "bei", "der", "CVI", "dar", ".", "Auf", "der", "Grundlage", "des", "novellierten", "Deutschen", "Behindertensportabkommens", "aus", "dem", "Jahre", "1994", "werden", "die", "Kosten", "von", "den", "gesetzlichen", "Krankenkassen", "getragen", ",", "solange", "das", "Training", "unter", "qualifizierter", "Anleitung", "indiziert", "ist", "." ]

[ "umlsterm" ]

ligament is an umlsterm, syndrome is an umlsterm, celiac artery is an umlsterm, ligament is an umlsterm, superior mesenteric arteries is an umlsterm, operation is an umlsterm, treatment is an umlsterm, symptoms is an umlsterm, ligament is an umlsterm, syndrome is an umlsterm, two - vessel is an umlsterm, surgical treatment is an umlsterm, ligament is an umlsterm, procedures is an umlsterm, blood is an umlsterm

Gefaesschirurgie.00050049.eng.abstr_task0

Sentence: In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow .

[ "In", "median", "avcuate", "ligament", "syndrome", ",", "compression", "of", "the", "celiac", "artery", "is", "caused", "by", "an", "abnormally", "low", "insertion", "of", "the", "median", "arcuate", "ligament", "in", "the", "presence", "of", "normally", "located", "celiac", "and", "superior", "mesenteric", "arteries", ".", "A", "lot", "of", "controversy", "exists", "concerning", "the", "indication", "for", "operation", "and", "the", "best", "mode", "of", "treatment", ".", "Depending", "on", "the", "presence", "and", "quality", "of", "collateral", "pathways", ",", "the", "symptoms", "vary", "considerably", ".", "We", "report", "a", "rare", "case", "of", "arcuate", "ligament", "syndrome", "with", "two", "-", "vessel", "involvement", ".", "In", "such", "cases", "surgical", "treatment", "seems", "to", "offer", "substantial", "benefit", ".", "Usually", "transsection", "of", "the", "compressing", "arcuate", "ligament", "is", "sufficient", ".", "Bypass", "procedures", "should", "remain", "limited", "to", "cases", "in", "which", "transsection", "does", "not", "enable", "a", "significant", "increase", "in", "splanchnic", "blood", "flow", "." ]

[ "umlsterm" ]

ligament is an umlsterm, syndrome is an umlsterm, celiac artery is an umlsterm, ligament is an umlsterm, superior mesenteric arteries is an umlsterm, operation is an umlsterm, treatment is an umlsterm, symptoms is an umlsterm, ligament is an umlsterm, syndrome is an umlsterm, two - vessel is an umlsterm, surgical treatment is an umlsterm, ligament is an umlsterm, procedures is an umlsterm, blood is an umlsterm

Gefaesschirurgie.00050049.eng.abstr_task1

Sentence: In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow . Instructions: please typing these entity words according to sentence: ligament, syndrome, celiac artery, ligament, superior mesenteric arteries, operation, treatment, symptoms, ligament, syndrome, two - vessel, surgical treatment, ligament, procedures, blood Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow .

[ "In", "median", "avcuate", "ligament", "syndrome", ",", "compression", "of", "the", "celiac", "artery", "is", "caused", "by", "an", "abnormally", "low", "insertion", "of", "the", "median", "arcuate", "ligament", "in", "the", "presence", "of", "normally", "located", "celiac", "and", "superior", "mesenteric", "arteries", ".", "A", "lot", "of", "controversy", "exists", "concerning", "the", "indication", "for", "operation", "and", "the", "best", "mode", "of", "treatment", ".", "Depending", "on", "the", "presence", "and", "quality", "of", "collateral", "pathways", ",", "the", "symptoms", "vary", "considerably", ".", "We", "report", "a", "rare", "case", "of", "arcuate", "ligament", "syndrome", "with", "two", "-", "vessel", "involvement", ".", "In", "such", "cases", "surgical", "treatment", "seems", "to", "offer", "substantial", "benefit", ".", "Usually", "transsection", "of", "the", "compressing", "arcuate", "ligament", "is", "sufficient", ".", "Bypass", "procedures", "should", "remain", "limited", "to", "cases", "in", "which", "transsection", "does", "not", "enable", "a", "significant", "increase", "in", "splanchnic", "blood", "flow", "." ]

[ "umlsterm" ]

ligament, syndrome, celiac artery, ligament, superior mesenteric arteries, operation, treatment, symptoms, ligament, syndrome, two - vessel, surgical treatment, ligament, procedures, blood

Gefaesschirurgie.00050049.eng.abstr_task2

Sentence: In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

In median avcuate ligament syndrome , compression of the celiac artery is caused by an abnormally low insertion of the median arcuate ligament in the presence of normally located celiac and superior mesenteric arteries . A lot of controversy exists concerning the indication for operation and the best mode of treatment . Depending on the presence and quality of collateral pathways , the symptoms vary considerably . We report a rare case of arcuate ligament syndrome with two-vessel involvement . In such cases surgical treatment seems to offer substantial benefit . Usually transsection of the compressing arcuate ligament is sufficient . Bypass procedures should remain limited to cases in which transsection does not enable a significant increase in splanchnic blood flow .

[ "In", "median", "avcuate", "ligament", "syndrome", ",", "compression", "of", "the", "celiac", "artery", "is", "caused", "by", "an", "abnormally", "low", "insertion", "of", "the", "median", "arcuate", "ligament", "in", "the", "presence", "of", "normally", "located", "celiac", "and", "superior", "mesenteric", "arteries", ".", "A", "lot", "of", "controversy", "exists", "concerning", "the", "indication", "for", "operation", "and", "the", "best", "mode", "of", "treatment", ".", "Depending", "on", "the", "presence", "and", "quality", "of", "collateral", "pathways", ",", "the", "symptoms", "vary", "considerably", ".", "We", "report", "a", "rare", "case", "of", "arcuate", "ligament", "syndrome", "with", "two", "-", "vessel", "involvement", ".", "In", "such", "cases", "surgical", "treatment", "seems", "to", "offer", "substantial", "benefit", ".", "Usually", "transsection", "of", "the", "compressing", "arcuate", "ligament", "is", "sufficient", ".", "Bypass", "procedures", "should", "remain", "limited", "to", "cases", "in", "which", "transsection", "does", "not", "enable", "a", "significant", "increase", "in", "splanchnic", "blood", "flow", "." ]

[ "umlsterm" ]

Circadian rhythm is an other_name, glucocorticoid receptors is a protein_family_or_group, human peripheral leukocytes is a cell_type, glucocorticoids is a lipid

99546_task0

Sentence: Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_family_or_group, lipid, other_name

[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "B-lipid", "O" ]

Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids.

[ "Circadian", "rhythm", "of", "glucocorticoid", "receptors", "in", "human", "peripheral", "leukocytes", "and", "their", "reactivity", "to", "glucocorticoids", "." ]

[ "cell_type", "other_name", "protein_family_or_group", "body_part", "lipid", "multi_cell" ]

Circadian rhythm is an other_name, glucocorticoid receptors is a protein_family_or_group, human peripheral leukocytes is a cell_type, glucocorticoids is a lipid

99546_task1

Sentence: Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids. Instructions: please typing these entity words according to sentence: Circadian rhythm, glucocorticoid receptors, human peripheral leukocytes, glucocorticoids Options: cell_type, protein_family_or_group, lipid, other_name

[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "B-lipid", "O" ]

Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids.

[ "Circadian", "rhythm", "of", "glucocorticoid", "receptors", "in", "human", "peripheral", "leukocytes", "and", "their", "reactivity", "to", "glucocorticoids", "." ]

[ "cell_type", "other_name", "protein_family_or_group", "body_part", "lipid", "multi_cell" ]

Circadian rhythm, glucocorticoid receptors, human peripheral leukocytes, glucocorticoids

99546_task2

Sentence: Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "B-lipid", "O" ]

Circadian rhythm of glucocorticoid receptors in human peripheral leukocytes and their reactivity to glucocorticoids.

[ "Circadian", "rhythm", "of", "glucocorticoid", "receptors", "in", "human", "peripheral", "leukocytes", "and", "their", "reactivity", "to", "glucocorticoids", "." ]

[ "cell_type", "other_name", "protein_family_or_group", "body_part", "lipid", "multi_cell" ]

Markraums is an umlsterm, Markrauminfektionen is an umlsterm, unteren Extremitaeten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Infektion is an umlsterm, Marknagel is an umlsterm, Patienten is an umlsterm, Nagelimplantation is an umlsterm, Patienten is an umlsterm, Nagels is an umlsterm, Markraumbohrung is an umlsterm, Rezidivfreiheit is an umlsterm, Extremitaet is an umlsterm, Patienten is an umlsterm, Nagel is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Rezidivfreiheit is an umlsterm, Patienten is an umlsterm, Nagel is an umlsterm, Patienten is an umlsterm, offene Fraktur is an umlsterm, Patienten is an umlsterm, Beruf is an umlsterm

DerUnfallchirurg.81010628.ger.abstr_task0

Sentence: Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen .

[ "Untersucht", "wurden", "die", "Ergebnisse", "der", "Aufbohrung", "des", "Markraums", "bei", "Markrauminfektionen", "der", "unteren", "Extremitaeten", "nach", "intramedullaerer", "Stabilisierung", "bei", "55", "Patienten", "aus", "den", "Jahren", "1980", "-", "1991", ".", "Der", "durchschnittliche", "Nachuntersuchungszeitraum", "betrug", "10,1", "+", "/-", "4,9", "Jahre", ";", "34", "Patienten", "erlitten", "die", "Infektion", "unter", "dem", "Marknagel", ",", "21", "Patienten", "hatten", "multiple", "Voreingriffe", "mit", "Infektzeichen", "schon", "vor", "der", "Nagelimplantation", ".", "Bei", "allen", "Patienten", "wurde", "nach", "Entfernung", "des", "Nagels", "eine", "Markraumbohrung", "durchgefuehrt", ".", "In", "38", "Faellen", "bestand", "eine", "Infektpseudarthrose", ",", "so", "dass", "gleichzeitig", "eine", "erneute", "stabilisierende", "Operation", "und", "Spongiosaplastik", "durchgefuehrt", "wurde", ".", "Zum", "Nachuntersuchungszeitpunkt", "wurde", "der", "Erfolg", "des", "Eingriffs", "hinsichtlich", "Rezidivfreiheit", ",", "Funktion", "der", "Extremitaet", "und", "subjektiver", "Zufriedenheit", "ueberprueft", ".", "Anhand", "dieser", "Kriterien", "fanden", "wir", "sehr", "gute", "Ergebnisse", "bei", "78", "%", "der", "Patienten", ".", "Bei", "Infekten", "nach", "primaerem", "Nagel", "war", "die", "Behandlung", "mit", "84", "%", "sehr", "guten", "Ergebnissen", "signifikant", "erfolgreicher", "als", "bei", "den", "Patienten", "mit", "multiplen", "Voreingriffen", ".", "Rezidivfreiheit", "liess", "sich", "in", "der", "Gruppe", "der", "primaeren", "Infekte", "bei", "allen", "Patienten", "erreichen", ",", "bei", "den", "sekundaer", "mit", "Nagel", "versorgen", "Patienten", "in", "62", "%", ".", "Eine", "primaer", "offene", "Fraktur", "verschlechterte", "die", "Erfolgsaussichten", "des", "Eingriffs", "nicht", ";", "82", "%", "der", "Patienten", "konnten", "ihren", "vorherigen", "Beruf", "wieder", "aufnehmen", "." ]

[ "umlsterm" ]

Markraums is an umlsterm, Markrauminfektionen is an umlsterm, unteren Extremitaeten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Infektion is an umlsterm, Marknagel is an umlsterm, Patienten is an umlsterm, Nagelimplantation is an umlsterm, Patienten is an umlsterm, Nagels is an umlsterm, Markraumbohrung is an umlsterm, Rezidivfreiheit is an umlsterm, Extremitaet is an umlsterm, Patienten is an umlsterm, Nagel is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Rezidivfreiheit is an umlsterm, Patienten is an umlsterm, Nagel is an umlsterm, Patienten is an umlsterm, offene Fraktur is an umlsterm, Patienten is an umlsterm, Beruf is an umlsterm

DerUnfallchirurg.81010628.ger.abstr_task1

Sentence: Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen . Instructions: please typing these entity words according to sentence: Markraums, Markrauminfektionen, unteren Extremitaeten, Patienten, Patienten, Infektion, Marknagel, Patienten, Nagelimplantation, Patienten, Nagels, Markraumbohrung, Rezidivfreiheit, Extremitaet, Patienten, Nagel, Behandlung, Patienten, Rezidivfreiheit, Patienten, Nagel, Patienten, offene Fraktur, Patienten, Beruf Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen .

[ "Untersucht", "wurden", "die", "Ergebnisse", "der", "Aufbohrung", "des", "Markraums", "bei", "Markrauminfektionen", "der", "unteren", "Extremitaeten", "nach", "intramedullaerer", "Stabilisierung", "bei", "55", "Patienten", "aus", "den", "Jahren", "1980", "-", "1991", ".", "Der", "durchschnittliche", "Nachuntersuchungszeitraum", "betrug", "10,1", "+", "/-", "4,9", "Jahre", ";", "34", "Patienten", "erlitten", "die", "Infektion", "unter", "dem", "Marknagel", ",", "21", "Patienten", "hatten", "multiple", "Voreingriffe", "mit", "Infektzeichen", "schon", "vor", "der", "Nagelimplantation", ".", "Bei", "allen", "Patienten", "wurde", "nach", "Entfernung", "des", "Nagels", "eine", "Markraumbohrung", "durchgefuehrt", ".", "In", "38", "Faellen", "bestand", "eine", "Infektpseudarthrose", ",", "so", "dass", "gleichzeitig", "eine", "erneute", "stabilisierende", "Operation", "und", "Spongiosaplastik", "durchgefuehrt", "wurde", ".", "Zum", "Nachuntersuchungszeitpunkt", "wurde", "der", "Erfolg", "des", "Eingriffs", "hinsichtlich", "Rezidivfreiheit", ",", "Funktion", "der", "Extremitaet", "und", "subjektiver", "Zufriedenheit", "ueberprueft", ".", "Anhand", "dieser", "Kriterien", "fanden", "wir", "sehr", "gute", "Ergebnisse", "bei", "78", "%", "der", "Patienten", ".", "Bei", "Infekten", "nach", "primaerem", "Nagel", "war", "die", "Behandlung", "mit", "84", "%", "sehr", "guten", "Ergebnissen", "signifikant", "erfolgreicher", "als", "bei", "den", "Patienten", "mit", "multiplen", "Voreingriffen", ".", "Rezidivfreiheit", "liess", "sich", "in", "der", "Gruppe", "der", "primaeren", "Infekte", "bei", "allen", "Patienten", "erreichen", ",", "bei", "den", "sekundaer", "mit", "Nagel", "versorgen", "Patienten", "in", "62", "%", ".", "Eine", "primaer", "offene", "Fraktur", "verschlechterte", "die", "Erfolgsaussichten", "des", "Eingriffs", "nicht", ";", "82", "%", "der", "Patienten", "konnten", "ihren", "vorherigen", "Beruf", "wieder", "aufnehmen", "." ]

[ "umlsterm" ]

Markraums, Markrauminfektionen, unteren Extremitaeten, Patienten, Patienten, Infektion, Marknagel, Patienten, Nagelimplantation, Patienten, Nagels, Markraumbohrung, Rezidivfreiheit, Extremitaet, Patienten, Nagel, Behandlung, Patienten, Rezidivfreiheit, Patienten, Nagel, Patienten, offene Fraktur, Patienten, Beruf

DerUnfallchirurg.81010628.ger.abstr_task2

Sentence: Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Untersucht wurden die Ergebnisse der Aufbohrung des Markraums bei Markrauminfektionen der unteren Extremitaeten nach intramedullaerer Stabilisierung bei 55 Patienten aus den Jahren 1980-1991 . Der durchschnittliche Nachuntersuchungszeitraum betrug 10,1 +/- 4,9 Jahre ; 34 Patienten erlitten die Infektion unter dem Marknagel , 21 Patienten hatten multiple Voreingriffe mit Infektzeichen schon vor der Nagelimplantation . Bei allen Patienten wurde nach Entfernung des Nagels eine Markraumbohrung durchgefuehrt . In 38 Faellen bestand eine Infektpseudarthrose , so dass gleichzeitig eine erneute stabilisierende Operation und Spongiosaplastik durchgefuehrt wurde . Zum Nachuntersuchungszeitpunkt wurde der Erfolg des Eingriffs hinsichtlich Rezidivfreiheit , Funktion der Extremitaet und subjektiver Zufriedenheit ueberprueft . Anhand dieser Kriterien fanden wir sehr gute Ergebnisse bei 78 % der Patienten . Bei Infekten nach primaerem Nagel war die Behandlung mit 84 % sehr guten Ergebnissen signifikant erfolgreicher als bei den Patienten mit multiplen Voreingriffen . Rezidivfreiheit liess sich in der Gruppe der primaeren Infekte bei allen Patienten erreichen , bei den sekundaer mit Nagel versorgen Patienten in 62 % . Eine primaer offene Fraktur verschlechterte die Erfolgsaussichten des Eingriffs nicht ; 82 % der Patienten konnten ihren vorherigen Beruf wieder aufnehmen .

[ "Untersucht", "wurden", "die", "Ergebnisse", "der", "Aufbohrung", "des", "Markraums", "bei", "Markrauminfektionen", "der", "unteren", "Extremitaeten", "nach", "intramedullaerer", "Stabilisierung", "bei", "55", "Patienten", "aus", "den", "Jahren", "1980", "-", "1991", ".", "Der", "durchschnittliche", "Nachuntersuchungszeitraum", "betrug", "10,1", "+", "/-", "4,9", "Jahre", ";", "34", "Patienten", "erlitten", "die", "Infektion", "unter", "dem", "Marknagel", ",", "21", "Patienten", "hatten", "multiple", "Voreingriffe", "mit", "Infektzeichen", "schon", "vor", "der", "Nagelimplantation", ".", "Bei", "allen", "Patienten", "wurde", "nach", "Entfernung", "des", "Nagels", "eine", "Markraumbohrung", "durchgefuehrt", ".", "In", "38", "Faellen", "bestand", "eine", "Infektpseudarthrose", ",", "so", "dass", "gleichzeitig", "eine", "erneute", "stabilisierende", "Operation", "und", "Spongiosaplastik", "durchgefuehrt", "wurde", ".", "Zum", "Nachuntersuchungszeitpunkt", "wurde", "der", "Erfolg", "des", "Eingriffs", "hinsichtlich", "Rezidivfreiheit", ",", "Funktion", "der", "Extremitaet", "und", "subjektiver", "Zufriedenheit", "ueberprueft", ".", "Anhand", "dieser", "Kriterien", "fanden", "wir", "sehr", "gute", "Ergebnisse", "bei", "78", "%", "der", "Patienten", ".", "Bei", "Infekten", "nach", "primaerem", "Nagel", "war", "die", "Behandlung", "mit", "84", "%", "sehr", "guten", "Ergebnissen", "signifikant", "erfolgreicher", "als", "bei", "den", "Patienten", "mit", "multiplen", "Voreingriffen", ".", "Rezidivfreiheit", "liess", "sich", "in", "der", "Gruppe", "der", "primaeren", "Infekte", "bei", "allen", "Patienten", "erreichen", ",", "bei", "den", "sekundaer", "mit", "Nagel", "versorgen", "Patienten", "in", "62", "%", ".", "Eine", "primaer", "offene", "Fraktur", "verschlechterte", "die", "Erfolgsaussichten", "des", "Eingriffs", "nicht", ";", "82", "%", "der", "Patienten", "konnten", "ihren", "vorherigen", "Beruf", "wieder", "aufnehmen", "." ]

[ "umlsterm" ]

Pankreatitis is an umlsterm, Patienten is an umlsterm, Pankreatitis is an umlsterm, Therapieergebnisse is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Pankreasnekrosen is an umlsterm, Sonographie is an umlsterm, Computertomographie is an umlsterm, Patienten is an umlsterm, Infektion is an umlsterm, Pankreasnekrosen is an umlsterm, Komplikationen is an umlsterm, Pankreatitis is an umlsterm, Cholezystektomie is an umlsterm, Rezidivprophylaxe is an umlsterm

DerAnaesthesist.80470765.ger.abstr_task0

Sentence: Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden .

[ "Die", "akute", "Pankreatitis", "ist", "eine", "multietiologische", "Erkrankung", "mit", "klinisch", "ausgesprochen", "unterschiedlichen", "Verlaeufen", ".", "Waehrend", "die", "oedematoese", "Verlaufsform", "heute", "eine", "Letalitaet", "von", "weniger", "als", "1", "%", "aufweist", ",", "erliegen", "immer", "noch", "rund", "20", "%", "der", "Patienten", "mit", "einer", "nekrotisierenden", "Pankreatitis", "ihrer", "Erkrankung", ".", "Um", "die", "Therapieergebnisse", "weiter", "zu", "verbessern", ",", "sollte", "die", "Behandlung", "nach", "einem", "standardisierten", "Schema", "vorgenommen", "werden", ".", "Entscheidend", "ist", "hierbei", "die", "Unterscheidung", "zwischen", "oedematoeser", "und", "nekrotisierender", "Verlaufsform", ".", "Alle", "Patienten", "mit", "Zeichen", "fuer", "Pankreasnekrosen", "in", "der", "Sonographie", "und", "jene", "mit", "Organinsuffizienzen", "sollten", "eine", "abdominelle", "Computertomographie", "erhalten", ".", "Primaer", "werden", "alle", "Patienten", "konservativ", "behandelt", ".", "Hauptindikationen", "fuer", "die", "operative", "Intervention", "sind", "Zeichen", "fuer", "eine", "Infektion", "der", "Pankreasnekrosen", "und", "ein", "akutes", "Abomen", "aufgrund", "lokaler", "Komplikationen", "der", "akuten", "Pankreatitis", ".", "In", "Faellen", "biliaerer", "Genese", "sollte", "im", "freien", "Intervall", "eine", "elektive", "Cholezystektomie", "zur", "Rezidivprophylaxe", "vorgenommen", "werden", "." ]

[ "umlsterm" ]

Pankreatitis is an umlsterm, Patienten is an umlsterm, Pankreatitis is an umlsterm, Therapieergebnisse is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Pankreasnekrosen is an umlsterm, Sonographie is an umlsterm, Computertomographie is an umlsterm, Patienten is an umlsterm, Infektion is an umlsterm, Pankreasnekrosen is an umlsterm, Komplikationen is an umlsterm, Pankreatitis is an umlsterm, Cholezystektomie is an umlsterm, Rezidivprophylaxe is an umlsterm

DerAnaesthesist.80470765.ger.abstr_task1

Sentence: Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden . Instructions: please typing these entity words according to sentence: Pankreatitis, Patienten, Pankreatitis, Therapieergebnisse, Behandlung, Patienten, Pankreasnekrosen, Sonographie, Computertomographie, Patienten, Infektion, Pankreasnekrosen, Komplikationen, Pankreatitis, Cholezystektomie, Rezidivprophylaxe Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden .

[ "Die", "akute", "Pankreatitis", "ist", "eine", "multietiologische", "Erkrankung", "mit", "klinisch", "ausgesprochen", "unterschiedlichen", "Verlaeufen", ".", "Waehrend", "die", "oedematoese", "Verlaufsform", "heute", "eine", "Letalitaet", "von", "weniger", "als", "1", "%", "aufweist", ",", "erliegen", "immer", "noch", "rund", "20", "%", "der", "Patienten", "mit", "einer", "nekrotisierenden", "Pankreatitis", "ihrer", "Erkrankung", ".", "Um", "die", "Therapieergebnisse", "weiter", "zu", "verbessern", ",", "sollte", "die", "Behandlung", "nach", "einem", "standardisierten", "Schema", "vorgenommen", "werden", ".", "Entscheidend", "ist", "hierbei", "die", "Unterscheidung", "zwischen", "oedematoeser", "und", "nekrotisierender", "Verlaufsform", ".", "Alle", "Patienten", "mit", "Zeichen", "fuer", "Pankreasnekrosen", "in", "der", "Sonographie", "und", "jene", "mit", "Organinsuffizienzen", "sollten", "eine", "abdominelle", "Computertomographie", "erhalten", ".", "Primaer", "werden", "alle", "Patienten", "konservativ", "behandelt", ".", "Hauptindikationen", "fuer", "die", "operative", "Intervention", "sind", "Zeichen", "fuer", "eine", "Infektion", "der", "Pankreasnekrosen", "und", "ein", "akutes", "Abomen", "aufgrund", "lokaler", "Komplikationen", "der", "akuten", "Pankreatitis", ".", "In", "Faellen", "biliaerer", "Genese", "sollte", "im", "freien", "Intervall", "eine", "elektive", "Cholezystektomie", "zur", "Rezidivprophylaxe", "vorgenommen", "werden", "." ]

[ "umlsterm" ]

Pankreatitis, Patienten, Pankreatitis, Therapieergebnisse, Behandlung, Patienten, Pankreasnekrosen, Sonographie, Computertomographie, Patienten, Infektion, Pankreasnekrosen, Komplikationen, Pankreatitis, Cholezystektomie, Rezidivprophylaxe

DerAnaesthesist.80470765.ger.abstr_task2

Sentence: Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Die akute Pankreatitis ist eine multietiologische Erkrankung mit klinisch ausgesprochen unterschiedlichen Verlaeufen . Waehrend die oedematoese Verlaufsform heute eine Letalitaet von weniger als 1% aufweist , erliegen immer noch rund 20% der Patienten mit einer nekrotisierenden Pankreatitis ihrer Erkrankung . Um die Therapieergebnisse weiter zu verbessern , sollte die Behandlung nach einem standardisierten Schema vorgenommen werden . Entscheidend ist hierbei die Unterscheidung zwischen oedematoeser und nekrotisierender Verlaufsform . Alle Patienten mit Zeichen fuer Pankreasnekrosen in der Sonographie und jene mit Organinsuffizienzen sollten eine abdominelle Computertomographie erhalten . Primaer werden alle Patienten konservativ behandelt . Hauptindikationen fuer die operative Intervention sind Zeichen fuer eine Infektion der Pankreasnekrosen und ein akutes Abomen aufgrund lokaler Komplikationen der akuten Pankreatitis . In Faellen biliaerer Genese sollte im freien Intervall eine elektive Cholezystektomie zur Rezidivprophylaxe vorgenommen werden .

[ "Die", "akute", "Pankreatitis", "ist", "eine", "multietiologische", "Erkrankung", "mit", "klinisch", "ausgesprochen", "unterschiedlichen", "Verlaeufen", ".", "Waehrend", "die", "oedematoese", "Verlaufsform", "heute", "eine", "Letalitaet", "von", "weniger", "als", "1", "%", "aufweist", ",", "erliegen", "immer", "noch", "rund", "20", "%", "der", "Patienten", "mit", "einer", "nekrotisierenden", "Pankreatitis", "ihrer", "Erkrankung", ".", "Um", "die", "Therapieergebnisse", "weiter", "zu", "verbessern", ",", "sollte", "die", "Behandlung", "nach", "einem", "standardisierten", "Schema", "vorgenommen", "werden", ".", "Entscheidend", "ist", "hierbei", "die", "Unterscheidung", "zwischen", "oedematoeser", "und", "nekrotisierender", "Verlaufsform", ".", "Alle", "Patienten", "mit", "Zeichen", "fuer", "Pankreasnekrosen", "in", "der", "Sonographie", "und", "jene", "mit", "Organinsuffizienzen", "sollten", "eine", "abdominelle", "Computertomographie", "erhalten", ".", "Primaer", "werden", "alle", "Patienten", "konservativ", "behandelt", ".", "Hauptindikationen", "fuer", "die", "operative", "Intervention", "sind", "Zeichen", "fuer", "eine", "Infektion", "der", "Pankreasnekrosen", "und", "ein", "akutes", "Abomen", "aufgrund", "lokaler", "Komplikationen", "der", "akuten", "Pankreatitis", ".", "In", "Faellen", "biliaerer", "Genese", "sollte", "im", "freien", "Intervall", "eine", "elektive", "Cholezystektomie", "zur", "Rezidivprophylaxe", "vorgenommen", "werden", "." ]

[ "umlsterm" ]

Retrospective is an umlsterm, evaluation is an umlsterm, treatment is an umlsterm, carcinoma is an umlsterm

DerRadiologe.90390795.eng.abstr_task0

Sentence: Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma .

[ "Purpose", ":", "Retrospective", "evaluation", "of", "percutaneous", "interventional", "treatment", "of", "locally", "advanced", "cervical", "carcinoma", "." ]

[ "umlsterm" ]

Retrospective is an umlsterm, evaluation is an umlsterm, treatment is an umlsterm, carcinoma is an umlsterm

DerRadiologe.90390795.eng.abstr_task1

Sentence: Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma . Instructions: please typing these entity words according to sentence: Retrospective, evaluation, treatment, carcinoma Options: umlsterm

[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma .

[ "Purpose", ":", "Retrospective", "evaluation", "of", "percutaneous", "interventional", "treatment", "of", "locally", "advanced", "cervical", "carcinoma", "." ]

[ "umlsterm" ]

Retrospective, evaluation, treatment, carcinoma

DerRadiologe.90390795.eng.abstr_task2

Sentence: Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Purpose : Retrospective evaluation of percutaneous interventional treatment of locally advanced cervical carcinoma .

[ "Purpose", ":", "Retrospective", "evaluation", "of", "percutaneous", "interventional", "treatment", "of", "locally", "advanced", "cervical", "carcinoma", "." ]

[ "umlsterm" ]

2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose is a CHEMICAL, TNF - α is a GENE-Y, glucose is a CHEMICAL, 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose is a CHEMICAL, Glucose is a CHEMICAL, glucose is a CHEMICAL, insulin is a GENE-N, TNF - α is a GENE-Y, Vescalagin is a CHEMICAL, glucose is a CHEMICAL, insulin is a GENE-N, vescalagin is a CHEMICAL, insulin is a GENE-N

10578_task0

Sentence: Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]

Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes.

[ "Effect", "of", "water", "extracts", "from", "edible", "myrtaceae", "plants", "on", "uptake", "of", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "in", "TNF", "-", "α", "-", "treated", "FL83B", "mouse", "hepatocytes", ".", "\n", "This", "study", "investigated", "the", "glucose", "uptake", "activity", "of", "the", "water", "extracts", "from", "the", "leaves", "and", "fruit", "of", "edible", "Myrtaceae", "plants", ",", "including", "guava", "(", "Psidium", "guajava", "Linn", ".", ")", ",", "wax", "apples", "[", "Syzygium", "samarangense", "(", "Blume", ")", "Merr", ".", "and", "L.M.", "Perry", "]", ",", "Pu", "-", "Tau", "[", "Syzygium", "jambo", "(", "L.", ")", "Alston", "]", ",", "and", "Kan", "-", "Shi", "Pu", "-", "Tau", "(", "Syzygium", "cumini", "Linn", ".", ")", "in", "FL83B", "mouse", "hepatocytes", ".", "The", "fluorescent", "dye", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "was", "used", "to", "estimate", "the", "uptake", "ability", "of", "the", "cells", ".", "Glucose", "uptake", "test", "showed", "that", "pink", "wax", "apple", "fruit", "extract", "(", "PWFE", ")", "exhibits", "the", "highest", "glucose", "uptake", "activity", ",", "at", "an", "increment", "of", "21", "%", "in", "the", "insulin", "-", "resistant", "FL83B", "mouse", "hepatocytes", "as", "compared", "with", "the", "TNF", "-", "α", "-", "treated", "control", "group", ".", "Vescalagin", "was", "isolated", "using", "column", "chromatography", "of", "PWFE", ".", "This", "compound", ",", "at", "the", "concentration", "of", "6.25", " ", "µg", "/", "mL", ",", "exhibits", "the", "same", "glucose", "uptake", "improvement", "in", "insulin", "-", "resistant", "cells", "as", "PWFE", "at", "a", "100-µg", "/", "mL", "dose", ".", "We", "postulate", "that", "vescalagin", "is", "an", "active", "component", "in", "PWFE", "that", "may", "alleviate", "the", "insulin", "resistance", "in", "mouse", "hepatocytes", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose is a CHEMICAL, TNF - α is a GENE-Y, glucose is a CHEMICAL, 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose is a CHEMICAL, Glucose is a CHEMICAL, glucose is a CHEMICAL, insulin is a GENE-N, TNF - α is a GENE-Y, Vescalagin is a CHEMICAL, glucose is a CHEMICAL, insulin is a GENE-N, vescalagin is a CHEMICAL, insulin is a GENE-N

10578_task1

Sentence: Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes. Instructions: please typing these entity words according to sentence: 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, TNF - α, glucose, 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, Glucose, glucose, insulin, TNF - α, Vescalagin, glucose, insulin, vescalagin, insulin Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]

Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes.

[ "Effect", "of", "water", "extracts", "from", "edible", "myrtaceae", "plants", "on", "uptake", "of", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "in", "TNF", "-", "α", "-", "treated", "FL83B", "mouse", "hepatocytes", ".", "\n", "This", "study", "investigated", "the", "glucose", "uptake", "activity", "of", "the", "water", "extracts", "from", "the", "leaves", "and", "fruit", "of", "edible", "Myrtaceae", "plants", ",", "including", "guava", "(", "Psidium", "guajava", "Linn", ".", ")", ",", "wax", "apples", "[", "Syzygium", "samarangense", "(", "Blume", ")", "Merr", ".", "and", "L.M.", "Perry", "]", ",", "Pu", "-", "Tau", "[", "Syzygium", "jambo", "(", "L.", ")", "Alston", "]", ",", "and", "Kan", "-", "Shi", "Pu", "-", "Tau", "(", "Syzygium", "cumini", "Linn", ".", ")", "in", "FL83B", "mouse", "hepatocytes", ".", "The", "fluorescent", "dye", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "was", "used", "to", "estimate", "the", "uptake", "ability", "of", "the", "cells", ".", "Glucose", "uptake", "test", "showed", "that", "pink", "wax", "apple", "fruit", "extract", "(", "PWFE", ")", "exhibits", "the", "highest", "glucose", "uptake", "activity", ",", "at", "an", "increment", "of", "21", "%", "in", "the", "insulin", "-", "resistant", "FL83B", "mouse", "hepatocytes", "as", "compared", "with", "the", "TNF", "-", "α", "-", "treated", "control", "group", ".", "Vescalagin", "was", "isolated", "using", "column", "chromatography", "of", "PWFE", ".", "This", "compound", ",", "at", "the", "concentration", "of", "6.25", " ", "µg", "/", "mL", ",", "exhibits", "the", "same", "glucose", "uptake", "improvement", "in", "insulin", "-", "resistant", "cells", "as", "PWFE", "at", "a", "100-µg", "/", "mL", "dose", ".", "We", "postulate", "that", "vescalagin", "is", "an", "active", "component", "in", "PWFE", "that", "may", "alleviate", "the", "insulin", "resistance", "in", "mouse", "hepatocytes", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, TNF - α, glucose, 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose, Glucose, glucose, insulin, TNF - α, Vescalagin, glucose, insulin, vescalagin, insulin

10578_task2

Sentence: Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O" ]

Effect of water extracts from edible myrtaceae plants on uptake of 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose in TNF-α-treated FL83B mouse hepatocytes. This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu-Tau [Syzygium jambo (L.) Alston], and Kan-Shi Pu-Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin-resistant cells as PWFE at a 100-µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes.

[ "Effect", "of", "water", "extracts", "from", "edible", "myrtaceae", "plants", "on", "uptake", "of", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "in", "TNF", "-", "α", "-", "treated", "FL83B", "mouse", "hepatocytes", ".", "\n", "This", "study", "investigated", "the", "glucose", "uptake", "activity", "of", "the", "water", "extracts", "from", "the", "leaves", "and", "fruit", "of", "edible", "Myrtaceae", "plants", ",", "including", "guava", "(", "Psidium", "guajava", "Linn", ".", ")", ",", "wax", "apples", "[", "Syzygium", "samarangense", "(", "Blume", ")", "Merr", ".", "and", "L.M.", "Perry", "]", ",", "Pu", "-", "Tau", "[", "Syzygium", "jambo", "(", "L.", ")", "Alston", "]", ",", "and", "Kan", "-", "Shi", "Pu", "-", "Tau", "(", "Syzygium", "cumini", "Linn", ".", ")", "in", "FL83B", "mouse", "hepatocytes", ".", "The", "fluorescent", "dye", "2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose", "was", "used", "to", "estimate", "the", "uptake", "ability", "of", "the", "cells", ".", "Glucose", "uptake", "test", "showed", "that", "pink", "wax", "apple", "fruit", "extract", "(", "PWFE", ")", "exhibits", "the", "highest", "glucose", "uptake", "activity", ",", "at", "an", "increment", "of", "21", "%", "in", "the", "insulin", "-", "resistant", "FL83B", "mouse", "hepatocytes", "as", "compared", "with", "the", "TNF", "-", "α", "-", "treated", "control", "group", ".", "Vescalagin", "was", "isolated", "using", "column", "chromatography", "of", "PWFE", ".", "This", "compound", ",", "at", "the", "concentration", "of", "6.25", " ", "µg", "/", "mL", ",", "exhibits", "the", "same", "glucose", "uptake", "improvement", "in", "insulin", "-", "resistant", "cells", "as", "PWFE", "at", "a", "100-µg", "/", "mL", "dose", ".", "We", "postulate", "that", "vescalagin", "is", "an", "active", "component", "in", "PWFE", "that", "may", "alleviate", "the", "insulin", "resistance", "in", "mouse", "hepatocytes", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Cell specific expression is an other_name, human Bruton 's agammaglobulinemia tyrosine kinase gene is a DNA_domain_or_region, Btk is a protein_molecule, Sp1- is a protein_family_or_group, Spi-1 / PU.1-family members is a protein_family_or_group

18949_task0

Sentence: Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, protein_family_or_group, protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-protein_molecule", "O", "O", "O", "O", "B-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]

Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members.

[ "Cell", "specific", "expression", "of", "human", "Bruton", "'s", "agammaglobulinemia", "tyrosine", "kinase", "gene", "(", "Btk", ")", "is", "regulated", "by", "Sp1-", "and", "Spi-1", "/", "PU.1-family", "members", "." ]

[ "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "(AND protein_family_or_group protein_family_or_group)", "protein_family_or_group", "(AND cell_type cell_type)", "cell_type", "", "multi_cell", "body_part" ]

Cell specific expression is an other_name, human Bruton 's agammaglobulinemia tyrosine kinase gene is a DNA_domain_or_region, Btk is a protein_molecule, Sp1- is a protein_family_or_group, Spi-1 / PU.1-family members is a protein_family_or_group

18949_task1

Sentence: Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Instructions: please typing these entity words according to sentence: Cell specific expression, human Bruton 's agammaglobulinemia tyrosine kinase gene, Btk, Sp1-, Spi-1 / PU.1-family members Options: DNA_domain_or_region, protein_family_or_group, protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-protein_molecule", "O", "O", "O", "O", "B-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]

Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members.

[ "Cell", "specific", "expression", "of", "human", "Bruton", "'s", "agammaglobulinemia", "tyrosine", "kinase", "gene", "(", "Btk", ")", "is", "regulated", "by", "Sp1-", "and", "Spi-1", "/", "PU.1-family", "members", "." ]

[ "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "(AND protein_family_or_group protein_family_or_group)", "protein_family_or_group", "(AND cell_type cell_type)", "cell_type", "", "multi_cell", "body_part" ]

Cell specific expression, human Bruton 's agammaglobulinemia tyrosine kinase gene, Btk, Sp1-, Spi-1 / PU.1-family members

18949_task2

Sentence: Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "I-other_name", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-protein_molecule", "O", "O", "O", "O", "B-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O" ]

Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members.

[ "Cell", "specific", "expression", "of", "human", "Bruton", "'s", "agammaglobulinemia", "tyrosine", "kinase", "gene", "(", "Btk", ")", "is", "regulated", "by", "Sp1-", "and", "Spi-1", "/", "PU.1-family", "members", "." ]

[ "DNA_domain_or_region", "protein_molecule", "other_name", "cell_line", "(AND protein_family_or_group protein_family_or_group)", "protein_family_or_group", "(AND cell_type cell_type)", "cell_type", "", "multi_cell", "body_part" ]

histone H4 is a Protein, histone is a Protein, K5 is a Entity, K8 is a Entity, histone H4 is a Protein, histone H4 is a Protein, histone is a Protein

439_task0

Sentence: Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors.

[ "Real", "-", "time", "imaging", "of", "histone", "H4", "hyperacetylation", "in", "living", "cells", ".", "\n", "To", "visualize", "histone", "acetylation", "in", "living", "cells", ",", "we", "developed", "a", "genetically", "encoded", "fluorescent", "resonance", "energy", "transfer", "(", "FRET)-based", "indicator", ".", "Response", "of", "the", "indicator", "reflects", "changes", "in", "the", "acetylation", "state", "of", "both", "K5", "and", "K8", "in", "histone", "H4", ".", "Using", "this", "acetylation", "indicator", ",", "we", "were", "able", "to", "monitor", "the", "dynamic", "fluctuation", "of", "histone", "H4", "acetylation", "levels", "during", "mitosis", ",", "as", "well", "as", "acetylation", "changes", "in", "response", "to", "structurally", "distinct", "histone", "deacetylase", "inhibitors", ".", "\n" ]

[ "Protein", "Entity" ]

histone H4 is a Protein, histone is a Protein, K5 is a Entity, K8 is a Entity, histone H4 is a Protein, histone H4 is a Protein, histone is a Protein

439_task1

Sentence: Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors. Instructions: please typing these entity words according to sentence: histone H4, histone, K5, K8, histone H4, histone H4, histone Options: Entity, Protein

[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors.

[ "Real", "-", "time", "imaging", "of", "histone", "H4", "hyperacetylation", "in", "living", "cells", ".", "\n", "To", "visualize", "histone", "acetylation", "in", "living", "cells", ",", "we", "developed", "a", "genetically", "encoded", "fluorescent", "resonance", "energy", "transfer", "(", "FRET)-based", "indicator", ".", "Response", "of", "the", "indicator", "reflects", "changes", "in", "the", "acetylation", "state", "of", "both", "K5", "and", "K8", "in", "histone", "H4", ".", "Using", "this", "acetylation", "indicator", ",", "we", "were", "able", "to", "monitor", "the", "dynamic", "fluctuation", "of", "histone", "H4", "acetylation", "levels", "during", "mitosis", ",", "as", "well", "as", "acetylation", "changes", "in", "response", "to", "structurally", "distinct", "histone", "deacetylase", "inhibitors", ".", "\n" ]

[ "Protein", "Entity" ]

histone H4, histone, K5, K8, histone H4, histone H4, histone

439_task2

Sentence: Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Real-time imaging of histone H4 hyperacetylation in living cells. To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors.

[ "Real", "-", "time", "imaging", "of", "histone", "H4", "hyperacetylation", "in", "living", "cells", ".", "\n", "To", "visualize", "histone", "acetylation", "in", "living", "cells", ",", "we", "developed", "a", "genetically", "encoded", "fluorescent", "resonance", "energy", "transfer", "(", "FRET)-based", "indicator", ".", "Response", "of", "the", "indicator", "reflects", "changes", "in", "the", "acetylation", "state", "of", "both", "K5", "and", "K8", "in", "histone", "H4", ".", "Using", "this", "acetylation", "indicator", ",", "we", "were", "able", "to", "monitor", "the", "dynamic", "fluctuation", "of", "histone", "H4", "acetylation", "levels", "during", "mitosis", ",", "as", "well", "as", "acetylation", "changes", "in", "response", "to", "structurally", "distinct", "histone", "deacetylase", "inhibitors", ".", "\n" ]

[ "Protein", "Entity" ]

Surgery is an umlsterm, direct is an umlsterm, media is an umlsterm, cause is an umlsterm, Economic is an umlsterm, pressures is an umlsterm, resources is an umlsterm, medicine is an umlsterm, medicine is an umlsterm, patient is an umlsterm, conflict is an umlsterm, power is an umlsterm, media is an umlsterm, public relations is an umlsterm, surgery is an umlsterm, surgical is an umlsterm, competence is an umlsterm, communication is an umlsterm

DerChirurg.80691292.eng.abstr_task0

Sentence: Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication .

[ "Surgery", "and", "surgeons", "have", "a", "direct", "relationship", "to", "publicity", ".", "In", "the", "media", ",", "the", "entertainment", "aspect", "prevails", "over", "information", "(", "infotainment", ")", ",", "and", "scandal", "also", "dominates", "because", "of", "negative", "reports", ".", "The", "cause", "in", "many", "cases", "is", "a", "lack", "of", "information", ",", "which", "is", "always", "a", "problem", "when", "transmitting", "scientific", "information", "to", "the", "public", ".", "Economic", "pressures", "and", "diminished", "resources", "as", "well", "as", "a", "simultaneous", "increase", "in", "the", "demands", "made", "on", "medicine", "make", "it", "mandatory", "that", "surgeons", "communicate", "properly", ".", "They", "are", "being", "degraded", "more", "and", "more", "to", "\"", "delivering", "\"", "medicine", ",", "and", "the", "relationship", "between", "the", "surgeon", "and", "his", "patient", "has", "been", "reduced", "to", "a", "collision", "of", "greediness", "on", "both", "sides", ".", "We", "are", "in", "continuous", "conflict", "with", "the", "power", "of", "the", "media", "and", "are", "being", "challenged", "to", "improve", "our", "public", "relations", ".", "The", "public", "image", "of", "surgery", "today", "is", "determined", "by", "surgical", "performance", "and", "competence", "in", "communication", "." ]

[ "umlsterm" ]

Surgery is an umlsterm, direct is an umlsterm, media is an umlsterm, cause is an umlsterm, Economic is an umlsterm, pressures is an umlsterm, resources is an umlsterm, medicine is an umlsterm, medicine is an umlsterm, patient is an umlsterm, conflict is an umlsterm, power is an umlsterm, media is an umlsterm, public relations is an umlsterm, surgery is an umlsterm, surgical is an umlsterm, competence is an umlsterm, communication is an umlsterm

DerChirurg.80691292.eng.abstr_task1

Sentence: Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication . Instructions: please typing these entity words according to sentence: Surgery, direct, media, cause, Economic, pressures, resources, medicine, medicine, patient, conflict, power, media, public relations, surgery, surgical, competence, communication Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication .

[ "Surgery", "and", "surgeons", "have", "a", "direct", "relationship", "to", "publicity", ".", "In", "the", "media", ",", "the", "entertainment", "aspect", "prevails", "over", "information", "(", "infotainment", ")", ",", "and", "scandal", "also", "dominates", "because", "of", "negative", "reports", ".", "The", "cause", "in", "many", "cases", "is", "a", "lack", "of", "information", ",", "which", "is", "always", "a", "problem", "when", "transmitting", "scientific", "information", "to", "the", "public", ".", "Economic", "pressures", "and", "diminished", "resources", "as", "well", "as", "a", "simultaneous", "increase", "in", "the", "demands", "made", "on", "medicine", "make", "it", "mandatory", "that", "surgeons", "communicate", "properly", ".", "They", "are", "being", "degraded", "more", "and", "more", "to", "\"", "delivering", "\"", "medicine", ",", "and", "the", "relationship", "between", "the", "surgeon", "and", "his", "patient", "has", "been", "reduced", "to", "a", "collision", "of", "greediness", "on", "both", "sides", ".", "We", "are", "in", "continuous", "conflict", "with", "the", "power", "of", "the", "media", "and", "are", "being", "challenged", "to", "improve", "our", "public", "relations", ".", "The", "public", "image", "of", "surgery", "today", "is", "determined", "by", "surgical", "performance", "and", "competence", "in", "communication", "." ]

[ "umlsterm" ]

Surgery, direct, media, cause, Economic, pressures, resources, medicine, medicine, patient, conflict, power, media, public relations, surgery, surgical, competence, communication

DerChirurg.80691292.eng.abstr_task2

Sentence: Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Surgery and surgeons have a direct relationship to publicity . In the media , the entertainment aspect prevails over information ( infotainment ) , and scandal also dominates because of negative reports . The cause in many cases is a lack of information , which is always a problem when transmitting scientific information to the public . Economic pressures and diminished resources as well as a simultaneous increase in the demands made on medicine make it mandatory that surgeons communicate properly . They are being degraded more and more to " delivering " medicine , and the relationship between the surgeon and his patient has been reduced to a collision of greediness on both sides . We are in continuous conflict with the power of the media and are being challenged to improve our public relations . The public image of surgery today is determined by surgical performance and competence in communication .

[ "Surgery", "and", "surgeons", "have", "a", "direct", "relationship", "to", "publicity", ".", "In", "the", "media", ",", "the", "entertainment", "aspect", "prevails", "over", "information", "(", "infotainment", ")", ",", "and", "scandal", "also", "dominates", "because", "of", "negative", "reports", ".", "The", "cause", "in", "many", "cases", "is", "a", "lack", "of", "information", ",", "which", "is", "always", "a", "problem", "when", "transmitting", "scientific", "information", "to", "the", "public", ".", "Economic", "pressures", "and", "diminished", "resources", "as", "well", "as", "a", "simultaneous", "increase", "in", "the", "demands", "made", "on", "medicine", "make", "it", "mandatory", "that", "surgeons", "communicate", "properly", ".", "They", "are", "being", "degraded", "more", "and", "more", "to", "\"", "delivering", "\"", "medicine", ",", "and", "the", "relationship", "between", "the", "surgeon", "and", "his", "patient", "has", "been", "reduced", "to", "a", "collision", "of", "greediness", "on", "both", "sides", ".", "We", "are", "in", "continuous", "conflict", "with", "the", "power", "of", "the", "media", "and", "are", "being", "challenged", "to", "improve", "our", "public", "relations", ".", "The", "public", "image", "of", "surgery", "today", "is", "determined", "by", "surgical", "performance", "and", "competence", "in", "communication", "." ]

[ "umlsterm" ]

thermotherapy is an umlsterm, method is an umlsterm, treatment is an umlsterm, liver tumors is an umlsterm, treatment is an umlsterm, use is an umlsterm, development is an umlsterm, test is an umlsterm, tip is an umlsterm, test is an umlsterm, connective - tissue is an umlsterm, organization is an umlsterm, period is an umlsterm, laser is an umlsterm, test is an umlsterm, liver is an umlsterm, perfusion is an umlsterm, animal is an umlsterm, blood is an umlsterm, perfusion is an umlsterm, laser is an umlsterm, thermotherapy is an umlsterm

DerChirurg.80690930.eng.abstr_task0

Sentence: Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled .

[ "Laser", "-", "induced", "thermotherapy", "is", "an", "in", "situ", "ablation", "method", "for", "the", "local", "treatment", "of", "liver", "tumors", ".", "The", "basic", "prerequisite", "for", "induction", "of", "adequate", "treatment", "volumes", "for", "clinical", "use", "was", "the", "development", "of", "a", "thermostable", "application", "system", ".", "In", "an", "ex", "vivo", "test", "series", ",", "the", "specially", "developed", "application", "system", "(", "diffuser", "tip", ")", "with", "5760", "J", "had", "a", "higher", "thermic", "loading", "capacity", "than", "the", "Ringmode", "applicator", "with", "4200", "J", ",", "thus", "enabling", "the", "induction", "of", "significantly", "larger", "lesions", "with", "a", "volume", "of", "7.6", "cm3", ".", "The", "results", "of", "a", "further", "in", "vivo", "test", "series", "demonstrated", "that", "the", "lesions", "were", "subject", "to", "a", "four", "-", "phase", "connective", "-", "tissue", "organization", "within", "a", "6-month", "period", ".", "Furthermore", ",", "the", "same", "laser", "energy", "(", "4200", "J", ")", "was", "associated", "with", "a", "significantly", "lower", "lesion", "volume", "of", "2.5", "cm3", "in", "the", "in", "vivo", "than", "in", "the", "ex", "vivo", "test", "series", ".", "The", "influence", "of", "liver", "perfusion", "on", "the", "inducible", "lesion", "volume", "was", "examined", "in", "a", "further", "animal", "experimental", "study", ".", "By", "temporarily", "interrupting", "hepatic", "blood", "perfusion", "(", "Pringle", "'s", "maneuver", ")", "during", "laser", "application", ",", "the", "effective", "volume", "could", "be", "increased", "to", "50.3", "cm3", "(", "P", "0.01", ")", "using", "an", "optical", "beam", "splitter", ".", "These", "results", "show", "that", "the", "technical", "prerequisites", "for", "reliable", "clinical", "application", "of", "laser", "-", "induced", "thermotherapy", "have", "been", "fulfilled", "." ]

[ "umlsterm" ]

thermotherapy is an umlsterm, method is an umlsterm, treatment is an umlsterm, liver tumors is an umlsterm, treatment is an umlsterm, use is an umlsterm, development is an umlsterm, test is an umlsterm, tip is an umlsterm, test is an umlsterm, connective - tissue is an umlsterm, organization is an umlsterm, period is an umlsterm, laser is an umlsterm, test is an umlsterm, liver is an umlsterm, perfusion is an umlsterm, animal is an umlsterm, blood is an umlsterm, perfusion is an umlsterm, laser is an umlsterm, thermotherapy is an umlsterm

DerChirurg.80690930.eng.abstr_task1

Sentence: Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled . Instructions: please typing these entity words according to sentence: thermotherapy, method, treatment, liver tumors, treatment, use, development, test, tip, test, connective - tissue, organization, period, laser, test, liver, perfusion, animal, blood, perfusion, laser, thermotherapy Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled .

[ "Laser", "-", "induced", "thermotherapy", "is", "an", "in", "situ", "ablation", "method", "for", "the", "local", "treatment", "of", "liver", "tumors", ".", "The", "basic", "prerequisite", "for", "induction", "of", "adequate", "treatment", "volumes", "for", "clinical", "use", "was", "the", "development", "of", "a", "thermostable", "application", "system", ".", "In", "an", "ex", "vivo", "test", "series", ",", "the", "specially", "developed", "application", "system", "(", "diffuser", "tip", ")", "with", "5760", "J", "had", "a", "higher", "thermic", "loading", "capacity", "than", "the", "Ringmode", "applicator", "with", "4200", "J", ",", "thus", "enabling", "the", "induction", "of", "significantly", "larger", "lesions", "with", "a", "volume", "of", "7.6", "cm3", ".", "The", "results", "of", "a", "further", "in", "vivo", "test", "series", "demonstrated", "that", "the", "lesions", "were", "subject", "to", "a", "four", "-", "phase", "connective", "-", "tissue", "organization", "within", "a", "6-month", "period", ".", "Furthermore", ",", "the", "same", "laser", "energy", "(", "4200", "J", ")", "was", "associated", "with", "a", "significantly", "lower", "lesion", "volume", "of", "2.5", "cm3", "in", "the", "in", "vivo", "than", "in", "the", "ex", "vivo", "test", "series", ".", "The", "influence", "of", "liver", "perfusion", "on", "the", "inducible", "lesion", "volume", "was", "examined", "in", "a", "further", "animal", "experimental", "study", ".", "By", "temporarily", "interrupting", "hepatic", "blood", "perfusion", "(", "Pringle", "'s", "maneuver", ")", "during", "laser", "application", ",", "the", "effective", "volume", "could", "be", "increased", "to", "50.3", "cm3", "(", "P", "0.01", ")", "using", "an", "optical", "beam", "splitter", ".", "These", "results", "show", "that", "the", "technical", "prerequisites", "for", "reliable", "clinical", "application", "of", "laser", "-", "induced", "thermotherapy", "have", "been", "fulfilled", "." ]

[ "umlsterm" ]

thermotherapy, method, treatment, liver tumors, treatment, use, development, test, tip, test, connective - tissue, organization, period, laser, test, liver, perfusion, animal, blood, perfusion, laser, thermotherapy

DerChirurg.80690930.eng.abstr_task2

Sentence: Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Laser-induced thermotherapy is an in situ ablation method for the local treatment of liver tumors . The basic prerequisite for induction of adequate treatment volumes for clinical use was the development of a thermostable application system . In an ex vivo test series , the specially developed application system ( diffuser tip ) with 5760 J had a higher thermic loading capacity than the Ringmode applicator with 4200 J , thus enabling the induction of significantly larger lesions with a volume of 7.6 cm3. The results of a further in vivo test series demonstrated that the lesions were subject to a four-phase connective-tissue organization within a 6-month period . Furthermore , the same laser energy ( 4200 J ) was associated with a significantly lower lesion volume of 2.5 cm3 in the in vivo than in the ex vivo test series . The influence of liver perfusion on the inducible lesion volume was examined in a further animal experimental study . By temporarily interrupting hepatic blood perfusion ( Pringle's maneuver ) during laser application , the effective volume could be increased to 50.3 cm3 ( P 0.01 ) using an optical beam splitter . These results show that the technical prerequisites for reliable clinical application of laser-induced thermotherapy have been fulfilled .

[ "Laser", "-", "induced", "thermotherapy", "is", "an", "in", "situ", "ablation", "method", "for", "the", "local", "treatment", "of", "liver", "tumors", ".", "The", "basic", "prerequisite", "for", "induction", "of", "adequate", "treatment", "volumes", "for", "clinical", "use", "was", "the", "development", "of", "a", "thermostable", "application", "system", ".", "In", "an", "ex", "vivo", "test", "series", ",", "the", "specially", "developed", "application", "system", "(", "diffuser", "tip", ")", "with", "5760", "J", "had", "a", "higher", "thermic", "loading", "capacity", "than", "the", "Ringmode", "applicator", "with", "4200", "J", ",", "thus", "enabling", "the", "induction", "of", "significantly", "larger", "lesions", "with", "a", "volume", "of", "7.6", "cm3", ".", "The", "results", "of", "a", "further", "in", "vivo", "test", "series", "demonstrated", "that", "the", "lesions", "were", "subject", "to", "a", "four", "-", "phase", "connective", "-", "tissue", "organization", "within", "a", "6-month", "period", ".", "Furthermore", ",", "the", "same", "laser", "energy", "(", "4200", "J", ")", "was", "associated", "with", "a", "significantly", "lower", "lesion", "volume", "of", "2.5", "cm3", "in", "the", "in", "vivo", "than", "in", "the", "ex", "vivo", "test", "series", ".", "The", "influence", "of", "liver", "perfusion", "on", "the", "inducible", "lesion", "volume", "was", "examined", "in", "a", "further", "animal", "experimental", "study", ".", "By", "temporarily", "interrupting", "hepatic", "blood", "perfusion", "(", "Pringle", "'s", "maneuver", ")", "during", "laser", "application", ",", "the", "effective", "volume", "could", "be", "increased", "to", "50.3", "cm3", "(", "P", "0.01", ")", "using", "an", "optical", "beam", "splitter", ".", "These", "results", "show", "that", "the", "technical", "prerequisites", "for", "reliable", "clinical", "application", "of", "laser", "-", "induced", "thermotherapy", "have", "been", "fulfilled", "." ]

[ "umlsterm" ]

Naevus is an umlsterm, Naevus is an umlsterm, Naevus is an umlsterm, Fallberichte is an umlsterm, Japan is an umlsterm, Naevus flammeus is an umlsterm, Ruecken is an umlsterm, Arm is an umlsterm, Naevus is an umlsterm

DerHautarzt.70480653.ger.abstr_task0

Sentence: Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies .

[ "Kombiniert", "auftretende", "Naevi", "flammei", "mit", "dermalen", "melanozytaeren", "Naevi", "wie", "Mongolenfleck", ",", "Naevus", "fuscocoeruleus", ",", "Naevus", "spilus", "und", "fakultativ", "kombiniert", "mit", "Naevus", "anaemicus", "werden", "klinisch", "-", "morphologisch", "nach", "den", "Erstbeschreibern", "Ota", "et", "al", ".", "als", "Phacomatosis", "pigmentovascularis", "bezeichnet", ".", "Zu", "dieser", "Gruppe", "gehoeren", "4", "Typen", ",", "die", "entweder", "ausschliesslich", "als", "kutane", "Naevi", "oder", "gemeinsam", "mit", "extrakutanen", "Organdefekten", ",", "hauptsaechlich", "in", "Form", "des", "Klippel", "-", "Trenaunay-", "und", "des", "Sturge", "-", "Weber", "-", "Krabbe", "-", "Syndroms", ",", "auftreten", "koennen", ".", "Die", "meisten", "Fallberichte", "ueber", "Phacomatosis", "pigmentovascularis", "stammen", "aus", "Japan", ".", "Wir", "berichten", "ueber", "eine", "30", "Jahre", "alte", "Patientin", ",", "die", "neben", "einem", "Naevus", "flammeus", "am", "Ruecken", "und", "rechten", "Arm", "einen", "dorsalen", "Naevus", "fuscocoeruleus", "aufwies", "." ]

[ "umlsterm" ]

Naevus is an umlsterm, Naevus is an umlsterm, Naevus is an umlsterm, Fallberichte is an umlsterm, Japan is an umlsterm, Naevus flammeus is an umlsterm, Ruecken is an umlsterm, Arm is an umlsterm, Naevus is an umlsterm

DerHautarzt.70480653.ger.abstr_task1

Sentence: Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies . Instructions: please typing these entity words according to sentence: Naevus, Naevus, Naevus, Fallberichte, Japan, Naevus flammeus, Ruecken, Arm, Naevus Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies .

[ "Kombiniert", "auftretende", "Naevi", "flammei", "mit", "dermalen", "melanozytaeren", "Naevi", "wie", "Mongolenfleck", ",", "Naevus", "fuscocoeruleus", ",", "Naevus", "spilus", "und", "fakultativ", "kombiniert", "mit", "Naevus", "anaemicus", "werden", "klinisch", "-", "morphologisch", "nach", "den", "Erstbeschreibern", "Ota", "et", "al", ".", "als", "Phacomatosis", "pigmentovascularis", "bezeichnet", ".", "Zu", "dieser", "Gruppe", "gehoeren", "4", "Typen", ",", "die", "entweder", "ausschliesslich", "als", "kutane", "Naevi", "oder", "gemeinsam", "mit", "extrakutanen", "Organdefekten", ",", "hauptsaechlich", "in", "Form", "des", "Klippel", "-", "Trenaunay-", "und", "des", "Sturge", "-", "Weber", "-", "Krabbe", "-", "Syndroms", ",", "auftreten", "koennen", ".", "Die", "meisten", "Fallberichte", "ueber", "Phacomatosis", "pigmentovascularis", "stammen", "aus", "Japan", ".", "Wir", "berichten", "ueber", "eine", "30", "Jahre", "alte", "Patientin", ",", "die", "neben", "einem", "Naevus", "flammeus", "am", "Ruecken", "und", "rechten", "Arm", "einen", "dorsalen", "Naevus", "fuscocoeruleus", "aufwies", "." ]

[ "umlsterm" ]

Naevus, Naevus, Naevus, Fallberichte, Japan, Naevus flammeus, Ruecken, Arm, Naevus

DerHautarzt.70480653.ger.abstr_task2

Sentence: Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Kombiniert auftretende Naevi flammei mit dermalen melanozytaeren Naevi wie Mongolenfleck , Naevus fuscocoeruleus , Naevus spilus und fakultativ kombiniert mit Naevus anaemicus werden klinisch-morphologisch nach den Erstbeschreibern Ota et al. als Phacomatosis pigmentovascularis bezeichnet . Zu dieser Gruppe gehoeren 4 Typen , die entweder ausschliesslich als kutane Naevi oder gemeinsam mit extrakutanen Organdefekten , hauptsaechlich in Form des Klippel-Trenaunay- und des Sturge-Weber-Krabbe-Syndroms , auftreten koennen . Die meisten Fallberichte ueber Phacomatosis pigmentovascularis stammen aus Japan . Wir berichten ueber eine 30 Jahre alte Patientin , die neben einem Naevus flammeus am Ruecken und rechten Arm einen dorsalen Naevus fuscocoeruleus aufwies .

[ "Kombiniert", "auftretende", "Naevi", "flammei", "mit", "dermalen", "melanozytaeren", "Naevi", "wie", "Mongolenfleck", ",", "Naevus", "fuscocoeruleus", ",", "Naevus", "spilus", "und", "fakultativ", "kombiniert", "mit", "Naevus", "anaemicus", "werden", "klinisch", "-", "morphologisch", "nach", "den", "Erstbeschreibern", "Ota", "et", "al", ".", "als", "Phacomatosis", "pigmentovascularis", "bezeichnet", ".", "Zu", "dieser", "Gruppe", "gehoeren", "4", "Typen", ",", "die", "entweder", "ausschliesslich", "als", "kutane", "Naevi", "oder", "gemeinsam", "mit", "extrakutanen", "Organdefekten", ",", "hauptsaechlich", "in", "Form", "des", "Klippel", "-", "Trenaunay-", "und", "des", "Sturge", "-", "Weber", "-", "Krabbe", "-", "Syndroms", ",", "auftreten", "koennen", ".", "Die", "meisten", "Fallberichte", "ueber", "Phacomatosis", "pigmentovascularis", "stammen", "aus", "Japan", ".", "Wir", "berichten", "ueber", "eine", "30", "Jahre", "alte", "Patientin", ",", "die", "neben", "einem", "Naevus", "flammeus", "am", "Ruecken", "und", "rechten", "Arm", "einen", "dorsalen", "Naevus", "fuscocoeruleus", "aufwies", "." ]

[ "umlsterm" ]

Healthy is a Condition, women is a Person, ages is a Person, 18 to 39yo is a Value, BMI is a Measurement, < 30 is a Value, Regular menstrual cycles is a Condition, duration is a Measurement, between 24 - 35 days is a Value, progesterone level is a Measurement, 5ng / mL or greater is a Value, non - hormonal form of contraception is a Procedure, sterilization ( tubal ligation , Essure ) , copper IUD ( intrauterine device ) , barrier methods or abstinence is a Scope

NCT03120728_inc_task0

Sentence: Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Procedure, Scope, Measurement

[ "B-Condition", "O", "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O" ]

Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish

[ "Healthy", ",", "women", "ages", "18", "to", "39yo", "with", "BMI", "<", "30", "\n", "Regular", "menstrual", "cycles", "with", "duration", "between", "24", "-", "35", "days", "\n", "Completion", "of", "screening", "visit", "where", "ovulation", "will", "be", "assessed", "with", "blood", "draw", "for", "progesterone", "level", "(", "must", "be", "5ng", "/", "mL", "or", "greater", ")", "\n", "Not", "seeking", "pregnancy", "during", "the", "study", "period", "\n", "Use", "of", "a", "non", "-", "hormonal", "form", "of", "contraception", ",", "such", "as", ":", "sterilization", "(", "tubal", "ligation", ",", "Essure", ")", ",", "copper", "IUD", "(", "intrauterine", "device", ")", ",", "barrier", "methods", "or", "abstinence", "\n", "Must", "speak", "English", "or", "Spanish", "\n" ]

[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Observation", "Person" ]

Healthy is a Condition, women is a Person, ages is a Person, 18 to 39yo is a Value, BMI is a Measurement, < 30 is a Value, Regular menstrual cycles is a Condition, duration is a Measurement, between 24 - 35 days is a Value, progesterone level is a Measurement, 5ng / mL or greater is a Value, non - hormonal form of contraception is a Procedure, sterilization ( tubal ligation , Essure ) , copper IUD ( intrauterine device ) , barrier methods or abstinence is a Scope

NCT03120728_inc_task1

Sentence: Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish Instructions: please typing these entity words according to sentence: Healthy, women, ages, 18 to 39yo, BMI, < 30, Regular menstrual cycles, duration, between 24 - 35 days, progesterone level, 5ng / mL or greater, non - hormonal form of contraception, sterilization ( tubal ligation , Essure ) , copper IUD ( intrauterine device ) , barrier methods or abstinence Options: Condition, Value, Person, Procedure, Scope, Measurement

[ "B-Condition", "O", "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O" ]

Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish

[ "Healthy", ",", "women", "ages", "18", "to", "39yo", "with", "BMI", "<", "30", "\n", "Regular", "menstrual", "cycles", "with", "duration", "between", "24", "-", "35", "days", "\n", "Completion", "of", "screening", "visit", "where", "ovulation", "will", "be", "assessed", "with", "blood", "draw", "for", "progesterone", "level", "(", "must", "be", "5ng", "/", "mL", "or", "greater", ")", "\n", "Not", "seeking", "pregnancy", "during", "the", "study", "period", "\n", "Use", "of", "a", "non", "-", "hormonal", "form", "of", "contraception", ",", "such", "as", ":", "sterilization", "(", "tubal", "ligation", ",", "Essure", ")", ",", "copper", "IUD", "(", "intrauterine", "device", ")", ",", "barrier", "methods", "or", "abstinence", "\n", "Must", "speak", "English", "or", "Spanish", "\n" ]

[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Observation", "Person" ]

Healthy, women, ages, 18 to 39yo, BMI, < 30, Regular menstrual cycles, duration, between 24 - 35 days, progesterone level, 5ng / mL or greater, non - hormonal form of contraception, sterilization ( tubal ligation , Essure ) , copper IUD ( intrauterine device ) , barrier methods or abstinence

NCT03120728_inc_task2

Sentence: Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish Instructions: please extract entity words from the input sentence

[ "B-Condition", "O", "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O" ]

Healthy, women ages 18 to 39yo with BMI <30 Regular menstrual cycles with duration between 24-35 days Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) Not seeking pregnancy during the study period Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence Must speak English or Spanish

[ "Healthy", ",", "women", "ages", "18", "to", "39yo", "with", "BMI", "<", "30", "\n", "Regular", "menstrual", "cycles", "with", "duration", "between", "24", "-", "35", "days", "\n", "Completion", "of", "screening", "visit", "where", "ovulation", "will", "be", "assessed", "with", "blood", "draw", "for", "progesterone", "level", "(", "must", "be", "5ng", "/", "mL", "or", "greater", ")", "\n", "Not", "seeking", "pregnancy", "during", "the", "study", "period", "\n", "Use", "of", "a", "non", "-", "hormonal", "form", "of", "contraception", ",", "such", "as", ":", "sterilization", "(", "tubal", "ligation", ",", "Essure", ")", ",", "copper", "IUD", "(", "intrauterine", "device", ")", ",", "barrier", "methods", "or", "abstinence", "\n", "Must", "speak", "English", "or", "Spanish", "\n" ]

[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Observation", "Person" ]

INVIRASE is a BRAND, FORTOVASE is a BRAND, FORTOVASE is a BRAND, INVIRASE is a BRAND, ritonavir is a DRUG, ritonavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, INVIRASE is a BRAND, Ritonavir is a DRUG, Antiarrhythmics is a GROUP, Amiodarone is a DRUG, bepridil is a DRUG, flecainide is a DRUG, propafenone is a DRUG, quinidine is a DRUG, Antihistamines is a DRUG, astemizole is a DRUG, terfenadine is a DRUG, Ergot Derivatives is a GROUP, Dihydroergotamine is a DRUG, ergonovine is a DRUG, ergotamine is a DRUG, methylergonovine is a DRUG, ergot is a GROUP, Antimycobacterial Agents is a GROUP, rifampin is a DRUG, saquinavir is a DRUG, antiretroviral is a GROUP, saquinavir is a DRUG, saquinavir is a DRUG, FORTOVASE is a BRAND, protease inhibitor is a GROUP, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, FORTOVASE is a BRAND, ritonavir is a DRUG, cisapride is a DRUG, INVIRASE is a BRAND, HMG - CoA Reductase Inhibitors is a GROUP, lovastatin is a DRUG, simvastatin is a DRUG, Sedatives is a GROUP, Hypnotics is a GROUP, triazolam is a DRUG, midazolam is a DRUG, calcium channel blockers is a GROUP, dapsone is a DRUG, disopyramide is a DRUG, quinine is a DRUG, amiodarone is a DRUG, quinidine is a DRUG, warfarin is a DRUG, tacrolimus is a DRUG, cyclosporine is a DRUG, ergot derivatives is a GROUP, pimozide is a DRUG, carbamazepine is a DRUG, fentanyl is a DRUG, alfentanyl is a DRUG, alprazolam is a DRUG, triazolam is a DRUG, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, ritonavir is a DRUG, phenobarbital is a DRUG, phenytoin is a DRUG, dexamethasone is a DRUG, carbamazepine is a DRUG, saquinavir is a DRUG

Saquinavir_ddi_task0

Sentence: DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG, BRAND

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]

DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.

[ "DRUG", "INTERACTIONS", "Several", "drug", "interaction", "studies", "have", "been", "completed", "with", "both", "INVIRASE", "and", "FORTOVASE", ".", "Observations", "from", "drug", "interaction", "studies", "with", "FORTOVASE", "may", "not", "be", "predictive", "for", "INVIRASE", ".", "Because", "ritonavir", "is", "coadministered", ",", "prescribers", "should", "also", "refer", "to", "the", "prescribing", "information", "for", "ritonavir", "regarding", "drug", "interactions", "associated", "with", "this", "agent", ".", "The", "metabolism", "of", "saquinavir", "is", "mediated", "by", "cytochrome", "P450", ",", "with", "the", "specific", "isoenzyme", "CYP3A4", "responsible", "for", "90", "%", "of", "the", "hepatic", "metabolism", ".", "Additionally", ",", "saquinavir", "is", "a", "substrate", "for", "P", "-", "Glycoprotein", "(", "Pgp", ")", ".", "Therefore", ",", "drugs", "that", "affect", "CYP3A4", "and", "/", "or", "Pgp", ",", "may", "modify", "the", "pharmacokinetics", "of", "saquinavir", ".", "Similarly", ",", "saquinavir", "might", "also", "modify", "the", "pharmacokinetics", "of", "other", "drugs", "that", "are", "substrates", "for", "CYP3A4", "or", "Pgp", ".", "Drugs", "that", "are", "contraindicated", "specifically", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "adverse", "events", "are", "listed", "CONTRAINDICATIONS", ".", "Additional", "drugs", "that", "are", "not", "recommended", "for", "coadministration", "with", "INVIRASE", "and", "ritonavir", "are", "included", "below", ".", "These", "recommendations", "are", "based", "on", "either", "drug", "interaction", "studies", "or", "predicted", "interactions", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "events", "or", "loss", "of", "efficacy", ".", "With", "some", "agents", ",", "the", "metabolism", "may", "be", "induced", ",", "resulting", "in", "decreased", "concentrations", ".", "Drugs", "That", "Should", "Not", "Be", "Coadministered", "With", "INVIRASE", "/", "Ritonavir", "Drug", "Class", ":", "Drug", "Name", "Clinical", "Comment", "Antiarrhythmics", ":", "Amiodarone", ",", "bepridil", ",", "flecainide", ",", "propafenone", ",", "quinidine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", ".", "Antihistamines", ":", "astemizole", "*", ",", "terfenadine", "*", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "cardiac", "arrhythmias", ".", "Ergot", "Derivatives", ":", "Dihydroergotamine", ",", "ergonovine", ",", "ergotamine", ",", "methylergonovine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "life", "-", "threatening", "reactions", "such", "as", "acute", "ergot", "toxicity", "characterized", "by", "peripheral", "vasospasm", "and", "ischemia", "of", "the", "extremities", "and", "other", "tissues", ".", "Antimycobacterial", "Agents", ":", "rifampin", "CONTRAINDICATED", "since", "the", "coadministration", "of", "this", "product", "with", "saquinavir", "in", "an", "antiretroviral", "regimen", "reduces", "the", "plasma", "concentrations", "of", "saquinavir", ".", "Garlic", "Capsules", "Garlic", "capsules", "should", "not", "be", "used", "while", "taking", "saquinavir", "(", "FORTOVASE", ")", "as", "the", "sole", "protease", "inhibitor", "due", "to", "the", "risk", "of", "decreased", "saquinavir", "plasma", "concentrations", ".", "No", "data", "are", "available", "for", "the", "coadministration", "of", "INVIRASE", "/", "ritonavir", "or", "FORTOVASE", "/", "ritonavir", "and", "garlic", "capsules", ".", "GI", "Motility", "Agent", ":", "cisapride", "*", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "cardiac", "arrhythmias", ".", "Herbal", "Products", ":", "St", ".", "John", "s", "wort", "(", "hypericum", "perforatum", ")", "WARNING", "coadministration", "may", "lead", "to", "loss", "of", "virologic", "response", "and", "possible", "resistance", "to", "INVIRASE", "or", "to", "the", "class", "of", "protease", "inhibitors", ".", "HMG", "-", "CoA", "Reductase", "Inhibitors", ":", "lovastatin", ",", "simvastatin", "WARNING", "potential", "for", "serious", "reactions", "such", "as", "risk", "of", "myopathy", "including", "rhabdomyolysis", ".", "Sedatives", "/", "Hypnotics", ":", "triazolam", ",", "midazolam", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "prolonged", "or", "increased", "sedation", "or", "respiratory", "depression", ".", "*", "No", "longer", "marketed", "in", "the", "US", ".", "Drugs", "That", "Are", "Mainly", "Metabolized", "by", "CYP3A4", "Although", "specific", "studies", "have", "not", "been", "performed", ",", "coadministration", "with", "drugs", "that", "are", "mainly", "metabolized", "by", "CYP3A4", "(", "eg", ",", "calcium", "channel", "blockers", ",", "dapsone", ",", "disopyramide", ",", "quinine", ",", "amiodarone", ",", "quinidine", ",", "warfarin", ",", "tacrolimus", ",", "cyclosporine", ",", "ergot", "derivatives", ",", "pimozide", ",", "carbamazepine", ",", "fentanyl", ",", "alfentanyl", ",", "alprazolam", ",", "and", "triazolam", ")", "may", "have", "elevated", "plasma", "concentrations", "when", "coadministered", "with", "saquinavir", ";", "therefore", ",", "these", "combinations", "should", "be", "used", "with", "caution", ".", "Since", "INVIRASE", "is", "coadministered", "with", "ritonavir", ",", "the", "ritonavir", "label", "should", "be", "reviewed", "for", "additional", "drugs", "that", "should", "not", "be", "coadministered", ".", "Inducers", "of", "CYP3A4", "Coadministration", "with", "compounds", "that", "are", "potent", "inducers", "of", "CYP3A4", "(", "eg", ",", "phenobarbital", ",", "phenytoin", ",", "dexamethasone", ",", "carbamazepine", ")", "may", "result", "in", "decreased", "plasma", "levels", "of", "saquinavir", "." ]

[ "GROUP", "DRUG", "BRAND" ]

INVIRASE is a BRAND, FORTOVASE is a BRAND, FORTOVASE is a BRAND, INVIRASE is a BRAND, ritonavir is a DRUG, ritonavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, INVIRASE is a BRAND, Ritonavir is a DRUG, Antiarrhythmics is a GROUP, Amiodarone is a DRUG, bepridil is a DRUG, flecainide is a DRUG, propafenone is a DRUG, quinidine is a DRUG, Antihistamines is a DRUG, astemizole is a DRUG, terfenadine is a DRUG, Ergot Derivatives is a GROUP, Dihydroergotamine is a DRUG, ergonovine is a DRUG, ergotamine is a DRUG, methylergonovine is a DRUG, ergot is a GROUP, Antimycobacterial Agents is a GROUP, rifampin is a DRUG, saquinavir is a DRUG, antiretroviral is a GROUP, saquinavir is a DRUG, saquinavir is a DRUG, FORTOVASE is a BRAND, protease inhibitor is a GROUP, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, FORTOVASE is a BRAND, ritonavir is a DRUG, cisapride is a DRUG, INVIRASE is a BRAND, HMG - CoA Reductase Inhibitors is a GROUP, lovastatin is a DRUG, simvastatin is a DRUG, Sedatives is a GROUP, Hypnotics is a GROUP, triazolam is a DRUG, midazolam is a DRUG, calcium channel blockers is a GROUP, dapsone is a DRUG, disopyramide is a DRUG, quinine is a DRUG, amiodarone is a DRUG, quinidine is a DRUG, warfarin is a DRUG, tacrolimus is a DRUG, cyclosporine is a DRUG, ergot derivatives is a GROUP, pimozide is a DRUG, carbamazepine is a DRUG, fentanyl is a DRUG, alfentanyl is a DRUG, alprazolam is a DRUG, triazolam is a DRUG, saquinavir is a DRUG, INVIRASE is a BRAND, ritonavir is a DRUG, ritonavir is a DRUG, phenobarbital is a DRUG, phenytoin is a DRUG, dexamethasone is a DRUG, carbamazepine is a DRUG, saquinavir is a DRUG

Saquinavir_ddi_task1

Sentence: DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir. Instructions: please typing these entity words according to sentence: INVIRASE, FORTOVASE, FORTOVASE, INVIRASE, ritonavir, ritonavir, saquinavir, saquinavir, saquinavir, saquinavir, INVIRASE, ritonavir, INVIRASE, Ritonavir, Antiarrhythmics, Amiodarone, bepridil, flecainide, propafenone, quinidine, Antihistamines, astemizole, terfenadine, Ergot Derivatives, Dihydroergotamine, ergonovine, ergotamine, methylergonovine, ergot, Antimycobacterial Agents, rifampin, saquinavir, antiretroviral, saquinavir, saquinavir, FORTOVASE, protease inhibitor, saquinavir, INVIRASE, ritonavir, FORTOVASE, ritonavir, cisapride, INVIRASE, HMG - CoA Reductase Inhibitors, lovastatin, simvastatin, Sedatives, Hypnotics, triazolam, midazolam, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, triazolam, saquinavir, INVIRASE, ritonavir, ritonavir, phenobarbital, phenytoin, dexamethasone, carbamazepine, saquinavir Options: GROUP, DRUG, BRAND

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]

DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.

[ "DRUG", "INTERACTIONS", "Several", "drug", "interaction", "studies", "have", "been", "completed", "with", "both", "INVIRASE", "and", "FORTOVASE", ".", "Observations", "from", "drug", "interaction", "studies", "with", "FORTOVASE", "may", "not", "be", "predictive", "for", "INVIRASE", ".", "Because", "ritonavir", "is", "coadministered", ",", "prescribers", "should", "also", "refer", "to", "the", "prescribing", "information", "for", "ritonavir", "regarding", "drug", "interactions", "associated", "with", "this", "agent", ".", "The", "metabolism", "of", "saquinavir", "is", "mediated", "by", "cytochrome", "P450", ",", "with", "the", "specific", "isoenzyme", "CYP3A4", "responsible", "for", "90", "%", "of", "the", "hepatic", "metabolism", ".", "Additionally", ",", "saquinavir", "is", "a", "substrate", "for", "P", "-", "Glycoprotein", "(", "Pgp", ")", ".", "Therefore", ",", "drugs", "that", "affect", "CYP3A4", "and", "/", "or", "Pgp", ",", "may", "modify", "the", "pharmacokinetics", "of", "saquinavir", ".", "Similarly", ",", "saquinavir", "might", "also", "modify", "the", "pharmacokinetics", "of", "other", "drugs", "that", "are", "substrates", "for", "CYP3A4", "or", "Pgp", ".", "Drugs", "that", "are", "contraindicated", "specifically", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "adverse", "events", "are", "listed", "CONTRAINDICATIONS", ".", "Additional", "drugs", "that", "are", "not", "recommended", "for", "coadministration", "with", "INVIRASE", "and", "ritonavir", "are", "included", "below", ".", "These", "recommendations", "are", "based", "on", "either", "drug", "interaction", "studies", "or", "predicted", "interactions", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "events", "or", "loss", "of", "efficacy", ".", "With", "some", "agents", ",", "the", "metabolism", "may", "be", "induced", ",", "resulting", "in", "decreased", "concentrations", ".", "Drugs", "That", "Should", "Not", "Be", "Coadministered", "With", "INVIRASE", "/", "Ritonavir", "Drug", "Class", ":", "Drug", "Name", "Clinical", "Comment", "Antiarrhythmics", ":", "Amiodarone", ",", "bepridil", ",", "flecainide", ",", "propafenone", ",", "quinidine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", ".", "Antihistamines", ":", "astemizole", "*", ",", "terfenadine", "*", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "cardiac", "arrhythmias", ".", "Ergot", "Derivatives", ":", "Dihydroergotamine", ",", "ergonovine", ",", "ergotamine", ",", "methylergonovine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "life", "-", "threatening", "reactions", "such", "as", "acute", "ergot", "toxicity", "characterized", "by", "peripheral", "vasospasm", "and", "ischemia", "of", "the", "extremities", "and", "other", "tissues", ".", "Antimycobacterial", "Agents", ":", "rifampin", "CONTRAINDICATED", "since", "the", "coadministration", "of", "this", "product", "with", "saquinavir", "in", "an", "antiretroviral", "regimen", "reduces", "the", "plasma", "concentrations", "of", "saquinavir", ".", "Garlic", "Capsules", "Garlic", "capsules", "should", "not", "be", "used", "while", "taking", "saquinavir", "(", "FORTOVASE", ")", "as", "the", "sole", "protease", "inhibitor", "due", "to", "the", "risk", "of", "decreased", "saquinavir", "plasma", "concentrations", ".", "No", "data", "are", "available", "for", "the", "coadministration", "of", "INVIRASE", "/", "ritonavir", "or", "FORTOVASE", "/", "ritonavir", "and", "garlic", "capsules", ".", "GI", "Motility", "Agent", ":", "cisapride", "*", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "cardiac", "arrhythmias", ".", "Herbal", "Products", ":", "St", ".", "John", "s", "wort", "(", "hypericum", "perforatum", ")", "WARNING", "coadministration", "may", "lead", "to", "loss", "of", "virologic", "response", "and", "possible", "resistance", "to", "INVIRASE", "or", "to", "the", "class", "of", "protease", "inhibitors", ".", "HMG", "-", "CoA", "Reductase", "Inhibitors", ":", "lovastatin", ",", "simvastatin", "WARNING", "potential", "for", "serious", "reactions", "such", "as", "risk", "of", "myopathy", "including", "rhabdomyolysis", ".", "Sedatives", "/", "Hypnotics", ":", "triazolam", ",", "midazolam", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "prolonged", "or", "increased", "sedation", "or", "respiratory", "depression", ".", "*", "No", "longer", "marketed", "in", "the", "US", ".", "Drugs", "That", "Are", "Mainly", "Metabolized", "by", "CYP3A4", "Although", "specific", "studies", "have", "not", "been", "performed", ",", "coadministration", "with", "drugs", "that", "are", "mainly", "metabolized", "by", "CYP3A4", "(", "eg", ",", "calcium", "channel", "blockers", ",", "dapsone", ",", "disopyramide", ",", "quinine", ",", "amiodarone", ",", "quinidine", ",", "warfarin", ",", "tacrolimus", ",", "cyclosporine", ",", "ergot", "derivatives", ",", "pimozide", ",", "carbamazepine", ",", "fentanyl", ",", "alfentanyl", ",", "alprazolam", ",", "and", "triazolam", ")", "may", "have", "elevated", "plasma", "concentrations", "when", "coadministered", "with", "saquinavir", ";", "therefore", ",", "these", "combinations", "should", "be", "used", "with", "caution", ".", "Since", "INVIRASE", "is", "coadministered", "with", "ritonavir", ",", "the", "ritonavir", "label", "should", "be", "reviewed", "for", "additional", "drugs", "that", "should", "not", "be", "coadministered", ".", "Inducers", "of", "CYP3A4", "Coadministration", "with", "compounds", "that", "are", "potent", "inducers", "of", "CYP3A4", "(", "eg", ",", "phenobarbital", ",", "phenytoin", ",", "dexamethasone", ",", "carbamazepine", ")", "may", "result", "in", "decreased", "plasma", "levels", "of", "saquinavir", "." ]

[ "GROUP", "DRUG", "BRAND" ]

INVIRASE, FORTOVASE, FORTOVASE, INVIRASE, ritonavir, ritonavir, saquinavir, saquinavir, saquinavir, saquinavir, INVIRASE, ritonavir, INVIRASE, Ritonavir, Antiarrhythmics, Amiodarone, bepridil, flecainide, propafenone, quinidine, Antihistamines, astemizole, terfenadine, Ergot Derivatives, Dihydroergotamine, ergonovine, ergotamine, methylergonovine, ergot, Antimycobacterial Agents, rifampin, saquinavir, antiretroviral, saquinavir, saquinavir, FORTOVASE, protease inhibitor, saquinavir, INVIRASE, ritonavir, FORTOVASE, ritonavir, cisapride, INVIRASE, HMG - CoA Reductase Inhibitors, lovastatin, simvastatin, Sedatives, Hypnotics, triazolam, midazolam, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, triazolam, saquinavir, INVIRASE, ritonavir, ritonavir, phenobarbital, phenytoin, dexamethasone, carbamazepine, saquinavir

Saquinavir_ddi_task2

Sentence: DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]

DRUG INTERACTIONS Several drug interaction studies have been completed with both INVIRASE and FORTOVASE. Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE. Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent. The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp. Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS. Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy. With some agents, the metabolism may be induced, resulting in decreased concentrations. Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir Drug Class: Drug Name Clinical Comment Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions. Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias. Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir. Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations. No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules. GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors. HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis. Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. * No longer marketed in the US. Drugs That Are Mainly Metabolized by CYP3A4 Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered. Inducers of CYP3A4 Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.

[ "DRUG", "INTERACTIONS", "Several", "drug", "interaction", "studies", "have", "been", "completed", "with", "both", "INVIRASE", "and", "FORTOVASE", ".", "Observations", "from", "drug", "interaction", "studies", "with", "FORTOVASE", "may", "not", "be", "predictive", "for", "INVIRASE", ".", "Because", "ritonavir", "is", "coadministered", ",", "prescribers", "should", "also", "refer", "to", "the", "prescribing", "information", "for", "ritonavir", "regarding", "drug", "interactions", "associated", "with", "this", "agent", ".", "The", "metabolism", "of", "saquinavir", "is", "mediated", "by", "cytochrome", "P450", ",", "with", "the", "specific", "isoenzyme", "CYP3A4", "responsible", "for", "90", "%", "of", "the", "hepatic", "metabolism", ".", "Additionally", ",", "saquinavir", "is", "a", "substrate", "for", "P", "-", "Glycoprotein", "(", "Pgp", ")", ".", "Therefore", ",", "drugs", "that", "affect", "CYP3A4", "and", "/", "or", "Pgp", ",", "may", "modify", "the", "pharmacokinetics", "of", "saquinavir", ".", "Similarly", ",", "saquinavir", "might", "also", "modify", "the", "pharmacokinetics", "of", "other", "drugs", "that", "are", "substrates", "for", "CYP3A4", "or", "Pgp", ".", "Drugs", "that", "are", "contraindicated", "specifically", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "adverse", "events", "are", "listed", "CONTRAINDICATIONS", ".", "Additional", "drugs", "that", "are", "not", "recommended", "for", "coadministration", "with", "INVIRASE", "and", "ritonavir", "are", "included", "below", ".", "These", "recommendations", "are", "based", "on", "either", "drug", "interaction", "studies", "or", "predicted", "interactions", "due", "to", "the", "expected", "magnitude", "of", "interaction", "and", "potential", "for", "serious", "events", "or", "loss", "of", "efficacy", ".", "With", "some", "agents", ",", "the", "metabolism", "may", "be", "induced", ",", "resulting", "in", "decreased", "concentrations", ".", "Drugs", "That", "Should", "Not", "Be", "Coadministered", "With", "INVIRASE", "/", "Ritonavir", "Drug", "Class", ":", "Drug", "Name", "Clinical", "Comment", "Antiarrhythmics", ":", "Amiodarone", ",", "bepridil", ",", "flecainide", ",", "propafenone", ",", "quinidine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", ".", "Antihistamines", ":", "astemizole", "*", ",", "terfenadine", "*", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "cardiac", "arrhythmias", ".", "Ergot", "Derivatives", ":", "Dihydroergotamine", ",", "ergonovine", ",", "ergotamine", ",", "methylergonovine", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "life", "-", "threatening", "reactions", "such", "as", "acute", "ergot", "toxicity", "characterized", "by", "peripheral", "vasospasm", "and", "ischemia", "of", "the", "extremities", "and", "other", "tissues", ".", "Antimycobacterial", "Agents", ":", "rifampin", "CONTRAINDICATED", "since", "the", "coadministration", "of", "this", "product", "with", "saquinavir", "in", "an", "antiretroviral", "regimen", "reduces", "the", "plasma", "concentrations", "of", "saquinavir", ".", "Garlic", "Capsules", "Garlic", "capsules", "should", "not", "be", "used", "while", "taking", "saquinavir", "(", "FORTOVASE", ")", "as", "the", "sole", "protease", "inhibitor", "due", "to", "the", "risk", "of", "decreased", "saquinavir", "plasma", "concentrations", ".", "No", "data", "are", "available", "for", "the", "coadministration", "of", "INVIRASE", "/", "ritonavir", "or", "FORTOVASE", "/", "ritonavir", "and", "garlic", "capsules", ".", "GI", "Motility", "Agent", ":", "cisapride", "*", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "cardiac", "arrhythmias", ".", "Herbal", "Products", ":", "St", ".", "John", "s", "wort", "(", "hypericum", "perforatum", ")", "WARNING", "coadministration", "may", "lead", "to", "loss", "of", "virologic", "response", "and", "possible", "resistance", "to", "INVIRASE", "or", "to", "the", "class", "of", "protease", "inhibitors", ".", "HMG", "-", "CoA", "Reductase", "Inhibitors", ":", "lovastatin", ",", "simvastatin", "WARNING", "potential", "for", "serious", "reactions", "such", "as", "risk", "of", "myopathy", "including", "rhabdomyolysis", ".", "Sedatives", "/", "Hypnotics", ":", "triazolam", ",", "midazolam", "CONTRAINDICATED", "due", "to", "potential", "for", "serious", "and", "/", "or", "life", "-", "threatening", "reactions", "such", "as", "prolonged", "or", "increased", "sedation", "or", "respiratory", "depression", ".", "*", "No", "longer", "marketed", "in", "the", "US", ".", "Drugs", "That", "Are", "Mainly", "Metabolized", "by", "CYP3A4", "Although", "specific", "studies", "have", "not", "been", "performed", ",", "coadministration", "with", "drugs", "that", "are", "mainly", "metabolized", "by", "CYP3A4", "(", "eg", ",", "calcium", "channel", "blockers", ",", "dapsone", ",", "disopyramide", ",", "quinine", ",", "amiodarone", ",", "quinidine", ",", "warfarin", ",", "tacrolimus", ",", "cyclosporine", ",", "ergot", "derivatives", ",", "pimozide", ",", "carbamazepine", ",", "fentanyl", ",", "alfentanyl", ",", "alprazolam", ",", "and", "triazolam", ")", "may", "have", "elevated", "plasma", "concentrations", "when", "coadministered", "with", "saquinavir", ";", "therefore", ",", "these", "combinations", "should", "be", "used", "with", "caution", ".", "Since", "INVIRASE", "is", "coadministered", "with", "ritonavir", ",", "the", "ritonavir", "label", "should", "be", "reviewed", "for", "additional", "drugs", "that", "should", "not", "be", "coadministered", ".", "Inducers", "of", "CYP3A4", "Coadministration", "with", "compounds", "that", "are", "potent", "inducers", "of", "CYP3A4", "(", "eg", ",", "phenobarbital", ",", "phenytoin", ",", "dexamethasone", ",", "carbamazepine", ")", "may", "result", "in", "decreased", "plasma", "levels", "of", "saquinavir", "." ]

[ "GROUP", "DRUG", "BRAND" ]

APC is a protein, β - Catenin is a protein-family, β - Catenin is a protein-family, Wingless ( Wnt ) signal transduction pathway is a process

1.0alpha7.train.1303_task0

Sentence: In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: process, protein-family, protein

[ "O", "O", "O", "O", "O", "B-protein", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "B-process", "I-process", "I-process", "I-process", "I-process", "I-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999).

[ "In", "particular", ",", "binding", "of", "APC", "to", "β", "-", "Catenin", "(", "Rubinfeld", "et", "al", ".", "1993", ")", "is", "thought", "to", "regulate", "the", "activity", "of", "β", "-", "Catenin", "in", "the", "evolutionary", "conserved", "Wingless", "(", "Wnt", ")", "signal", "transduction", "pathway", "(", "for", "review", ",", "see", "Polakis", "1997", ";", "Wodarz", "and", "Nusse", "1998", ";", "Peifer", "1999", ")", "." ]

[ "process", "protein-family", "protein" ]

APC is a protein, β - Catenin is a protein-family, β - Catenin is a protein-family, Wingless ( Wnt ) signal transduction pathway is a process

1.0alpha7.train.1303_task1

Sentence: In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999). Instructions: please typing these entity words according to sentence: APC, β - Catenin, β - Catenin, Wingless ( Wnt ) signal transduction pathway Options: process, protein-family, protein

[ "O", "O", "O", "O", "O", "B-protein", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "B-process", "I-process", "I-process", "I-process", "I-process", "I-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999).

[ "In", "particular", ",", "binding", "of", "APC", "to", "β", "-", "Catenin", "(", "Rubinfeld", "et", "al", ".", "1993", ")", "is", "thought", "to", "regulate", "the", "activity", "of", "β", "-", "Catenin", "in", "the", "evolutionary", "conserved", "Wingless", "(", "Wnt", ")", "signal", "transduction", "pathway", "(", "for", "review", ",", "see", "Polakis", "1997", ";", "Wodarz", "and", "Nusse", "1998", ";", "Peifer", "1999", ")", "." ]

[ "process", "protein-family", "protein" ]

APC, β - Catenin, β - Catenin, Wingless ( Wnt ) signal transduction pathway

1.0alpha7.train.1303_task2

Sentence: In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-protein", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "B-process", "I-process", "I-process", "I-process", "I-process", "I-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In particular, binding of APC to β-Catenin (Rubinfeld et al. 1993) is thought to regulate the activity of β-Catenin in the evolutionary conserved Wingless (Wnt) signal transduction pathway (for review, see Polakis 1997; Wodarz and Nusse 1998; Peifer 1999).

[ "In", "particular", ",", "binding", "of", "APC", "to", "β", "-", "Catenin", "(", "Rubinfeld", "et", "al", ".", "1993", ")", "is", "thought", "to", "regulate", "the", "activity", "of", "β", "-", "Catenin", "in", "the", "evolutionary", "conserved", "Wingless", "(", "Wnt", ")", "signal", "transduction", "pathway", "(", "for", "review", ",", "see", "Polakis", "1997", ";", "Wodarz", "and", "Nusse", "1998", ";", "Peifer", "1999", ")", "." ]

[ "process", "protein-family", "protein" ]

lorglumide is a CHEMICAL, cholecystokinin is a GENE-Y, 5-(dipentylamino)-5-oxo - pentanoic acid is a CHEMICAL, cholecystokinin is a GENE-Y, CCK is a GENE-Y, D , L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo - pen tanoic acid is a CHEMICAL, lorglumide is a CHEMICAL, CR 1409 is a CHEMICAL, CCK receptors is a GENE-N, CCK is a GENE-Y, CCK is a GENE-Y, amylase is a GENE-N, lorglumide is a CHEMICAL, CCK-8 is a GENE-N, ceruletide is a CHEMICAL, caerulein is a CHEMICAL, CCK-8 is a GENE-Y, Lorglumide is a CHEMICAL, CCK is a GENE-Y, lorglumide is a CHEMICAL, CCK is a GENE-Y

24137_task0

Sentence: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O" ]

Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected.

[ "Pharmacological", "properties", "of", "lorglumide", "as", "a", "member", "of", "a", "new", "class", "of", "cholecystokinin", "antagonists", ".", "\n", "Derivatives", "of", "5-(dipentylamino)-5-oxo", "-", "pentanoic", "acid", "are", "a", "new", "class", "of", "non", "-", "peptide", "cholecystokinin", "(", "CCK", ")", "antagonists", ".", "The", "most", "potent", "compound", ",", "D", ",", "L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo", "-", "pen", "tanoic", "acid", "(", "lorglumide", ",", "CR", "1409", ")", ",", "has", "a", "great", "affinity", "for", "the", "pancreatic", "CCK", "receptors", "and", "is", "a", "competitive", ",", "specific", "and", "potent", "CCK", "antagonist", "on", "the", "smooth", "muscles", "of", "the", "gall", "bladder", "and", "ileum", "of", "the", "guinea", "pig", "and", "on", "the", "CCK", "-", "induced", "amylase", "secretion", "of", "isolated", "pancreatic", "acini", ".", "In", "vivo", "lorglumide", "antagonizes", "the", "contraction", "of", "the", "gall", "bladder", "of", "the", "guinea", "pig", "and", "of", "the", "dog", "provoked", "by", "i.v", ".", "CCK-8", "or", "ceruletide", "(", "caerulein", ")", ".", "It", "antagonizes", "the", "satiety", "effect", "of", "CCK-8", "in", "the", "rat", "and", "is", "protective", "against", "ceruletide-", ",", "taurocholate-", "and", "diet", "-", "induced", "pancreatitis", ".", "Lorglumide", "is", "therefore", "a", "useful", "pharmacological", "tool", "to", "study", "the", "functions", "of", "CCK", ".", "For", "its", "pharmacological", "properties", ",", "its", "relatively", "low", "toxicity", "and", "because", "it", "is", "active", "also", "after", "oral", "administration", ",", "lorglumide", "is", "a", "candidate", "for", "diagnostic", "or", "therapeutic", "use", "in", "man", "when", "an", "involvement", "of", "CCK", "is", "suspected", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

lorglumide is a CHEMICAL, cholecystokinin is a GENE-Y, 5-(dipentylamino)-5-oxo - pentanoic acid is a CHEMICAL, cholecystokinin is a GENE-Y, CCK is a GENE-Y, D , L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo - pen tanoic acid is a CHEMICAL, lorglumide is a CHEMICAL, CR 1409 is a CHEMICAL, CCK receptors is a GENE-N, CCK is a GENE-Y, CCK is a GENE-Y, amylase is a GENE-N, lorglumide is a CHEMICAL, CCK-8 is a GENE-N, ceruletide is a CHEMICAL, caerulein is a CHEMICAL, CCK-8 is a GENE-Y, Lorglumide is a CHEMICAL, CCK is a GENE-Y, lorglumide is a CHEMICAL, CCK is a GENE-Y

24137_task1

Sentence: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected. Instructions: please typing these entity words according to sentence: lorglumide, cholecystokinin, 5-(dipentylamino)-5-oxo - pentanoic acid, cholecystokinin, CCK, D , L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo - pen tanoic acid, lorglumide, CR 1409, CCK receptors, CCK, CCK, amylase, lorglumide, CCK-8, ceruletide, caerulein, CCK-8, Lorglumide, CCK, lorglumide, CCK Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O" ]

Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected.

[ "Pharmacological", "properties", "of", "lorglumide", "as", "a", "member", "of", "a", "new", "class", "of", "cholecystokinin", "antagonists", ".", "\n", "Derivatives", "of", "5-(dipentylamino)-5-oxo", "-", "pentanoic", "acid", "are", "a", "new", "class", "of", "non", "-", "peptide", "cholecystokinin", "(", "CCK", ")", "antagonists", ".", "The", "most", "potent", "compound", ",", "D", ",", "L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo", "-", "pen", "tanoic", "acid", "(", "lorglumide", ",", "CR", "1409", ")", ",", "has", "a", "great", "affinity", "for", "the", "pancreatic", "CCK", "receptors", "and", "is", "a", "competitive", ",", "specific", "and", "potent", "CCK", "antagonist", "on", "the", "smooth", "muscles", "of", "the", "gall", "bladder", "and", "ileum", "of", "the", "guinea", "pig", "and", "on", "the", "CCK", "-", "induced", "amylase", "secretion", "of", "isolated", "pancreatic", "acini", ".", "In", "vivo", "lorglumide", "antagonizes", "the", "contraction", "of", "the", "gall", "bladder", "of", "the", "guinea", "pig", "and", "of", "the", "dog", "provoked", "by", "i.v", ".", "CCK-8", "or", "ceruletide", "(", "caerulein", ")", ".", "It", "antagonizes", "the", "satiety", "effect", "of", "CCK-8", "in", "the", "rat", "and", "is", "protective", "against", "ceruletide-", ",", "taurocholate-", "and", "diet", "-", "induced", "pancreatitis", ".", "Lorglumide", "is", "therefore", "a", "useful", "pharmacological", "tool", "to", "study", "the", "functions", "of", "CCK", ".", "For", "its", "pharmacological", "properties", ",", "its", "relatively", "low", "toxicity", "and", "because", "it", "is", "active", "also", "after", "oral", "administration", ",", "lorglumide", "is", "a", "candidate", "for", "diagnostic", "or", "therapeutic", "use", "in", "man", "when", "an", "involvement", "of", "CCK", "is", "suspected", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

lorglumide, cholecystokinin, 5-(dipentylamino)-5-oxo - pentanoic acid, cholecystokinin, CCK, D , L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo - pen tanoic acid, lorglumide, CR 1409, CCK receptors, CCK, CCK, amylase, lorglumide, CCK-8, ceruletide, caerulein, CCK-8, Lorglumide, CCK, lorglumide, CCK

24137_task2

Sentence: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O" ]

Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini. In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein). It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis. Lorglumide is therefore a useful pharmacological tool to study the functions of CCK. For its pharmacological properties, its relatively low toxicity and because it is active also after oral administration, lorglumide is a candidate for diagnostic or therapeutic use in man when an involvement of CCK is suspected.

[ "Pharmacological", "properties", "of", "lorglumide", "as", "a", "member", "of", "a", "new", "class", "of", "cholecystokinin", "antagonists", ".", "\n", "Derivatives", "of", "5-(dipentylamino)-5-oxo", "-", "pentanoic", "acid", "are", "a", "new", "class", "of", "non", "-", "peptide", "cholecystokinin", "(", "CCK", ")", "antagonists", ".", "The", "most", "potent", "compound", ",", "D", ",", "L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo", "-", "pen", "tanoic", "acid", "(", "lorglumide", ",", "CR", "1409", ")", ",", "has", "a", "great", "affinity", "for", "the", "pancreatic", "CCK", "receptors", "and", "is", "a", "competitive", ",", "specific", "and", "potent", "CCK", "antagonist", "on", "the", "smooth", "muscles", "of", "the", "gall", "bladder", "and", "ileum", "of", "the", "guinea", "pig", "and", "on", "the", "CCK", "-", "induced", "amylase", "secretion", "of", "isolated", "pancreatic", "acini", ".", "In", "vivo", "lorglumide", "antagonizes", "the", "contraction", "of", "the", "gall", "bladder", "of", "the", "guinea", "pig", "and", "of", "the", "dog", "provoked", "by", "i.v", ".", "CCK-8", "or", "ceruletide", "(", "caerulein", ")", ".", "It", "antagonizes", "the", "satiety", "effect", "of", "CCK-8", "in", "the", "rat", "and", "is", "protective", "against", "ceruletide-", ",", "taurocholate-", "and", "diet", "-", "induced", "pancreatitis", ".", "Lorglumide", "is", "therefore", "a", "useful", "pharmacological", "tool", "to", "study", "the", "functions", "of", "CCK", ".", "For", "its", "pharmacological", "properties", ",", "its", "relatively", "low", "toxicity", "and", "because", "it", "is", "active", "also", "after", "oral", "administration", ",", "lorglumide", "is", "a", "candidate", "for", "diagnostic", "or", "therapeutic", "use", "in", "man", "when", "an", "involvement", "of", "CCK", "is", "suspected", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

vascular endothelial growth factor receptors is a Gene_or_gene_product, tumor is a Pathological_formation, Vascular endothelial growth factor is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, neuroblastoma is a Pathological_formation, Tumor biopsy specimens is a Multi-tissue_structure, serum is a Organism_substance, neuroblastoma is a Pathological_formation, patients is a Organism, adrenal biopsy sections is a Multi-tissue_structure, sera is a Organism_substance, children is a Organism, Biopsy specimens is a Multi-tissue_structure, serum is a Organism_substance, VEGF - A(165 ) is a Gene_or_gene_product, B is a Gene_or_gene_product, C is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, neuroblastoma is a Pathological_formation, tissues is a Tissue, VEGF - B is a Gene_or_gene_product, C is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, tissue lysates is a Organism_substance, VEGF - A is a Gene_or_gene_product, Serum is a Organism_substance, VEGF is a Gene_or_gene_product, VEGF - A(165 ) is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, KDR is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, stage III neuroblastoma is a Pathological_formation, VEGF - A(165 ) is a Gene_or_gene_product, serum is a Organism_substance, VEGF is a Gene_or_gene_product

100_task0

Sentence: Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Gene_or_gene_product, Pathological_formation, Organism, Multi-tissue_structure, Organism_substance

[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "O", "B-Pathological_formation", "B-Organism", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma.

[ "Upregulation", "of", "vascular", "endothelial", "growth", "factor", "receptors", "is", "associated", "with", "advanced", "neuroblastoma", ".", "\n\n", "BACKGROUND", ":", "Angiogenesis", "is", "essential", "for", "tumor", "growth", "and", "relies", "on", "the", "production", "of", "angiogenic", "factors", ".", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "is", "a", "major", "regulator", "of", "angiogenesis", "that", "binds", "to", "tyrosine", "kinase", "receptors", "Flt-1", "and", "KDR", ".", "The", "interaction", "of", "VEGF", "and", "its", "receptors", "at", "gene", "and", "protein", "levels", "in", "neuroblastoma", "remains", "widely", "unknown", ".", "METHODS", ":", "Tumor", "biopsy", "specimens", "and", "serum", "were", "obtained", "from", "37", "neuroblastoma", "patients", ";", "adrenal", "biopsy", "sections", "and", "sera", "of", "7", "normal", "children", "served", "as", "controls", ".", "Biopsy", "specimens", "were", "examined", "by", "real", "-", "time", "reverse", "transcription", "polymerase", "chain", "reaction", "(", "RT", "-", "PCR", ")", "and", "Western", "blotting", ";", "serum", "was", "analyzed", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "VEGF", "-", "A(165", ")", ",", "B", ",", "C", ",", "Flt-1", ",", "and", "KDR", "were", "analyzed", ".", "RESULTS", ":", "VEGF", "isoforms", "and", "its", "receptors", "'", "mRNA", "were", "expressed", "in", "neuroblastoma", "and", "control", "tissues", ".", "Whereas", "the", "ligands", "were", "increased", "in", "stages", "III", "and", "IV", ",", "the", "receptors", "were", "upregulated", "in", "stage", "III", "only", ".", "At", "protein", "level", ",", "VEGF", "-", "B", "and", "C", ",", "Flt-1", ",", "and", "KDR", "were", "not", "detectable", "in", "tissue", "lysates", ",", "whereas", "VEGF", "-", "A", "was", "increased", "in", "stages", "III", "and", "IV", ".", "Serum", "VEGF", "protein", "levels", "were", "upregulated", "in", "stage", "III", ".", "CONCLUSIONS", ":", "VEGF", "-", "A(165", ")", "is", "one", "of", "the", "major", "angiogenesis", "regulators", "among", "the", "ligands", "'", "family", "of", "VEGF", ",", "whereas", "its", "receptors", "KDR", ",", "and", "most", "probably", "Flt-1", ",", "may", "contribute", "to", "a", "poor", "prognosis", "(", "angiogenic", ")", "phenotype", ",", "as", "indicated", "by", "their", "upregulated", "MRNA", "levels", "in", "stage", "III", "neuroblastoma", ".", "VEGF", "-", "A(165", ")", "mainly", "contributes", "to", "increased", "serum", "VEGF", "levels", "and", "may", "serve", "as", "a", "diagnostic", "tool", "in", "advanced", "-", "stage", "neuroblastoma", ".", "\n" ]

[ "Gene_or_gene_product", "Multi-tissue_structure", "Pathological_formation", "Organism_substance", "Organism", "Tissue" ]

vascular endothelial growth factor receptors is a Gene_or_gene_product, tumor is a Pathological_formation, Vascular endothelial growth factor is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, neuroblastoma is a Pathological_formation, Tumor biopsy specimens is a Multi-tissue_structure, serum is a Organism_substance, neuroblastoma is a Pathological_formation, patients is a Organism, adrenal biopsy sections is a Multi-tissue_structure, sera is a Organism_substance, children is a Organism, Biopsy specimens is a Multi-tissue_structure, serum is a Organism_substance, VEGF - A(165 ) is a Gene_or_gene_product, B is a Gene_or_gene_product, C is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, neuroblastoma is a Pathological_formation, tissues is a Tissue, VEGF - B is a Gene_or_gene_product, C is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, KDR is a Gene_or_gene_product, tissue lysates is a Organism_substance, VEGF - A is a Gene_or_gene_product, Serum is a Organism_substance, VEGF is a Gene_or_gene_product, VEGF - A(165 ) is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, KDR is a Gene_or_gene_product, Flt-1 is a Gene_or_gene_product, stage III neuroblastoma is a Pathological_formation, VEGF - A(165 ) is a Gene_or_gene_product, serum is a Organism_substance, VEGF is a Gene_or_gene_product

100_task1

Sentence: Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma. Instructions: please typing these entity words according to sentence: vascular endothelial growth factor receptors, tumor, Vascular endothelial growth factor, VEGF, Flt-1, KDR, VEGF, neuroblastoma, Tumor biopsy specimens, serum, neuroblastoma, patients, adrenal biopsy sections, sera, children, Biopsy specimens, serum, VEGF - A(165 ), B, C, Flt-1, KDR, VEGF, neuroblastoma, tissues, VEGF - B, C, Flt-1, KDR, tissue lysates, VEGF - A, Serum, VEGF, VEGF - A(165 ), VEGF, KDR, Flt-1, stage III neuroblastoma, VEGF - A(165 ), serum, VEGF Options: Tissue, Gene_or_gene_product, Pathological_formation, Organism, Multi-tissue_structure, Organism_substance

[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "O", "B-Pathological_formation", "B-Organism", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma.

[ "Upregulation", "of", "vascular", "endothelial", "growth", "factor", "receptors", "is", "associated", "with", "advanced", "neuroblastoma", ".", "\n\n", "BACKGROUND", ":", "Angiogenesis", "is", "essential", "for", "tumor", "growth", "and", "relies", "on", "the", "production", "of", "angiogenic", "factors", ".", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "is", "a", "major", "regulator", "of", "angiogenesis", "that", "binds", "to", "tyrosine", "kinase", "receptors", "Flt-1", "and", "KDR", ".", "The", "interaction", "of", "VEGF", "and", "its", "receptors", "at", "gene", "and", "protein", "levels", "in", "neuroblastoma", "remains", "widely", "unknown", ".", "METHODS", ":", "Tumor", "biopsy", "specimens", "and", "serum", "were", "obtained", "from", "37", "neuroblastoma", "patients", ";", "adrenal", "biopsy", "sections", "and", "sera", "of", "7", "normal", "children", "served", "as", "controls", ".", "Biopsy", "specimens", "were", "examined", "by", "real", "-", "time", "reverse", "transcription", "polymerase", "chain", "reaction", "(", "RT", "-", "PCR", ")", "and", "Western", "blotting", ";", "serum", "was", "analyzed", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "VEGF", "-", "A(165", ")", ",", "B", ",", "C", ",", "Flt-1", ",", "and", "KDR", "were", "analyzed", ".", "RESULTS", ":", "VEGF", "isoforms", "and", "its", "receptors", "'", "mRNA", "were", "expressed", "in", "neuroblastoma", "and", "control", "tissues", ".", "Whereas", "the", "ligands", "were", "increased", "in", "stages", "III", "and", "IV", ",", "the", "receptors", "were", "upregulated", "in", "stage", "III", "only", ".", "At", "protein", "level", ",", "VEGF", "-", "B", "and", "C", ",", "Flt-1", ",", "and", "KDR", "were", "not", "detectable", "in", "tissue", "lysates", ",", "whereas", "VEGF", "-", "A", "was", "increased", "in", "stages", "III", "and", "IV", ".", "Serum", "VEGF", "protein", "levels", "were", "upregulated", "in", "stage", "III", ".", "CONCLUSIONS", ":", "VEGF", "-", "A(165", ")", "is", "one", "of", "the", "major", "angiogenesis", "regulators", "among", "the", "ligands", "'", "family", "of", "VEGF", ",", "whereas", "its", "receptors", "KDR", ",", "and", "most", "probably", "Flt-1", ",", "may", "contribute", "to", "a", "poor", "prognosis", "(", "angiogenic", ")", "phenotype", ",", "as", "indicated", "by", "their", "upregulated", "MRNA", "levels", "in", "stage", "III", "neuroblastoma", ".", "VEGF", "-", "A(165", ")", "mainly", "contributes", "to", "increased", "serum", "VEGF", "levels", "and", "may", "serve", "as", "a", "diagnostic", "tool", "in", "advanced", "-", "stage", "neuroblastoma", ".", "\n" ]

[ "Gene_or_gene_product", "Multi-tissue_structure", "Pathological_formation", "Organism_substance", "Organism", "Tissue" ]

vascular endothelial growth factor receptors, tumor, Vascular endothelial growth factor, VEGF, Flt-1, KDR, VEGF, neuroblastoma, Tumor biopsy specimens, serum, neuroblastoma, patients, adrenal biopsy sections, sera, children, Biopsy specimens, serum, VEGF - A(165 ), B, C, Flt-1, KDR, VEGF, neuroblastoma, tissues, VEGF - B, C, Flt-1, KDR, tissue lysates, VEGF - A, Serum, VEGF, VEGF - A(165 ), VEGF, KDR, Flt-1, stage III neuroblastoma, VEGF - A(165 ), serum, VEGF

100_task2

Sentence: Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "O", "B-Pathological_formation", "B-Organism", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "B-Organism_substance", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Organism_substance", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. BACKGROUND: Angiogenesis is essential for tumor growth and relies on the production of angiogenic factors. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis that binds to tyrosine kinase receptors Flt-1 and KDR. The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown. METHODS: Tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients; adrenal biopsy sections and sera of 7 normal children served as controls. Biopsy specimens were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting; serum was analyzed by enzyme-linked immunosorbent assay (ELISA). VEGF-A(165), B, C, Flt-1, and KDR were analyzed. RESULTS: VEGF isoforms and its receptors' mRNA were expressed in neuroblastoma and control tissues. Whereas the ligands were increased in stages III and IV, the receptors were upregulated in stage III only. At protein level, VEGF-B and C, Flt-1, and KDR were not detectable in tissue lysates, whereas VEGF-A was increased in stages III and IV. Serum VEGF protein levels were upregulated in stage III. CONCLUSIONS: VEGF-A(165) is one of the major angiogenesis regulators among the ligands' family of VEGF, whereas its receptors KDR, and most probably Flt-1, may contribute to a poor prognosis (angiogenic) phenotype, as indicated by their upregulated MRNA levels in stage III neuroblastoma. VEGF-A(165) mainly contributes to increased serum VEGF levels and may serve as a diagnostic tool in advanced-stage neuroblastoma.

[ "Upregulation", "of", "vascular", "endothelial", "growth", "factor", "receptors", "is", "associated", "with", "advanced", "neuroblastoma", ".", "\n\n", "BACKGROUND", ":", "Angiogenesis", "is", "essential", "for", "tumor", "growth", "and", "relies", "on", "the", "production", "of", "angiogenic", "factors", ".", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "is", "a", "major", "regulator", "of", "angiogenesis", "that", "binds", "to", "tyrosine", "kinase", "receptors", "Flt-1", "and", "KDR", ".", "The", "interaction", "of", "VEGF", "and", "its", "receptors", "at", "gene", "and", "protein", "levels", "in", "neuroblastoma", "remains", "widely", "unknown", ".", "METHODS", ":", "Tumor", "biopsy", "specimens", "and", "serum", "were", "obtained", "from", "37", "neuroblastoma", "patients", ";", "adrenal", "biopsy", "sections", "and", "sera", "of", "7", "normal", "children", "served", "as", "controls", ".", "Biopsy", "specimens", "were", "examined", "by", "real", "-", "time", "reverse", "transcription", "polymerase", "chain", "reaction", "(", "RT", "-", "PCR", ")", "and", "Western", "blotting", ";", "serum", "was", "analyzed", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "VEGF", "-", "A(165", ")", ",", "B", ",", "C", ",", "Flt-1", ",", "and", "KDR", "were", "analyzed", ".", "RESULTS", ":", "VEGF", "isoforms", "and", "its", "receptors", "'", "mRNA", "were", "expressed", "in", "neuroblastoma", "and", "control", "tissues", ".", "Whereas", "the", "ligands", "were", "increased", "in", "stages", "III", "and", "IV", ",", "the", "receptors", "were", "upregulated", "in", "stage", "III", "only", ".", "At", "protein", "level", ",", "VEGF", "-", "B", "and", "C", ",", "Flt-1", ",", "and", "KDR", "were", "not", "detectable", "in", "tissue", "lysates", ",", "whereas", "VEGF", "-", "A", "was", "increased", "in", "stages", "III", "and", "IV", ".", "Serum", "VEGF", "protein", "levels", "were", "upregulated", "in", "stage", "III", ".", "CONCLUSIONS", ":", "VEGF", "-", "A(165", ")", "is", "one", "of", "the", "major", "angiogenesis", "regulators", "among", "the", "ligands", "'", "family", "of", "VEGF", ",", "whereas", "its", "receptors", "KDR", ",", "and", "most", "probably", "Flt-1", ",", "may", "contribute", "to", "a", "poor", "prognosis", "(", "angiogenic", ")", "phenotype", ",", "as", "indicated", "by", "their", "upregulated", "MRNA", "levels", "in", "stage", "III", "neuroblastoma", ".", "VEGF", "-", "A(165", ")", "mainly", "contributes", "to", "increased", "serum", "VEGF", "levels", "and", "may", "serve", "as", "a", "diagnostic", "tool", "in", "advanced", "-", "stage", "neuroblastoma", ".", "\n" ]

[ "Gene_or_gene_product", "Multi-tissue_structure", "Pathological_formation", "Organism_substance", "Organism", "Tissue" ]

apelin is a Protein, APJ is a Protein, Apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin-13 is a Protein, APJ is a Protein, APJ is a Protein, apelin is a Protein, apelin-13 is a Protein, apelin is a Protein, APJ is a Protein

218_task0

Sentence: Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy.

[ "Ischemic", "heart", "failure", "enhances", "endogenous", "myocardial", "apelin", "and", "APJ", "receptor", "expression", ".", "\n", "Apelin", "interacts", "with", "the", "APJ", "receptor", "to", "enhance", "inotropy", ".", "In", "heart", "failure", ",", "apelin", "-", "APJ", "coupling", "may", "provide", "a", "means", "of", "enhancing", "myocardial", "function", ".", "The", "alterations", "in", "apelin", "and", "APJ", "receptor", "concentrations", "with", "ischemic", "cardiomyopathy", "are", "poorly", "understood", ".", "We", "investigated", "the", "compensatory", "changes", "in", "endogenous", "apelin", "and", "APJ", "levels", "in", "the", "setting", "of", "ischemic", "cardiomyopathy", ".", "Male", ",", "Lewis", "rats", "underwent", "LAD", "ligation", "and", "progressed", "into", "heart", "failure", "over", "6", "weeks", ".", "Corresponding", "animals", "underwent", "sham", "thoracotomy", "as", "control", ".", "Six", "weeks", "after", "initial", "surgery", ",", "the", "animals", "underwent", "hemodynamic", "functional", "analysis", "in", "the", "presence", "of", "exogenous", "apelin-13", "infusion", "and", "the", "hearts", "were", "explanted", "for", "western", "blot", "and", "enzyme", "immunoassay", "analysis", ".", "Western", "blot", "analysis", "of", "myocardial", "APJ", "concentration", "demonstrated", "increased", "APJ", "receptor", "protein", "levels", "with", "heart", "failure", "(", "1890750+/-133500", "vs", ".", "901600+/-143120", "intensity", "units", ",", "n=8", ",", "p=0.00001", ")", ".", "Total", "apelin", "protein", "levels", "increased", "with", "ischemic", "heart", "failure", "as", "demonstrated", "by", "enzyme", "immunoassay", "(", "12.0+/-4.6", "vs", ".", "1.0+/-1.2", "ng", "/", "ml", ",", "n=5", ",", "p=0.006", ")", "and", "western", "blot", "(", "1579400+/-477733", "vs", ".", "943000+/-157600", "intensity", "units", ",", "n=10", ",", "p=0.008", ")", ".", "Infusion", "of", "apelin-13", "significantly", "enhanced", "myocardial", "function", "in", "sham", "and", "failing", "hearts", ".", "We", "conclude", "that", "total", "myocardial", "apelin", "and", "APJ", "receptor", "levels", "increase", "in", "compensation", "for", "ischemic", "cardiomyopathy", ".", "\n" ]

[ "Protein" ]

apelin is a Protein, APJ is a Protein, Apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin is a Protein, APJ is a Protein, apelin-13 is a Protein, APJ is a Protein, APJ is a Protein, apelin is a Protein, apelin-13 is a Protein, apelin is a Protein, APJ is a Protein

218_task1

Sentence: Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy. Instructions: please typing these entity words according to sentence: apelin, APJ, Apelin, APJ, apelin, APJ, apelin, APJ, apelin, APJ, apelin-13, APJ, APJ, apelin, apelin-13, apelin, APJ Options: Protein

[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy.

[ "Ischemic", "heart", "failure", "enhances", "endogenous", "myocardial", "apelin", "and", "APJ", "receptor", "expression", ".", "\n", "Apelin", "interacts", "with", "the", "APJ", "receptor", "to", "enhance", "inotropy", ".", "In", "heart", "failure", ",", "apelin", "-", "APJ", "coupling", "may", "provide", "a", "means", "of", "enhancing", "myocardial", "function", ".", "The", "alterations", "in", "apelin", "and", "APJ", "receptor", "concentrations", "with", "ischemic", "cardiomyopathy", "are", "poorly", "understood", ".", "We", "investigated", "the", "compensatory", "changes", "in", "endogenous", "apelin", "and", "APJ", "levels", "in", "the", "setting", "of", "ischemic", "cardiomyopathy", ".", "Male", ",", "Lewis", "rats", "underwent", "LAD", "ligation", "and", "progressed", "into", "heart", "failure", "over", "6", "weeks", ".", "Corresponding", "animals", "underwent", "sham", "thoracotomy", "as", "control", ".", "Six", "weeks", "after", "initial", "surgery", ",", "the", "animals", "underwent", "hemodynamic", "functional", "analysis", "in", "the", "presence", "of", "exogenous", "apelin-13", "infusion", "and", "the", "hearts", "were", "explanted", "for", "western", "blot", "and", "enzyme", "immunoassay", "analysis", ".", "Western", "blot", "analysis", "of", "myocardial", "APJ", "concentration", "demonstrated", "increased", "APJ", "receptor", "protein", "levels", "with", "heart", "failure", "(", "1890750+/-133500", "vs", ".", "901600+/-143120", "intensity", "units", ",", "n=8", ",", "p=0.00001", ")", ".", "Total", "apelin", "protein", "levels", "increased", "with", "ischemic", "heart", "failure", "as", "demonstrated", "by", "enzyme", "immunoassay", "(", "12.0+/-4.6", "vs", ".", "1.0+/-1.2", "ng", "/", "ml", ",", "n=5", ",", "p=0.006", ")", "and", "western", "blot", "(", "1579400+/-477733", "vs", ".", "943000+/-157600", "intensity", "units", ",", "n=10", ",", "p=0.008", ")", ".", "Infusion", "of", "apelin-13", "significantly", "enhanced", "myocardial", "function", "in", "sham", "and", "failing", "hearts", ".", "We", "conclude", "that", "total", "myocardial", "apelin", "and", "APJ", "receptor", "levels", "increase", "in", "compensation", "for", "ischemic", "cardiomyopathy", ".", "\n" ]

[ "Protein" ]

apelin, APJ, Apelin, APJ, apelin, APJ, apelin, APJ, apelin, APJ, apelin-13, APJ, APJ, apelin, apelin-13, apelin, APJ

218_task2

Sentence: Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ coupling may provide a means of enhancing myocardial function. The alterations in apelin and APJ receptor concentrations with ischemic cardiomyopathy are poorly understood. We investigated the compensatory changes in endogenous apelin and APJ levels in the setting of ischemic cardiomyopathy. Male, Lewis rats underwent LAD ligation and progressed into heart failure over 6 weeks. Corresponding animals underwent sham thoracotomy as control. Six weeks after initial surgery, the animals underwent hemodynamic functional analysis in the presence of exogenous apelin-13 infusion and the hearts were explanted for western blot and enzyme immunoassay analysis. Western blot analysis of myocardial APJ concentration demonstrated increased APJ receptor protein levels with heart failure (1890750+/-133500 vs. 901600+/-143120 intensity units, n=8, p=0.00001). Total apelin protein levels increased with ischemic heart failure as demonstrated by enzyme immunoassay (12.0+/-4.6 vs. 1.0+/-1.2 ng/ml, n=5, p=0.006) and western blot (1579400+/-477733 vs. 943000+/-157600 intensity units, n=10, p=0.008). Infusion of apelin-13 significantly enhanced myocardial function in sham and failing hearts. We conclude that total myocardial apelin and APJ receptor levels increase in compensation for ischemic cardiomyopathy.

[ "Ischemic", "heart", "failure", "enhances", "endogenous", "myocardial", "apelin", "and", "APJ", "receptor", "expression", ".", "\n", "Apelin", "interacts", "with", "the", "APJ", "receptor", "to", "enhance", "inotropy", ".", "In", "heart", "failure", ",", "apelin", "-", "APJ", "coupling", "may", "provide", "a", "means", "of", "enhancing", "myocardial", "function", ".", "The", "alterations", "in", "apelin", "and", "APJ", "receptor", "concentrations", "with", "ischemic", "cardiomyopathy", "are", "poorly", "understood", ".", "We", "investigated", "the", "compensatory", "changes", "in", "endogenous", "apelin", "and", "APJ", "levels", "in", "the", "setting", "of", "ischemic", "cardiomyopathy", ".", "Male", ",", "Lewis", "rats", "underwent", "LAD", "ligation", "and", "progressed", "into", "heart", "failure", "over", "6", "weeks", ".", "Corresponding", "animals", "underwent", "sham", "thoracotomy", "as", "control", ".", "Six", "weeks", "after", "initial", "surgery", ",", "the", "animals", "underwent", "hemodynamic", "functional", "analysis", "in", "the", "presence", "of", "exogenous", "apelin-13", "infusion", "and", "the", "hearts", "were", "explanted", "for", "western", "blot", "and", "enzyme", "immunoassay", "analysis", ".", "Western", "blot", "analysis", "of", "myocardial", "APJ", "concentration", "demonstrated", "increased", "APJ", "receptor", "protein", "levels", "with", "heart", "failure", "(", "1890750+/-133500", "vs", ".", "901600+/-143120", "intensity", "units", ",", "n=8", ",", "p=0.00001", ")", ".", "Total", "apelin", "protein", "levels", "increased", "with", "ischemic", "heart", "failure", "as", "demonstrated", "by", "enzyme", "immunoassay", "(", "12.0+/-4.6", "vs", ".", "1.0+/-1.2", "ng", "/", "ml", ",", "n=5", ",", "p=0.006", ")", "and", "western", "blot", "(", "1579400+/-477733", "vs", ".", "943000+/-157600", "intensity", "units", ",", "n=10", ",", "p=0.008", ")", ".", "Infusion", "of", "apelin-13", "significantly", "enhanced", "myocardial", "function", "in", "sham", "and", "failing", "hearts", ".", "We", "conclude", "that", "total", "myocardial", "apelin", "and", "APJ", "receptor", "levels", "increase", "in", "compensation", "for", "ischemic", "cardiomyopathy", ".", "\n" ]

[ "Protein" ]

fractures is an umlsterm, knee is an umlsterm, arthroscopy is an umlsterm, visualization is an umlsterm, joint is an umlsterm, dissection is an umlsterm, irrigation is an umlsterm, paper is an umlsterm, fractures is an umlsterm, knee is an umlsterm, May is an umlsterm, patients is an umlsterm, fractures is an umlsterm, knee is an umlsterm, patients is an umlsterm, fracture is an umlsterm, classification is an umlsterm, patients is an umlsterm, fracture is an umlsterm, anterior cruciate ligament is an umlsterm, classification is an umlsterm, patients is an umlsterm, fractures is an umlsterm, patient is an umlsterm, fracture is an umlsterm, patella is an umlsterm, passive motion is an umlsterm, exercises is an umlsterm, Patients is an umlsterm, fractures is an umlsterm, patient is an umlsterm, fracture is an umlsterm, patella is an umlsterm, weight bearing is an umlsterm, patients is an umlsterm, fractures is an umlsterm, fractures is an umlsterm, weight is an umlsterm, fractures is an umlsterm, dislocation is an umlsterm, dislocation is an umlsterm, All is an umlsterm, patients is an umlsterm, knees is an umlsterm, range of motion is an umlsterm, patients is an umlsterm, fracture is an umlsterm, anterior cruciate ligament is an umlsterm, patient is an umlsterm, fractures is an umlsterm, anatomical is an umlsterm, fractures healed is an umlsterm, patients is an umlsterm, pain is an umlsterm, fracture is an umlsterm, patella is an umlsterm, knee is an umlsterm, synovitis is an umlsterm, complications is an umlsterm, fractures is an umlsterm, knee is an umlsterm, treatment is an umlsterm, surgical treatment is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, hospitalization is an umlsterm, rehabilitation is an umlsterm, times is an umlsterm

Arthroskopie.80110246.eng.abstr_task0

Sentence: Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented .

[ "Certain", "intra", "-", "articular", "fractures", "of", "the", "knee", "can", "be", "managed", "by", "arthroscopically", "assisted", "reduction", "and", "fixation", ".", "The", "known", "benefits", "of", "arthroscopy", "include", "better", "visualization", "of", "the", "entire", "joint", ",", "limited", "dissection", ",", "and", "thorough", "irrigation", ".", "The", "purpose", "of", "this", "paper", "is", "to", "present", "our", "experience", "with", "arthroscopically", "assisted", "reduction", "and", "fixation", "of", "certain", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "From", "May", "1995", "to", "November", "1997", ",", "34", "patients", "with", "intra", "-", "articular", "fractures", "of", "the", "knee", "were", "treated", "by", "arthroscopic", "reduction", "and", "fixation", ".", "We", "treated", "11", "patients", "with", "tibial", "plateau", "fracture", "type", "I", ",", "II", "and", "III", "(", "according", "to", "J.", "Schatzker", "classification", ")", ",", "20", "patients", "with", "avulsion", "fracture", "of", "the", "tibial", "insertion", "of", "the", "anterior", "cruciate", "ligament", "(", "intercondylar", "eminence", ")", "type", "II", ",", "III", "and", "IV", "(", "according", "to", "Meyers", ",", "McKeever", "and", "Zariczny", "classification", ")", ",", "two", "patients", "with", "completely", "dislocated", "osteochondral", "flake", "fractures", "of", "the", "femoral", "condyle", ",", "and", "one", "patient", "with", "a", "minimally", "displaced", "fracture", "of", "the", "patella", ".", "Postoperatively", "they", "were", "all", "allowed", "passive", "motion", "exercises", ".", "Patients", "with", "avulsion", "fractures", "of", "the", "ACL", "and", "the", "patient", "with", "fracture", "of", "the", "patella", "were", "allowed", "immediate", "weight", "bearing", ",", "while", "patients", "with", "tibial", "plateau", "fractures", "and", "osteochondral", "fractures", "were", "allowed", "weight", "bearing", "only", "after", "12", "weeks", ".", "Results", ":", "Of", "the", "11", "tibial", "plateau", "fractures", ",", "8", "were", "anatomically", "reduced", ",", "and", "in", "2", "the", "dislocation", "was", "less", "than", "2", "mm", ".", "No", "further", "dislocation", "of", "the", "fragment", "followed", ".", "All", "patients", "but", "one", "reported", "stable", "knees", "and", "they", "all", "had", "a", "full", "range", "of", "motion", "at", "follow", "-", "up", ".", "Of", "the", "20", "patients", "with", "avulsion", "fracture", "of", "the", "anterior", "cruciate", "ligament", ",", "19", "were", "anatomically", "reduced", ".", "Except", "in", "one", "patient", ",", "functional", "results", "were", "excellent", "(", "KT1000", "was", "1.3", "mm", ",", "average", "loss", "of", "flexion", "was", "2.5", "°", ",", "loss", "of", "extension", "was", "1.3", "°", ")", ".", "In", "two", "cases", "of", "osteochondral", "fractures", "of", "the", "femoral", "condyle", ",", "reduction", "was", "anatomical", ".", "The", "fractures", "healed", ",", "the", "patients", "were", "free", "of", "pain", "and", "had", "full", "ROM", "at", "the", "follow", "-", "up", ".", "The", "fracture", "of", "the", "patella", "healed", "in", "4", "weeks", "with", "full", "ROM", "of", "the", "knee", ".", "There", "was", "one", "case", "of", "aseptic", "synovitis", "and", "no", "other", "major", "complications", ".", "Conclusions", ":", "Arthroscopic", "reduction", "and", "fixation", "are", "technically", "possible", "in", "certain", "types", "of", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "Provided", "indications", "are", "good", ",", "results", "of", "arthroscopic", "treatment", "are", "better", "than", "in", "classical", "surgical", "treatment", "through", "arthrotomy", ".", "There", "is", "less", "postoperative", "morbidity", ",", "and", "hospitalization", "and", "total", "rehabilitation", "times", "are", "shorter", ".", "Some", "technical", "hints", "are", "presented", "." ]

[ "umlsterm" ]

fractures is an umlsterm, knee is an umlsterm, arthroscopy is an umlsterm, visualization is an umlsterm, joint is an umlsterm, dissection is an umlsterm, irrigation is an umlsterm, paper is an umlsterm, fractures is an umlsterm, knee is an umlsterm, May is an umlsterm, patients is an umlsterm, fractures is an umlsterm, knee is an umlsterm, patients is an umlsterm, fracture is an umlsterm, classification is an umlsterm, patients is an umlsterm, fracture is an umlsterm, anterior cruciate ligament is an umlsterm, classification is an umlsterm, patients is an umlsterm, fractures is an umlsterm, patient is an umlsterm, fracture is an umlsterm, patella is an umlsterm, passive motion is an umlsterm, exercises is an umlsterm, Patients is an umlsterm, fractures is an umlsterm, patient is an umlsterm, fracture is an umlsterm, patella is an umlsterm, weight bearing is an umlsterm, patients is an umlsterm, fractures is an umlsterm, fractures is an umlsterm, weight is an umlsterm, fractures is an umlsterm, dislocation is an umlsterm, dislocation is an umlsterm, All is an umlsterm, patients is an umlsterm, knees is an umlsterm, range of motion is an umlsterm, patients is an umlsterm, fracture is an umlsterm, anterior cruciate ligament is an umlsterm, patient is an umlsterm, fractures is an umlsterm, anatomical is an umlsterm, fractures healed is an umlsterm, patients is an umlsterm, pain is an umlsterm, fracture is an umlsterm, patella is an umlsterm, knee is an umlsterm, synovitis is an umlsterm, complications is an umlsterm, fractures is an umlsterm, knee is an umlsterm, treatment is an umlsterm, surgical treatment is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, hospitalization is an umlsterm, rehabilitation is an umlsterm, times is an umlsterm

Arthroskopie.80110246.eng.abstr_task1

Sentence: Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented . Instructions: please typing these entity words according to sentence: fractures, knee, arthroscopy, visualization, joint, dissection, irrigation, paper, fractures, knee, May, patients, fractures, knee, patients, fracture, classification, patients, fracture, anterior cruciate ligament, classification, patients, fractures, patient, fracture, patella, passive motion, exercises, Patients, fractures, patient, fracture, patella, weight bearing, patients, fractures, fractures, weight, fractures, dislocation, dislocation, All, patients, knees, range of motion, patients, fracture, anterior cruciate ligament, patient, fractures, anatomical, fractures healed, patients, pain, fracture, patella, knee, synovitis, complications, fractures, knee, treatment, surgical treatment, postoperative, morbidity, hospitalization, rehabilitation, times Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented .

[ "Certain", "intra", "-", "articular", "fractures", "of", "the", "knee", "can", "be", "managed", "by", "arthroscopically", "assisted", "reduction", "and", "fixation", ".", "The", "known", "benefits", "of", "arthroscopy", "include", "better", "visualization", "of", "the", "entire", "joint", ",", "limited", "dissection", ",", "and", "thorough", "irrigation", ".", "The", "purpose", "of", "this", "paper", "is", "to", "present", "our", "experience", "with", "arthroscopically", "assisted", "reduction", "and", "fixation", "of", "certain", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "From", "May", "1995", "to", "November", "1997", ",", "34", "patients", "with", "intra", "-", "articular", "fractures", "of", "the", "knee", "were", "treated", "by", "arthroscopic", "reduction", "and", "fixation", ".", "We", "treated", "11", "patients", "with", "tibial", "plateau", "fracture", "type", "I", ",", "II", "and", "III", "(", "according", "to", "J.", "Schatzker", "classification", ")", ",", "20", "patients", "with", "avulsion", "fracture", "of", "the", "tibial", "insertion", "of", "the", "anterior", "cruciate", "ligament", "(", "intercondylar", "eminence", ")", "type", "II", ",", "III", "and", "IV", "(", "according", "to", "Meyers", ",", "McKeever", "and", "Zariczny", "classification", ")", ",", "two", "patients", "with", "completely", "dislocated", "osteochondral", "flake", "fractures", "of", "the", "femoral", "condyle", ",", "and", "one", "patient", "with", "a", "minimally", "displaced", "fracture", "of", "the", "patella", ".", "Postoperatively", "they", "were", "all", "allowed", "passive", "motion", "exercises", ".", "Patients", "with", "avulsion", "fractures", "of", "the", "ACL", "and", "the", "patient", "with", "fracture", "of", "the", "patella", "were", "allowed", "immediate", "weight", "bearing", ",", "while", "patients", "with", "tibial", "plateau", "fractures", "and", "osteochondral", "fractures", "were", "allowed", "weight", "bearing", "only", "after", "12", "weeks", ".", "Results", ":", "Of", "the", "11", "tibial", "plateau", "fractures", ",", "8", "were", "anatomically", "reduced", ",", "and", "in", "2", "the", "dislocation", "was", "less", "than", "2", "mm", ".", "No", "further", "dislocation", "of", "the", "fragment", "followed", ".", "All", "patients", "but", "one", "reported", "stable", "knees", "and", "they", "all", "had", "a", "full", "range", "of", "motion", "at", "follow", "-", "up", ".", "Of", "the", "20", "patients", "with", "avulsion", "fracture", "of", "the", "anterior", "cruciate", "ligament", ",", "19", "were", "anatomically", "reduced", ".", "Except", "in", "one", "patient", ",", "functional", "results", "were", "excellent", "(", "KT1000", "was", "1.3", "mm", ",", "average", "loss", "of", "flexion", "was", "2.5", "°", ",", "loss", "of", "extension", "was", "1.3", "°", ")", ".", "In", "two", "cases", "of", "osteochondral", "fractures", "of", "the", "femoral", "condyle", ",", "reduction", "was", "anatomical", ".", "The", "fractures", "healed", ",", "the", "patients", "were", "free", "of", "pain", "and", "had", "full", "ROM", "at", "the", "follow", "-", "up", ".", "The", "fracture", "of", "the", "patella", "healed", "in", "4", "weeks", "with", "full", "ROM", "of", "the", "knee", ".", "There", "was", "one", "case", "of", "aseptic", "synovitis", "and", "no", "other", "major", "complications", ".", "Conclusions", ":", "Arthroscopic", "reduction", "and", "fixation", "are", "technically", "possible", "in", "certain", "types", "of", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "Provided", "indications", "are", "good", ",", "results", "of", "arthroscopic", "treatment", "are", "better", "than", "in", "classical", "surgical", "treatment", "through", "arthrotomy", ".", "There", "is", "less", "postoperative", "morbidity", ",", "and", "hospitalization", "and", "total", "rehabilitation", "times", "are", "shorter", ".", "Some", "technical", "hints", "are", "presented", "." ]

[ "umlsterm" ]

fractures, knee, arthroscopy, visualization, joint, dissection, irrigation, paper, fractures, knee, May, patients, fractures, knee, patients, fracture, classification, patients, fracture, anterior cruciate ligament, classification, patients, fractures, patient, fracture, patella, passive motion, exercises, Patients, fractures, patient, fracture, patella, weight bearing, patients, fractures, fractures, weight, fractures, dislocation, dislocation, All, patients, knees, range of motion, patients, fracture, anterior cruciate ligament, patient, fractures, anatomical, fractures healed, patients, pain, fracture, patella, knee, synovitis, complications, fractures, knee, treatment, surgical treatment, postoperative, morbidity, hospitalization, rehabilitation, times

Arthroskopie.80110246.eng.abstr_task2

Sentence: Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Certain intra-articular fractures of the knee can be managed by arthroscopically assisted reduction and fixation . The known benefits of arthroscopy include better visualization of the entire joint , limited dissection , and thorough irrigation . The purpose of this paper is to present our experience with arthroscopically assisted reduction and fixation of certain intra-articular fractures of the knee . From May 1995 to November 1997 , 34 patients with intra-articular fractures of the knee were treated by arthroscopic reduction and fixation . We treated 11 patients with tibial plateau fracture type I , II and III ( according to J. Schatzker classification ) , 20 patients with avulsion fracture of the tibial insertion of the anterior cruciate ligament ( intercondylar eminence ) type II , III and IV ( according to Meyers , McKeever and Zariczny classification ) , two patients with completely dislocated osteochondral flake fractures of the femoral condyle , and one patient with a minimally displaced fracture of the patella . Postoperatively they were all allowed passive motion exercises . Patients with avulsion fractures of the ACL and the patient with fracture of the patella were allowed immediate weight bearing , while patients with tibial plateau fractures and osteochondral fractures were allowed weight bearing only after 12 weeks . Results : Of the 11 tibial plateau fractures , 8 were anatomically reduced , and in 2 the dislocation was less than 2 mm . No further dislocation of the fragment followed . All patients but one reported stable knees and they all had a full range of motion at follow-up . Of the 20 patients with avulsion fracture of the anterior cruciate ligament , 19 were anatomically reduced . Except in one patient , functional results were excellent ( KT1000 was 1.3 mm , average loss of flexion was 2.5 ° , loss of extension was 1.3 ° ) . In two cases of osteochondral fractures of the femoral condyle , reduction was anatomical . The fractures healed , the patients were free of pain and had full ROM at the follow-up . The fracture of the patella healed in 4 weeks with full ROM of the knee . There was one case of aseptic synovitis and no other major complications . Conclusions : Arthroscopic reduction and fixation are technically possible in certain types of intra-articular fractures of the knee . Provided indications are good , results of arthroscopic treatment are better than in classical surgical treatment through arthrotomy . There is less postoperative morbidity , and hospitalization and total rehabilitation times are shorter . Some technical hints are presented .

[ "Certain", "intra", "-", "articular", "fractures", "of", "the", "knee", "can", "be", "managed", "by", "arthroscopically", "assisted", "reduction", "and", "fixation", ".", "The", "known", "benefits", "of", "arthroscopy", "include", "better", "visualization", "of", "the", "entire", "joint", ",", "limited", "dissection", ",", "and", "thorough", "irrigation", ".", "The", "purpose", "of", "this", "paper", "is", "to", "present", "our", "experience", "with", "arthroscopically", "assisted", "reduction", "and", "fixation", "of", "certain", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "From", "May", "1995", "to", "November", "1997", ",", "34", "patients", "with", "intra", "-", "articular", "fractures", "of", "the", "knee", "were", "treated", "by", "arthroscopic", "reduction", "and", "fixation", ".", "We", "treated", "11", "patients", "with", "tibial", "plateau", "fracture", "type", "I", ",", "II", "and", "III", "(", "according", "to", "J.", "Schatzker", "classification", ")", ",", "20", "patients", "with", "avulsion", "fracture", "of", "the", "tibial", "insertion", "of", "the", "anterior", "cruciate", "ligament", "(", "intercondylar", "eminence", ")", "type", "II", ",", "III", "and", "IV", "(", "according", "to", "Meyers", ",", "McKeever", "and", "Zariczny", "classification", ")", ",", "two", "patients", "with", "completely", "dislocated", "osteochondral", "flake", "fractures", "of", "the", "femoral", "condyle", ",", "and", "one", "patient", "with", "a", "minimally", "displaced", "fracture", "of", "the", "patella", ".", "Postoperatively", "they", "were", "all", "allowed", "passive", "motion", "exercises", ".", "Patients", "with", "avulsion", "fractures", "of", "the", "ACL", "and", "the", "patient", "with", "fracture", "of", "the", "patella", "were", "allowed", "immediate", "weight", "bearing", ",", "while", "patients", "with", "tibial", "plateau", "fractures", "and", "osteochondral", "fractures", "were", "allowed", "weight", "bearing", "only", "after", "12", "weeks", ".", "Results", ":", "Of", "the", "11", "tibial", "plateau", "fractures", ",", "8", "were", "anatomically", "reduced", ",", "and", "in", "2", "the", "dislocation", "was", "less", "than", "2", "mm", ".", "No", "further", "dislocation", "of", "the", "fragment", "followed", ".", "All", "patients", "but", "one", "reported", "stable", "knees", "and", "they", "all", "had", "a", "full", "range", "of", "motion", "at", "follow", "-", "up", ".", "Of", "the", "20", "patients", "with", "avulsion", "fracture", "of", "the", "anterior", "cruciate", "ligament", ",", "19", "were", "anatomically", "reduced", ".", "Except", "in", "one", "patient", ",", "functional", "results", "were", "excellent", "(", "KT1000", "was", "1.3", "mm", ",", "average", "loss", "of", "flexion", "was", "2.5", "°", ",", "loss", "of", "extension", "was", "1.3", "°", ")", ".", "In", "two", "cases", "of", "osteochondral", "fractures", "of", "the", "femoral", "condyle", ",", "reduction", "was", "anatomical", ".", "The", "fractures", "healed", ",", "the", "patients", "were", "free", "of", "pain", "and", "had", "full", "ROM", "at", "the", "follow", "-", "up", ".", "The", "fracture", "of", "the", "patella", "healed", "in", "4", "weeks", "with", "full", "ROM", "of", "the", "knee", ".", "There", "was", "one", "case", "of", "aseptic", "synovitis", "and", "no", "other", "major", "complications", ".", "Conclusions", ":", "Arthroscopic", "reduction", "and", "fixation", "are", "technically", "possible", "in", "certain", "types", "of", "intra", "-", "articular", "fractures", "of", "the", "knee", ".", "Provided", "indications", "are", "good", ",", "results", "of", "arthroscopic", "treatment", "are", "better", "than", "in", "classical", "surgical", "treatment", "through", "arthrotomy", ".", "There", "is", "less", "postoperative", "morbidity", ",", "and", "hospitalization", "and", "total", "rehabilitation", "times", "are", "shorter", ".", "Some", "technical", "hints", "are", "presented", "." ]

[ "umlsterm" ]

Risiko is an umlsterm, tierexperimentell is an umlsterm

DerNervenarzt.90701104.ger.abstr_task0

Sentence: Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge .

[ "Anhand", "einer", "Kasuistik", "weisen", "wir", "auf", "das", "Risiko", "des", "Auftretens", "nonkonvulsiver", "Status", "epileptici", "(", "NCSE", ")", "bei", "der", "Gabe", "des", "Antikonvulsivums", "Tiagabin", "in", "hoeheren", "Dosierungen", "und", "bei", "Dosissteigerungen", "hin", ".", "Das", "mehrmalige", "Auftreten", "von", "NCSE", "kurz", "nach", "der", "Tiagabin", "-", "Einnahme", "bei", "bisher", "unauffaelliger", "Status", "-", "Anamnese", "macht", "einen", "kausale", "Zusammenhang", "in", "diesem", "Fall", "sehr", "wahrscheinlich", ".", "Eine", "solche", "inverse", "Wirkung", "ist", "auch", "tierexperimentell", "gezeigt", "worden", ".", "Ein", "dosisabhaengiges", "Ungleichgewicht", "zwischen", "glialer", "und", "neuronaler", "GABA", "-", "Aufnahme", "hat", "ein", "Versagen", "der", "inhibitorischen", "GABA", "-", "Wirkung", "zur", "Folge", "." ]

[ "umlsterm" ]

Risiko is an umlsterm, tierexperimentell is an umlsterm

DerNervenarzt.90701104.ger.abstr_task1

Sentence: Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge . Instructions: please typing these entity words according to sentence: Risiko, tierexperimentell Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge .

[ "Anhand", "einer", "Kasuistik", "weisen", "wir", "auf", "das", "Risiko", "des", "Auftretens", "nonkonvulsiver", "Status", "epileptici", "(", "NCSE", ")", "bei", "der", "Gabe", "des", "Antikonvulsivums", "Tiagabin", "in", "hoeheren", "Dosierungen", "und", "bei", "Dosissteigerungen", "hin", ".", "Das", "mehrmalige", "Auftreten", "von", "NCSE", "kurz", "nach", "der", "Tiagabin", "-", "Einnahme", "bei", "bisher", "unauffaelliger", "Status", "-", "Anamnese", "macht", "einen", "kausale", "Zusammenhang", "in", "diesem", "Fall", "sehr", "wahrscheinlich", ".", "Eine", "solche", "inverse", "Wirkung", "ist", "auch", "tierexperimentell", "gezeigt", "worden", ".", "Ein", "dosisabhaengiges", "Ungleichgewicht", "zwischen", "glialer", "und", "neuronaler", "GABA", "-", "Aufnahme", "hat", "ein", "Versagen", "der", "inhibitorischen", "GABA", "-", "Wirkung", "zur", "Folge", "." ]

[ "umlsterm" ]

Risiko, tierexperimentell

DerNervenarzt.90701104.ger.abstr_task2

Sentence: Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anhand einer Kasuistik weisen wir auf das Risiko des Auftretens nonkonvulsiver Status epileptici ( NCSE ) bei der Gabe des Antikonvulsivums Tiagabin in hoeheren Dosierungen und bei Dosissteigerungen hin . Das mehrmalige Auftreten von NCSE kurz nach der Tiagabin-Einnahme bei bisher unauffaelliger Status-Anamnese macht einen kausale Zusammenhang in diesem Fall sehr wahrscheinlich . Eine solche inverse Wirkung ist auch tierexperimentell gezeigt worden . Ein dosisabhaengiges Ungleichgewicht zwischen glialer und neuronaler GABA-Aufnahme hat ein Versagen der inhibitorischen GABA-Wirkung zur Folge .

[ "Anhand", "einer", "Kasuistik", "weisen", "wir", "auf", "das", "Risiko", "des", "Auftretens", "nonkonvulsiver", "Status", "epileptici", "(", "NCSE", ")", "bei", "der", "Gabe", "des", "Antikonvulsivums", "Tiagabin", "in", "hoeheren", "Dosierungen", "und", "bei", "Dosissteigerungen", "hin", ".", "Das", "mehrmalige", "Auftreten", "von", "NCSE", "kurz", "nach", "der", "Tiagabin", "-", "Einnahme", "bei", "bisher", "unauffaelliger", "Status", "-", "Anamnese", "macht", "einen", "kausale", "Zusammenhang", "in", "diesem", "Fall", "sehr", "wahrscheinlich", ".", "Eine", "solche", "inverse", "Wirkung", "ist", "auch", "tierexperimentell", "gezeigt", "worden", ".", "Ein", "dosisabhaengiges", "Ungleichgewicht", "zwischen", "glialer", "und", "neuronaler", "GABA", "-", "Aufnahme", "hat", "ein", "Versagen", "der", "inhibitorischen", "GABA", "-", "Wirkung", "zur", "Folge", "." ]

[ "umlsterm" ]

promoter is a DNA_domain_or_region, enhancer shuffling is an other_name

89925_task0

Sentence: Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling? Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, other_name

[ "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling?

[ "Every", "enhancer", "works", "with", "every", "promoter", "for", "all", "the", "combinations", "tested", ":", "could", "new", "regulatory", "pathways", "evolve", "by", "enhancer", "shuffling", "?" ]

[ "DNA_domain_or_region", "other_name", "protein_subunit", "multi_cell", "cell_line", "DNA_family_or_group" ]

promoter is a DNA_domain_or_region, enhancer shuffling is an other_name

89925_task1

Sentence: Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling? Instructions: please typing these entity words according to sentence: promoter, enhancer shuffling Options: DNA_domain_or_region, other_name

[ "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling?

[ "Every", "enhancer", "works", "with", "every", "promoter", "for", "all", "the", "combinations", "tested", ":", "could", "new", "regulatory", "pathways", "evolve", "by", "enhancer", "shuffling", "?" ]

[ "DNA_domain_or_region", "other_name", "protein_subunit", "multi_cell", "cell_line", "DNA_family_or_group" ]

promoter, enhancer shuffling

89925_task2

Sentence: Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling? Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling?

[ "Every", "enhancer", "works", "with", "every", "promoter", "for", "all", "the", "combinations", "tested", ":", "could", "new", "regulatory", "pathways", "evolve", "by", "enhancer", "shuffling", "?" ]

[ "DNA_domain_or_region", "other_name", "protein_subunit", "multi_cell", "cell_line", "DNA_family_or_group" ]

Hh is a protein, Ptc is a protein-family, Smo is a protein, Ptc is a protein-family

1.0alpha7.train.887_task0

Sentence: Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein

[ "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes.

[ "Binding", "of", " ", "Hh", "to", " ", "Ptc", "frees", " ", "Smo", "from", " ", "Ptc", "repression", ",", "which", "then", "goes", "on", "to", "activate", "downstream", " ", "target", "genes", "." ]

[ "protein", "protein-family" ]

Hh is a protein, Ptc is a protein-family, Smo is a protein, Ptc is a protein-family

1.0alpha7.train.887_task1

Sentence: Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes. Instructions: please typing these entity words according to sentence: Hh, Ptc, Smo, Ptc Options: protein-family, protein

[ "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes.

[ "Binding", "of", " ", "Hh", "to", " ", "Ptc", "frees", " ", "Smo", "from", " ", "Ptc", "repression", ",", "which", "then", "goes", "on", "to", "activate", "downstream", " ", "target", "genes", "." ]

[ "protein", "protein-family" ]

Hh, Ptc, Smo, Ptc

1.0alpha7.train.887_task2

Sentence: Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "B-protein", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Binding of Hh to Ptc frees Smo from Ptc repression, which then goes on to activate downstream target genes.

[ "Binding", "of", " ", "Hh", "to", " ", "Ptc", "frees", " ", "Smo", "from", " ", "Ptc", "repression", ",", "which", "then", "goes", "on", "to", "activate", "downstream", " ", "target", "genes", "." ]

[ "protein", "protein-family" ]

Androgenablation is an umlsterm, therapy is an umlsterm, choice is an umlsterm, treatment is an umlsterm, metastatic is an umlsterm, prostate cancer is an umlsterm, patients is an umlsterm, disease is an umlsterm, androgenablation is an umlsterm, castration is an umlsterm, apoptotic is an umlsterm, treatment is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, toxicity is an umlsterm, treatment costs is an umlsterm, tumor is an umlsterm, survival is an umlsterm, clinical trials is an umlsterm

DerUrologeA.80370153.eng.abstr_task0

Sentence: Androgenablation is the therapy of choice for the treatment of advanced and metastatic prostate cancer . However , in more than half of the patients the disease will ultimately progress within 2 years . Intermittent androgenablation through medical castration maintains the apoptotic potential . By periodically changing phases on and off treatment the quality of life of the patients is improved . Apart from reduced toxicity treatment costs are lowered and tumor progression is possibly delayed . In how far survival is influenced is presently not clear and remains to be evaluated in further clinical trials . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Androgenablation is the therapy of choice for the treatment of advanced and metastatic prostate cancer . However , in more than half of the patients the disease will ultimately progress within 2 years . Intermittent androgenablation through medical castration maintains the apoptotic potential . By periodically changing phases on and off treatment the quality of life of the patients is improved . Apart from reduced toxicity treatment costs are lowered and tumor progression is possibly delayed . In how far survival is influenced is presently not clear and remains to be evaluated in further clinical trials .

[ "Androgenablation", "is", "the", "therapy", "of", "choice", "for", "the", "treatment", "of", "advanced", "and", "metastatic", "prostate", "cancer", ".", "However", ",", "in", "more", "than", "half", "of", "the", "patients", "the", "disease", "will", "ultimately", "progress", "within", "2", "years", ".", "Intermittent", "androgenablation", "through", "medical", "castration", "maintains", "the", "apoptotic", "potential", ".", "By", "periodically", "changing", "phases", "on", "and", "off", "treatment", "the", "quality", "of", "life", "of", "the", "patients", "is", "improved", ".", "Apart", "from", "reduced", "toxicity", "treatment", "costs", "are", "lowered", "and", "tumor", "progression", "is", "possibly", "delayed", ".", "In", "how", "far", "survival", "is", "influenced", "is", "presently", "not", "clear", "and", "remains", "to", "be", "evaluated", "in", "further", "clinical", "trials", "." ]

[ "umlsterm" ]